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The continuing worldwide increase in the incidence of chronic obstructive pulmonary 
disease (COPD) has led to international initiatives to improve surveillance and 
identify preventable risk factors for this and related chronic lung diseases. The 
studies reported here aimed to examine the prevalence and risk factors for 
respiratory symptoms and COPD; to introduce and test surveillance methodologies; 
and to inform treatment and control measures for this disease. The Lung Health 
Survey 2002 sampled 3512 individuals aged 215 years from an urban population of 
36,334 in the predominantly low-income area of Ravensmead and Uitsig, Cape 
Town, South Africa. Information on respiratory symptoms, risk factors and healthcare 
utilisation was collected using a respiratory questionnaire which included questions 
that had been validated elsewhere. In 2005, a subsample of 960 persons aged ~O 
years participated in the Burden of Obstructive Lung Disease (BOLD) study 
comprised of a questionnaire and pre and postbronchodilator spirometry, in order to 
assess the prevalence of COPD. 
A high prevalence of respiratory symptoms of 38.3% was reported. Tobacco smoking 
showed a consistent positive association with chronic bronchitis, wheeze, dyspnoea 
and cough. Strong associations with cannabis smoking, pulmonary tuberculosis, 
occupational exposures and low soci economic status were found. The association 
of cannabis smoking with respiratory symptoms suggest that it may be a risk factor 
for CO PD. 
The BOLD study revealed an exceptionally high prevalence of COPD in both men 
and women aged 40 years and older (29% and 20%, respectively) reflecting the very 
high prevalence of smoking in both sexes in the test area. The majority of those 
affected had moderate to severe disease, that is, symptoms with spirometric 
impairment (GOLD Stage II and higher). Even non-smoking women had a 
comparatively high prevalence of CO PO (12.6%), attributable to other risk factors 
such as tuberculosis and occupational exposures. Previous pulmonary tuberculosis 
was shown to be a strong predictor of COPD, which warrants further study. Review 
of healthcare utilisation confirmed significant under-recognition and undertreatment 
within local health services. 
These results confirm the need to prioritise preventative and treatment strategies for 
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CHAPTER 1: INTRODUCTION 
1.1. Background 
Chronic Obstructive Pulmonary Disease (COPO) has in recent years become an 
emerging public health crisis with new smoking in developing countries and aging 
populations worldwide. 1 Both rich and poor are affected, but it remains mainly a 
disease of the poor which has long been marginalised by government health 
departments and even scientists to a certain extent. 1 Other diseases of abuse 
associated with the affluent are the subject of lots of research, government guidelines 
etc. COPO remains shrouded by nihilism and has not completely lost its ignominious 
historic label of a self-inflicted disease. Although not yet displaying the full pattern of 
a world epidemic, prevalence appears to be rising worldwide, despite decreases 
seen in developed countries. 
Reasons for the growing importance of COPO and the urgency to study it include the 
following. Firstly, in the developed world, life expectancy continues to increase, 
resulting in an aging population. Although smokers die younger than their peers, 
improved survival from infectious diseases and other degenerative diseases such as 
cardiovascular disease creates scope for more to develop this form of degenerative 
lung disease. Secondly, a consequence of globalisation is the opening up of new 
markets in developing countries for multinational tobacco companies. 1 Finally, it is 
becoming evident that other factors contribute aetiologically to the development of 
this disease, and a significant proportion of those affected are not smokers. In 
addition, smoking is not a sufficient explanation for COPO. There is therefore a need 
to study the causes and nature of the COPO that forms part of this 'new epidemic' in 
the developing world and in countries undergoing epidemiologic transition. 2 
In a World Health Organisation (WHO) commissioned study, Murray and Lopez 
estimated that COPO was the sixth most common cause of mortality in 1990 and 
predicted that it would move into 3rd position by 2020. 3 Unlike asthma, premature 
death is common in COPO and the resulting years of life lost and those spent with a 
decreased quality of life are considerable. Morbidity and disability from symptomatic 
disease results in decreased productivity, high costs from health service use and 
treatment, work absenteeism and psychosocial effects on the individual and the 
family. Termed the "hidden epidemic,,4, the affected people are elderly and become 











country level, South Africa can ill-afford this added burden of chronic disease, faced 
as it is with the burden of trauma, infectious disease, and H IV, resulting in a 
quadruple burden of disease.5 Although COPD is ranked 16th in the top twenty 
individual causes of premature mortality (years of life lost), and seventh as a cause of 
morbidity, its true impact might be underestimated by under registration of deaths 
and underrecognition of disease.6 Despite this, COPD is ranked 8th as a cause of 
death in the Western Cape Province.? 
Over the last few decades, there has been an increase in the burden of obstructive 
lung disease worldwide accompanied by a greater awareness of and changes in the 
profile of risk factors for the disease. COPD is currently one of the most common 
chronic diseases in adults and is likely to be responsible for considerable morbidity 
and mortality in South Africa. However, to date there are no population-based 
studies to assess the prevalence of CO PO in South Africa, and thereby stimulate 
awareness of the disease. This awareness is necessary for both healthcare 
practitioners and society, as it will facilitate prevention, early and correct diagnosis, 
and appropriate information and treatment for patients.8 This will also allow for better 
advocacy to reduce smoking and other risk factors for the disease. The diagnostic 
shift that has occurred in developed countries appears to be slower in South Africa. 
But in order for early diagnosis to occur, there needs to be a higher suspicion, in 
order to assist with prevention of disease progression. 
Also of importance is the identification and control of risk factors for COPD as the first 
step in the primary prevention of this disease, and the most appropriate and cost-
effective way of tackling health problems. In the case of tobacco use and COPD, this 
approach has been recommended by the WHO to be feasible and effective.9 The 
most practical and effective of measures are anti-smoking initiation and smoking 
cessation initiatives. 
The first comprehensive study of health was the South Africa Demographic and 
Health Survey of 1998 (SADHS). According to this survey, the prevalence of self-
reported doctor-diagnosed chronic bronchitis in men from the Western Cape 
Province was higher than in other provinces, affecting 9.4% of men of all ages, 
compared to 0.7% in the Free State Province and 5.7% in Gauteng.lO Even though 
the differences may represent inequitable health services, the high prevalence 
amongst women in the Western Cape women (11.4%) was of concern.1O While 











complexes that represent disease trends, and point to the likelihood of high COPO 
prevalence in both sexes in this province. This is in contrast to a global trend of 
higher reported prevalence of COPO in men compared to women. 
The use of standardised questionnaires for collecting data on symptoms is 
considered the method of choice in "first phase" population surveys. These have 
been used successfully in asthma studies to make comparisons of prevalence 
between regions and countries. 29 Until recently, this has been difficult in COPO 
studies. In the absence of established longitudinal study cohorts, sentinel 
surveillance is useful to examine whether obstructive lung disease is becoming more 
common. In addition, the current objective gold standard for COPO diElgnosis 
requires the use of spirometry in order to accurately stage disease and it is essential 
to have a baseline prevalence of disease in order to inform and plan healthcare 
strategies, policy and legislation. 
Results of studies of the prevalence and risk factors for respiratory symptoms and 
CO PO have to be interpreted in the context of the past few centuries' political, social 
and economic circumstances in South Africa. 11 These forces have shaped the 
distribution and determinants of both obstructive and infective lung diseases. They 
are reflected in the lung health of this community and other similar communities 
affected by poverty. Poverty is associated with noxious agents such as occupational 
exposures, tobacco and a high burden of infectious disease such as tuberculosis. 
The increasing worldwide burden of COPO has made the measurement of 
prevalence a global research priority. Assessing the size of the problem is a first step 
in attracting public interest, driving political will, legislation and allocation of the 
resources necessary to address COPO. This thesis reports one of the first 
community studies in South Africa to assess the prevalence and risk factors for 
respiratory symptoms in a defined population. It comprises two linked studies, the 
first involving a respiratory questionnaire supported by investigations in a carefully 
sampled population, and the second, performed in a subsample, providing 
spirometric assessment using the internationally standardised Burden of Obstructive 











1.2. Historical perspective 
The segregation of South African society along ethnic lines that was national 
government policy until 1994, resulted in exaggerated social, geographical and 
economic differentiation that have had a profound effect upon all spheres of life, 
including education and health. In spite of the reforms of the past ten years of 
democracy, this differentiation persists today. The population in the Western Cape 
Province comprises several groups of varying size, which reflect the process of 
colonisation, migration patterns and the laws enforced by the apartheid government. 
Until recently the largest group was of mixed ancestry, the so-called 'Cape Coloured'; 
group. 
The diversity of the population of the Western Cape presented a challenge for the 
design of the studies reported in this thesis. Since socioeconomic status is a powerful 
determinant of health in general and lung health in particular, one is faced with a 
situation of sampling a city with such extremes of socioeconomic status. Different 
options were considered. The first was to select a sample representative of the 
demographics of the population. Although ideal in terms of representation, this 
approach has the potential to dilute local risk factors that might operate in sections of 
the community, and a far larger sample size would be needed to analyse 
associations with risk factors. However, other objectives of the study influenced the 
selection of the study population. Established residential areas in the Western Cape 
have relatively stable, non-mobile communities. Secondly, these communities being 
largely a working class group, many persons are low to intermediate with respect to 
income and education, but at high risk of lung disease because of their pattern of 
smoking and occupational exposures. Thirdly, the opportunity was presented to study 
two suburbs of Cape Town that had been well characterised by researchers from the 
University of Stellenbosch who have been investigating tuberculosis in the 
community. The suburbs are two adjacent predominantly low-income suburbs known 
as Ravensmead and Uitsig. Further details of the study population and area are 
presented in Chapter 4. 
--------
; This term had been introduced by the apartheid government to refer to persons of mixed ancestry who form a large 
proportion of the Western Cape Province. The term continues to be used by the democratically elected government 











1.3. The Lung Health Survey 2002 (LHS2002) and the Burden of 
Obstructive Lung Disease (BOLD) Study 
The community of Ravensmead and Uitsig, and the Western Cape region it belongs 
to, is firstly distinguished by a high prevalence of smoking - reported in the SADHS 
as being 57% in men and 40% in women. These are one of the highest smoking 
prevalences amongst the nine provinces of South Africa, and among the highest in 
the world. However, the number of cigarettes consumed per capita, is in a low range 
of 1-14 cigarettes per day.1O 
The second distinguishing factor of this community is that it has a very high 
prevalence of pulmonary tuberculosis (TB) estimated at 10 per 1000 population. ii This 
'epidemic' of tuberculosis has occurred over decades, and in spite of considerable 
research into possible reasons, the causes of the epidemic are elusive. iii There are 
some clues, such as the very well-recognised association of tuberculosis with urban 
poverty, harking back to the time of the industrial revolution in England; and the 
association of TB with tobacco smoking. It is suspected that this high burden of 
tuberculosis might have an impact on chronic lung disease. 
An increase in tuberculosis has occurred in spite of what has been judged by the 
WHO Stop TB Programme as a Tuberculosis Control Programme of "moderate" 
quality.12 It also preceded the appearance of the Human Immunodeficiency Virus 
(HIV) infection as a risk factor for acquiring tuberculosis, the Western Cape currently 
being the least affected province of South Africa. 
Thirdly, it is possible that Cape Town has a higher prevalence of asthma and allergic 
diseases than other parts of the country; however there are few data on the 
prevalence of COPD. Most asthma prevalence data from South Africa is from the 
Western Cape Province with a prevalence of 10.8% reported among chiidren. 13 The 
SADHS reported a national self-reported asthma prevalence of 7% in men and 9% in 
women, and a prevalence of chronic bronchitis of 2.8% in women and 2.3% in men. 
10 While statistics for most of South Africa and the rest of the continent of Africa are 
sparse, these diseases are thought to be less common in other regions than they are 
in the Western Cape. Using the globally validated epidemiologic methods of the 
ii Den Boon S, van Lill SWP, Borgdorff MW, Enarson DA, Verver S, Bateman ED, Irusen E, Lombard CJ, White NW, 












International Study of Asthma and Allergy in Children methodology (ISAAC) for 
children aged 13-14 years, 13.3% reported that they had ever had asthma, while 
16.0% had experienced wheeze in the last 12 months, which is above the global 
average.14 South Africa (Western Cape) is ranked 25th amongst almost 100 countries 
of the world recently surveyed in the Global Burden of Asthma Survey, published by 
the Global Initiative for Asthma (GINA) in 2004. This estimate is based on symptom 
data of children in a single area of South Africa and has limited generalisability to the 
country, as wide variations in the prevalence of current asthma symptoms are 
thought to apply. 
The burden of respiratory disease in Cape Town is suspected to be high. In 1999, a 
survey of patients presenting to a primary care centre in Cape Town confirmed that 
28% of patients presented for treatment of respiratory symptoms.15 It is suspected 
that much of this is chronic respiratory disease such as asthma, COPD and 
tuberculosis (TB). 
Over the past fifteen years the TB Research Unit of Stellenbosch University has been 
involved in multidisciplinary research focussing on reasons for the high incidence of 
TB in the Western Cape. These studies have been performed in Ravensmead and 
Uitsig. In addition to TB, it was suspected that other forms of lung disease were also 
highly prevalent, which lead to an interest in further research in these areas. 
During 2001, the University of Stellenbosch TB Research Unit in collaboration with 
the UCT Lung Institute began a project that developed into a mUlti-component survey 
of the two suburbs of interest. This study, the Lung Health Survey 2002 (LHS2002) 
aimed to establish the prevalence of lung diseases and their possible contributory 
causes. This was a comprehensive survey, unique in studying respiratory disease in 
all age groups. 
The LHS2002 provided an opportunity to study not only diseases that present the 
greatest burden upon health resources, but also their relation to one another and with 
co-morbidities, and the ability to investigate the influence of environmental factors 
upon the prevalence of disease. An added benefit of undertaking this research in 
Ravensmead and Uitsig was the low prevalence of HIV infection in these suburbs, a 
prevalence that is expected to rise over the next decade. It is anticipated that the 
prevalence and profile of lung disease is going to change, and that the HIV epidemic 











increase the prevalence of active TB, but untreated, it could be associated with a fall 
in the prevalence of COPD through its effect upon life expectancy. 
Improvements in economic status which occur without measures to reduce the 
prevalence of smoking might lead to increased cigarette consumption. This could 
result in increasing morbidity from chronic bronchitis and COPD, and in due course of 
lung cancer and other smoking related pathology. 
The initial survey was followed by three separate Part Two studies, performed 
independently by different investigators. The first was a detailed study of asthma and 
allergy in children aged 0 -14 years who participated in the Lung Health Survey 2002. 
This study by Dr Charles Obihara et al was designed to assess the prevalence of 
symptoms of asthma and allergic disorders, the associations between these 
disorders and tuberculosis, and the influence of co-morbidities like helminth infection 
and environmental factors upon the development of allergic disease - the "hygiene 
hypothesis".16 iii 
The second study by Dr Emmerentia Van Schalkwyk et al examined the prevalence 
of asthma in young adults between the ages 15 and 44 years using the European 
Community Respiratory Health Survey (ECRHS) methods to assess airway 
hyperresponsiveness (AHR) and asthma. 17 
The third 'follow-up' study is the Burden of Obstructive Lung Disease (BOLD) study, 
performed by the author in collaboration with researchers from the Oregon Health 
Sciences University and Kaiser Permanente Centre for Health Research in Portland, 
Oregon in the United States. The BOLD study is a worldwide initiative aimed at 
developing a standardised protocol to obtain information about the prevalence and 
burden of Chronic Obstructive Pulmonary Disease (COPD) and of factors 
responsible for, or associated with this disease. The BOLD protocol has been 
developed with the intention that it be used in many countries and regions in the 
world to generate reliable, comparable data on COPD and smoking. One of the foci 
is an economic evaluation of the burden of tobacco-related disease, to inform health 
interventions and the development of tobacco control policies. 
iii Jithoo A, Bateman ED, van Lill S, Irusen E, Van Schalkwyk E, Beyers N. The Lung Health Survey 2002. Protocol 











Although ideally the BOLD study could have been performed at the same time as the 
LHS2002, and a spirometric assessment as an immediate second phase of the 
LHS2002 was originally envisaged and planned, the latter was amended because it 
became obvious that using the BOLD methodologies would have several advantages 
over the locally developed protocol. Since the BOLD methodology was under 
development, this involved a delay of almost two years before the second phase 
could be performed, and the Cape Town site became only the fourth international site 
to use this methodology. Obvious advantages of this decision were the following: 
(a) Using an internationally standardised protocol allowed for 
accurate comparisons of results with other sites and countries. 
(b) The quality control process provided by the BOLD operations centre 
added value to the test results. 
(c) The prescribed spirometric equipment, having been 
internationally accepted, ensured acceptability of the results to 
an international audience. 
The methodology has been developed and tested by the BOLD researchers under 
the auspices of the Global Initiative for Chronic Obstructive Lung Disease (GOLD).18 
Initial validation/pilot studies were performed in Turkey and China. In the next phase, 
it was used in Austria, Iceland, Sweden and in this study site in Cape Town, South 
Africa. This was the first population-based study of CO PO in South Africa iv , and to 
our knowledge, one of the first in Africa. The skills and expertise gained may be used 
to assist with the performance of the BOLD methodology in other parts of South and 
southern Africa. The information gained will also be used to highlight the impact of 
smoking upon lung health, and the importance of COPD. 
Besides providing data on the prevalence and severity of COPD in the 
Ravensmead/Uitsig area, and the burden that this places upon health and social 
services, it was hoped that the study would provide information on the ways in which 
smoking and other risk factors contribute to diseases of the lungs in low-income 
communities. It was also intended to provide baseline data that might be used to 
track the effectiveness of anti-smoking legislation and other health measures. 











1.4. Thesis Objectives 
This thesis investigates the prevalence of respiratory symptoms and COPD, and 
associated risk factors in a predominantly low-income urban community of Cape 
Town, South Africa. Since distinguishing asthma from CO PO on the basis of 
symptoms alone is not possible, some data relating to asthma will also be presented 
but is not the focus of the work. 
The two hypotheses that will be investigated are that in this community in Cape 
Town: 
1. The prevalence of respiratory symptoms is high, and may be higher than that 
estimated in the SADHS. 
2. Factors other than tobacco smoking e.g. occupational exposures, cannabis 
smoking, poverty and previous TB are causatively linked to respiratory 
symptoms and COPD. 
Five Questions are addressed: 
1. What is the prevalence of respiratory symptoms (cough and sputum 
production, wheeze and dyspnoea) in adults ~ 5 years of age in 
Ravensmead and Uitsig, Cape Town? 
2. What are the risk factors for respiratory symptoms (determinants of 
obstructive lung disease) in this community? 
3. What is the prevalence of CO PO as defined by the Global Obstructive Lung 
Disease Initiative (GOLD)? 
4. What are the associated risk factors for COPD? 
5. What proportion of respiratory symptoms and obstructive lung disease is 
being recognised and treated and what are the implications of the prevalence 
of respiratory symptoms and CO PO for healthcare services? 
1.5. Thesis structure 
This introductory chapter provides some general background on obstructive lung 
disease in South Africa and study objectives. It also presents definitions and 
nomenclature. Chapter Two is a literature review on the prevalence and risk factors 
for COPD such as tobacco smoking, occupational exposures and socio-demographic 
factors. Chapter Three reviews adult obstructive lung disease in South Africa, with 











Chapter Four describes the methods of the two studies - the LHS2002 and the BOLD 
study, and Chapters Five and Six contain the results of the LHS2002. Chapter Five 
presents the prevalence of respiratory symptoms, prevalence of exposures and data 
on healthcare utilisation. Chapter Six reports an analysis of obstructive lung disease 
symptom-outcomes with various risk factors. 
Chapter Seven reports results from the BOLD study in terms of prevalence of COPD 
and results of multiple logistic regression analysis of associations with risk factors. 
The results are discussed in Chapter Eight. 
1.6. Nomenclature and Definitions 
The use of different definitions and defining criteria for each of the diseases COPD 
and asthma have made it difficult to compare estimates from different studies in the 
past. 19 During the last decade, efforts have been made to standardise not only the 
definition of COPD, but also the diagnosis and treatment of CO PO, notably by the 
Global Initiative for Chronic Obstructive Lung Disease (GOLD)18 and the Global 
Initiative for Asthma (GINA).20 A recent consensus document by the European 
Respiratory Society and American Thoracic Society served to unify global definitions 
and solidified the departure from older definitions of COPD. 19 21 
1.6.1. Chronic bronchitis 
For the purposes of this thesis the original British Medical Research Council (MRC) 
definition of chronic bronchitis is used: "cough with phlegm for three successive 
months for at least two successive years".22 This definition has been used in studies 
worldwide for over forty years and is advantageous in that it allows for comparison of 
prevalence across different studies. 19 
Chronic bronchitis is distinct from but often associated with COPD. Chronic bronchitis 
is a symptom complex and it must be noted that it occurs probably just as frequently 
as a symptom of asthma, as was first described by the great physician Osler who 
named it "chronic eosinophilic bronchitis" in the late 19th century.23 In each individual, 
a different degree of inflammation and/or airways hyperresponsiveness (AHR) may 
occur with chronic bronchitis which mayor may not result in airway obstruction. In the 
absence of spirometry, the prevalence of COPD cannot be directly inferred from the 











symptoms, reflecting the respiratory health of a population. Other measures of 
reporting such as "doctor-diagnosed chronic bronchitis" or >3 episodes of 
bronchitis25 in the past 12 months have also been used in population based studies, 
making some comparisons difficult because of a lack of standardisation of the 
definition across studies. 
1.6.2. Emphysema 
Emphysema is not a clinical but an anatomical definition referring to the "destruction 
of alveolar walls and the permanent enlargement of the airspaces distal to the 
terminal bronchioles".3o 31 It results in loss of elastic recoil, collapse of the terminal 
bronchioles and loss of intraluminal pressure 30 , which results in airflow obstruction. 
The predominant symptom is progressively worsening dyspnoea, and clinically, CT 
imaging evidence can be used to make the diagnosis. 
1.6.3. COPD 
GOLD defines COPD as "a disease state characterised by airflow limitation that is 
not fully reversible. The airflow limitation is usually both progressive and associated 
with an abnormal inflammatory response of the lungs to noxious particles or gases".18 
The GOLD guidelines and staging of disease are reviewed in Chapter 2. It refers to 
both symptoms and a history of exposure to risk factors as a basis for suspecting 
COPD, but spirometry is required to confirm the diagnosis. 19 The GOLD definition 
refers to chronic bronchitis without airflow limitation as Stage 0 (at risk). This 
acknowledges that some persons may either have mildly reduced lung function that 
has not yet reached the threshold for diagnosis of COPD, or may simply have cough 
and phlegm that is unrelated to decline in lung function. The initial concept that Stage 
o represented persons at risk of developing COPD has however recently been 
questioned, as it has not been shown in prospective studies to be predictive. 26 For 
this reason Stage 0 has been omitted from the 2006, as yet unpublished update of 
the GOLD Severity Classification. However, the presence of symptoms provides a 
useful opportunity to review and prevent exposures to potential causative factors 
such as tobacco smoking, occupational or biomass fuel exposure. Stage I or higher 
COPD requires evidence of airflow limitation in terms of a post-bronchodilator ratio of 
Forced Expiratory Volume in one second (FEV1) to Forced Vital Capacity (FVC) of 
less than 70%, with or without symptoms. Post-bronchodilator FEV1 as a percentage 
of predicted value is used to determine the staging of severity of COPO from Stage I 












GINA defines asthma as "a chronic inflammatory disorder of the airways in which 
many cells and cellular elements playa role. The chronic inflammation causes an 
associated increase in airway hyperresponsiveness that leads to recurrent episodes 
of wheezing, breathlessness, chest tightness and coughing, particularly at night or in 
the early morning. These episodes are usually associated with widespread but 
variable airflow obstruction that is often reversible either spontaneously or with 
treatment".20 A postbronchodilator FEV1/FVC ;gO% and reversibility :?200ml and 
~ 2% of baseline FEV1 is required for the diagnosis of asthma but asthmatics on 
treatment or between attacks may have normal lung function. 
1.6.5. Respiratory Symptoms 
Questionnaire reporting of respiratory symptoms such as wheeze, cough and 
dyspnoea as well as symptom complexes are accepted methods of assessing 
disease at a population level. A symptom is defined as "any sensation or change in 
bodily function that is experienced by a patient and is associated with a particular 
disease"27 and refers to the "subjective experience of disease, or a phenomenon that 
is experienced by an individual".28 Owing to its subjective nature, the reporting of 
symptoms may be biased, but for diseases such as asthma and COPD, 
questionnaire-based symptom definitions can be a useful alternative (in prevalence 
studies) to objective tests such as non-specific airway hyperresponsiveness (AHR).19 
29 Symptoms are defined as per questionnaire responses in this thesis. 
As in the clinical setting, it is not easy to distinguish clearly between asthma and 
COPD in population studies on the basis of symptoms alone, particularly in smokers 
and the elderly. Many studies rely on symptom questionnaires such as the British 
MRC questionnaire that have been standardised and validated among adults in 
developed countries, but their validity in South Africa has not been established. 
Spirometry-based studies are lacking. The contribution of asthma, chronic bronchitis, 
emphysema and COPD to obstructive lung disease is not entirely clear. This 
interrelationship has been the source of controversy in the past, and continues to be 
so today. 
Figure 1 shows the nonproportional Venn diagram published by the ATS in 1995 
describing the relationships between the components of a spectrum of obstructive 
disease possible in persons with respiratory symptoms, a large proportion of which is 











airflow obstruction, the evidence of obstruction may have to be sought by methods 
such as the methacholine challenge testing or exercise. Those with completely 
reversible obstruction or "pure asthma" are represented by subset 9. It is sometimes 
clinically difficult to differentiate between partially reversible asthma and chronic 
bronchitis/emphysema patients with AHR, resulting in the former group being 
classified as having COPD (subset 6, 7 and 8) Subset eight refers to persons with all 
three diagnoses - asthma, chronic bronchitis and emphysema. 31 32 
Emphysema and chronic bronchitis with airflow obstruction can occur together 
(subset 5). Asymptomatic or symptomatic emphysema is represented by subset 2 
and 11 and chronic bronchitis without airflow obstruction by subset 1. Other lung 
diseases causing airflow obstruction such as cystic fibrosis are outside of the circles 
but within the box (subset 10).31 32 The GOLD definition of COPD would further 
include those with irreversible or partially reversible airflow limitation that would be a 
further subset of subset 10, and also those persons with reversible airflow limitation 
































Figure 1: Nonproportional Venn diagram of COPD showing subsets of patients with 
chronic bronchitis, emphysema, and asthma (subsets with COPD shaded) from the 
American Thoracic Society: Standards for the diagnosis and care of patients with 
chronic obstructive pulmonary disease. 31 32 
The proportions in each category may vary according to the diagnostic criteria used 
and whether based on symptoms alone, spirometry, or symptoms and spirometry, 
and whether additional investigations like bronchial challenge are used. 
Proportionality has been ascribed to this diagram for some populations in developed 
countries such as the U.S. and the U.K.32 
The studies reported in this thesis permit comparison of respiratory disease detected 
with the first two of these diagnostic approaches (questionnaires and spirometry), 
and allow a comprehensive epidemiological perspective of the relationship between 
symptoms and the presence of obstructive lung disease in adults. 
1.7. References 
1 Burney P. Introduction: The Pharmacoepidemiology of COPD: Recent Advances and 
methodological discussion. Eur Respir J 2003; 22:1 S-44S. 
2 Omran AR. The epidemiologic transition. A theory of the Epidemiology of population change. 
1971 Bull World Health Organ. 2001; 79(2):161-70 
:l Murray CJL Lopez AD editors. The Global Burden of Disease: A Comprehensive 
Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and 











~ Enarson DA. The hidden epidemic: chronic obstructive pulmonary disease. Int J Tuberc 
Lung Dis 2004; 8: 157 -158. 
5 Bradshaw D, Schneider M, Dorrington R, Bourne DE, Laubscher R.South African cause-of-
death profile in transition - 1996 and future trends S Afr Med J 2002; 92:618-623. 
G Bradshaw D, Groenewald P, Laubscher R, Nannan N, NOJilana B, Norman R, Pieterse D, 
Schneider M, Bourne DE, Timaeus 1M, Dorrington R, Johnson L. Initial burden of disease 
estimates for South Africa, 2000. S Afr Med J. 2003 Sep; 93(9):682-8. 
7 Bradshaw D, Nannan N, Laubscher R, Groenewald P, Joubert J, Nojilana B, Norman R, 
Pieterse D, Schneider M. South African National Burden of Disease Study 2000: Estimates of 
Provincial Mortality. Cape Town: South African Medical Research Council, 2004. 
B Lindberg A. COPD: Prevalence, Incidence, Decline in lung function and Risk Factors. The 
Obstructive Lung Disease in Northern Sweden Studies. PhD Thesis. 2004. University of 
Umea. 
"World Health Organisation. WHO/MNC/CRA/02.2. Meeting Report. February 2002. 
Implementation of the WHO Strategy for the Prevention and Control of Chronic Respiratory 
Diseases. URL: http://whqlibdoc.who.inUHQ/2002IWHO_MNC_CRA_02.2.pdf. Accessed 
February 2006. 
10 Department of Health. South Africa Demographic and Health Survey Report 1998. Pretoria: 
Department of Health, 2002: 1-338. 
11 Bateman ED, Jithoo A. Lung Disease in South Africa: An overview. In: Innate immunity to 
pulmonary infection. Wiley, Chichester (Novartis Foundation Symposium 279). 2006:4-16. 
12 WHO STOP TB Programme. URL: www.stoptb.org. Accessed February 2005. 
13 Ehrlich RI, Du Toit D, Jordaan E,Volmink JA, Weinberg EG, Zwarenstein M. Prevalence 
and Reliability of asthma symptoms in primary school children in Cape Town .. Int J Epi. 1995; 
24(6):1138-1146. 
1~ Poyser MA, Nelson H, Ehrlich RI, Bateman ED, Parnell S, Puterman A, Weinberg E. 
Socioeconomic deprivation and asthma prevalence and severity in young adolescents. Eur 
Respir J. 2002 May; 19(5):892-8. 
15 Fairall L, Donald K, Zwarenstein M, Scherpbier R. "Evaluation of clinical predictors of lung 
diagnosis in primary care in Cape Town." Paper presented at the 2001 Annual South African 
Thoracic Society (SATS) Congress. Bloemfontein, Free State: 2001. 
16 Strachan DP. Family size, infection and atopy: the first decade of the "hygiene hypothesis". 
Thorax. 2000 Aug; 55 Suppl1 :S2-1 O. 
11 Van Schalkwyk E, Lombard C, Beyers N, Bateman E, Irusen E. Prevalence of bronchial 
hyperresponsiveness in a low-income urban area of Cape Town, South Africa. Eur Respir J 
2005; 26: Suppl. 49, 
18 Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS, GOLD Scientific Committee. 
Global strategy for the diagnosis, management, and prevention of chronic obstructive 
pulmonary disease. NHLBI Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
Workshop summary. Am ~I Respir Crit Care Med 2001; 163: 1256-1276. 
19 Ehrlich R, Jithoo A. Chronic Respiratory Diseases in South Africa. In: Jean Fourie, Norman 
Temple, Krisela Steyn (Eds). Chronic Diseases of Lifestyle in South Africa: Review of 











20 Global Initiative for Asthma (GII\JA).Global Strategy for Asthma Management and 
Prevention. NIH Publication 02-3659, 1995. Updated 2002 and 2004. 
21 Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of 
patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 
23(6):932-946. 
22 Fletcher CM, Pride NB. Definitions of emphysema, chronic bronchitis, asthma, and airflow 
obstruction: 25 years on from the Ciba symposium. Thorax 1984; 39(2):81-85. 
23 Osler W. The Principles and Practice of Medicine. New York: Appleton and Co. 1892:497. 
24 Richter DC, Irusen EM. COPD - misconceptions of spirometry and stqging. S Afr Respir J 
2002; 8:152-157. 
25 Mannino DM. Epidemiology and global impact of Chronic Obstructive Pulmonary Disease. 
Seminars in Respiratory and Critical Care Medicine 2005; 26(2)204-210. 
26 Vestbo J, Lange P. Can GOLD Stage 0 Provide information of Prognostic value in Chronic 
Obstructive Pulmonary Disease. Am J Resp Crit Care Med 2002; 166:329-332. 
27 Anonymous. Princeton University word net search. URL: 
http://wordnet.princeton . ed u/perl/webwn ?s=s ym ptom. Accessed Septem ber 2006. 
28 Meren M. Asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD) and 
respiratory symptoms among adults in Estonia: prevalence and risk factors- comparison with 
Sweden and Finland. PhD Thesis. 2005. Karolinska University Press. 
29 Pekkanen J, Pearce N. Defining asthma in epidemiological studies. Eur Respir J 1999; 
14:951-957. 
30 Mannino DM. Epidemiology, Prevalence, Morbidity and Mortality, and Disease 
Heterogeneity. Chest. 2002 May; 121(5):121S-126S. 
31 American Thoracic Society. Standards for the diagnosis and care of patients with chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152,s 77 -s 121 
32 Soriano ~IB, Davis KJ, Coleman B, Visick G, Mannino D, Pride NB. The proportional Venn 
diagram of obstructive lung disease: two approximations from the United States and the 











CHAPTER 2: LITERATURE REVIEW: PREVALENCE AND RISK 
FACTORS FOR COPD 
2.1. Introduction 
The aim of this chapter is to provide a brief historical perspective and a broad 
overview of the world literature on population-based studies of obstructive lung 
disease with respect to COPD prevalence and risk factors. 
As outlined in Chapter 1, the obstructive lung diseases include asthma, COPD and a 
number of other less common forms of lung disease that affect the airways. Owing to 
the to the wide aetiology of COPD, this chapter is not intended to be an exhaustive 
review of the literature on prevalence and each risk factor, but rather gives an 
overview with the focus on some important themes and an emphasis on more recent 
studies. With some exceptions, the studies for review were chosen on the basis of 
merit; the result of considerations of sample size, strength of associations and 
robustness of study design. 
2.2. Historical Perspective 
2.2.1. Recognition and terminology of Chronic Obstructive Pulmonary Disease 
Chronic bronchitis and COPD are not new diseases. The ancients referred to many 
respiratory diseases under an umbrella term of 'catarrh'.1 The invention of the 
stethoscope by the Frenchman Laennac in 1819 stimulated interest into lung disease 
and it was Laennac himself who made the classical description of emphysema as an 
anatomical construct in 1827.1 2 Badham is thought to have coined the term chronic 
bronchitis in 1808.3 A further development in understanding lung diseases was the 
invention of the spirometer by Hutchinson in 1842.1 
However, three prominent events in the 20th century stimulated interest in obstructive 
lung disease - the Meuse Valley poisonous smog in Belgium, the Donora catastrophe 
in Pennsylvania in 1948, and the great London Fog of 1952. All were associated with 
many deaths from respiratory disease. The Meuse Valley was the first recorded 
severe air pollution episode that resulted from industrial processes. A temperature 
inversion in the valley trapped poisonous smog thought to be fluorine from local 
factories, killing sixty inhabitants and affecting scores more. 4 5 In Donora, twenty 
people died and over 7000 were hospitalised with respiratory symptoms after having 
been exposed to poisonous smog from a local industry where most of the residents 











persons with chronic respiratory and cardiac disease.7 Later research has suggested 
that the figure may have been even as high as 12000.B The London Fog resulted in 
increased awareness and provided the focus and motivation for the British MRC to 
research chronic bronchitis in ensuing years. 
A milestone in our understanding of obstructive lung diseases was the CIBA 
symposium of 1958 which for the first time recommended that asthma and chronic 
bronchitis and emphysema be viewed as different diseases for classification, clinical 
and coding purposes. 9 Prior to this, these terms were used interchangeably. A 
distinction was made between irreversible obstructive lung disease and emphysema, 
as it was recognised that some patients with irreversible obstructive lung disease 
showed no evidence of emphysema on post mortem examination. It was proposed 
that the term emphysema be reserved for those with clear radiological, clinical and 
physiologic evidence of emphysema. 9 
In the early 1960's, the American Thoracic Society and the British Medical Research 
Council concurred with this viewpoint at their respective meetings. 1O 11 In 1966, 
Briscoe 12 suggested that the term chronic obstructive pulmonary disease be used to 
cover chronic bronchitis and emphysema while Burrows et al 13 preferred to 
distinguish between chronic airways obstruction (emphysema) and chronic 
bronchitis. In 1977, Fletcher and Peto described the natural history of the disease 
and described the two conditions, chronic bronchitis and emphysema, as different 
manifestations caused by cigarette smoking. 14 However, the uncertainty of how to 
diagnose and describe the disease has continued well into the current era, and even 
within the last year, new recommendations for defining and staging CO PO have been 
proposed (GOLD 2006 update - in press). 
The role of measurements of lung function in the diagnosis and staging of obstructive 
lung disease had now become more important. Early attempts to measure lung 
function included the maximum breathing capacity as a measure of impairment. 
Tiffeneau was most famous for the Tiffeneau Index (FEV1/FVC) which is used in the 
current definition criterion for COPD according to GOLD. Tiffeneau and Pinelli 
proposed the use of the forced expiratory volume in 1 second (FEV1) as the basis for 
diagnosis and staging in 1947. 15 This proposal was supported by Gaensler16 in 1951, 
and subsequently adopted by the British Thoracic Society in 1957.1 Over half a 












Along with this research came the recognition of the need to standardise 
questionnaires and methodology as major tools for use in respiratory epidemiologic 
studies. The British IVIRC questionnaire, published in 1960 was the first. 17 It 
attempted to limit observer bias and some questions focused on the identification of 
chronic bronchitis. It also included questions on breathlessness as an indicator of 
respiratory disability.18 In 1962, the European Community for Coal and Steel (ECCS) 
built on the MRC questionnaire by adding questions on medical and occupational 
history.19 Subsequently, the American Thoracic Society (ATS) in collaboration with 
the Division of Lung Diseases (DLD) produced a questionnaire in 1978 (ATS-DLD-
78).20 Comstock et al compared the MRC questionnaire to this new instrument and 
viewed their performance as similar.21 
The evolution of knowledge on COPD has resulted in changes in later versions of the 
MRC and ECCS questionnaires over the last three decades. Other questionnaires 
have also been developed - the International Union Against Tuberculosis and Lung 
Diseases (IUATLD) questionnaire (1984)22 provided more focus on asthma, as did 
the European Community Respiratory Health Survey (ECRHS) questionnaire. 23 
However questions relating to chronic cough and phlegm continued to be borrowed 
from the revised MRC questionnaire. Despite major advances in technology and the 
development of lung function tests such as spirometry, diffusing capacity and CT 
lung density, questionnaires remain a major tool for population-based studies for their 
ease of use, low cost and the option of self-administration by participants. 
Concepts and understanding of the pathogenesis and natural history of obstructive 
lung diseases evolved over the past fifty years, and at times have been polarised by 
contributions made by prominent researchers in different countries. 
2.2.2. The British Hypothesis 
The work of British clinicians and researchers, notably Fletcher, Peto, Reid, Holland 
and colleagues, resulted in the formulation of the so-called British hypothesis which 
stated that recurrent bronchial infections were the cause of progressive decline in 
lung function in smokers. 
Chief amongst this evidence was the work by Fletcher and Peto who espoused the 
hypothesis and performed a study that was meant to demonstrate it, comparing the 











Two phenotypes were described - chronic bronchitis with progressive lung function 
impairment and parenchymal damage/emphysema and chronic bronchitis without 
emphysema. Both were related to smoking and could co-exist in the same person. 
Additionally they concluded that neither mucous hypersecretion nor bronchial 
infection cause CO PO to progress more rapidly, and that chronic bronchitis and 
COPO were largely unrelated disease processes but both were caused 
predominantly by smoking. 14 A subsequent 20 -25 year follow-up study of the 
Fletcher and Peto cohort found that the risk of death from COPO was strongly 
associated with the initial degree of airflow limitation, but not with mucous 
hypersecretion, further supporting the independence of the two processes. 24 This has 
been challenged by Annesi and Kauffmann (1986) who found that chronic mucous 
hypersecretion was significantly associated with mortality (OR 1.35 p<0.01) in a 
cohort of working men after correcting for age, smoking and occupational exposures, 
suggesting that it is not an "innocent condition".25 Vestbo et al also found it to be 
associated with an increased risk of hospitalisation for COPO which could be related 
to an increased risk of bronchial infection.29 
Fletcher and Peto found that tobacco smoke exposure accelerated the decline in 
lung function in susceptible smokers and that those who stop smoking return to the 
rate of decline of never-smokers but do not regain their lung function. 14 This view was 
later supported by the l\Jorth American Lung Health Study which confirmed that in 
subjects who stop smoking the rate of FEV1 decline was half that in intermittent 
quitters or continuing smokers, and comparable to that of never smokers.26 
The role of cigarette smoking as the sole cause of COPO was challenged by Holland 
and Reid who described an urban-rural difference in respiratory symptoms and lung 
function of postal service workers in London and three rural areas in the early 
1960'S.27 They ascribed this difference to air pollution after correcting for smoking, 
occupation and socioeconomic status. 28 
The relationship between respiratory infection and airflow limitation continues to be 
controversial. The British hypothesis was shelved for a while largely because of 
Fletchers' work which showed that the number of infections did not alter the slope of 
the decline in lung function but only caused temporary depressions in lung function. It 
is now being revived slightly for advanced COPO, the argument being that Fletcher's 
subjects were still relatively mild. The following studies have taken another look at 











The Copenhagen City Heart Study, a cohort study supported the original British 
hypothesis (but not Fletcher's subsequent opinion) by showing an increase in FEV1 
decline of 22.8ml/yr in men and 12.6ml/yr in women associated with chronic mucous 
hypersecretion. 29 The early identification of persons likely to have more rapid decline 
in lung function is still elusive as we are still unable to predict which chronic bronchitis 
patients will have accelerated decline or predict the rate of decline. Studies have 
been performed to examine levels of inflammatory markers (e.g. Von Willebrand 
Factor, a product of the respiratory and systemic endothelium30 ), but none have 
yielded clinically useful results as yet. 
Wilkinson et al and Hill et al have found that the rate of decline of lung function is 
related to bacterial load and species changes, independent of whether organisms 
were pathogenic or not .31 32 The role of inflammatory indicators in patients with and 
without pathogenic bacteria was examined by Banerjee et ai, indicating that 
pathogenic bacteria cause more inflammation than their non-pathogenic 
counterparts. 33 Exacerbations of COPD seem to accelerate lung function decline34 
and it seems that chronic bronchitis is not entirely irrelevant to the progress of 
obstructive lung disease35, but the contribution of chronic infection is still unclear. 
2.2.3. The Dutch Hypothesis 
In contrast to the British hypothesis, the Dutch hypothesis, developed in the 1960's 
by Orie et al 36( 1961) and van der Lende (1969)37, considered asthma, chronic 
bronchitis and emphysema to be different subgroups of the same disease process, 
with the possibility of overlap between them, meaning that more than one form may 
be present in the same person. According to this view pre-existing or hereditary 
hyper-responsiveness and atopy predispose to COPD as well as to asthma. Host 
characteristics such as atopy and airways hyperresponsiveness (AHR) influence and 
might determine an individual's responses to environmental exposures such as 
smoking and air pollution. Interaction of host and environmental factors determine 
whether an individual is healthy, develops asthma or irreversible lung function 
impairment.38 The focus is on endogenous host characteristics as the principal 
determinant for the development of COPD, as opposed to exogenous factors as in 
the British hypothesis. 
There appears to be more than circumstantial evidence for the Dutch hypothesis. Xu 
et al (1997) analysed a 24 year follow-up on the Vlagtwedde and Vlaardingen cohort 











with the development of chronic respiratory symptoms and negatively associated with 
the remission of these symptoms, in support of the hypothesis. 39 However, the 
question of whether the AHR is a cause or a result of the pathological process 
remains. It is already known that narrowed airways are more hyperreactive than 
normal airways, as an increased resting bronchomotor tone may potentiate a 
subsequent constrictor stimulus.40 41 The argument that the AHR is measured prior to 
obvious obstruction39 depends on how sensitive FEV1 is for the abnormality and there 
is reasonable evidence that it is not very sensitive (see Chapter 8).42 In addition, 
accelerated annual decline in FEV1 in smokers is associated with an increase in AHR 
as the FEV1 falls.
41 
2.2.4. The American Perspective and mortality studies 
Examination of the differences in the patterns and rates of mortality between the US 
and the UK in the 1960's and 70's have been of benefit in drawing attention to 
problems of disease definitions, classification and reporting. These mortality studies 
benefited their respective populations and the medical community by resulting in 
critical appraisal of the validity of mortality data and also resulted in an improvement 
in the definition of respiratory disease.43 44 45 They have highlighted problems with the 
classification of obstructive lung disease, particularly in relation to death certification, 
upon which the mortality statistics were based. Misclassification and incorrect 
attribution of cause of death data was shown to have resulted in much 
underestimation of disease, even as it does today in South Africa. 45 46 
Subsequently, comparisons of the accuracy of death certification of respiratory 
disease have been made within the European Economic Community wrlich showed 
differences between countries and within each country. These have highlighted the 
need for standardisation of respiratory disease classifications in order to achieve 
more accurate mortality statistics. 47 
Reporting systems for mortality data in South Africa are lagging behind in making this 
transition to more accurate mortality reporting and in defining and communicating 
about respiratory disease.48 These limitations occur particularly at the primary health 
care level49 , where asthma and bronchitis are terms often used interchangeably, and 
also to describe COPD. Diagnostic tools such as spirometry are not widely available 
or often used correctly.50 This diagnostic misclassification probably makes South 
African mortality and morbidity data less reliable than data from established market 











countries have better access to good quality spirometry, particularly at the primary 
care level. Regarding morbidity, questionnaire-based surveys play an important role 
in identifying those with respiratory symptoms, but are not good tools for identifying 
or classifying obstruction. Good local research is thus essential to provide data for 
estimating the burden of disease. 
2.3. The Global Burden of COPD 
COPD is a common cause of mortality and morbidity worldwide, and although the 
prevalence of disease varies widely within and between countries and regions, it 
presents a heavy direct and indirect economic and social burden in all countries of 
the world. 51 However, recognition of this fact has been slow, and only in recent years 
has its true prevalence been established in some countries. In others, and in 
particular for the continent of Africa, very little data is available. This process has 
been slowed because of poor definitions of disease, methodological issues and 
resource constraints. In 1990, the World Health Organisation (WHO) commissioned a 
Global Burden of Disease study which estimated the current all-cause burden of 
disease in terms of morbidity (prevalence and quality of life), mortality and costs. In 
2001, COPD was the fifth most common cause of death worldwide52, responsible for 
4.7% of deaths and 2.0% of disability adjusted life years (DALYs).53 A 30-year 
projection from 1990 predicted a steady rise in the number of COPD deaths to the 
third most common cause worldwide by 2020. 54 Most of the projected DALY burden 
will fallon developing countries. 54 In 1990, COPD was ranked as the twelfth most 
common cause of DAL Ys but this is set to rise to fifth by the year 2020. 54 55 
Estimates for the developed world approximate that 400 000 deaths occur yearly in 
first world countries. 6o Data from the United States National Health and Nutrition 
Examination Surveys (NHANES) indicate that the burden of COPD has been 
increasing in the United States for the last few decades, where it is currently the 
fourth leading cause of death.56 Death rates for men have showed signs of stabilising 
recently, but death rates for women appear to be increasing.57 
The lack of data for middle and low income countries is the result of poor routine data 
systems and a paucity of surveys.58 59 A reasonable prediction is that the prevalence 
of COPD will rise as tobacco use increases and populations age, particularly 
amongst women and older people.(j9 Although the accuracy of estimates is 











than that estimated in the WHO report. 59 About 2.7 million deaths from CO PO 
occurred in 2000, an increase of half a million from 1990. Half of the deaths were 
from the Western Pacific region, the majority of these in China.5o 
In 2002, the estimates for Sub-Saharan Africa regional prevalence of mortality and 
morbidity were 65,000 deaths and 668,000 DAL Ys. This was estimated to be 0.3% of 
the regional total DAL YS.60 These estimates seem low, and the methods of collection 
of this ecologic data has been criticised by Halbert et al72 (see Section 2.4) as well as 
by the authors of the Global Burden of Disease Report themselves, emphasising that 
the quality and coverage of these statistics vary greatly. Table 1 presents the WHO 
COPD estimates of COPD while Tables 3 - 5 show the results of population-based 
studies.72 It is thought that the former has underestimated the prevalence of disease 
in Sub -Saharan Africa at 0.34% (see Table 1.). However, one of the reasons for this 
low estimate is that it samples all ages. Firstly, COPD in children and adults under 
the age of 40 is very rare and secondly, the population distribution in Sub-Saharan 
Africa is comprised disproportionately of these very groups. The WHO has used 
expert opinion for these prevalence estimates, which has been shown to differ in 
comparison with evidence based studies, most likely in favour of underestimation in 
this region. 72 
One of the other major problems with the WHO estimates is that they are based on 
vital registration systems. In man  countries, failure to capture all deaths, record the 
correct cause of death and specify underlying cause of death, and other coding 
problems can be substantial and even more so in developing countries. 4760 
Additionally, predicting future trends in disease is difficult. The two methods used 
(risk factor models and extrapolation of past trends) are complex, and based on 
assumptions e.g. that the dose response relationship with a risk factor will remain 
constant into the future. 6o In reality, these relationships are dynamic and vary over 











Table 1: COPD prevalence estimates based on Expert opinion (WHO) 72* 
--------------- -------~--------~---------~----- -.---------------------------------- --- ,~____c~-----.----
Country Prevalence (%) Diagnostic criteria Sample, age Study, year 
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~ Halbert et ai, 2003 
'*Global Burden of Disease Study 
It is estimated that approximately 1 % of the entire global population, and >10% of 
persons over 40 years suffer from COPD126, but this estimate may be misleading 
because of the markedly heterogeneous nature of the world's communities, each 
with a different set of competing risk factors. There appear to be two reasons for the 
increasing prevalence - firstly, a true increase in cases of capo and secondly, as a 
consequence of the successful reduction of premature deaths from infectious and 
cardiovascular disease in developed countries.12G141 The latter increases the 
potential for other degenerative diseases in the survivor population, and constitutes a 
shift in the burden of disease. As a consequence of these two factors, capo is 
projected to move still higher in the rankings of morbidity and mortality in developed 
countries. However, in developing countries other factors may influence increases in 
prevalence such as increased tobacco smoking, poverty and infectious diseases 
such as tuberculosis. Where deaths from infectious diseases are in decline, and 
cigarette smoking and environmental air pollution increases, more capo can be 
expected. 141 On the other hand, reduction in life expectancy resulting from infection 











2.4. Definitions of COPD 
Despite many advances having been made in the terminology and staging of COPD, 
we have yet to derive a meaningful and unifying definition. The various definitions of 
COPD, including the current GOLD definition do not meet the criteria for a definition 
completely. Scadding (1963) asserted that a definition should provide a means by 
which an individual can be said to have a specific disease. 61 A point of departure of 
the modern definitions is the fact that they are descriptive and contain features 
shared by other respiratory conditions and that are not exclusive to COPD, and they 
have many exceptions. 
The definition and classification severity of COPD have an impact upon estimates of 
prevalence and are important in prevalence surveys. These have undergone some 
change over the last decade, and a variety of versions are currently in use. Each has 
its own advantages and limitations, and is used for different purposes, be they 
epidemiological, clinical or pathological. The British Thoracic Society (BTS), the 
National Institute of Clinical Excellence (NICE), the European Respiratory Society 
(ERS) and the American Thoracic Society (ATS) and the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) have all produced classification and staging 
systems that differ from one another, sometimes markedly. 
The most widely used definitions are those from the ATS/ERS in 2004 and GOLD 
guidelines (2005).f32 63 For the purposes of this thesis, the GOLD definition and 
staging criteria have been used, as required by the BOLD protocol (see Chapter 4). 
The definitions and staging of severity in the South African Thoracic Society COPD 
guidelines are based upon and are very similar to the GOLD guidelines. 
COPD is defined by GOLD as "a disease state characterized by airflow limitation that 
is not fully reversible. The airflow limitation is usually both progressive and 
associated with an abnormal inflammatory response of the lungs to noxious particles 
or gases.,,63 According to Scadding's essay on definitions, this can be criticised as not 











Table 2: Classification of severity and Staging of COPD according to the GOLD 
guidelines63 
-~ --~-.---~-----.---"-.. ------.--- ---.--.-.~-----.--------------.-.. ---.-.- .. -.----~--------------------.----------.-.---.----~--
Stage Characteristics 
_ .. __ .. _._._--_._. __ . --... -.-------- _ .. - .. --.-.---~----------.- _. - ._--------_._--_._---_._--
0: At Risk • normal Spirometry 
• chronic symptoms (cough, sputum production) 
I: Mild COPD • FEV1/FVC < 70% 
• FEV1 ;j30%, predicted 
• with or without chronic symptoms (cough, sputum production) 
II: Moderate COPD • FEV l/FVC < 70% 
·50% §EV1 < 80% predicted 
• with or without chronic symptoms (cough, sputum production) 
III: Severe COPD • FEV1/FVC < 70% 
·30% :::;FEV 1 < 50% predicted 
• with or without chronic symptoms (cough, sputum production) 
IV: Very Severe COPD • FEV1/FVC < 70% 
• FEV1 < 30% predicted or FEV1 < 50% predicted plus chronic 
. _____ . __________________ . ____ ._. _____ ~_~2.iE~~()r)'_ fail ur~ ___________________________ . ______ .. _____ . __ ...... _ .... __ ._ 
Classification based on postbronchodilator FEV1 
FEV1 : forced expiratory volume in one second; FVC: forced vital capacity; respiratory failure: arterial 
partial pressure of oxygen (Pa02) less than 8.0 kPa (60 mm Hg) with or without arterial partial pressure 
of C02 (PaC02) greater than 6.7 kPa (50 mm Hg) while breathing air at sea level. 
The GOLD classification of severity and staging is shown in Table 2. The cut-points 
between stages are pragmatic and have not having been clinically validated. 63 Its 
authors also acknowledge that there is an imperfect relationship between symptoms 
and airflow limitation, and that the severity of symptoms (quality of life limitation) and 
its complications are the most significant aspects of the disease. Using the GOLD 
classification system for staging in epidemiological studies is a robust way of 
diagnosing COPD, particularly because it uses postbronchodilator FEV1.
64 The 
choice of a fixed criterion of FEV1/FVC instead of using 70% of the age-predicted 
ratio has been criticised for overdiagnosing GOLD Stage I CO PO and for 
overdiagnosing CO PO in the elderly.55 71 In addition, GOLD stage 0 was found to be 
poorly predictive of progression of disease. The Copenhagen Heart Study found that 
21 % of those with GOLD Stage 0 had progressed to Stage I after 15 years and a 
further 19% without respiratory symptoms now met criteria for GOLD Stage 1. 66 This 
emphasised the unreliability of symptoms i.e. the poor correlation between chronic 
bronchitis and COPD. 
A comparison of the prevalence of GOLD Slage II and higher was made using the 
fixed ratio and the % predicted ratio (from the I\IHAI\IES study), and this was found to 
be very similar. A paper by Celli et al67 (2003) compared the following five criteria for 
definition of COPD and reported that estimates differed by more than 200%, 











1) Self-reported chronic bronchitis or emphysema 
2) FEV1 IFVC < 70% and FEV1 <80% predicted (GOLD Stage II) 
3) FEV1 IFVC below the lower limit of normal 
4) FEV1 IFVC < 88% predicted in males and <89% predicted in females (ERS 
criteria) 
5) FEV1 IFVC <70% (fixed ratio) 
The fixed ratio gave the highest estimates for older subgroups (>50 years), whereas 
the GOLD Stage II criteria produced the lowest estimates of all definitions that 
included spirometry. A case was made for considering the GOLD staging as superior 
to other definitions on the basis of simplicity and accuracy. 57 However, Hardie et al 
criticised this level of accuracy by providing results of 71 asymptomatic older non-
smoking persons. Fifty percent of those over 80 years and 35% of those over 70 
years had a prebronchodilator ratio of <70%, and a third of those over 80 years met 
the criteria for GOLD Stage II despite having had no smoking history or reported 
symptoms.68 However, the GOLD classification can only be applied to 
postbronchodilator measurements69 , and therefore conclusions based on 
prebronchodilator measurements may be inaccurate. Bronchodilators may not make 
a significant difference to GOLD Stage I COPD as both FEV1 and FVC are equally 
affected. GOLD uses a rather arbitrarily defined dose of 400 micrograms of 
salbutamol for bronchodilation, but one might equally argue that two weeks of a trial 
of steroids would be even more convincing at excluding asthma. This is often done in 
a clinical setting to classify cases, but in population studies it is not an option (for 
pragmatic and ethical reasons) and bronchodilators provide some practical attempt at 
addressing reversibility. Using a postbronchodilator ratio will reduce, but not 
eliminate, misclassification of asthma as COPD. For the purposes of epidemiological 
studies, this is an advantage. However, tests such as methacholine or histamine 
challenge are better indicators of AHR. 
Self-reporting of both symptoms and doctor diagnoses have the problem of being 
non-specific and may result in overestimation of disease, and doctor-diagnosed 
disease may lack sensitivity as mild disease is frequently undiagnosed. 113 Language 
also plays a significant role in the interpretation of questions that predict COPD. One 
language may use different words to describe breathlessness or wheeze and yet 
another may describe both symptoms using one word. In addition, questionnaires 











GOLD uses FEV1 to classify severity and this measure is known to correlate poorly 
with quality of life, symptoms, exacerbation frequency and exercise tolerance.71 In 
addition, these FEV1 cut-points were based on expert opinion and not evidence, for 
want of a better solution, and provide an attempt at classifying COPD without taking 
into account other components such as gas exchange derangements, hyperinflation, 
systemic effects 7!, which can only be gathered by clinical examination and 
investigations. Thus the GOLD classification, for the purpose of population surveys is 
easy to apply, but its limitations should be noted. 
2.5. Prevalence of Obstructive Lung Disease from Population studies 
Many population studies of COPD prevalence have been performed with the majority 
in Europe and North America. In 2003, Halbert et al have published a comprehensive 
review of population-based studies. 72 A modified and updated version of information 
in tables from this review is presented in Tables 3 to.S. These list studies of chronic 
bronchitis and COPD worldwide according to survey methods used - spirometry-
based, symptom-based (questionnaire-based) and patient-reported (either physician-












Table 3: COPD prevalence estimates from spirometry-based studies 72 
-- -_._. -. ---~- -----... -.---------------~--~--.-----~--~-----------.--.----~------.-.------~---------- ----- -----------
Prevalence 
f~~L!!!!r}' . ~tLJ_d Y'~~J.~. Pa rtLc i.I~~CI.~~...Q! agn O!!!lc criter@ ... __ §a m pl~!_Cl.9.E!!Y!.!!L___ .. { 't01 
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Viegi et al232 , 
2000*" 
Fukllchi et 
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FEV1 IFVC < 70%, Population-based, 




































.... ~.~.~ _____ .~._ . _ ~ __ .~_Q.r:~ecJlc;t~cJ. __ .. __ ~ ___ ~.~ ... __._~~~_~_. _~_.__~_.__. 
*Copenhagen City Heart Study 
**Po Delta Valley 
***IBERPOC 
**** National Health and Nutrition Examination Survey III (NHANES III) 
t NICE study 











Table 4: COPD prevalence estimates from symptom-based studies (chronic bronchitis) 
n 
Prevalence 
._ ._(;ou~.!!}'_~§tucl.y .... ~~_p_~rticiP.~~t~ __ .DJi!9Il~stic crite!@. ___ .§amj!le, ag~~_.~_._ j~L._ .. _._ 
Australia Cullen et 3331 MRC criteria Busselton 9 (M) 
a181 , 1968 :=21 3 (F) 
Brazil Menezes 120, 1046 MRC criteria Pelotas 7.8 (all) 
2004 ~O 
Brazil Menezes et 1053 MRC criteria Pelotas 12.7 (all) 
a182 , 1994 ~O 17.9 (M) 
9.1 (F) 
Denmark Lange et 12698 Daily phlegm :£ Random, 10.1 (all) 
al73 ,1989* mo for 21 yr Copenhagen 12.5 (M) 
20-90 8.2 (F) 
England Littlejohns et 1444 MRC criteria General practice 16.7 (M) 
al83 84, 1989 group, 40-74 7.1 (F) 
Iceland Magnusson 1175 ATS criteria Icelandic males 7.1, 16.7(M) 
,Gislason85 , born in 1913 and 
1999 1943 (50,80) 
India Qureshi8o, 560 M RC criteria Residents of two 7.7 (all) 
1994 Kashmir villages 7.6 (M) 
:215 7.8 (F) 
India Jindal et 35295 MRC criteria Random, Urban 4.1 (all) 
a1139, 2006 rural, 4 centres 
Nepal Pandel08, 2826 M RC criteria Residents of two 18.3 (all) 
1984 rural 17.6 (M) 
communities :=20 18.9 (F) 
Former Cookson, 9287 MRC criteria Gatooma 1.12 (all) 
Rhodesia Mataka121 , 215 1.2 (M) 
1978 2.8 (F) 
South Ehrlich et 13826 MRC criteria Nationally 2.3 (M) 
Africa af7,2004 representative 2.8 (F) 
Spain Marco 600 ECSC***** criteria Random, 9.2 (IVI) 
Jordan et Guizpuzcoa 
al8o , 1998 40-60 
Sweden Irnell and 41679 Cough :£ mo for Uppsala and 2.1 (all) 
KiviloogB8 , :=2 yr environs 2.7 (M) 
1968 30-64 1.5 (F) 
United Mueller et 609 MRC criteria Glenwood 17 (M) 
States a1 108 ,1971 Springs, 20-69 10 (F) 
Higgins et 4699 Cough and phlegm Tecumseh, MI 17 (M) 
al ,1977** ?3 mo 20-74 6 (F) 
Multiple Menotti et 8122 Three criteria 15 cohorts of 1.2-12.9 (M) 
al9o, 1997*** based on history men ,7 countries 
and symptoms 50-69 
Europe, 16 Cerveri et 17966 M RC criteria 35 selected 3.2 (all) 
countries a191 , centres 3.7 (M) 
.jJ:::gg!j$) __ .~.Q9J..:~=-_. _______ ... __ ... __ .. _._. ____ . ___ . _ ... _ 20-44 _ __ .~~I3JD. _____ . __ ... 
*Copenhagen City Heart Study 
.. * Tecumseh 
*"'Seven Countries Study 
H**ECRHS == European Community Respiratory Health Survey 











Table 5: COPD prevalence estimates from studies of patient-reported diagnosis 72 
.. -..... -.---~----. -.- ... -------~-~--.-. 
Prevalence 
Country Study, year Participants criteria Sample, age (%) 
Canada Chen 8t 7210 Physician Representative 1.8 (M) 
al23o , 2000* diagnosed Canadians, 35-44 3.5 (F) 
Representative 1.5 (M) 
Canadians, 45~54 3.6 (F) 
Representative 5.0 (M) 
Canadians, 55-64 4.5 (F) 
Lacasse et 17626 Physician Representative 5.7 (all) 
al92 , 1999* diagnosed Canadians 6.3(M) 
;:55 5.2 (F) 
England Liltl~ohns et 1444 Patient report Single general 3.9 (M) 
a18:, ~,198£) (chronic practice group 2.1 (F) 
bronchitis) 40-74 
Estonia Meren et 17525 Physician Random, 10.7 (all) 
af3, 2001** diagnosed 3 urban areas 9.3(M) 
(chronic 15~64 11.5 (F) 
bronchitis) 
Finland Pallasaho et 6062 Physician Random, 3.7 (all) 
a194 , 1999*** diagnosed Helsinki, 20-69 
Hong Kong Lai et al95 , 2032 Patient report of Random, 8.0 (aU) 
1995 disease Hong Kong 10.7(M) 
:gO 5.5 (F) 
South Ehrlich et 13826 Physician Nationally 4.2 (M) 




Sweden Lundback et 5698 Physician Non-random 4.1 (aU) 
a196 , 1991 diagnosed Norrbotten 4.7 (M) 
35-36,50--51, and 4.0 (F) 
65-66 
Montnemery 8469 Physician Random, 3:1 (all) 
et a1 97 , 1998 diagnosed Malmohus, 20--59 
United Lebowitz et 3805 Patient report Random, 6.6 (all) 
States a198 , (chronic Anglo-white 
1975'*'" b ronch itis ) households in 
Tucson,AZ 
All ages 
Adams et 63402 Patient report Population-based, 5.4 (all) 
l'l9 (chronic a , non-




H*** National Health Interview Survey 
Prevalence studies in Europe 
From a European perspective, two large population-based studies stand out from the 
rest. The first, the European Community Respiratory Health Survey (ECRHS) 
illustrates the wide variance in population prevalence of chronic bronchitis across 
countries. 91 Performed in 35 centres across 16 countries, 18000 individuals aged 20-
44 years were surveyed. The median prevalence of chronic bronchitis was 3.2%, but 
ranged from 0.7 to 9.7% (see Table 4). A second major observation was that the 
presence of symptoms of chronic bronchitis was found to be unrelated to airflow 











chronic bronchitis is a marker for COPD. 100 Diagnosed asthma, followed by 
symptoms of wheeze and shortness of breath were found to be better predictors of 
airflow obstruction in the ECRHS study, suggesting rather that a variety of lung 
diseases associated with wheezing may be associated with decreased pulmonary 
function. 10o However, in terms of its relevance to COPD, it must be noted that this 
was a relatively young cohort. 
The second major study was the IBERPOC Project (Estudio Epidemiologico de la 
EPOC en Espana), a Spanish epidemiologic study of 4035 persons aged 40 to 69 
years which reported a prevalence of COPD of 14.3% in men and 3.9% in women. 101 
Half of the cases occurred in persons aged 60- 69 years and a quarter in each of age 
groups 40 - 49 and 50 - 59 years. There was a considerable degree of intra-country 
variability between the different sites. One of the limitations of this study was the 
upper age cut-off, which makes comparisons with other studies problematic as most 
do not set an upper age limit. The reported prevalence of symptoms is usually high in 
persons over the age of 70, but diagnostic confusion occurs because of cardiac and 
other co-morbidity. The IBERPOC study reported the prevalence of wheeze as 40%, 
cough as 13.8%, sputum production in 10.7% and exertional dyspnoea in 10.4%, 
with 48% of the population over 40 years reporting any respiratory symptom. 
Similarly another European study also reported high symptom prevalences in mild to 
moderate COPD cases. 102 The ELiROSCOP study, though not a population 
prevalence study, highlighted a considerable degree of underdiagnosis across many 
European countries. 103 
In 2004, Tzanakis et al reported a prevalence of 8.4% in persons aged >35 years in 
Greece.104 This study was restricted to smokers over >100 lifetime cigarettes who 
had no other current/past other pulmonary disease or comorbid conditions that 
prevented either spirometry from being performed or the use of a bronchodilator, and 
accordingly cannot be viewed as a prevalence estimate. Only smokers were 
sampled, on the assumption that COPD is rare in never-smoking Greek adults, just 
as it is in other European countries. 101 However, recent data from the BOLD study in 
Austria suggest that COPD in never smoking European adults may not be as rare as 











Prevalence studies in the United States 
As in Europe, the prevalence of symptoms of COPD varies widely in different states 
and between men and women. Three early studies 106 107108 summarised below, used 
different definitions for COPD, and in these studies, attempts were made to separate 
persons with CO PO from those with asthma. 
A 1962 study of Berlin, New Hampshire by Ferris et al used the term chronic non-
specific respiratory diseases and reported prevalence of 15.4 to 39.1 % in men and 
15.2 to 20.9% in women. IOg 106 A second outcome, irreversible obstructive disease 
(FEV1 <60%) was present in 3.1 to 21.7% in men and 6.2 to 13.9% in women. 106 
Among men, occupational exposures were considered to have been an important 
risk factor in this study setting. 109 
In 1967, a study in Glenwood Springs, Colorado that employed a definition that 
included FEV1/FVC ratio of <60% with respiratory symptoms of cough, sputum 
expectoration, wheeze or dyspnoea as indicating the presence of COPD, and 
reported a prevalence of CO PO of 13% and of chronic bronchitis of 17% in men, and 
4% and 10% respectively in women. 110 A follow-up study seven years later by Petty 
et al found that those with spirometric abnormalities had showed worsening of these 
abnormalities, whereas those with symptoms alone had not developed spirometric 
abnormalities in the intervening years.111 This result is consistent with results from 
the paper by Peto et al that related airflow limitation but not mucous hypersecretion 
to mortality from chronic lung disease.112 These were also some of the first findings 
to provide evidence for the hypothesis that chronic bronchitis alone without airflow 
limitation is not related to the development of COPD. Of note, there were no 
identifiable sources of industrial or ambient air pollution in the study area. 
In 1984, a third study from Tecumseh, Michigan was published which reported a 
prevalence of chronic bronchitis and/or obstructive airways disease of 14% in men 
and 8% in women, using a definition of FEV1/FVC ratio of <80% and FEV1 <65% 
predicted. 113 There were also no other identifiable risk factors in Tecumseh at the 
time, apart from tobacco smoking. 
Subsequently, two large cohort studies have tracked CO PO prevalence in the United 
States - the l\Jational Health and l\Jutrition Examination Survey (NHANES III) and the 
Lung Health Study.51 114 The NHANES III study reported prevalences ranging from 











prevalence of 13.9% in adults, most with mild to moderate disease. The prevalence 
of mild or moderate COPD in the <55 year age group was lower, which may be 
attributed to the decline in smoking rates in the US. Reversibility testing or tests of 
AHR were not performed in this study. However, the overall prevalence of COPD 
appeared to be increasing. 
Stang et al (2000) have used smoking rates in a model to estimate COPD prevalence 
in countries where population-based spirometric studies have not been performed, 
and have suggested that the proportion of cases of COPD diagnosed in the U.S. is 
between 14 and 46% of the actual number of COPD cases in the population, 
suggesting that even in developed economies, underdiagnosis is common. 115 This 
proportion is assumed to be even lower in developing countries, where under 
recognition and misdiagnosis is a considerable problem. 
Another first world example: Japan 
The prevalence of CO PO also varies amongst first world countries. Early reports from 
Japan suggested a very low population prevalence rate of 0.17%116 and in 1999 
national prevalence was reported as 0.3%.117 These figures gave rise to postulations 
that the low prevalence was due to a long delay in the uptake of tobacco smoking 
after World War 2, for socioeconomic and cultural reasons. The increase in smoking 
accompanied economic growth from 1955 to 1973.116 118 The findings of the Nippon 
COPD Epidemiology (NICE) study in which the prevalence of COPD was found to be 
10.9% in persons over the age of 40 using the GOLD criteria. 119 This casts doubt 
upon the earlier figures, suggesting that there could have been methodological 
issues in the earlier studies, and has gone some way to countering the suggestion 
that the Japanese are genetically or constitutionally resistant to the effects of 
smoking. 116 
Studies from developing countries 
There are few studies from developing countries. In contrast to developed countries, 
developing country smoking rates remain high and in some cases are even rising, 
particularly amongst women. This suggests that prevalence in these countries will 
increase, The effect of cigarette smoking in these countries is compounded by 
exposures to smoke from biomass fuels and outdoor air pollution. 
Non-standardised study methods and definitions of COPD make comparisons of 











Latinoamericano de Investigacion en Obstruccion Pulmonar) was unique in that it is 
the only published population-based cross sectional study of COPD examining five 
major Latin American cities (see Table 3).77 PLATINO, being a precursor to the 
BOLD study, used standardised methods and quality control measures to ensure 
comparability across sites. Prevalence of COPD, defined as a postbronchodilator 
FEV1/FVC ratio of <70%, ranged from 7.8% in Mexico City to 19.7% in Montevideo. 77 
Only one other prevalence estimate from Pelotas, Brazil reported a prevalence of 
15.8% in 2004. 120 
Prior to the work reported in this thesis, the only population-based study from Africa 
was performed in Zimbabwe (former Rhodesia). In this study, the symptom-based 
prevalence of chronic bronchitis was 1.12%, using the I\IIRC definition.121 Chaulet 
(1989) reviewed prevalence surveys of chronic bronchitis in occupational groups and 
hospital inpatient groups from some African countries, and estimated that "10 to 20% 
of the adult population had symptoms of chronic bronchitis". 122 
2.6. Risk Factors for Adult Obstructive Lung Disease 
2.6.1. Introduction 
Tobacco smoking and age are the two risk factors for CO PO for which most evidence 
exists. 123 m 101 125 However, evidence that has emerged over the last two decades 
has shifted the focus of COPD research toward examining other factors that may 
playa role. There is epidemiological evidence that a significant proportion of COPD 
worldwide is attributable to ri k factors other than tobacco. 126 
Both host and environmental exposures playa role in the aetiology of COPD. The 
NHLBIIWHO/GOLD definition of CO PO makes reference to exposure to "noxious 
particles or gases".63 Non-smoking exposures are increasingly well recognised, 
especially host factors such as airway hyperresponsiveness (AHR), occupational 
exposures, outdoor and indoor air pollution, infections and low socioeconomic status. 
Genetic predisposition is also likely to playa role, but research to date is still in 
progress 127 Table 6 summarises the current state of knowledge of risk factors for 
COPD, initially tabulated by Siafakas et al 123 and subsequently by Viegi 138 , which has 











Table 6: Known risk factors for COPD123 138 







Certain occupational exposures 
Outdoor air Pollution 
Indoor air pollution (Biomass fuel) 
Low socioeconomic status 
ETS in childhood 





Dietary deficiency of vitamin C 
Poor glycaemic control 
'Immunoglobulin E ; **Immunoglobulin A 
2.6.2. Brief reviews of individual risk factors 
2.6.2.1. Tobacco smoking 
Early studies 
Host factors 
01 -antitypsin deficiency 
Low birth weight 




Atopy (high IgE*) 
Genetic predisposition 
Blood group A 
IgA ** nonsecretor 
Tobacco smoking is the most well known risk factor for COPD, particularly in 
developed countries. After Fletcher's sentinel work described above 14, evidence for 
smoking as a risk factor for COPD has been described in many studies.128 101 113 129 
UO Most have been cross sectional in design, but a few provide longitudinal data. 
One of the most important studies is that of Peto describing the consequences of 
tobacco smoking in a 40 year follow-up of British doctors. 131 Smokers were found to 
have a seven fold higher mortality from COPD than non-smokers. A clear 'dose 
response' relationship was described with increasing number of cigarettes smoked 
per day and increasing mortality, with heavy smokers of >25 cigarettes per day 
having a 21 fold increased risk. Earlier results from this study (and other studies) had 
underestimated the risk associated with tobacco smoking, presumably owing to the 
short duration of follow-up. To quote Doll et al - referring to mortality from all tobacco-
related disease: 
"It now seems that about half of all regular cigarette smokers will eventually 











A further analysis of this study showed that tobacco smoking increased the risk of 
dying from COPD almost 13 fold. 132 
Italian studies with diffusing capacity 
Studies from the Po Delta and Northern and central Italy showed a higher prevalence 
of chronic cough and sputum in men and women who smoked, compared to their 
non-smoking counterparts. 133 134 A notable difference in one of these studies was the 
use of diffusing capacity in a population-based survey. Those who smoked 10 
cigarettes per day were almost twice as likely to have an abnormal diffusing capacity 
and a decrease in diffusing capacity was noted with cumulative cigarette use even in 
healthy smokers. 134 1:>5 Another population study to use this measurement was a 
recent Australian work by Matheson et al (2005) examining occupational 
exposures. 161 (See section 2.7.2.2.) 
Tobacco in developing countries: China and India. 
The focus of tobacco use has shifted to developing countries, where it competes with 
other risk factors such as biomass fuel exposure and infectious diseases like 
tuberculosis. Tobacco companies have rapidly expanded their business in low and 
middle income developing countries which have among the highest rates of smoking 
in the world. Knowledge and understanding of the effects of tobacco smoking 
amongst laypersons in developing countries has been patchy and slow to develop. 
This is due to the power of political and economic entanglements that tobacco 
companies have with some governments and the strength of their advertising 
campaigns and sponsorship of sporting events and popular culture. 
There are three recent large population-based prevalence surveys from developing 
countries. In the first, a prospective cohort study from China, a country with one of 
the highest smoking prevalences in the world, a strong relationship between all 
cause mortality and tobacco smoking was demonstrated, particularly among men (56 
- 61 %).1:>6 137 Another longitudinal cohort study from Shanghai reported a 2.5 fold 
increased risk of death in male smokers after adjustment, and this study confirmed 
the strong positive dose response.137 138 
Finally, a recent Indian study reported ever-smoking rates of 28.5 % in men and 
2.1 % in women, most smoking bidi. 139 , This highlights the socio-cultural differences 
between countries (developing vs. developed) that result in low smoking rates among 











age, low socioeconomic status and rural residence were associated with higher 
smoking rates. 139 Compared to a developed country like Sweden, where smoking 
rates in men and women are almost equal140, this gender disparity is striking. The 
population attributable fraction (PAF) for smoking-related CO PO is a moving target 
owing to rising smoking rates and heterogeneous exposure patterns in South Africa 
and in many developing countries. 
Establishing the Propottion of smokers who will develop COPO. 
A widely quoted figure for the proportion of regular smokers that develop COPO is 
15%.141 142 However the basis for this estimate is uncertain and has been 
questioned.143 It can be argued that providing a single number is misleading, as 
prevalence is determined by definition of COPO, age-group, smoking history (pack 
years) and a number of other factors described in this chapter. The proportion that 
develop symptomatic disease (Stage II and higher) is probably the most important 
estimate to establish, although in view of the fact that early smoking cessation is the 
most effective intervention, the diagnosis of even Stage I disease is important. There 
are few studies that provide this information on the risk of developing COPO. 
Longitudinal studies are necessary for this purpose. In one study of longitudinal 
design, accelerated decline in lung function of two to five times that of the normal rate 
of 15 - 30ml/year has been reported in 15% of whites and 5% of Asians who 
smoke. 141 
In the cross sectional I\JHANES III study of persons aged 18 and older, 12.5% of 
current smokers, 9.4% of ex smokers, 3.1 % of cigar smokers and 5.8% of never 
smokers were found to have COPO. Lundback et al (2003) challenged these 
estimates and suggested that "not 15 but 50% of smokers" will develop COPD.144 
Reporting results from the OLIN (Obstructive Lung Disease in Northern Sweden) 
cohort study, the prevalence of COPD according to the GOLO criteria was fifty 
percent in smokers aged 76-77 years, illustrating the point that prevalence in a cohort 
of smokers is highly dependent on age, and that if they lived long enough and had 
smoked sufficiently, a majority would develop symptomatic COPD. However, an 
important confounding factor in Lundback's calculations is the unreliability of the 
GOLD diagnostic criteria in the elderly, and the FEV1/FVC ratio of <70% that defines 











Environmental tobacco smoke (ETS) 
A paper by Svanes et al from the ECRHS assessed parental smoking in childhood 
and the risk of subsequent adult lung disease. 145 Despite the comparatively young 
age of the cohort of 20-44 years, there was a statistically significant association with 
both doctor-diagnosed chronic bronchitis (OR 1.3; CI: 1.1 - 1.6). A reduced 
FEV1/FVC ratio was demonstrated if both parents smoked, and an association of 
borderline significance if one parent smoked. Another paper from the same study by 
Radon et ai, examined workplace and home passive smoke exposure in German 
adults, reporting an adjusted risk of 1.9 for chronic bronchitis, which increased to a 3 
fold risk with daily exposure on >8 hours a day. Likewise the risk of both asthma and 
wheezing doubled with increased exposure.146 A third paper by Janssen et al found 
ETS (particularly in the workplace) to be associated with an increased risk of all 
respiratory symptoms (OR=1.3) and increased bronchial hyperresponsiveness. 141 
A large sample size is necessary to show associations with ETS. A recent Indian 
study by Jindal et ai, of over 35000 participants aged :i35 years reported an odds 
ratio of 1.4 for chronic bronchitis among non-smokers with ETS exposure. In addition, 
a cornbination of ETS and exposure to solid fuel combustion revealed a stronger 
association. 148 
Evidence from a meta-analysis by Strachan and Cook (1998) has confirmed that the 
maternal smoking is associated with a higher prevalence of reported wheeze in 
children. 149 Young children tend to spend more time with their mother and this is 
thought to be an important risk factor. Whether childhood ETS exposure is a risk 
factor for COPD later in life is not known. This is of particular relevance in the thesis 
study area (Ravensmead and Uitsig) as historically there is a high prevalence of 
women smokers in these areas. 
2.6.2.2. Occupational Exposures 
One in five cases of COPD (20%) is attributable to occupational exposures.150 Many 
different occupational exposures have been implicated in the aetiology of both 
chronic bronchitis and COPD, such as mineral dusts, metals, smoke from biomass 
sources, organic dusts etc. 
Overall, the effects of occupational exposures are thought to be less strong than that 
of smoking. However, recent evidence has shown that this may not be true of all 











Fletcher's associations with smoking may be possible, with a subgroup of persons 
having a large decline. 151 Many studies have been performed in miners and 
pneumoconioses have been recognised as causing not only interstitial disease, but 
to have a major obstructive component. 
Early studies 
Early publications related specific industry exposures to respiratory symptoms and 
some to measures of lung function. The fact that only small effects were found by 
these studies could be attributed to the healthy worker bias, which should not be 
underestimated. Becklake published a review in 1985 suggesting that there was a 
causal association between occupational dust exposure and loss of lung function 
evidenced by longitudinal studies of industrial populations. 152 A particularly important 
longitudinal study in support of this conclusion was by Kauffmann et al who showed 
an accelerated rate of decline in FEV1 in dust exposed Parisian factory workers. 153 
This study also found that exposure to dust, heat or certain gases alone or in 
combination caused an accelerated decline in FEV1 in a dose related way. Greater 
effects were found in those with low occupational status (considered an indicator of 
low socioeconomic status) which was a risk factor independent of occupational 
exposure. 153 
The Cracow study was a longitudinal thirteen year follow-up that showed a 
significantly increased rate of decline in FEV1 with exposure to occupational dusts in 
men and with occupational exposure to variable temperatures in women. 154 Similarly, 
the Zutphen study followed up 878 men for 25 years and found an increased 
incidence density ratio of chronic respiratory symptoms or diagnoses in blue collar 
workers. Using a job exposure matrix, heavy metals, mineral dust and adhesives 
were associated with increased incidence of chronic non-specific lung disease. 155 
Another population-based study of occupational exposures and respiratory 
symptoms by Korn et al (1987) showed a positive association of occupational dust or 
gas/fume exposure with chronic cough, chronic phlegm, persistent wheeze and 
breathlessness with odds ratios ranging from 1.3 to 1.6.156 Occupational dust was 
also associated with a 1.5 times increased risk of COPD, defined as an FEV1/FVC 
ratio of less than 0.6. This was a large population-based survey (8515 persons), as 
opposed to an industrial population, and it used a definition of COPD that would 












In 2003, The American Thoracic Society published a comprehensive review of 
studies of occupational exposures and COPD calculating a population attributable 
risk of 14 - 19%.157 The main epidemiologic findings from this review were: 
1. Most studies showed an annual decline in FEV1 of 7-8 ml per year, after adjusting 
for smoking and age. 
2. The effects of dust alone may be greater than that of tobacco smoking alone, in 
those workers who are heavily exposed. 
3. In coal and hard rock miners, a relationship between dust exposure and the 
degree of emphysema was found, independent of tobacco smoking. 
ECRHS- population sample 
The European Community Respiratory Health Survey (ECRHS) group reported that 
occupational exposure to vapours, dust, gases or fumes was associated with chronic 
bronchitis among current smokers only (prevalence ratio of 1.2 - 1.7). Agricultural 
work, textile, paper, wood, chemical and food processing were associated with 
chronic bronchitis 158, but there was no clear association of self-reported occupational 
exposure with lung function 158, in contrast to other studies. The lack of association 
with lung function, most probably due to a healthy worker bias, is likely to be very 
important in this young population. A strength of this study is that it combined results 
from 14 European industrialised countries and thus had a large sample size of 13243 
with some level of heterogeneity. Additionally it studied asthmatics and non 
asthmatics, smokers, ex and non smokers separately, which could be viewed as 
either a strength or a weakness of the study analysis. This was done on the basis of 
controlling for 'residual confounding' from smoking in unstratified analyses. 
NHANES population sample 
Two papers by Hnizdo et al 159 160 (2004, 2002) from the United States NHANES III, 
involving a cohort of approximately 9500 persons aged 30-75 years, examined the 
risk of COPD associated with employment. The first paper reported that the 
estimated population attributable fraction (PAF) for COPD attributable to occupational 
exposures was 19.2% overall and 31.1 % among never smokers; and implicated 
various jobs in armed forces, rubber, plastics and leather manufacturing, utilities, 
textile mill manufacturing, repair services and gas stations, transportation and 











The second paper analysed the difference in the fraction of airflow obstruction cases 
associated with work, for three ethnic groups. The PAF was 22.2% for Caucasians, 
23.4% for African Americans and 49% for Mexican Americans. 16o Mexican Americans 
are overrepresented in construction and agriculture which are two broad occupations 
that are associated with heavy dust exposure - different job predilections accounting 
for the difference in ethnic group prevalence. 151 Other confounders such as 
socioeconomic differences, smoking and age were adjusted for in the analyses. It 
should be noted that these two papers used different definitions for COPD - the 
former classified COPD as FEV1/FVC <70% and FEV1 <80%, while the latter paper 
used a FEV1/FVC ratio of <75% and FEV1 of <80%. Using different definitions of 
COPD make comparisons between these two studies and with other COPD studies 
slightly inaccurate. However, the public health message is the demonstration of 
consistently high PAFs for work-associated COPD. 
Australian population sample 
A well-designed population based study among 1232 adults aged 25-70 years in 
Melbourne, Australia used a job exposure matrix (rather than a question on 
exposure), and detailed information on exposures was collected on work-history 
calendars. Symptoms and lung function were analysed and diffusing capacity was 
used to define COPD. For biological dusts, there was a 3 fold increased risk for 
chronic bronchitis and emphysema and 2.7 for COPD; the risks being higher in 
women than men. 161 One major drawback of this study was the poor response rate of 
42%, which may limit the generalisation of its conclusions. 
Spanish community with duration of exposure 
A Catalonian study of predominantly textile industry exposures showed a relationship 
with symptoms of chronic cough, sputum and wheeze.162 Those exposed to more 
than 15 years of dusts, gases or fumes had lower lung function than non exposed 
persons (decrease in FEV1 of 80ml; decrease in FEV1/FVC ratio of 1.7%). The 
measurement of duration of exposure was an important feature of this study 
distinguishing it from previous studies that reported only whether participants were 
ever exposed or not. 
Deve/oping country example: China - and interaction with tobacco smoking 
A recent study from Southern China confirms the risk for COPD in coke oven 
workers. 163 A dose-dependent relationship was found between lung function and 











emissions. The odds ratio for COPD was 5.8 (95% CI: 3.13 - 10.76) for high 
cumulative exposure. The corresponding odds ratio for chronic cough and phlegm in 
this high exposure group was 3.1 (CI: 1.91 - 5.03). Even in the non smokers, a dose-
response with odds ratios ranging from 3 to 6 was found. The highest exposure 
groups for both cigarette smoking and emissions had a 58 times increased risk of 
COPD compared to non exposed non-smokers. There is thus a significant interaction 
between smoking and coke oven emission exposure. This study is in keeping with 
another study on soft coal/anthracite exposure in the home, which was also 
associated with a high risk of COPD (OR 4.4).163 Apart from the expected exposure-
response gradient, an important finding was that cigarette smoking was shown to 
significantly interact with coke oven emission exposure. 
Gene-environment interactions of occupational exposures and alpha 1 antitrypsin 
deficiency have also been described by Mayer et al (2000).164 The major risk factor 
for CO PO apart from the gene is tobacco smoking and this study identified 
occupational exposures as a significant independent risk factor in individuals with the 
deficiency. 
Many of the studies on the relationship between occupational exposure and 
obstructive lung disease rely on self-reporting of ever being exposed to "vapours 
dusts, gases or fumes". As this is a crude measurement of occupational exposure, 
one would expect that studies would be biased to the nUll, particularly when studying 
a heterogeneous, complex disease like COPD. 
Occupational asthma, as it is a separate entity, is discussed briefly in Chapter 3. 
2.6.2.3. Cannabis 
Cannabis is classified as an illegal drug in most countries. In developed countries 
such as the UK, a recent media focus has made cannabis the focus of a political and 
public debate surrounding its reclassification. The adverse effects of cannabis 
smoking are numerous and probably underestimated - such as cardiovascular 
vasospastic effects, potential carcinogenic effects and the well-known neurologic 
effects 165 but comment here will be limited to the association with obstructive lung 
disease only. 
An early study of the effects of cannabis on the lung performed on post mortem 
specimens of the lungs of cannabis smokers' revealed evidence of histopathologic 











pigmented monocytes, and monocytic and lymphocytic interstitial infiltrations, 
pointing to an association with respiratory disease. 166 
In 2002, the British Lung Foundation published a review of the impact of cannabis 
smoking on respiratory health, and cited that 3-4 cannabis cigarettes a day were 
associated with the same evidence of acute and chronic bronchitis and the same 
degree of damage to the bronchial mucosa as 20 or more cigarettes per day.167 
Another finding was that longitudinal studies carried out in the 1960's and '70's may 
not be indicative of the effects of cannabis smoked currently, because a modern 
"joint" may contain as much as 300mg of tetrahydrocannabinol (THC) compared to 
10mg in the 1960'S.168 169 
As with any material that is smoked, chronic cannabis smoking produces 
bronchitis.17o There is evidence from many studies that smoking cannabis is 
associated with an increased prevalence of respiratory symptoms such as chronic 
cough and sputum production, wheeze, acute bronchitis and chronic bronchitis. 
Population studies 
To date, only four published studies have assessed the respiratory effects of 
cannabis at a population level - the Los Angeles, Tucson, Dunedin and NHAf\IES 
cohorts.171 172 173 174 
In 1991, Sherrill et al analysed data on "non-tobacco cigarettes" from four 
consecutive surveys of the Tucson longitudinal study in Arizona, which spanned a six 
year period with 1802 participants aged 15 - 60 years. 171 They found significant 
associations with wheeze (OR = 2.0), chronic cough (OR = 1.7) and chronic sputum 
(OR = 1.5), after adjusting for tobacco smoking. The participants showed no 
immediate decrease in symptoms after stopping smoking. Additionally, a reduction in 
FEV1, Vmax50 and FEV1 IFVC occurred a year or more after reporting non- tobacco 
smoking. Despite a low level of average consumption of less than one non- tobacco 
cigarette per day, it is notable that both respiratory symptoms and pulmonary function 
were affected. This cohort had been studied in 1987 by Bloom et ai, and the 
important finding then was that non tobacco smoking alone had a larger effect on 
respiratory function than tobacco smoking alone in adults aged less than 40 years of 
age. 175 The study showed a small significant decrement in FEV1 that was twice that 











Taylor et al (2000) studied 943 young adults in Dunedin New Zealand (aged 21 
years) and found that cannabis smokers reported more wheezing, exertional 
dyspnoea, night waking, chest tightness and early morning sputum production when 
compared to non smokers, after controlling for tobacco use. 173 The prevalence of 
these symptoms was found to be similar to persons smoking 1 - 10 tobacco 
cigarettes per day. Despite this being a young cohort, the proportion of cannabis 
smokers with an FEV1/FVC ratio of <80% was significantly greater than that of non 
smokers (36% vs. 20%, p=0.04). Arguably, the effects of cannabis on respiratory 
function would only be expected to be evident after longer exposure, and at a later 
age, but these findings suggest that even with a relatively short duration of cannabis 
exposure, decline in lung function and presence of symptoms are significant. 
However, Tashkin et al (1997) published data from a Los Angeles study of heavy 
cannabis-only smokers (>3 joints per day) and found that there was no evidence of 
an accelerated decline in FEV1 with age in comparison with tobacco smoking. In 
addition, this study contradicted the other studies by noting that tobacco and 
cannabis did not appear to have additive effects on the lung.172 In support of the 
argument that cannabis is not associated with COPD, diffusing capacity for carbon 
monoxide (DLGO - which is usually a sensitive indicator for emphysema) was not 
reduced in the regular cannabis smokers. 181 Limitations of this study include that it 
had a small number of participants who were also were relatively young (mean age 
of 33 years). 
In this study, airways hyper-responsiveness (AHR) to methacholine was present in 
23.3% of cannabis only smokers, 29.4% of tobacco smokers and 37.3% of mixed 
cannabis/tobacco smokers in comparison with 17.2% of non smokers. 176 Although 
the first two groups appear to have a higher prevalence AHR than non smokers, this 
difference was not significant, but mixed smoking was significant with AHR being 
more than twice that in non smokers (p<0.01) 
The t\lHAt\lES III was the first study providing evidence of the respiratory effects of 
cannabis in a large nationally representative sample. 174 Cannabis was found to be 
associated with chronic bronchitis, coughing on most days, sputum production, 
wheezing and chest sounds without a cold. A limitation of this study is that no 
information was collected regarding the frequency and amount used per day, the 
number of years of use or the modality of use (smoking vs. ingestion). Therefore 











sample was restricted to persons aged 20 - 59 years of age, not allowing for analysis 
of the longer-term effects of cannabis in persons over 60 years, the age group at 
which COPD is most prevalent. Interestingly, there have been no studies assessing 
the effect of cannabis in persons over the age of 60. If we liken cannabis to tobacco 
smoking, a latent period between the onset of smoking and the development of lung 
damage is to be expected. 177 
Some studies have implicated cannabis in the aetiology of COPD, and other studies 
are contradictory, suggesting that further research is necessary to provide more 
conclusive evidence. Another paper by Taylor et al (2002) from the Dunedin birth 
cohort found a marginally significant dose response relationship of cumulative 
cannabis use on FEV1/FVC (p<0.09), after adjusting for tobacco use, age and weight. 
A limitation, which is also a strength of this study, is that it again focussed on a young 
population, where one would not expect to find effects, but actually found that the 
effect of smoking cannabis in youth is not negligible and young cannabis smokers 
(particularly heavy smokers) were at a greater risk than previously supposed. 178 A 
more sceptical interpretation might be that such an "unlikely" result was more 
probably the result of residual confounding and that a smaller effect would be more 
plausible. Another notable point was that cannabis and tobacco smoking acted 
additively to influence FEV1/FVC. There was no evidence of an interaction between 
the two exposures. Cannabis was both an independent and an additive risk factor for 
obstructive lung disease. 
The percentage of cannabis smokers that develop COPD is not known.172 179 As 
mentioned previously, the presence of chronic bronchitis does not predict the 
development of airflow obstruction. A significant challenge in answering this question 
is the difficulty in quantifying exposures, which in turn makes it difficult to perform 
dose-response analyses. Quantification is hampered by the relatively greater number 
of tobacco cigarettes that most cannabis users smoke, and the varied methods of 
smoking cannabis. Issues include different sizes of cigarettes or pipe volumes, the 
tendency for joints to be shared, unreliable self reporting, varying puff volumes, 
differing retention times, filtering etc.172 
In summary, although there is strong evidence to suggest that cannabis smoking is 
associated with chronic bronchitis and upper airway pathology, its association with 











Bullous lung disease 
Cannabis has also been linked to the development of bullous lung disease, but 
evidence for this association appears to be lacking, and has recently been 
challenged. It is largely based on a report of only four cases.177 180 181 182 Cannabis 
use has not been definitively linked to mortality from lung disease. 183 
Underreporting and concomitant tobacco use 
An important issue in the quantification of cannabis use is underreporting. This may 
cause a significant bias in countries where cannabis is illegal, and reduce the 
strength of the signal in studies, suggesting that study results may be a conservative 
estimate of the true effects of cannabis on respiratory health. 174 
It has also been reported that most users of cannabis also smoke tobacco, making it 
difficult to assess individual risks.177 However, multivariable analysis should at least 
in part account for this, leaving misclassification as the main concern rather than 
residual confounding. 
Infections and TB 
Cannabis has been shown to reduce the generation of proinflammatory cytokines 
including TI\JF-alpha and granulocyte macrophage-colony stimulating factor (GM-
CSF) as well as to impair the production of nitric oxide by alveolar macrophages. In 
theory this might impair host defences against lung pathogens, reduce immune 
function and predispose to the carcinogenesis and opportunistic infections.184 
These mechanisms could theoretically result in increased susceptibility to infections 
such as tuberculosis. Apart from one case report of chronic cannabis smoking 
leading to necrotising pulmonary granulomata as a result of possible fungal 
contamination of cannabis, no associations between cannabis and respiratory 
infections including tuberculosis have been confirmed. 185 However, the practice of 
sharing joints and other smoking appliances (e.g. pipes) might put smokers at some 
risk of cross-infection if shared with persons with TB.186 This point may be of 
importance in this thesis study area, because social activities such as drinking in 
informal taverns (known as shebeens) have been shown to be associated with the 













Previous pulmonary tuberculosis (TB) has been recognised as a risk factor for the 
development of obstructive lung disease, but whether lung function impairment 
caused by this disease should be included in the definition of capo is uncertain. As 
mentioned above, the GOLD definition of capo refers to inhaling of "noxious 
particles or gases".63 
The exact mechanisms leading to airflow obstruction in patients with tuberculosis are 
not known, but are likely to include bronchial and peribronchial granulomas and 
fibrosis in the early recovery stages, with bronchiectasis and cystic changes in its 
more advanced cases. Clearly the latter can be distinguished, both radiologically and 
pathophysiologically, from capo, but to exclude tuberculosis per se, is inconsistent 
since other infections are not excluded and they are likely to play a role. For 
example, a latent viral aetiology for the development of capo has been proposed by 
Hogg (2001 )188 and recurrent infections are thought to be involved in its progression. 
In high TB prevalence areas, a significant proportion of the general population 
provide a history of TB infection. Are all to be excluded from the diagnosis of COPD? 
This and related questions need to be addressed. 
Evidence of airflow obstruction in patients with TB. 
Several studies have shown an association of pulmonary tuberculosis with 
obstructive lung disease at the time of diagnosis, during and after treatment. 189 190 1»1 
192193 Ahn et al (1976) found that 57.5% of patients with mycobacterium tuberculosis 
infection had an FEV1/FVC ratio of <70% and that worse lung function was 
associated with a greater extent of disease. H)4 A South African study by PI it et al 
(1998) reported that after treatment 54% had improvement in pulmonary function, 
28% had obstruction and 24% restriction post treatment. 195 The extent of pulmonary 
parenchymal involvement on pre-treatment chest radiography measured by a 
radiographic score was significantly associated with impairment of FEV1 (% 
predicted). 
It is interesting that other studies (including Plit et al) could not show a significant 
association between smoking and obstruction in TB patients. 195 Plit et al suggested 
that it was probable that the effect of inflammation from TB predominates over the 
slowly evolving effects of smoking. 195 It seems that tuberculous inflammation most 
likely occurs relatively rapidly and has greater potential for airway damage in a 











pulmonary tuberculosis. However, one should note that most studies have been 
performed in hospital patients, who are expected to be a more severe or complicated 
group. This could bias the characterisation of airflow obstruction. Most patients with 
pulmonary TB are treated as outpatients and population level data would include the 
full range of severity, from mild to severe. It would be useful to examine the 
association of obstruction (and restriction) with pulmonary TB at this level. 
However classified, a large proportion of persons with a history of pulmonary 
tuberculosis have impaired lung function - obstruction or restriction. 193 Longitudinal 
studies have shown a decrease in lung function follow up. Vargha (1983)196 found 
one group (60% of cases) to have obstruction and another group (40% of cases) to 
have no obstruction at discharge after treatment for pulmonary tuberculosis. At fifteen 
year follow-up, a decrease in FVC of 54ml per year occurred in those who had 
obstruction at discharge and a decrease of 28ml per year in those who were not 
obstructed at discharge, and suggesting that some patients had an ongoing 
obstructive process and some did not. There was no significant difference in loss of 
FEV1 in the two groups (35m I and 29ml in obstructed and non obstructed groups 
respectively). One can draw a parallel with tobacco exposure, where some smokers 
have rapidly deteriorating lung function with smoking over time and some do not, 
following different courses. The course of disease can be postulated to be dependent 
on host factors such as pre-existing/precipitated AHR and/or environmental factors 
such as the strain of TB. 
Of relevance to the study site of this thesis, a study from Cape Town, South Africa by 
Willcox and Fergusen (1989) found evidence of obstructive lung disease in 68% of 
patients treated for TB sixteen years before.197 In keeping with the findings by other 
authors, an inverse relationship was found between FEV1 and extent of disease on 
the original chest radiograph. 
Only one longitudinal study in an occupational cohort of South African gold miners 
has compared pre TB and post TB lung functions. This study adjusted for both 
silicosis and smoking and found that 18.4% of miners had an FEV1 <80% predicted 
after one episode of pulmonary tuberculosis. 193 This percentage rose to 27% after 
two episodes, and 35.2% after three or more episodes of TB.198 The corresponding 
decrease in FEV1 was 153ml, 326ml and 410ml respectively with proportional 
reductions in FVC. Miners who had an episode of TB had a 40ml per year greater 











at follow up, compared to miners who did not have TB. Of note, the overall 
assessment was that the defect caused by TB was restrictive in nature. The risk of 
having restrictive impairment was ten fold greater than in those without TB, but there 
was no increased risk of obstructive lung disease, a finding that is at odds with other 
studies. 193 These results could possibly be biased by quality control of spirometry as 
poor quality spirometry can result in a false "restrictive" pattern. 
A hospital-based study from Indonesia showed that even patients with mild 
tuberculosis may develop significant airway obstruction.59 199 Other smaller studies 
suggest that active tuberculosis is associated with bronchial hyperreactivit/oo , but 
whether this phenomenon persists is not known. In addition, tobacco smoking may 
play an important role as a confounder; because it has been identified as a risk factor 
for both tuberculosis infection and CO PO (see Chapter 3).59 Immune function can be 
corn promised by many factors, including tobacco smoking, alcohol abuse, poor 
nutrition201 and potentially even cannabis smoking, which may play a role in 
increasing the risk of infection and activation of TB. Overall, age, cumulative tobacco 
exposure and the extent of initial tuberculous disease are factors that contribute to 
the severity of airflow obstruction in patients who have been treated for pulmonary 
tuberculosis. 59 190 192 To date, there appear to be no published studies that examine 
tuberculosis as a risk factor for COPD at the population level. 
2.6.2.5. Air pollution 
2.6.2.5.1. Indoor Air Pollution 
In many countries, most people spend over three quarters of their time indoors202 and 
this exposure to indoor air pollutants is of concern regarding the development of lung 
disease. Indoor pollutants of note are nitrogen dioxide, sulphur dioxide, particulates, 
tobacco smoke, asbestos and volatile organic compounds202 among others, of which 
particulates pose the greatest risk, especially in developing countries. 
The most important predictor of indoor air quality is outdoor air204 and levels of indoor 
air pollutants depend on other factors such as ventilation, dispersal and absorption. 
Particulate matter, CO, CH4, N02 and various other pollutants which are similar to 
those found in tobacco smoke and coal, result from the burning of biomass fuels. 
Indoor open fires are inefficient and result in copious amounts of large particulate 
smoke (1-2mg particles). The exposure is also not consistent, so measurement by 











considerably to exposures and 60% of exposure occurs when a fire is either started 
or put OUt. 203 
A common scenario in many developing countries is the indoor use of a single 
source of biomass fuel for cooking and/or heating in poorly ventilated dwellings. Use 
of biomass fuels is closely linked to poverty and the majority of exposure occurs in 
developing countries and in women. Approximately 50% of the world population is 
thought to be exposed to biomass fuels. This constitutes more than 3 billion people 
and 90 percent of rural households, and the exposure contributes to 2 million deaths 
per yea r. 204 
Biomass fuel exposure features prominently in global exposure to toxins and the 
number of biomass stoves is expected to rise due to poverty and 
underdevelopment. 204 In never smokers and non smokers it is one of the largest risk 
factors for obstructive lung disease, and is estimated to be the 10th largest cause of 
death in the world. 205 Dossing et al (1994) showed that two thirds of Saudi Arabian 
non-smoking women with CO PO had >20 years of biomass fuel exposure. 206 
There are relatively few population studies that investigate biomass fuels as a risk 
factor for obstructive lung disease. About thirty studies have shown a clear 
association with chronic bronchitis, but there are few studies with lung function and 
these show a mild association with the exposure. The collection of data in these 
studies could be a factor - few studies have actually measured the exposure and 
many rely on self-reporting. Exposure is often expressed in a similar fashion to pack 
years, known as hour years which is the number of hours per day multiplied by the 
number of years of exposure. A threshold value of >100 hour years has been used in 
some studies. 
A 'first world' example 
A Spanish study of 60 cases and 60 controls, with 50% being never smokers, 
reported an odds ratio of 1.8 for wood, 1.5 for charcoal and 4.5 for a combined 
exposure. LO ? One cannot ignore the fact that even populations in developed countries 
have a rural component and many older persons, irrespective of their current 











Studies from developing countries 
One of the first studies was by Pandey at al in 1984 who reported increased risk of 
chronic bronchitis in smokers and nonsmokers with biomass exposure in NepaL208 
In 1995 Zhou and colleagues reported a difference in comparative risk for CO PO -
using soft coal or anthracite was associated with a higher risk of 4.4 compared to 
firewood which had a risk of 1.5.209 A Turkish study showed a 2.5 times increased 
risk of COPD or chronic bronchitis with exposure to biomass fuel when compared to 
liquid petroleum gas exposure. 210 A study from Bogota, Columbia compared women 
with and without obstructive airways disease and found that the use of wood for 
indoor cooking was associated with a 3.4 times increased risk for obstructive lung 
disease.211 Passive (and active) smoking was also identified as significant risk factors 
in this setting. 
A very recent study by Regalado et al (2006, in press), looked at 871 rural Mexican 
never smoking females aged over 38 years with no occupational exposures - a good 
group in which to study biomass fuel exposures, but nonetheless not a population 
sample. This is probably one of the first community studies to measure biomass in 
domestic smoke exposure. Overall, an association with cough and phlegm was 
confirmed, but no significant increased prevalence of COPD was found in exposed 
women. A decrease in FEV1 of 81 ml was noted in houses that had exposure of >2.6 
rng/m3 and that the FEV1/FVC ratio was also reduced with GOLD Stage II COPD 
more prevalent in the houses with higher exposures. 203 
Ramirez - Venegas et al (2006) recently published the first longitudinal study on the 
survival of biomass exposed women. They found that biomass exposed women had 
clinical COPD characteristics, quality of life and use of health resources that were 
similar to that of tobacco smokers.212 Mortality was also similar to tobacco smokers 
after taking into account that smokers developed more severe obstructive lung 
disease, confirming that biomass exposure contributes to premature mortality, 
despite overall severity of airflow obstruction being less than that of tobacco 
smokers. 
2.6.2.5.2. Outdoor Air pollution 
Outdoor air pollution from traffic, industry and other sources is the only exposure that 
affects almost the entire global human population. As mentioned earlier, the two 
major catastrophes this century should have intensified world efforts for clean air. 











around the time of the industrial revolution. Holland published the earliest work in the 
1960's comparing urban and rural post office employees, and found a greater 
prevalence of symptoms and lower lung function in the urban group, after taking into 
account smoking patterns, suggesting that local levels of air pollution could be 
implicated. 27 28 The fact that they were all mail van drivers could have also suggested 
a link with transport as an occupation, implicated much later by Hnidzo et al from the 
NHANES III data. 159 
Hodgkin et al (1984) found that persons living in a high photochemical pollution area 
had a 15 percent higher risk of CO PO than those in a low photochemical pollution 
area, after adjusting for other important risk factors in a multivariate analysis. 213 This 
study is of note as the findings may be of relevance to this thesis' study site in Cape 
Town, which is often covered by a blanket of photochemical smog, known as the 
'brown haze effect' (see Chapter 3). 
Does air pollution merely exacerbate existing obstructive lung disease or is it an 
independent risk factor for the development of CO PO? In order to answer this 
question one would need data from longitudinal studies, of which there is little, apart 
from the UCLA population studies of COPD. These which showed relatively large 
annual declines in FEV1 which could be attributed to chemical pollutants, 
photochemical oxidants and particulates found in three urban areas that were 
studied. The comparison of two never smoking cohorts in Southern California found 
that SOx, NOx , hydrocarbons and particulates were associated with greater 
deterioration of spirometric measurements and delta N2 , suggesting that both the 
large and small airways were affected.214 In addition, some recent cross sectional 
population studies give insight into the effects. 
The effect of long term air pollution exposure on risk of respiratory symptoms was 
examined in a Swiss Study of Air Pollution and Lung Disease in Adults (SAPALDIA). 
This cross sectional study (which is now prospective) assessing 10 000 adults 18 -
60 years found that both annual mean N02 and total suspended particles of PM10 
were significantly associated with four symptoms: chronic cough, chronic phlegm, 
breathlessness and dyspnoea on exertion. The odds ranged from 1.3 to 1.5 for every 
10 microgram increase in the PM10 level
215 (particulate matter size of 10 micrograms). 
The effects of traffic have also been implicated in the aetiology of obstructive lung 











heavily populated with cars and trucks and many people spend outdoor time along 
the traffic routes. 216 A recent series of cross sectional studies of 55 year old German 
women examined the effects of living less than 100m from a major road. Physician 
diagnosis of chronic bronchitis was associated with a higher level of annual N02 . 
Frequent cough was associated with 1\102 and living 100m from a major road; and 
FEV1 /FVC ratio with 1\102, annual PM 10 and living 100 m from main road.
217 The 
obvious limitation of this study was that it sampled only women, and is therefore not 
generalisable to the whole population, but points to the respiratory hazards of urban 
air pollution. 
Levels of air pollution in most developed countries appear to be declining. 
Unfortunately, developing countries have an added burden owing to unregulated 
industry or poor enforcement of legislature as well as use of biomass fuels. However, 
there are few data from some of the most polluted areas of the world. 
2.6.2.6. Socio-economic factors 
Lower socioeconomic status is consistently associated with poorer health, high 
morbidity and high mortality.218 Many cross sectional studies have examined the 
relationship of CO PO with socioeconomic status, measured as level of education, 
income or occupation. 219 220 221 222 223 224 Some have used place of residence225 
and/or housing conditions22G among other indicators. 
In their review of socioeconomic status and COPO, Prescott and Vestbo suggested 
that the impact of socioeconomic status on COPO is the next most important factor 
after smoking. 227 Socioeconomic status is also associated with other risk factors 
associated with lung function such as tuberculosis, childhood respiratory infections, 
smoking and occupation. It is difficult to disentangle the many factors that cluster with 
socioeconomic status, and might affect health - for example, housing, nutrition and 
life choices such as smoking. 
Low socioeconomic status was associated with increased mortality from chronic 
bronchitis and emphysema in a large retrospective analysis from the UK.228 In 
addition a British cohort study revealed an association of respiratory symptoms and 
airflow limitation with both current low socioeconomic level and poor home 
environment at the age of two years.229 In Canada, a study that used income showed 
1I1at men from low-income families had a 3.7 times increased risk of COPO compared 











From a developing country perspective, Menezes et al found the prevalence of 
chronic bronchitis to be higher in persons with a low socioeconomic status in a study 
from Pelotas, Brazil.82 
Eagan et al (2004) was the only cohort study that examined the cumulative incidence 
of respiratory symptoms by educational level found that the incidences decreased 
with increasing educational level, for all symptoms. 218 After adjusting for smoking, 
age, sex, hay fever, pack years and occupational exposures, those with a primary 
school education had an odds ratio of 1.4 for incidence of chronic cough and 2.5 for 
incidence of grade two dyspnoea, when compared to those with a university 
education. Similarly, another Nordic study found that those with primary school 
education were five times more likely to have airflow limitation than their university 
graduate counterparts, independent of smoking (OR 5.2; CI: 2.0 - 13.4).220 The 
corresponding risk for secondary school education was an odds ratio of 1.8 (1.2-
2.7). 
2.6.2.7. Gender 
Apart from being considered as a risk factor for COPD, gender differences have also 
been considered in COPD severity, prevalence and mortality as well as airway 
hyperresponsiveness. 231 In 2000, studies by Sobradillo-Pena et al lOl , Viegi et al232 
and Mannino et al233 have all reported the prevalence of chronic bronchitis and 
COPD to be higher in men than in women. This is to be expected since historically, 
men have smoked more, and may be exposed more in the workplace. 
Smoking rates in women are rising worldwide.51 As smoking rates in women have 
increased, so too has the prevalence of COPD in women in developed countries 
such as the UK.234 Gender differences in tobacco exposure are discussed in Section 
2.6.1. Becklake and Kauffmann (1999) have published a comprehensive review on 
gender differences in airway behaviour examining biological and sociocultural 
determinants and suggest that the influence of sex and gender on airways diseases 
requires special study owing to inherent physiological differences between the 
sexes. 235 It is possible that differences in airway behaviour could result in a different 
dose response or pattern of response to noxious agents. 
It is thought by some that women are more predisposed to develop CO PO from 











than men.231.Three studies support the hypothesis that women are more susceptible 
to the noxious effects of tobacco smoke than men and therefore at a greater risk of 
developing COPD than men.236 237 238 However, findings from longitudinal studies 
such as the Lung Health Study, an Australian and a US study failed to demonstrate 
this effect 239240241 as did a large metaregression analysis of eight studies.242 In the 
EUROSCOP study, decreased baseline FEV1 was associated with respiratory 
symptoms in male but not in female smokers, suggesting that FEV1 in male and 
female smokers have a different pattern of response. 231 248 Women are also thought 
to benefit more from smoking cessation than men and are more likely to reduce or 
quit.231243 
In the developing country context, the contributions of other risk factors such as 
domestic biomass fuel exposure affect women disproportionately in addition to 
gender specific occupational exposures and certain infections.244 The effects of 
various risk factors other than smoking and biomass fuels in men and women have 
not been investigated to a great extent from a gender perspective. 
CO PO in nonsmokers with no clearly identifiable cause points to possible causes 
such as air pollution. Birring et al (2002) found that CO PO in nonsmokers 
predominantly affects older females. 142 By examining induced sputum, two pathologic 
subgroups were identified - a group with neutrophilic inflammation associated with 
organ specific autoimmune disease, commonly thyroid disease, and an eosinophilic 
group. The eosinophilic group was not associated with longstanding asthma and 
fixed airflow limitation from airway remodelling, nor was it associated with 
eosinophilic bronchitis/bronchiolitis. For the neutrophilic group, causes such as air 
pollution, occupational exposures and idiopathic constrictive bronchiolitis were 
considered. However, the frequency of autoimmune disease was much higher in this 
group, and the authors suggested an unrecognised autoimmune bronchitis or a 
postulated inflammatory component of the autoimmune disease arising from the 
shared embryologic origins of cells. 
2.6.2.8. Body Mass Index 
Body mass index (BMI) has in recent years been identified as a prognostic indicator 
in COPD, and is not a "risk factor" as such. The BODE Index is a grading system that 
is used to predict risk of death in persons with COPD. BODE is an acronym for Body 











index of -:21 is associated with increased mortality and it is thought that the negative 
effects of low body weight may be at least partially reversed by nutrition. 
Many studies that have examined the relationship between BMI with asthma, but few 
have examined the relationship with chronic bronchitis or capo. Chinn et al showed 
that weight change had an independent effect on decline in FEV1.
246 Weight gain 
diminished the effect of quitting smoking by 38% in men and 17% in women. Guerra 
et al (2002) examined data from the Tucson study and showed that persons with 
asthma were more likely to be overweight or obese, those with chronic bronchitis to 
be obese and those with emphysema to be underweight.247 The EUROSCOP study 
suggested that obesity is a risk factor for dyspnoea and greater severity of COPD.24B 
The relationship between the onset of capo and being underweight is not clear. The 
supposed direction of effect is that capo is a "cause" for being underweight. 
Whether being underweight makes one more likely to develop capo is not certain. A 
paper from the Baltimore Longitudinal Study on Aging, by Harik-Khan et al (2003) 
suggested that low BMI could be a risk factor for capo rather than just an effect of 
the disease. Body Mass Index was measured before the diagnosis of capo and an 
increased risk of developing capo was found for men with a low BMI even after 
adjusting for many other known risk factors. 249 
However a Canadian study found that overweight women had a 2.4 times increased 
risk of CO PO which was defined as self-reported doctor-diagnosed chronic bronchitis 
or emphysema. 
2.6.2.9. Asthma, Airway Hyper responsiveness (AHR) and allergy 
The role of AHR and allergy as risk factors for COPD is still uncertain.250 251 Early 
studies by Fletcher et al found that the rate of decline of FEV1 was significantly higher 
for asthmatics compared to non-asthmatics, after adjusting for smoking. 252 Studies in 
children have shown that AHR contributes to lower lung growth. Juan et al compared 
the FEV1/FVC curves for children aged 8-20 years over time and concluded that 
those with AHR progressed less favourably than their counterparts in terms of 
expected lung developmene53 
0' Connor et al reported that AHR (to methacholine) predicted accelerated lung 
function decline after adjusting for confounders in a cohort of 912 men followed up for 











methacholine was associated with accelerated decline in lung function over 5 years, 
and suggested that AHR is an important predictor of "progression of obstructive lung 
disease in continuing smokers with early COPD".255 In addition Tashkin (1996) also 
found an interaction between smoking and AHR in this study. 
A longitudinal study of 3099 participants at 20 year follow-up produced results in 
support of asthma as a risk factor for COPD. The Tucson Epidemiologic study of 
Airway Obstructive Diseases reported that active asthmatics (those that had ongoing 
asthma at the time of the first measurements) had a hazard ratio of 12.5 for 
developing COPD. 256 The definition of COPD involved having a diffusing capacity or 
an FEV1 of less than 80% predicted, accompanied by either physician-diagnosed 
emphysema or symptomatic chronic bronchitis. In addition, active asthmatics had a 
10 fold greater risk for acquiring chronic bronchitis and a 17 times higher risk of being 
diagnosed with ernphysema. 256 Initial misclassification could have played some part 
in increasing the strength of associations, but is unlikely to be wholly responsible for 
these associations. Asthma and COPD diagnoses were also not fully validated, as 
there was no measurement of airway hyper-responsiveness or reversibility, but again 
misclassification from this source is likely to be limited in view of the fact that an 
objective measurement of diffusing capacity was included in the definitions. 
An earlier paper from the Tucson study argued the reverse and classified asthma-
related chronic airflow obstruction as "chronic asthmatic bronchitis"257 (not COPD). 
Similarly, a review of longitudinal changes in FEV1 in asthma (from the Copenhagen 
City Heart Study) suggested that a subset of asthmatics may have nonreversible 
decline in lung function, but that this could not be called COPD. 258 However, a 
subsequent revision removed the longitudinal part of the analysis and reached a 
different conclusion showing that the rate of decline in FEV1 was increased in 
persons with new onset asthma (in a 5 year period). Those with chronic asthma had 
the same decline in FEV1 as nonasthmatics.
259 Another American study also found 
an effect of accelerated loss of lung function associated with asthma.26D 
The Busselton study suggested a real decline associated with asthma, finding 
reduced lung function at the beginning of adult life as well as an increased rate of 
decline thereafter. The authors suggested abnormalities in airway structure and 
function before the age of 19 (probably stating in early life) contribute to decreased 












It has been suggested that atopy and high serum IgE are risk factors for COPD, 118 123 
but this does not appear to be a widely accepted view. A study by Hospers et al 
(1999) reported that the presence of eosinophilia was associated with increased 
mortality from COPD, but only in association with a past history of asthma attacks.2G3 
The Tucson study after adjusting for other important risk factors, failed to show 
associations between IgE and positive skin prick tests, and COPD. In contrast, 
Tracey et al found that positive skin prick tests, elevated IgE and AHR were 
associated with accelerated decline in FEV1 in 324 elderly participants. This was 
evident especially in former and current smokers, and AHR preceded the onset of 
chronic lung symptoms. 256 2G4 265 This may not be considered a convincing argument 
in the light of findings by Lim et al (1988) who studied changes in AHR to inhaled 
histamine over four years and found that ex-smokers had comparable levels of AHR 
at baseline and a normal age related decline thereafter. 41 
The mechanisms whereby the presence of asthma may contribute to the 
development of COPD are still uncertain, and require further research. The Dutch 
hypothesis, described above, considers AHR and atopy as host factors that can lead 
to airway remodelling and in due course to irreversible obstruction. However, cough 
and phlegm are symptoms of both asthma and COPD independently, and this is not 
necessarily related to chronic bronchitis. 
2.6.2.10. Childhood chest disease 
Some population studies have shown an association between childhood respiratory 
illness and resultant respiratory symptoms and decreased pulmonary function later in 
life. Cohort studies by Shaheen et al (1994, 1998) examined the effect of lower 
respiratory tract infections in childhood and found that pneumonia before the age of 
two years was associated with a decrease in mean FEV1 in men, independent of 
smoking. 266 267 Bronchitis, pneumonia and whooping cough in infancy were 
associated with a significant decrease in FEV1, wheezing and persistent sputum 
production in later life.275 Pneumonia before the age of seven years was also 
associated with a significant decrease in FEV1 and FVC in a cohort examined at age 
35.2flB 
There is also some suggestion that even earlier lung insults play a role in adult 
COPD. Prematurity with bronchopulmonary dysplasia (BPD), ventilator dependency 











such article was curious: "Some CO PO will originate in neonatal Intensive Care 
Units" ,269 Prematurity has been shown to result in frequent respiratory 
illnesses/infections in the first year of life, and persistent respiratory symptoms during 
childhood. Based on CT studies, the authors postulated that these individuals are 
likely to suffer from CO PO in later life. 
A paper by Northway et al (1990) assessed survivors of BPD and compared them to 
survivors of prematurity without BPD and to normal individuals.270 The survivors of 
BPD had lower FEV1 , FVC, air trapping (measured by a higher residual volume/TLC 
ratio) and a substantial number had a minimal response to bronchodllators, 
suggesting some evidence that early life exposures could be more closely related to 
adult CO PO than was previously supposed. 
"Wheezy bronchitis" is a term not used much now, but in the 1960's, it was common 
nomenclature. A 1964 cohort containing asthmatics, normals and those with a history 
of "wheezy bronchitis", now 45 - 50 years old were followed up by Edwards in 1989 
and 2001.271 The 1989 follow up of these patients showed no evidence of a 
difference in early adulthood, but a decade later (in 2001) revealed an average 
annual decline of 0.59L for those with no symptoms. Those with wheezy bronchitis 
had a greater average annual decline of 0.75L, suggesting that this accelerated 
decline could progress to COPD.271 This highlights that fact that these effects may 
take decades to emerge or become apparent. 
2.6.2.11. Other risk factors 
Genetic host factors include the well-known alpha-1-antitrypsin deficiency, and the 
lesser-mentioned Ehrlers-Danlos Syndrome, cutis laxa and Marfan syndrome. 244 
There appears to be a female preponderance of these genetic factors in the 5-12% of 
persons with CO PO who have never smoked. 181 244 Sandford and Silverman (2002) 
examined particular 3 genotypes of alpha-1-antitrypsin and the least favoured (PiZ) 
showed evidence of a gene-environment interaction - as pack years increased there 
was less favourable response to tobacco exposure. 272 Other genetic factors 
associated include alpha 1 antichymotrypsin, alpha-2-macroglobulin, vitamin 0 
binding protein and blood group antigens.273 
Low birth weight has also been implicated in the aetiology of COPD suggesting that it 
is probably related to poor lung development from poor nutrition in utero. This results 











lower peak value than normal. The main evidence for this is from studies in England 
and Wales which found that low birth weight and childhood respiratory infection were 
associated with decreased adult lung function. In addition, death from COPD was 
associated with low birth weight and weight at one year. They found that infection in 
early childhood had a greater influence than cigarette smoking in determining the 
geographical distribution of chronic bronchitis.274 275 Similarly a South Indian study 
found both low birth weight and small head circumference at birth to be associated 
with a decreased FEV1/FVC in men. This finding was independent of smoking.2?6 
Results from the Copenhagen City Heart Study found alcohol consumption of more 
than 3 drinks a day to be associated with an almost 2 fold increase in risk for chronic 
bronchitis in the elderly.277 However, a Canadian study found no relationship of 
regular drinking with self-reported doctor-diagnosed chronic bronchitis or 
emphysema. 
Apart from alcohol, other novel associations include an inverse association of 
glycaemic control with FEV1 from the Framingham H art Studl
78 and the Fremantle 
Diabetes studl79 ; findings that could be relevant in diabetics, and deserve further 
attention as the obesity epidemic increases worldwide. 
A review by Rornieu and Trenga (2001) suggested that by decreasing the insults of 
oxidants, antioxidants in fresh fruit and vegetables (particularly vitamin C and E) 
could temper the development of chronic lung disease and decrease in lung function, 
encouraging higher intake and further longitudinal studies to investigate the 
hypothesis. 28o 
HIV infection has recently been implicated in accelerating the onset of smoking-
related emphysema. Diaz et al (2000) found that the incidence of emphysema in HIV 
positive patients was significantly higher than in HIV negative patients (15 vs. 2%).;;81 
HIV positive patients developed emphysema at a younger age than their negative 
counterparts. It was suggested that larger numbers of cytotoxic lymphocytes found in 
the bronchoalveolar lavage fluid may have a role in the pathogenesis of emphysema. 
2.7. Conclusion 
There are many methodological issues that have arisen in this review, such as 











capo are difficult to apply in practice, as studies are not usually able to routinely 
check or prove that there is an "abnormal inflammatory response". Problems with 
comparisons of self-reported chronic bronchitis, different/changing spirometric 
criteria, and limitations of these criteria such as the reliability of a fixed ratio in older 
adults, all contribute to a non-standard approach to disease. Definitions are not 
applied uniformly across studies, and in addition, the epidemiological definition is not 
the same as the clinical or pathological definition of capo. 
The potential for publication bias also needs to be considered as a suspected factor 
even though there may be no clear evidence for it. An example is a review by Bero et 
al found that 80% of original journal articles on the effects of ETS reported a positive 
association, compared to 51 % of symposium articles, suggesting that cigarette-
industry sponsored symposia publish more negative findings than journals.282 283 
Different studies rely on different indicators of disease e.g. spirometry, diffusing 
capacity; others have reported only symptoms, and others have even performed CT 
scans. In a clinical situation, one is able to integrate symptoms, pulmonary function, 
CT etc. and make a diagnosis based on these, like the pieces of a puzzle. 126 
However, in population studies, one often has only one or two pieces of the puzzle, 
sometimes based on crude measures of risk factors such as general occupational 
exposure questions, and therefore one would expect relationships to be biased 
towards the null, for a heterogeneous disease like capo. A balance between the 
use of simple indicators that are useful and convenient and the more complex 
indictors needs to be decided upon, depending on the specific hypothesis of a study. 
Overall, there has been an advance in the methodologies for studying the prevalence 
of capo by means of standardised questionnaires and ways of measuring 
pulmonary function and there is some measure of agreement on the definition and 
classification of capo. Epidemiological data on the prevalence and risk factors for 
capo is an essential requirement for tracking trends, planning preventive strategies, 
improving healthcare and motivating governmental intervention. This review has 
highlighted some encouraging trends in the developed world including reductions in 
smoking amongst men. However, in some cases this gain has been diminished by an 
increase in smoking amongst women. 
For the developing world, and countries in epidemiological transition such as South 











factors highlights the need for surveys in Africa to consider factors other than 
cigarette smoking, and in particular the role of domestic and industrial pollution, 
infections, including tuberculosis, and cannabis use. In the light of this, the South 
African perspective on obstructive lung disease is presented in the following chapter. 
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CHAPTER 3: LITERATURE REVIEW: ADULT OBSTRUCTIVE 
LUNG DISEASE IN SOUTH AFRICA 
3.1. Introduction and aim 
The purpose of this chapter is to review obstructive lung disease in South Africa with 
respect to prevalence data, potential risk factors and management in the public 
health sector. In general, the pattern of obstructive lung disease in South Africa is 
similar to that in other developing countries and countries in epidemiologic transition, 
but the unique history of South Africa has played an important role in shaping the 
profile of risk factors. Interest in population research on obstructive lung disease has 
grown over the last decade with the recognition of the burden that these diseases 
place upon the health of the population. 1 The major risk factors that will be reviewed 
are tobacco smoking, cannabis smoking, TB, occupational exposures and air 
pollution. These risk factors may not necessarily be independent from one another. 
Added to these is the impact of the rapid increase in the prevalence of tuberculosis 
and HIV-related lung disease over the past 10 years, which has changed the face of 
respiratory health in South Africa. The work reported in this thesis was performed in a 
setting of low HIV infection, but it is important to consider that as the prevalence of 
HIV increases in a community, the pattern of disease changes rapidly to one of more 
infections, both usual and opportunistic, and shortened life expectancy with reduced 
opportunity for the development of chronic degenerative diseases like COPD. This 
shift will not be considered in detail for two reasons. Firstly, because it is not relevant 
at the time of the studies reported here, and secondly, because it is difficult to predict 
the impact of the recent introduction of anti-retroviral drugs in South Africa upon this 
shift. Separate studies are required to examine these trends. 
Some portions of this chapter have been adapted from a recent review of respiratory 
diseases in South Africa which was co-written by the author. 1 
3.2. Methods used in the literature review. 
Effort has been made to obtain South African publications on obstructive lung 
disease and the focus of this review is on literature published in the last decade. 
Important citations prior to 1994 are included. An internet search using the Pubmed 











etc. The first South African Demographic and Health Survey as well as the South 
African Medical Research Council's technical reports have also been referenced. 
References from "grey" literature from the South African Medical Research Council's 
research database were also obtained. In addition, relevant theses and published 
books were consulted. 
3.3. Burden of mortality and morbidity of COPO 
Over the last decade, South Africa has been undergoing an epidemiological 
transition with increases in the burden of both poverty-related pre-transitional 
diseases such as tuberculosis, as well as post-transitional chronic diseases such as 
COPD.:l The coexistence of these diseases is responsible for much premature 
mortality and morbidity. South Africa suffers from a quadruple burden of disease of 
HIV/AIDS, diseases of poverty, emerging chronic diseases and injuries. 2 
Respiratory diseases excluding tuberculosis were ranked as the seventh highest 
cause of Disease Adjusted Life Years (DAL Ys) lost of 4.7%, according to the South 
African National Burden of Disease Study of 2000.3 COPD was responsible for 2.3% 
of all deaths, although only 1.1 % of years of life lost (YLL), in keeping with the fact 
that most morbidity is experienced by older persons. 4 
The true proportion of deaths attributable to COPD is almost certainly higher, 
because of the inaccuracy of cause of death data. CO PO is likely to be under-
certified as an underlying cause where the immediate cause is stated as respiratory 
infection.1 Inconsistent use of nomenclature by doctors, misdiagnosis and the lack of 
standard guidelines regarding the reporting of cause of death are factors that 
significantly obscure this estimate. Despite significant limitations (mainly 
underreporting) associated with cause of death reporting, COPD is ranked eighth 
amongst the leading causes of death in the Western Cape Province, being 
responsible for 3.8% of provincial deaths.4 
The absence of accurate prevalence data on COPD in South Africa further hampers 
estimates of morbidity. To date there have been very few studies involving 
spirometry, which is necessary to make the diagnosis. The best available study is the 
South African Demographic and Health Survey performed in 1998, in which both 
symptoms of airflow limitation (e.g. wheeze and cough), self-reported respiratory 











obtained. Although the latter is not considered an adequate test for confirming the 
presence of COPD, it provided at least some indication of airl'low limitation.s These 
results will be considered below. 
Unlike COPD, which is in 6th position as a cause of death globally, asthma is not 
ranked among the top 15 causes of death as it is largely an adequately controlled 
disease in developed countries. The prevalence of asthma in South Africa is 
estimated at 8.1 % over all ages. South Africa ranked fourth in asthma mortality rate 
in the 5-34-year age group at approximately 1.5 per 100 000, falling between 
Turkmenistan and Uzbekistan in the ranking. 5 Similarly, the asthma case fatality rate 
in South Africa was reported to be the fifth highest in the world at 18.5 per 100 000 
asthmatics. 5 If these statistics are viewed as health indicators, they suggest that the 
treatment of asthma in South Africa is suboptimal. Whether this is because of the 
relative unavailability of inhaled corticosteroids in many parts of the country, their use 
being associated with much of the decline in hospitalisations and deaths from asthma 
in other countries, or because of other deficiencies in care is not clear. This requires 
further research. 
Since globally the burden of COPD is considered to be higher than that of asthma, 
one can expect that the situation for CO PO in South Africa will be worse than that 
described for asthma. Although there is some evidence that overall tobacco use has 
decreased slightly over the last few years, the burden of smoking-related disease is 
likely to continue for many years and estimates of current and potential future burden 
is important for health planning. 1O Current smokers are growing older and will soon 
place a further burden on an already strained South African public health service. 
In developed countries, CO PO is primarily caused by tobacco smoking, and 
prevention activities are appropriately directed at tobacco control. Though this has 
been the focus, studies have also shown substantial effects of occupational 
exposures. The contributions of these and other risk factors in a transitional country 
like South Africa are likely to be significant, but need to be assessed. 
In South Africa, the patterns of asthma and COPD reflect the structure of society with 
industrialisation, high rates of smoking among some sections of the population, 
extensive urban and rural poverty, and the persistence of epidemic infectious 
diseases. In addition to tobacco smoking, post-tuberculous lung damage, 











smoking have been identified as potential risk factors for adult obstructive lung 
disease, particularly COPD. 
3.4. Review of CO PO Prevalence Studies 
Studies of self-reported chronic bronchitis and respiratory symptoms in South Africa 
are presented in Table 7. Only one study, performed almost 30 years ago, involved 
lung function measurements. 
Table 7: Prevalence of COPO and chronic bronchitis, respiratory symptoms and COPO in 
population surveys in South Africa 1 
Study (yr 
published) 
Population, (N, age 
range) 
Outcome measure 







(507, 20-80 yr) 
National sample** 
(13468, > 14 yr) 
South-central Durban* 
(693, > 17 yr) 
Chronic bronchitis*** 
Chronic bronchitis*** 
-Chronic phlegm> 3 
months in past year 
-Doctor -diagnosed 
bronchitis 




















* Area in vicinity of petrochemical refineries and other industry; ** SADHS; *** Self-reported British MRC definition 
Diffuse Obstructive Pulmonary Syndrome" (DOPSl 
A study by Wicht et al. 7 examined the "Diffuse Obstructive Pulmonary Syndrome" 
which was published in 1977. This study was performed in Bellville, a suburb of Cape 
Town adjacent to Ravensmead and Uitsig (see Figure 4), with a population of 48000. 
Only 20 000 were included in the sampling frame. This study was performed during 
the height of the apartheid regime of the Nationalist government and had a sampling 











'~ sequential sampling technique enjoys a specific advantage inasmuch as the 
inclusion of persons in the survey in the order in which their names appear on the roll 
ensures unbiased sampling which is truly representative of the population ,,7 
The first limitation was that over eighteen thousand blacks had been excluded from 
the sample which was claimed to be truly representative of the areas of Tygerberg. In 
addition, only two thirds of the adult white population were on the Voters' Roll. The 
second issue was a low response rate of 40 and 45% for women and men 
respectively, possibly attributable to the fact that participants were required to visit a 
hospital for investigations to be performed. Although unavoidable, this introduced 
further potential sampling bias as persons who considered themselves healthy or 
those who were already on treatment may have been underrepresented. 
The clinical assessment of 272 men and 237 women participants included a 
respiratory questionnaire, detailed clinical examination, electrocardiography, chest 
radiography and pulmonary function testing. Approximately half the population was 
under the age of forty and therefore more likely to have asthma. The questionnaire 
was based on the 1966 British MRC questionnaire and included questions on 
respiratory symptoms and risk factors such as smoking and occupational exposure. 
The design of the study suggests that authors were examining the Dutch hypothesis. 
This is evident in their choice of terminol gy to describe obstructive lung disease. 
Diffuse obstructive pulmonary syndrome (OOPS) was a definition that included 
asthma, emphysema and chronic bronchitis. OOPS was categorised into three 
groups: those with respiratory symptoms or diagnosis of asthma/emphysema, those 
with FEV1/FVC<70%, or both. 
The prevalence of OOPS defined as respiratory symptoms/diagnosis of bronchial 
asthma or emphysema and/or FEV1IVC<70%) was 45% and 43% in men and women 
respectively. It was also found that there was no statistically significant difference in 
prevalence of "OOPS" in smokers and non smokers. The symptoms of dyspnoea 
were excluded as a determinant of the diagnosis as the authors thought that there 
would be a problematic overlap with other conditions such as obesity or other non-
respiratory conditions, implying that those with dyspnoea but no objective obstruction 
on spirometry were excluded. As dyspnoea is the predominant symptom of airflow 
obstruction, this was a curious exclusion. However, it was reasoned that as 











would have been identified by spirometry. An exception might be in asthma where 
airflow obstruction is intermittent and dyspnoea can occur without cough or wheeze. 
In this study, the prevalence of chronic bronchitis was reported to be 8.1 % in men 
and 3.4% in women (British MRC definition) overall, and 10.6% in persons over 40 
years (12.2% in men and 4.7% in women). There was a high overall prevalence of 
ever wheezing of 19.2 and 12.5% in men and women respectively and 7.7 and 
11.9% of men and women reported "bronchial asthma". Increasing age was 
associated with increasing prevalence of all respiratory symptoms, particularly 
chronic bronchitis and wheeze, in keeping with the added burden of capo. The 
prevalence of smoking in the study cohort was 71 % in men and 38% in women. 
Evidence of airflow obstruction (FEV1IVC <70%) was found in 22.4% in men and 
25.7% in women. This definition differs from that of the current GOLD definition of 
capo, in that it applied to prebronchodilator rather than postbronchodilator values. 
The authors found that the use of the term emphysema was of no value in the 
questionnaire, presumably due to the unfamiliarity of the term in the study population. 
The thesis study population is likely to have a similar lack of familiarity with the term 
today, and even less familiarity with the medical acronym 'capo'. The terms 
'bronchitis' or 'asthma' are often used by both practitioners and participants to 
describe either asthma or capo. 
Chronic bronchitis in the SAOHS 
The South African Demographic and Health Survey of 1998 (SADHS) was the first 
study to provide national prevalence figures for chronic bronchitis, viz. 2.3% in men 
and 2.8% in women > 14 years of age. Chronic bronchitis was defined as usual 
cough with phlegm every day for at least 3 months a year for at least 2 successive 
years.8 This prevalence is lower than that reported from other African countries. 
However, most of the latter have been performed in workforces exposed to dust and 
other respiratory hazards, and might not have reflected the general population of 
those countries. 9 The slight female excess observed in the SADHS is surprising 
given that national figures for current smoking were 42% in men and only 11 % 
among women. This raises the possibility of other significant exposures in women. s 
Self-reported doctor-diagnosed "chronic bronchitis/emphysema" was reported by 
4.2% of men and 4.8% of women with 2-3% in younger persons and 7-9% in the 











The South African population is heterogeneous in nature and South Africa still 
remains a country largely divided geographically along ethnic and socioeconomic 
lines as a legacy of the apartheid regime. In view of the diversity of the South African 
population, national prevalence figures have limited value, and more is gained from 
examining different communities and regions for locally applicable risk factors and 
associations. Important community-specific factors, especially those related to low 
socioeconomic status may apply even within cities like Cape Town or Johannesburg. 
In the SADHS, men with the least and most education had higher prevalence than 
those with intermediate education. However, chronic bronchitis (defined by the rvlRC 
question) was highest in rural women, but urban prevalence of reported "chronic 
bronchitis/emphysema" was higher than non urban rates. Women with highest levels 
of education had the highest prevalence of airflow limitation defined by wheeze and 
shortness of breath, which could reflect a higher prevalence and/or greater 
awareness of symptoms. Although this was the case in women, the rate of airflow 
limitation generally increased with decreasing education. 
In order to get an idea of the burden of chronic bronchitis and COPD, estimations of 
the prevalence of chronic bronchitis over the age of 40 are more useful. In reports 
from Asia and Africa the prevalence of chronic bronchitis in women over 45 ranges 
from 6.0 to 7.4 percent and in their male counterparts from 6.7 to 8.7 per cent. 9 
However, in the SADHS, the prevalence of self-reported doctor-diagnosed chronic 
bronchitis also varied markedly in different provinces. In the Western Cape chronic 
bronchitis was reported in 11.4% of women and 9.4% of men, with most other 
provinces reporting much lower rates. 8 Similarly the incidence of self-reported 
(doctor-diagnosed) chronic bronchitis was 2767 and 2031 per 100 000 for Western 
Cape women and men respectively. 
Prevalences in the age group 15-43 years in the SADHS were low compared to 
those from the European Community Respiratory Health Survey (age group 20-44 
years) which reported a median prevalence of 2.6% with wide variations across 
countries (0.7% - 9.7%).10 Even in young persons, the authors suggested that only 
30% of the geographical variability in prevalence could be accounted for by 
differences in smoking prevalence, indicating that the role of other environmental or 
genetic factors may be more significant than previously supposed.1O Similarly wide 











In a recent French study the prevalence of chronic bronchitis (British MRC definition) 
was 4.1 %, and that of chronic cough and expectoration 11.7%11 showing that chronic 
cough and chronic expectoration are more prevalent than the classic British MRC 
definition of chronic bronchitis, and one should also consider persons with these 
symptoms to be at risk for COPD, as the GOLD Stage 0 suggests. 
Tobacco smoking and a past history of tuberculosis emerged as important risk 
factors for chronic bronchitis in both men and women in the SADHS. 56 Occupational 
exposure to smoke, dust, fumes, strong smells, or working underground in a mine for 
more than a year was associated with chronic bronchitis in men. Domestic exposure 
to smoky fuels (coal, wood or other biomass) was associated with chronic bronchitis 
in women. 
Further analysis of the SADHS (unpublished data, R Ehrlich) has confirmed that the 
highest prevalence of chronic bronchitis adjusted for age and smoking occurred in 
rural African women (3.2% ).1 As the prevalence of daily or occasional smoking in this 
group was only 7.5%, it was proposed that this excess might be the result of 
domestic pollution caused by fuel used in the home, especially that of biomass origin 
(wood, coal and dung). 
Industrial air pollution in South Central Durban: respiratory symptomsG 
The importance of environmental conditions in the aetiology of chronic bronchitis in 
South Africa is sl1ggested by a study by l\Jriagu et al (1999).6 This study focused on 
the prevalence of asthma in a south-central Durban community, an area that had 
been identified as being severely polluted by heavy local industry such as refineries, 
petrochemical plants, pulp and paper mills lead, chromium and other metal 
processing plants. What is unique about the history of this area is its geographical 
location - a low-lying area adjacent to heavy industry, chosen as a black residential 
area by the apartheid government. 
The authors found high prevalences of respiratory symptoms. The awareness of local 
industry as a potential health hazard could have created a source of reporting bias 
even though the authors cited that they had no reason to suspect such overreporting. 
The study was focused on persons with the highest risk of exposure to atmospheric 
pollution in the hope of highlighting environmental health risks associated with 
apartheid. Participants may have been more likely to report respiratory symptoms as 











overreporting could have been wholly responsible for the increased prevalence of 
symptoms in this area, and the results are plausible. 
These local data report prevalences that are much higher than the national 
prevalence and may reflect the susceptibility of the lung to insults from the noxious 
effects of local air pollution. Although the study collected data on respiratory 
symptoms in adults, no mention is made of COPD. However, smoking was 
associated with both wheeze (OR 2.9; 95% CI 1.5 - 4.9) and shortness of breath with 
wheeze (OR 2.6; 95% CI: 1.4 - 4.8). The authors sL1ggested that these results were 
consistent with other studies showing that ETS exposure is associated with asthma 
and wheeze. It is possible that some symptoms in older adults were related to active 
smoking, either alone or in association with air pollution. As a cross sectional study it 
had limitations in ascribing causality to the local air pollution, but certainly 
emphasised the role of industrial air pollution as a potent risk factor for the increased 
prevalence of respiratory symptoms. 
Attributable fractions 
Population studies may be used to estimate population attributable fractions, i.e. the 
proportion of the disease occurring in the population that is attributable to specified 
risk factors, on the assumption that the association is causal and that all causes have 
been identified and measured. This measure provides a broad perspective of the 
relative contributions of different putative factors. For example, in the analysis by 
Ehrlich (2004) of the contributions of past tuberculosis and occupational exposures 
on the prevalence of chronic bronchitis in South Africa56 (see Table 8), the combined 
burden of past tuberculosis and occupational exposure in men was found to equal 
that of smoking. In women the combined burden of past tuberculosis and domestic 











Table 8: Population attributable fractions for modifiable risk factors for chronic 
bronchitis in South Africa56 
Men (N=5 671} Women (N=7 929} 
P POR PAF P POR PAF 
Past tuberculosis 2.9 4.9 10 2.0 6.6 10 
Occupational exposure 26.8 1.6 14 
Smoky domestic fuel 33.8 1.5 14 
Current smoking, 1-14/day 30.6 1.5 13 8.7 2.3 10 
Current smoking, 15+/day 8.7 2.5 12 1.9 1.8 
P: Population prevalence of exposure; POR: prevalence odds ratio; PAF: population attributable fraction 
(rounded) 
3.5. Review of Asthma Prevalence Studies 
Adult asthma has not received the same level of attention as childhood asthma in 
South Africa, and very few studies have been performed. The three surveys 
described above also reported on asthma (Tables 7 and 9). The SADHS reported a 
prevalence of wheeze of 11.7% in men and 14.5% in women aged 20 - 44 years 
compared to 2.7 and 3.1 % for asthma diagnosis.57 These figures are slightly lower 
than those reported for Europe in the ECRHS study, but underdiagnosis is likely. In 
the SADHS, a lower attained educational level was identified as a risk factor for 
wheeze. 
Overall, in adults, wheeze was associated with age older than 44 years, indicating 
the non-specific nature and poor performance of wheeze in distinguishing between 
asthma and COPD. Three outcomes - wheeze, self-reported asthma diagnosis and 
chronic bronchitis - resulted in a similar risk factor profile comprising tuberculosis, 
tobacco smoking and occupational exposures, supporting the concept that these 
outcomes are non-specific. At a population level, unfamiliarity with terms like COPD, 
and lack of awareness of the disease, contribute to poor recognition of CO PO in 
questionnaire-based studies in South Africa. A similar problem has been observed in 
other countries where community studies have shown that tobacco smoking was a 
stronger predicator than atopy for non-specific AHR in persons over 40 years 











Table 9: Prevalence of self-reported asthma and wheezing in adult populations in South 
Africa 1 
.. _ .. _ ... - ---.--.. ---.. --.. -----~-----.-----~------.----.-------. __ . -.----~~-----.------
Study (yr 
published) 
Population, (N, age range) Outcome measure 
Prevalence % 
Male Female 
--.-.--.-.. ------.--.--.-.---.~-----~----------.--------._----_._ .. _------.-- .. __ .. _--------_._---_ .. _---_ .. -_._---
- Self-reported asthma 7.7 11.9 
Wicht? (1977) 
Northern Suburbs, Cape 
- Ever wheeze with shortness 9.6 8.9 
Town (507, 20-80 yr) 
of breath 
- Shortness of breath with 
wheeze past 12 months 28 
Nriagu6 (1999) 
South-Central Durban* (693, 
- Chest tightness 42 
~17 yrs) 
- Wheezy chest ever 40 
- Asthma ever 12 
Ehrlich5? (2005) 
National sample - Wheeze past 12 months 14.4 17.6 
(13826, > 14 yr) - Asthma ever 3.7 3.8 
.-----~-.-------.----- ---~--.. --.-
* Residential areas in close proximity to petrochemical refineries and other industry 
Asthma in children was addressed in the ISAAC (International Study of Asthma and 
Allergy in Children) which reported a questionnaire based prevalence of 16% for 
wheeze in the past 12 months and 13.3% for "asthma ever" in Cape Town (13-14 
year 0Ids).13 A higher prevalence of symptoms of asthma was associated with higher 
socioeconomic status, but poorer children had greater severity and frequency of 
symptoms.14 Low socioeconomic status was also strongly associated with asthma 
mortality and intensive care admission.l 13 This socioeconomic difference is probably 
an indicator of inadequate access to healthcare services and environmental 
exposures that aggravate asthma such as fungi in homes, ETS exposure etc. 
Although there has been a decline in childhood asthma mortality overall in South 
Africa, the incidence of ventilation and ICU admissions remains unchanged. 15 A 
socioeconomic divide is evident however, in that, in Cape Town, while asthma 
mortality in whites has halved over two decades, mortality in coloureds is 
unchanged. 16 
De Klerk et al have examined risk factors for near fatal asthma in adults presenting to 
a tertiary hospital in Cape Town and found no difference in access to care or 
medication when compared to controls with acute asthma from the same facility.l1 











population where there is little variation in access to care and medication, one would 
expect to find the full spectrum of asthma severity. The controls may simply have had 
milder disease. In this study, the asthma cases had a lower mean beta agonist use in 
the 24 hours preceding admission possibly suggesting inadequate patient education 
or impaired perception of the severity of symptoms. An association between near 
fatal asthma and previous tuberculosis was also found suggesting a previously 
undocumented role for tuberculosis in severe asthma. Tuberculosis was also shown 
to be an independent risk factor for both doctor-diagnosed asthma and wheezing at 
the national level. 5? 
Efforts to improve the quality of care offered to patients with asthma and other 
common respiratory disease at a primary care level has been addressed by the 
PALSA (Practical Approach to Lung Health in South Africa) initiative. This 
programme was first developed and tested in the Free State province and involved 
the development of a syndromic, integrated guideline for the diagnosis and care of 
patients with priority respiratory diseases including asthma and COPO. It comprised 
an educational outreach programme to enable nurse practitioners to use the 
guideline to manage these diseases, and an evaluative component that examined its 
utility in the field. 18 The guideline was validated by comparing the nurse diagnosis 
and treatment to specialist diagnosis and treatment, confirming its performance. 18 A 
second study, a pragmatic randomised controlled trial in 40 rural primary care clinics 
in the Free State province, examined its impact in changing clinical practice and 
certain process outcomes. Favourable outcomes included increased prescription of 
inhaled corticosteroids in the intervention group (OR 1.9; 95%CI 1.14 - 3.18) and 
more appropriate referrals of patients with lung disease to the next level of care. H) 
3.6. lVIanagement of COPD in South Africa 
3.6.1. Guidelines for COPO management 
The most recent South African consensus guidelines for the management of COPO 
were published in 2004.20 These are similar to the GOLO guidelines but modifications 
relate chiefly to cost compromises required to make them relevant for the public 
health sector in South Africa. In addition, the South African guidelines acknowledge 
the impact of domestic and occupational exposures and previous lung infections, 
such as tuberculosis, in addition to tobacco consumption as risk factors for COPO. 
Major themes are smoking cessation strategies, the need to prevent exacerbations 











agonists and long-acting anticholinergic drugs in achieving sustained 
bronchodilatation, and emerging evidence for a limited role for inhaled corticosteroids 
in the treatment of COPD. 
3.6.2. Health Services and Essential Drug List Provision 
The South African state-run health system is responsible for healthcare of the 
majority of the population. Twenty eight percent of all persons attending emergency 
care facilities at a local community health centre in Cape Town presented with cough 
and difficulty breathing.21 We can suggest from this estimate that respiratory disease 
accounts for significant use of public sector health resources in this setting. 
The Standard Treatment guidelines and Essential Drug Lists (EDL) for South Africa 
firstly advise smoking cessation, "chest physiotherapy during infective episodes" and 
pulmonary rehabilitation.22 Inhaled ipratropium bromide and oral prednisone are 
suggested for management of chronic bronchitis/COPD, with addition of oral 
theophylline if the former two have "failed in exacerbations", (a rather odd reversal of 
prednisone and theophylline).22 Inhaled steroids are suggested if reversibility of 15% 
and more than 200ml improvement in FEV1 is present on lung function testing. 
However, the delivery of these measures may be limited owing to a lack of trained 
staff and facilities, accompanied by a lack of awareness of guidelines or inability to 
deliver appropriate care. The National Primary Health Care Facilities Survey of 2003 
found that there were both shortages and an inequitable distribution of healthcare 
personnel across provinces; community based service providers were few; 
equipment was seldom found in sufficient quantity and there was a lack of 
infrastructure and problems with crime at many facilities. 23 Less than 10% of the 
facilities had the full complement of the 25 drugs on the essential drug list in stock. 23 
Steyn et al reported that 24.3% of all men who use prescription drugs in South Africa 
were taking them for asthma or chronic bronchitis and that blacks used drugs less 
frequently than any other ethnic group, suggesting inequitable use. 24 
Recommendations from the SADHS suggested that there is a need to increase 
awareness of the South African guidelines for the management of COPD, by active 
professional development approaches aimed at smoking cessation advice, and 
training of primary care practitioners in the clinical evaluation of COPD, as well as the 











primary care level, making confirmation of the diagnosis of CO PO impossible without 
referral to a tertiary level hospital. 
Early diagnosis and treatment of COPO is essential for effective management of 
patients and in order to reduce healthcare utilisation and thereby costs to the 
healthcare system. Smith et al (2001) performed a systematic review and found that 
patients with moderate COPO may gain from a nursing outreach programme in terms 
of decreased mortality and increased quality of life, but not those with severe 
disease, who have no reduction in hospital admissions. 25 In the South African 
context, it is suspected that most mild to moderate COPO is underrecognised and 
undertreated. Symptoms only occur when approximately 40% of lung function has 
been lost and people are likely to present late owing to this fact, and also as result of 
widespread lack of awareness and access to healthcare. 
Smoking cessation is the most effective way of halting the progression of COPO in 
smokers. However, many smokers are unaware of effective cessation methods or 
underestimate the benefit thereof. The perception of smokers regarding their belief in 
the effectiveness of cessation methods is critical to their success. A Canadian study 
by Hammond et al (2004) found that participants who perceived cessation methods 
to be effective at baseline, were almost twice as likely to intend to quit, make a quit 
attempt at follow-up, and just under 4 times as more likely to use cessation 
assistance, e.g. nicotine patches, bupropion etc. 26 This has a bearing on the South 
African situation in that there are no formal group counselling or quit programmes 
and counselling by health professionals is limited. Faced with heavy patient loads, 
little time and limited support from other categories of health personnel in public 
sector clinics and hospitals, the importance of smoking cessation counselling is 
forgotten. Nicotine replacement therapy and bupoprion are not available on the EOL, 
and healthcare practitioners receive little training on smoking cessation counselling. 
The PALSA initiative addresses advice and counselling for smoking cessation in its 
integrated guideline. 19 
3.6.3. Diagnosing COPD and the status of spirometry in South Africa 
Spirometry is essential in the diagnosis and management of respiratory disease. An 
investigation into the quality of spirometry in South Africa performed in 1991 found 
very poor quality spirometry practice among 45 medical practitioners, including 26 
physicians. 27 Knowledge of international spirometry standards, methods of 











completely unsatisfactory in most practices, as was the standard of test quality 
assessment and interpretation of results. Quality control is a key issue in spirometry 
since it is influenced not only by the properties of the instrument, but by patient and 
operator issues and a good understanding between them. There are no recent 
published data on the proportion of routine spirometry performed outside of specialist 
or research centres that meet these quality criteria. 
Attempts to improve the standard of spirometry in South Africa is a long-standing 
issue and a number of guidelines on the subject have been published, applicable 
either to the occupational health arena, where routine spirometry is common, or for 
primary care. 28 29 30 Spirometry is almost unheard of in the public primary health care 
system and is very rare in the private practices. 
Recent improvements in technology may have come some way to improving the 
prospect of quality spirometry in primary care. The development of small accurate 
hand-held spirometers such as the ndd easyone® may make them suitable for the 
office/clinic setting in selected circumstances. With proper training, such devices 
could be useful in the diagnosis and management of COPD (and asthma) in South 
Africa as they are easy to use, do not require temperature and pressure controlled 
circumstances, have a reduced risk of cross infection and are easy to maintain (no 
closed systems with tubing etc). However, use of spirometry in primary care settings 
elsewhere has provided good evidence that it may not be practical or useful in 
resource-limited settings, owing to the cost of equipment, lack of access, and the 
time required to perform pre and postbronchodilator testing, as well as lack of 
familiarity with the tests. 31 32 Moreover, the need for well-trained technologists and 
physicians31 is imperative if spirometry is to be helpful, without which it can even be a 
hindrance to syndromic management if not properly performed or interpreted. 
Identification of high risk persons by means of a questionnaire, in order to facilitate 
appropriate referral, may be more feasible in the primary care setting. 33 
Application of appropriate predicted values for spirometry is essential to the 
identification of abnormal values and, in the context of COPD, for detecting those 
patients with early disease, so that secondary prevention can be offered. These need 
to be applicable to, and preferably derived from surveys performed in the community 
under study, because predicted values may differ for different groups. The obvious 
approach, recommended in most guidelines, of basing predicted values upon 











surrogate for socioeconomic status and reveal other exposures that influence lung 
capacity at the population level. 34 This will be considered further in this thesis. 
Considering its history, this is particularly true in South Africa. Louw and Goldin 
(1996) studied healthy South African men and published normal values for 
spirometry.35 They supported the hypothesis that the ethnic differences in lung 
function measurements were not the result of genetic differences but, in common 
with other anthropometric parameters, these resulted from socio-economic 
deprivation. 36 Ethnicityf"race" were hypothesised not to be a direct predictor of lung 
size. The effects of the latter could be mediated by intrauterine conditions, poor 
nutrition and recurrent infections, all associated with low socioeconomic status. They 
found that "sitting height was a better anthropometric predictor of spirometry than 
standing height" and suggested that sitting height and socioeconomic status 
indicators should be included in regression equations. 
There are few community-based surveys of lung function from which population-wide 
prediction equations can be derived. Most, like those by Hznido (2000) and Mokoetle 
(1994), have been performed in industry.37 :lfl Such surveys have significant 
limitations: they are usually confined to males in the working adult age-groups, and a 
healthy worker effect applies in many, especially in occupations like mining that 
involve manual labour. In 1994, White et al reviewed spirometric values reported in 
29 studies of healthy African adults and pointed out that most variation is attributable 
to differences in population selection, altitude (elevation above sea level) of the test 
site, the date of the study (older studies may not represent current anthropomorphic 
features of modern populations), and other biological sources of variation, like 
subject height. These factors are important when evaluating inter- and intra-
population comparisons of spirometric measurements. 39 
The use of correction factors for different ethnic groups in South Africa is debatable, 
and may have more relevance in the individual clinical situations when trying to 
decide on the presence of lung pathology for treatment purposes. However, in the 
epidemiological context of population studies, their use is difficult to justify. The main 
objection to their use is that they may mask the effects of poverty, which in South 
Africa is strongly associated with ethnicity. Eliminating the contributions of 
socioeconomic status from studies assessing ethnic differences is almost impossible 











3.7. Important risk factors in the South African and the local setting 
3.7.1. Tobacco smoking 
The prevalence of tobacco smoking in South Africa is high. Tobacco smoking was 
introduced by settlers in the 1 ih century and is a popular and socially acceptable 
habit, particularly in the Western Cape. It was not initially common amongst the 
indigenous peoples of Africa, and until recently, surveys of miners have confirmed 
low to moderate tobacco use, and little cigarette smoking.;; Little expendable income, 
and long shifts underground, where smoking is not permitted, may have served to 
limit opportunities for acquiring the habit. However, in the industry as a whole, the 
range of cigarette use varies over a wide range of 10 -75 packyears.4o Cowie et al 
reported an average of 13.7 pack years in a cohort of gold miners who had been 
mining for an average of 29 years. 41 
The population of the Western Cape has had centuries to acquire the habit, which 
was introduced in the 1 ih century.; Until recently, smoking might have been 
constrained by their relatively low incomes.;; Until 20 years ago, part payment for 
workers was in the form of a ration of wine known as the "dop" system, a legacy of 
slave labour on the Cape wine farms. This system was limited in 1928 and outlawed 
in 1961, but it continued on some farms into the 1990s.42 Tobacco often formed part 
of this "privilege". Wine, bread and tobacco were the "payment" that created 
entrenched social behaviour patterns and addiction to alcohol and tobacco. 43 Much 
has been written about the resultant alcoholism, but very little on the origins of the 
tobacco addiction that is still so prevalent in the Western and Northern Cape regions. 
Tobacco smoking in these areas is likely to have a large social component to 
addiction apart from the physiological addiction. Although practiced by both men and 
women, heavy smoking is not common. However, the improving economic status 
since democratisation in 1994 carries with it the risk that "light to moderate" smoking 
habits may be transformed into heavier smoking. 
In studies conducted in 1995 and 1996 the South African adult smoking prevalence 
was 34% and 25% in 1998.4445 The Global Youth Tobacco Survey of 1999 reported 
i "To animate their lessons and to make them really hear the Christian prayers, each slave should be given a small 
glass of brandy and two inches of tobacco,'" An excerpt on "educating slave children" from the diary of Jan Van 
Riebeeck, a Dutch explorer who established the Cape Dutch settlement and introduced winemaking to the Cape, 
Motta M, South Africa's Children Are Victims of Nation's Alcoholism Culture, Stell en bosch, South Africa 
29 December 2005, URL: http://www.voanews.com/english/archiveJ2005-12/2005-12-29 












that 23% of South African adolescents aged between the ages of 13 and 15 years 
were current smokers with 28.8% of boys and 17.5% of girls smoking daily.4G A 
repeat of this study in 2002 showed a drop in prevalence to 18.5% overall. 47 . 
Coloured iii boys were more likely to smoke than their African counterparts, and 18% 
of adolescents smoked their first cigarette before the age of ten. 
Smoking prevalence and patterns from the SADHS8 
Prevalence varies greatly according to gender, ethnic group, education and 
geographical location and urban or non-urban residence. The SADHS recorded the 
first ever national prevalence of 24% overall, comprising 42% for men and 11 % for 
women in 1998. Later national estimates from a different source reported a 
prevalence of 27.1 % overall (44% in men and 11.7% in women) in 2000.48 
With increasing employment and expendable income, coupled with urbanisation and 
aggressive marketing by cigarette companies, more teenagers and young adults 
from previously disadvantaged backgrounds have started smoking. The SADHS 
reported that 75% of persons aged 15-24 years had attempted to stop smoking with 
a success rate of 14% of males and 39% in females, suggesting that it is difficult to 
quit (a worldwide phenomenon), and that men have greater difficulty doing SO.8 
Coloured (57%) and Asian men (54%) were more likely to smoke than African men 
(40%) or white men (39%), with men form the Western and Northern Cape having 
the highest rates. i The Northern and Western Cape had the highest prevalence, and 
the Northern Province the lowest. Those with the least formal education had the 
highest smoking rates, and more urban residents had ever used tobacco. Smoking 
starts early in life (24% of men in the 15-24 age group smoke) with a mean start age 
of 20 years and most persons smoke manufactured cigarettes. The practice of pipe 
smoking by middle-aged or older women was more common in some rural areas of 
South Africa. Older rural African men and women were more likely to smoke pipes 
than other groups. 











Table 10: Prevalence of tobacco smoking in South Africa by Province in 19988 
Men (%) Women (%) 
Eastern Cape 46 11 
Free State 44 11 
Gauteng 42 12 
Kwa Zulu Natal 38 5 
Limpopo 29 2 
Mpumalanga 40 6 
Northern Cape 58 31 
North West 45 8 
Western Cape 49 29 
South Africa (Total) 42 11 
There has also been an increase in the prevalence of smoking in women over the 
last few decades. These trends are evident in the wide range of prevalence or 
reported smoking amongst women in the different provinces. Women in the Western 
and Northern Cape provinces have a significantly higher prevalence of smoking than 
in any of the other provinces (see Table 10), and 40% of Coloured women are 
smokers, four times higher than their Asian counterparts (see Figure 2). Very few 
African and Asian women smoke, but there is a higher use of smokeless tobacco 
(snuff) in non-urban African women. 8 
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Figure 2: The South African national prevalence of smoking by population group and 
sex, South Africa, 19988 
A gender disparity is also evident in certain provinces such as Kwa Zulu Natal and 
Mpumalanga. Socio-cultural differences in composition of the population could 











highest rates of smoking during pregnancy were noted among coloured women.8 49 A 
recent cross sectional study of pregnant coloured women in the Western Cape has 
found that 46% are smokers. 49 While the majority of women were aware of some of 
the dangers of smoking during pregnancy, 56% and 45% were unaware of the risk of 
premature labour and miscarriage respectively. Many (28%) had no intention of 
quitting and 20% of those who expressed a desire to quit had never made an attempt 
to do SO.49 
3.7.2. Cannabis smoking 
Cannabis has a long history of use in Cape Town, having been smoked since the 1 yth 
century'V and is probably the most widely consumed recreational drug in the world. 
Cannabis use in South Africa, although illegal, is widespread and its potential harmful 
effects upon the respiratory system have been little researched or publicised. 
Cannabis is the most commonly used illicit drug in South African adolescents, with 
particularly high rates of usage in Cape Town. A significant proportion of adult 
patients attending a public hospital trauma unit tested positive for cannabis, 
suggesting a link between its use and trauma, criminal activity and lawlessness.5o 
Thirty two percent of male and 13% of female adolescents in Cape Town reported 
lifetime use, with 21.5% of males and 8.6% of females reporting use in the past year, 
reflecting that it appears to be a predominantly male phenomenon. Seven percent of 
adolescents reported use in the last year.51 
Between 1990 and 2003, cannabis use doubled. Flischer et al have postulated that 
this may be due to more vigorous law enforcement in developed economies resulting 
in the exploitation of the South African market, and increased import across open 
borders after 1994.52 The cost of cannabis in South Africa is very low; only two Rands 
per 'bank bag'. An association with duration of urban residence has been reported. 
Rapid urbanisation and its accompanying problems of poverty, crime and housing 
predisposes to cannabis and other substance abuse. 
;V "As the story goes Jan van Hunks, a pirate in the early 18'" century, retired from his eventful life at sea 10 live on 
Ihe slopes of Devil's Peak. He spent his days sitting on the mountain smoking weed on his pipe. One day a stranger 
approached and asked to borrow some 'splitf'. After a bit of bragging, a smoking contest ensued which lasted for 
days. Van Hunks finally defeated the stoned stranger· who unfortunately turned out to be the devil - and they both 
vanished in a puff of cannabis smoke. Legend has it that the cloud of "tobacco" smoke they left became the "table-












Cannabis smoked with methaquolone (a non-barbiturate sedative hypnotic) is the 
second most commonly abused drug in Cape Town and is known as a "white -pipe", 
a form of drug abuse that appears to be unique to South Africa. Cannabis alone, or 
mixed with tobacco and/or methaquolone, is smoked in a makeshift pipe fashioned 
from a broken bottie neck (see Figure 3.).53 As self-reported usage is likely to be 
understated owing to the sensitive nature of such questions, it is suspected that true 
prevalence of cannabis, and particularly methaquolone usage is considerably higher 
than that reported. There are no South African data on the effect of cannabis 
smoking on respiratory health in terms of risk of chronic bronchitis or COPD. 
Figure 3: "White pipe" method of smoking cannabis in a makeshift "pipe" fashioned 
from a broken bottle neck53 
(With kind permission from H. Danson) 
3.7.3. Tuberculosis 
Studies of airflow obstruction as a result of past tuberculosis are few and have been 
reviewed in Chapter 2. Churchyard et al (2001) have shown that symptoms of cough 
and phlegm are associated with a past TB in South African gold miners, and its 
prevalence increased with severity of tuberculosis and lung function loss with the 
number of previous episodes of TS54 , suggesting greater damage to the airways. The 
proportion with chronic airflow limitation rose with each further episode.55 
A history of pulmonary tuberculosis has been shown to be the strongest predictor of 
both chronic bronchitis and wheeze in the general population in the SADHS. 56,57 In 
the first paper on chronic bronchitis, past tuberculosis was associated with a 
significant odds ratio of 4.9 (95% CI 2.6 - 9.2) in men and 6.6 (95%CI 3.7 - 11.9) in 
women.56 Past TB contributed a substantial population attributable fraction of 10%, 











3%) in comparison with other factors such as tobacco smoking. 56 The strength of 
association of past tuberculosis with chronic bronchitis exceeded that of smoking. 
This study confirmed the impact of the tuberculosis epidemic on chronic bronchitis at 
a national population level in South Africa. 
The second paper from the SAOHS found that a history of tuberculosis was also 
independently associated with both recent wheeze (OR 3.4; 95% CI 2.5 - 4.7) and 
asthma diagnosis (OR 2.2; 95% CI 1.5 - 3.2).57 Past TB was also strongly associated 
with wheeze with breathlessness, wheeze without a cold and night waking due to 
wheeze. The authors suggested that misdia.gnosis of post TB airflow limitation as 
asthma was possible. One does not know whether these persons had reversible 
airflow limitation or not. Secondly, the prescription of medications that are used to 
treat asthma could have led to participants reporting a diagnosis of asthma, and 
thirdly, both the wheeze and asthma question lack specificity to differentiate between 
asthma and COPO.57 Further research into the pathophysiology of post TB airflow 
obstruction is required. 
Some interesting research questions arise from this study regarding the 
characterisation of post tuberculous lung disease: What percentage has AHR and 
how should post TB lung disease, with and without AHR, be classified? Does TB 
cause asthma-like symptoms that are responsive to bronchodilators and steroids? 
What proportion have COPO and how should they be treated? Additionally, what is 
the nature or range of pathological lesions in the lungs in these patients? However 
classified, tuberculosis appears to be an important cause of chronic lung disease in 
South Africa. 
An important observation in the LHS2002, reported by den Boon et ai, is that tobacco 
smoking increased the risk of tuberculous infection as judged by a positive tuberculin 
reaction. Smokers had almost twice the risk of TB infection compared to never 
smokers, and those with a history of > 15 pack years had the highest risk (OR 1.9, 
95% CI 1.28 - 2.81 ).58 The mechanism proposed was the reduction of host defences 
"favouring the persistence and/or replication of ingested mycobacteria by impairing 
the macrophage or dendritic cell function". These results have implications for public 
health in South Africa. Although TIB control is a national priority, prevalence and 
incidence continues to rise in the Western Cape, and also in other parts of the 











3.7.4. Environmental air pollution 
3.7.4.1. Indoor air 
Combustion of biomass fuel in poorly ventilated dwellings is a recognised cause of 
chronic bronchitis in rural homes in several countries such as Columbia, Bolivia, 
Turkey Mexico and Iran.59-51 The SADHS reported that in South Africa 32.6% of men 
and 38.2% of women were exposed to smoky domestic fuel (wood, coal or dung).8 62 
A very strong association between exposure to smoky domestic fuel and markers of 
poverty and rural residence was observed. The same survey found an association 
between chronic bronchitis and smoky domestic fuel, but only amongst women. 8 In 
South Africa, exposures in rural African women, the group most exposed to this form 
of indoor air pollution, are thus a major contributor to the higher prevalence of chronic 
bronchitis overall in women compared to men, despite lower smoking prevalences. li3 
In addition to smoking, environmental and occupational exposure to asbestos, dusty 
occupations (in men) and indoor air pollution (biomass fuels) are also thought to 
contribute to the prevalence of lung cancer in the Northern Province of South Africa.64 
However, the situation in this and other parts of South Africa is also changing owing 
to an ambitious government programme to provide electricity to the majority of 
households. This programme has resulted in an increase in the proportion of 
households electrified from 36% in 1994 to about 68% (of 10 million households) at 
the end of 1999.65 The percentage of urban households that had received this 
service was much higher than those in rural communities (80% versus 46%). 
A significant proportion of the population is thus still dependent on highly polluting 
biomass fuel (wood, grass or dung) and fossil fuels (coal) for their indoor cooking and 
heating requirements. Rural homes in South Africa have been shown to have a 
higher level of respirable particulate matter and carbon monoxide than their 
electrified counterparts.66 Even those with currently electrified dwellings may have 
had significant past exposure. In a survey performed in Cape Town, the use of 











3.7.4.2. Outdoor air 
In Cape Town, early 18th century legislation included strict fire safety measures, 
including rules against smoking outdoors, but this was obviously unrelated to air 
pollution concerns.v However, air quality monitoring in South Africa is a relatively new 
phenomenon, unlike in the United Kingdom where it attracted a great deal of public 
health interest after the London Fog incident in 1952. The location of air sampling 
sites in the greater Cape Town Metropolitan area is shown in Figure 4. 69 High PM10 
levels have been recorded at informal settlements where biomass fuels are used. 
Both industry and vehicular emissions contribute to S02 (sulphur dioxide) and PM 10 
(particulate matter size of 10 micrograms) emissions, nitrogen oxides (NOx ) carbon 
monoxide (CO) and volatile organic compounds. The most evidence exists for the 
role of S02 and PM lO in exacerbating asthma and other chronic respiratory conditions 
in adults and children.vi 
There have been relatively few studies of air pollution in South Africa. The largest 
was the Vaal Triangle study undertaken in the early 1990s.68 In this longitudinal study 
of children aged 8-12 years living in the northern regions of South Africa, lower 
respiratory tract illness ("bronchitis, chronic cough and chronic chest illnesses") were 
reported in 28.9% of children. 
In the City of Cape Town atmospheric concentrations of PM10 particles have risen 
steadily over the last five years. 59 For example, levels in July 2005 exceeded the air 
quality guideline levels on 24 days.59 A phenomenon known as the Brown Haze 
occurs over Cape Town during the less windy months of March to August. As a result 
of low level temperature inversion (when a layer of cold descending air traps air at 
the ground level) pollutants, and in particular PM2.5 particles from diesel- and petrol-
powered vehicles, wood burning and industrial boilers, in addition to a significant 
organic carbon from an unknown source result in heavy pollution across the Cape 
flats.70 
v Simon "Van der Stel proclaimed building safety regulations for houses, bams and kraals. Other regulations later 
followed regarding storage of wood, while inhabitants building new homes were encouraged to use tiles instead of 
thatch, and smoking in the streets were declared punishable by public lashings." 











The study areas of Ravensmead and Uitsig lie within a zone containing both light and 
heavy industries (see Goodwood and Belville South in Figure 4) and within the areas 
subjected to the brown haze described above.70 
• Ravensmeadl Uitsig 
4 0 4 8 Kilometers 
I""""'I~-~~"'Ii;;;;;iiiiiiiiil 
Figure 4: Map of Cape Town showing air pollution monitoring sites69 
The health effects of local air pollution in residential suburbs close to industrial areas 
have been investigated in both Durban and Cape Town. In the study by Nriagu et al. 
(discussed above) very high prevalences of respiratory symptoms were observed in 
South Central Durban.6 However, 12% of adults reported doctor-diagnosed asthma, 
in keeping with the prevalence in the rest of country, suggesting either under-











this study was asthma, the results point to the potential of air pollution contributing to 
the development of COPD. This potential also applies to Ravensmead and Uitsig. 
In a second study, White et al also found a high prevalence of respiratory symptoms 
in children in the northwest suburbs of Cape Town in the vicinity of a petrochemical 
refinery. Twenty-four percent of children reported current and/or previous asthma, 
(see Figure 4, Tableview area)"i considerably higher than the 13.3% reported for 
Cape Town as a whole in the 1995 ISAAC (p<0.01).71 The prevalence of wheeze in 
the last 12 months was also double that of the whole city (31.6% vs. 16.0%), and 
64.6% reported hayfever. Asthma and wheeze were associated with an estimated 
petrochemical emission exposure, incorporating wind direction and speed and 
distance from the refinery, using a meteorological instrument known as a wind-rose. 
A specific agent could not be identified. Monitored levels of sulphur dioxide in the 
area were relatively low. However, the study concluded that the petrochemical 
refinery emissions were a significant risk factor for asthma and asthma exacerbations 
among children in this area. The effect of these emissions on adults was not 
assessed and it is plausible that these exposures could be of importance in triggering 
asthma and CO PO exacerbations in adults and may even be of importance in terms 
of lung function decline. This is a subject for future investigation. 
3.7.5. Occupational Exposures 
Occupational exposures contribute significantly to the prevalence of respiratory 
symptoms at the general population level, as described in Chapter 2 and above. The 
occupational lung diseases that have received the most attention over the past 
decade have been pneumoconiosis, particularly silicosis in gold miners, and 
occupational asthma. 74 92 94 9597 
Inhalation of silica dust is associated with silicosis, an increased lifetime risk of 
tuberculosis, COPD and even lung cancer.72 Black mineworkers have had the most 
significant exposure to mineral dusts, but prior to 1994, very few studies have been 
published73 74 and the intermediate and long term effects of occupational exposures 
in black miners are only now being highlighted. Prior studies were inhibited by large 
multinational mining companies, and attempts at improving work conditions and 
providing adequate compensation were suppressed by the apartheid government. 74 
VI White NW. Ehrlich RI, teWaterNaude J. Schutle A, Essack N, Roberts W. A study of allergic diseases and the 












Very high prevalences of radiological silicosis of between 22 and 36% (depending on 
the reader) have been reported in migrant labourers from the Eastern Cape75 and 
Botswana.76 In addition both pneumoconiosis and tuberculosis were associated with 
airflow limitation. Past tuberculosis is a common cause of lung function loss in miners 
exposed to silica dust, irrespective of the presence of sllicosis.77 Having been 
exposed to significant quantity and duration of dust exposure, large fluctuations in 
temperature, overcrowded and unsatisfactory living conditions in compounds, and 
poor nutrition are all thought to contribute to the very high risk of contracting 
tuberculosis among black miners.74 The life-long consequences of silica dust 
exposure are experienced in the progressive nature of silicosis long after ceasing 
dust exposure. 75 76 
Churchyard et al (2004) have shown that this risk is present at a mean quartz 
exposure below the occupational exposure limit of 0.1 mg/m:l. 78 Long average 
duration of work, heavy dust exposure for shorter periods of time and failure to 
recognise mineral dust as a health hazard have contributed to a rising prevalence of 
silicosis especially in black mineworkers. 73, 79 However, Marks (2001) noted that white 
mineworkers benefited from adequate compensation, paid leave and medical 
benefits, indicating recognition of the cause by the mining industry.74 
Dust exposure has been shown to be associated with the development of COPD. In 
1990, Hnizdo showed that smoking and silica exposure acted synergistically in 
increasing the risk of death from COPD in white miners80 and subsequently found 
that the average loss of FEV1 attributable to the effects of 25 years of gold mining 
was 236 ml. This compares with a loss of 552ml associated with smoking one packet 
of cigarettes per day for 30 years. 81 As smoking becomes more common among 
black mineworkers, the prevalence and severity of COPD can be expected to rise. A 
recent autopsy study of coal miners found length of service to be associated not only 
with silicosis and coal workers' pneumoconiosis defined pathologically, but also with 
emphysema after controlling for smoking. 82 
The relationship between cor pulmonale and factors such as emphysema and 
silicosis was investigated in a necropsy based case control study which revealed 
marked emphysema as the highest risk factor for airflow obstruction (OR 21.32, CI 
5.02 - 90.7), followed by extensive silicosis (OR 4.95, CI 2.92 -8.38), which was also 











borne by those with occupational exposures in South Africa. B3 Smoking was related 
to all outcomes of bronchitis and emphysema, but assumptions of high smoking rates 
as the major confounder of the effects of occupational exposure are too simplistic 
and need to be interrogated further. 84 Recent studies have supported that smoking 
and occupational exposures are associated with COPD both additively and 
independently.85 
Prior to the HIV pandemic, the incidence of tuberculosis, though high, was showing a 
decreasing trend. However, over the last decade, the impact of HIV has been very 
significant, causing a rise in the prevalence of tuberculosis in South Africa. HIV co-
infection has led to a fourfold increase in the incidence rate among gold miners, 
reaching approximately 2000 per 100 000 miners in one group of mines in 2000.86 
Corbett et al (2000) have examined the effect of HIV infection and silicosis on the 
incidence of tuberculosis and found that HIV infection increased the incidence of 
tuberculosis fivefold and that silicosis increased the incidence of tuberculosis 
threefold. 711 The combined effect was multiplicativ , increasing the incidence of 
tuberculosis 15 times. In light of this, control of silica exposure must be an urgent 
priority in all at risk settings. Unfortunately, the large pool of ex-miners with past silica 
exposure remain at lifelong risk of TB which will serve to perpetuate the epidemic. 78 
81 
3.7.5.1. Occupational asthma 
A Cape Town study of acute asthma cases showed that 12.9% of cases fulfilled the 
criteria for a diagnosis of occupational asthma (mainly spray painters and domestic 
workers) and 25.7% reported aggravation of asthma by occupational exposures.88 As 
most cases of occupational asthma are not likely to be reported, the national 
incidence of 17.5 per million employed persons (based on 324 recorded cases over 2 
years from a voluntary register) is understood to be a marked underestimation.89 
South African studies of occupational asthma report a prevalence of 12% and 9.2% 
respectively.90 91 In four studies by Jeebhay et al performed in the Western Cape 
Province, asthma attributed to spider mites, fish products and fish parasites, flour, 
grain and storage pests were reported with prevalences ranging from 3 to 13% of 
exposed workers.92 93 94 95 In addition to the agents mentioned above, isocyanates 
from products such as spray paints are also implicated. A follow-up study of 
occupational asthma reported that 16.2% of cases were no longer working and only 











the respiratory symptomatology recorded in the LHS2002 survey might have been 
due to occupational asthma or COPD caused by occupational exposures. 
The last few years have seen an increased focus on the management of 
occupational lung disease, and guidelines for diagnosis, management and 
compensation have been published. 97 98 The South African Department of Labour 
has recently published compensation guidelines that cover a wide range of 
conditions warranting compensation, most notably for tuberculosis in silica exposed 
workers and lung cancer. 99 
3.8. Conclusion 
Obstructive lung disease in South Africa is a source of both considerable mortality 
and decreased quality of life to the individual, and a drain on medical resources of 
the public sector. Very few studies have attempted to quantify the prevalence of 
disease and the burden that it imposes in South Africa. 
However, the diversity in ethnicity, socioeconomic status and exposures in South 
African people makes it imperative that studies focus on different contexts and areas, 
particularly when aetiological relationships are being investigated. Such research is 
of more than academic interest as a large proportion of these diseases is preventable 
and measures to curtail exposures to such factors as tobacco smoke, occupational 
dusts and air pollution can be expected to result in improvements in the health of 
society. 
The study of obstructive lung disease in a community like Ravensmead and Uitsig is 
useful owing to the fact that this community is exposed to a range of risk factors for 
lung disease common to large sections of the South African population, and provides 
the opportunity to examine the effects of these factors in a community setting. The 
study population, study area and methods used are described in the next chapter. 
3.9. References 
1 Ehrlich R, Jithoo A. Chronic Respiratory Diseases in South Africa. In: Jean Fourie, Norman 
Temple, Krisela Steyn (Eds). Chronic Diseases of Lifestyle in South Africa: Review of 
Research 1995-2005. MRC Technical Report. May 2006. 
;, Bradshaw D, Schneider M, Dorrington R, Bourne DE, Laubscher R. South African cause- of 











:) Bradshaw D, Groenewald P, Laubscher R, Nannan N, NOJilana B, Norman R, Pieterse D, 
Schneider M. Initial estimates from the South African National Burden of Disease Study, 
2000. Policy Brief No.1. Cape Town: Medical Research Council, 2003. URL: 
http://www.mrc.ac.za/policybriefs/initialestimates.pdf. Accessed Februrary 2006. 
4 Bradshaw D, Nannan N, Laubscher R, Groenewald P, Joubert J, Nojilana B, Norman R, 
Pieterse D, Schneider M. South African National Burden of Disease Study 2000: Estimates of 
Provincial Mortality. Cape Town: South African Medical Research Council, 2004. 
5 Masoli M, Fabian D, Holt S, Beasley R. Global Burden of Asthma. 2003. 
http://ginasthma.com/Reportltem.asp?11 =2&12=2&intld=95 Accessed March 2006. 
6 Nriagu J, Robins TR, Gary L, Liggans G, Davila R, Supuwood K, Harvey C, Jinabhai CC, 
Naidoo R. Prevalence of asthma and respiratory symptoms in south-central Durban, South 
Africa. Eur J EpidemioI1999;15:747-755. 
7 Wicht CL, de Kock MA, Kotze T JvW. An epidemiological study of the diffuse obstructive 
pulmonary syndrome. S Afr Med J 1977;52(suppl.):1-15. 
8 Department of Health. South Africa Demographic and Health Survey Report 1998. Pretoria: 
Department of Health, 2002:1-338. URL: 
http://www.healthnet.org.za/Publications/DemographicSurvey/demographicsurvey.htm 
9 Chan-Yeung M, Ait-Khaled N, White N, Tsang KW, Tan W-C. Management of chronic 
obstructive pulmonary disease in Asia and Africa. Int J Tuberc Lung Dis 2004;8: 159-170. 
10 Cerveri I, Accordini S, Verlato G, Corsico A, Zoia MC, Casali L, Burney P, De Marco R; 
European Community Respiratory Health Survey (ECRHS) Study Group. Variations in the 
prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur 
Respir J 2001; 18:85-92. 
11 Huchon GJ, Vergnenegre A, Neukirch F, Brami G, Roche N, Preux PM. Chronic bronchitis 
among French adults: high prevalence and underdiagnosis. Eur Respir J. 2002 
Oct;20( 4 ):806-12. 
12 Burney PGJ, Britton clR, Chinn S, et al. Descriptive epidemiology of bronchial reactivity in 
an adult population: results from a community study. Thorax 1987; 42:38-44. 
13 Poyser MA Social Deprivation and asthma prevalence. ICU admissions and mortality in 
Cape Town. MSc thesis, University of Cape Town. 
14 Poyser MA, Nelson H, Ehrlich RI, Bateman ED, Parnell S, Puterman A, Weinberg E. 
Socioeconomic deprivation and asthma prevalence and severity in young adolescents. Eur 
Respir J 2002;19:1-7. 
15 Zar HJ, Stickells D, Toerien A, Wilson D, Klein M, Bateman ED. Changes in fatal and near-
fatal asthma in an urban area of South Africa from 1980-1997. Eur Respir J 2001; 18:33-37. 
Hi Ehrlich RI, Bourne DE. Asthma deaths among coloured and white South Africans: 1962-
1988. Respir Med 1994;88:195-202. 
17 De Klerk A, van Schalkwyk E, Williams Z, Lee W, Bardin P. Risk factors for near-fatal 
asthma -- a case-control study in a Western Cape teaching hospital. S Afr Med J 
2002;92:140-144. 
18 English RG, Bachmann M, Naidoo S, Zwarenstein M, Bateman ED. (Abstract). The 













19 Fairall L, Zwarenstein M, Bateman E, Bachmann M, Lombard C, Majara B, Joubert G, 
English RG, Bheekie A, van Rensburg D, Myers P, Peters AC, Chapman RD. Effect of 
educational outreach to nurses on tuberculosis case detection and primary care of respiratory 
illness: a pragmatic cluster randomised controlled trial. BMJ 2005;331 :750-754. 
20 Bateman ED, Feldman C, O'Brien J, Plit M, Joubert JR. COPD Guideline Working Group of 
the South African Thoracic Society. Guideline for the management of chronic obstructive 
pulmonary disease (COPD): 2004 revision. S Afr Med J 2004;94:559-575. (Erratum in: S Afr 
Med J 2004;94:872). 
21 Fairall L, Donald K, Zwarenstein M, Scherpbier R. "Evaluation of clinical predictors of lung 
diagnosis in primary care in Cape Town." Paper presented at the 2001 Annual South African 
Thoracic Society (SATS) Congress. Bloemfontein, Free State: 2001. 
22 South African Standard Treatment Guidelines and Essential Drugs List for Primary Health 
Care, 2003 Edition. Published by: The National Department of Health, Pretoria. South Africa. 
2:3 Reagan G, Irlam J, Levin J.The National Primary Health Care Facilities Survey 2003. 
Health Systems Trust. 2004. URL: http://www.hsLorg.za/publications/617/ Accessed July 
2006. 
24 Steyn K, Bradshaw 0, Norman R, Bradley H, Laubscher R; Research team of theSouth 
African Demographic and Health Survey. The use of prescribed drugs for common chronic 
conditions in South Africa in 1998. Pharmacoepidemiol Drug Safe 2005 Feb;14(2):91-1 00. 
25 Smith B, Appleton S, Adams R, Southcott A, Ruffin R. Home care by outreach nursing for 
chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2001 ;(3):CD000994_ 
26 Hammond D, McDonald PW, Fong GT, Borland R. Do smokers know how to quit? 
Knowledge and perceived effectiveness of cessation assistance as predictors of cessation 
behaviour. Addiction 2004; 99(8):1042-8. 
27 Basson E, Stewart RI. The standard of spirometry in the RSA. S Afr Med J 1991 ;79:361-
363. 
28 White N, Ehrlich R, Rees D. A guide to spirometry as applied to occupational health. S Afr 
Med J 1996;86:807-813. 
29 Ehrlich R, White N, Myers J, Thompson ML, Churchyard G, Barnes D, de Villiers DB. 
Development of Lung Function Reference Tables Suitable for Use in the South African Mining 
Industry (SIMHEAL TH 610A). Johannesburg: Safety in Mines Research Advisory Committee, 
2000. 
-10 van Schalkwyk EM, Schultz C, Joubert JR, White NW; South African Thoracic Society 
Standards of Spirometry Committee. Guideline for office spirometry in adults, 2004. S Afr Med 
J 2004;94:576-587. 
31 Hueto J, Cebollero P, Pascali, Cascante JA, Eguia VM, Teruel F, Carpintero M. 
Spirometry in primary care in Navarre, Spain. Arch Bronconeumol. 2006 Jul;42(7):326-31. 
32 Buist S. COPD: a common disease that is preventable and treatable. Prim Care Respir J. 
2006 Feb;15(1 ):7-9. Epub 2006 Jan 18. 
:tJ Price DB, Tinkelman DG, Nordyke RJ, Isonaka S, Halbert RJ; COPD Questionnaire Study 
Group. Scoring system and clinical application of COPD diagnostic questionnaires. Chest. 
2006 Jun;129(6):1531-9. 












35 Goldin JG, Louw SJ, Joubert G. Spirometry of healthy adult South African men. Part II. 
Interrelationship between socio-environmental factors and 'race' as determinants of 
spirometry. 
S Afr Med J. 1996 Jul;86(7):820-6. 
3f) Louw SJ, Goldin JG, Joubert G. Spirometry of healthy adult South African men. Part I. 
Normative values. S Afr Med J. 1996 Jul;86(7):814-9. 
37 Hnizdo, Lung function prediction equations derived from healthy South African gold miners. 
Occup Environ Med. 2000 Oct;57(10):698-705. 
38 Mokoetle KE, de Beer M, Becklake MR A respiratory survey in a black Johannesburg 
workforce. Thorax. 1994 Apr;49( 4 ):340-6. 
39 White 1994 White NW, Hanley .IH, Lalloo UG, Becklake MR. Review and analysis of 
variation between spirometric values reported in 29 studies of healthy African adults. Am J 
Respir Crit Care Med. 1994 AUg;150(2):348-55. 
40 Kleinschmidt I. Predictors of smoking in a cross section of novice mine workers. Central Afr 
J Med 1997;43:321-324. 
41 Cowie RL. The influence of silicosis on deteriorating lung function in gold miners. Chest 
1998; 13,340-343. 
42 Anonymous. Fruits of the Vine. The lie of the land. URL: 
http://www.nlsa.ac.za/vine/lieoftheland.html. Accessed July 2006 
43 McKinstry J. Using the Past to Step Forward: Fetal Alcohol Syndrome in the Western Cape 
Province of South Africa. American Journal of Public Health 2005;95(7):1097-1099. 
44 Reddy P, Meyer-Weitz A, Yach D. Smoking status, knowledge of health effects and 
attitudes towards tobacco control in South Africa. S Afr Med J. 1996 Nov;86( 11): 1389-93. 
45 Meyer-Weitz A, Reddy P, Levine J. A comparison of the effects of South Africa's first 
tobacco control legislation on adult South African's smoking status, their knowledge of 
smoking related diseases and perceptions regarding the legislation: February 1995-0ctober 
1996. Cape Town: Medical Research Council (SA); 1998. 
46 Swart D, Reddy P, Ruiter RA, de Vries H. Cigarette use among male and female grade 8-
10 students of different ethnicity in South African schools. Tob Control. 2003 Mar;12(1 ):e1. 
47 Swart D, Reddy SP, Panday S, Philip JL, Naidoo N, Ngobeni N. The 2002 Global Youth 
Tobacco Survey (GYTS): The 2nd GYTS in South Africa (SA) - A comparison between GYTS 
(SA) 1999 and GYTS (SA) 2002. Cape Town: South African MRC; 2004.URL: 
http://www.mrc.ac.za/healthpromotion/healthpromotion.htm 
48 Van Walbeek C. Recent trends in Cigarette Smoking Prevalence in South Africa: Some 
evidence from AMPS data. S Afr Med J 2002;92(6):468-72. 
49 Petersen Z. Women's Knowledge, Practices and beliefs of smoking during pregnancy: A 
study of low-income pregnant Coloured women attending public sector antenatal Clinics in 
South Africa. MSc thesis. University of Cape Town, South Africa. October 2004. (Abstract). 
50 Parry CD, Pluddemann A, Louw A, Leggett T. The 3-metros study of drugs and crime in 












51 Parry CD, Myers B, Morojele NK, Flisher AJ, Bhana A, Donson H, Pluddemann A. Trends 
in adolescent alcohol and other drug use: findings from three sentinel sites in South Africa 
(1997-2001). J Adolesc. 2004 Aug;27(4):429-40. 
52 Flisher AJ, Parry CD, Evans J, Muller M, Lombard C. Substance use by adolescents in 
Cape Town: prevalence and correlates. J Adolesc Health. 2003 Jan;32(1 ):58-65. 
:;3 Maziko M, Peden M, Donson H. Road to Research. August 1999. Presentation. URL: 
http://www.sahealthinfo.org/violence/roadresearch.pdf. Accessed: March 2006. 
54 Churchyard GJ, Hnizdo E, White N. Pulmonary Tuberculosis in relation to Lung Function 
Loss. SIMHEAL TH 617. Final Report 25 June 2001. 
55 Hnizdo E, Singh T, Churchyard G. Chronic pulmonary function impairment caused by initial 
and recurrent pulmonary tuberculosis following treatment. Thorax. 2000 Jan;55(1 ):32-8. 
~i6 Ehrlich R, White N, Norman R, Laubscher R, Steyn K, Lombard C, Bradshaw D. Predictors 
of chronic bronchitis in South African adults. Int J Tuberc Lung Dis 2004;8:369-376. 
57 Ehrlich RI, White N, Norman R, Laubscher R, Steyn K, Lombard C, Bradshaw D. Wheeze, 
asthma diagnosis and medication use: a national adult survey in a developing country. Thorax 
2005;60:895-901. 
n~ 
.), den Boon S, van Lill SW, Borgdorff MW, Verver S, Bateman ED, Lombard CJ, Enarson DA, 
Beyers N. Association between smoking and tuberculosis infection: a population survey in a 
high tuberculosis incidence area. Thorax. 2005 Jul;60(7):555-7. 
59 Albalak R, Frisancho AR, Keeler GJ. Domestic biomass fuel combustion and chronic 
bronchitis in two rural Bolivian villages. Thorax 1999;54:1004-1008. 
60 Cetinkaya F. Gulmez I, Aydin T, Ozturk Y, Ozesmi M, Demir R. Prevalence of chronic 
bronchitis and associated risk factors in a rural area of Kayseri, Central Anatolia, Turkey. 
Monaldi Arch Chest Dis 2000;55:189-193. 
61 Golshan M, Faghihi M, Marandi MM. Indoor women jobs and pulmonary risks in rural areas 
of Isfahan, Iran, 2000. Respir Med 2002;96:382-388. 
G2 Bradshaw D, Steyn K. Poverty and Chronic Diseases in South Africa. MRC Technical 
Report. Parow: Medical Research Council, 2001. 
G3 Steyn K, Bradshaw D, Norman R, Laubscher R, Saloojee Y. Tobacco use in South Africans 
during 1998: the first Demographic and Health Survey. J Cardiovasc Risk 2002;9:161-170. 
(;4 Mzileni 0, Sitas F, Steyn K, Carrara H, Bekker P. Lung cancer, tobacco, and environmental 
factors in the African population of the Northern Province, South Africa. Tob Control. 1999 
Winter;8( 4 ):398-401. 
1i5 Kotze IA. The South African national electrification programme: past lessons and future 
prospects. s.a. URL: http://wireO.ises.org/wire/doclibs/AUtiISEREA.nsf/id/. Accessed February 
2005. 
liGRollin H B, Mathee A, Bruce N, Levin J, von Schirnding YE. Comparison of Indoor air 
auality in electrified and unelectrified dwellings in rural South African villages. Indoor Air 
2004; 14:208-216. 
(i7 Bailie R, Truluck T, Ehrlich RI. Trends in photochemical smog in Cape Town and 












68 Louw S. Respiratory diseases. In: Fourie J, Steyn K, eds. Chronic Diseases of lifestyle in 
South Africa. Parow: Medical Research Council, 1995. 
69 City of Cape Town: Air Quality monitoring network. URL: 
http://www.capetown.gov.za/airqual/ Accessed Oct 2005. 
70 Wicking -Baird MC, De Villiers MG, Dutkiewicz RK. The Cape Town Brown Haze Study. 
Executive Report. U RL: http://www.eri.uct.ac.za/Brown%20Haze/Brown_ Haze. pdf. Accessed 
June 2006. 
71 Poyser MA, Nelson H, Ehrlich RI, Bateman ED, Parnell S, Puterman A, Weinberg E. 
Socioeconomic deprivation and asthma prevalence and severity in young adolescents. Eur 
Respir J 2002 May;19(5):892-8. 
72 National Institute for Occupational Safety and Health (NIOSH). Health Effects of 
Occupational Exposure to Respirable Crystalline Silica. Cincinnati, Ohio: Department of 
Health and Human Services (NIOSH) 2002; Publication No. 2002-129:1-127. 
73 Leger J-P. Occupational diseases in South African mines: a neglected epidemic. S Afr Med 
J 1992;81:197-201. 
74 Marks S. The silent scourge? Silicosis, respiratory disease and gold-mining in South Africa. 
Paper presented at the University of the Witwatersrand Institute for Social and Economic 
Research, International Visitors Seminar Series, June 2003. URL: 
http://wiserweb.wits.ac.za/archive%20-%20events%202003.htm#visitors. Accessed June 
2006. 
75 Trapido AS, Mqoqi !\Jp, Williams BG, White NW, Solomon A, Goode RH, Macheke eM, 
Davies AJ, Panter C. Prevalence of occupational lung disease in a random sample of former 
mineworkers, Libode District, Eastern Cape Province, South Africa. Am J Ind Med 
1998;34:305-313. 
76 Steen TW, Gyi KM, White NW, Gabosianelwe T, Ludick S, Mazonde GN, Mabongo N, 
Ncube M, Monare N, Ehrlich RI, Schierhout G. Prevalence of occupational lung disease 
among Botswana men formerly employed in the South African mining industry. Occup 
Environ Med 1997;54: 19-26. 
77 Hnizdo E, Murray J. Risk of pulmonary tuberculosis relative to silicosis and exposure to 
silica dust in South African gold miners. Occup Environ Med1998;55:496-502. 
78 Churchyard G, Ehrlich R, teWaterNaude J, Pemba L, Dekker K, Vermeijs M, White N, 
Myers J. Silicosis prevalence and exposure response relationships in South African 
goldminers. Occup Environ Med 2004;61 :811-816. 
79 White N. Health hazards in the mining industry: An overview. Pretoria: South African 
Department of Mineral and Energy. Submission to the Commission of Inquiry into Health and 
Safety in the Mining Industry, 1995. 
80 Hnizdo E. Combined effect of silica dust and tobacco smoking on mortality from chronic 
obstructive lung disease in gold miners. Brit J Ind Med 1990:47:656-664. 
81 Hnizdo E. Health risks among white South African goldminers - dust, smoking and chronic 
obstructive pulmonary disease. S Afr Med J 1992;81 :512-517. 
82 Naidoo RN, Robins TG, Murray J. Respiratory outcomes among South African coal miners 












83 Hnizdo E, Murray J, Davison A. Correlation between autopsy findings for chronic 
obstructive airways disease and in-life disability in South African gold miners. Int Arch Occup 
Environ Health. 2000 May;73(4):235-44. 
n4 Kleinschmidt I. Predictors of smoking in a cross section of novice mine workers. Cent Afr J 
Med. 1997 Nov;43(11 ):321-4. 
fl5 Hu Y, Chen B, Yin Z, Jia L, Zhou Y, Jin T. Increased risk of chronic obstructive pulmonary 
diseases in coke oven workers: interaction between occupational exposure and smoking. 
Thorax. 2006 Apr; 61 (4 ):290-5. Epub 2006 Feb 7. 
ilG Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. HIV and 
pulmonary tuberculosis: the impact goes beyond those infected with HIV. AIDS 2004;18:657-
662. 
H7 teWaternaude JM, Ehrlich RI, Churchyard GJ, Pemba L, Dekker K, Vermeis M, White NW, 
Thompson NIL, Myers JE. Tuberculosis and silica exposure in South African gold miners. 
Occup Environ Med. 2006 Mar;63(3): 187 -92. 
88 Buck RG, Miles AJ, Ehrlich RI. Possible occupational asthma among adults presenting with 
acute asthma. S Afr Med J 2000;90:884-888. 
WJ Esterhuizen TM, Hnizdo E, Rees D. Occurrence and causes of occupational asthma in 
South Africa - results from SORDSA's Occupational Asthma Registry, 1997-1999. S Afr Med 
J 2001 ;91 :509-513. 
90 Calverley AE, Rees D, Dowdeswell RJ, Linnett PJ, Kielkowski D. Platinum salt sensitivity in 
refinery workers: incidence and effects of smoking and exposure. Occup Environ Med 
1995;52:661-666. 
91 Rees D, Nelson G, Kielkowski D, Wasserfall C, Da Costa A. Respiratory health and 
immunological profile of poultry workers. S Afr Med J 1998;88:1110-1117 
'12 Jeebhay MF, Baatjies R, Lopata AL, Sander I, Raulf-Heimsoth M, Barnard V, Bateman E, 
Robins TG. Occupational allergy and asthma in small bakeries of a supermarket chain store 
in South Africa (abstract 1036). Allergy Clin Immunollnt 2005;S(1 ):379. 
93 Jeebhay MF, Stark J, Fourie A, Robins T, Ehrlich R. Grain dust allergy and asthma among 
grain mill workers in Cape Town. Current Allergy Clin Immunol 2000;13:23-25. 
9·1 Jeebhay IVIF, Baatjies R, Lopata AL. Occupational allergy among table grape farm workers 
in South Africa. Current Allergy Clin Immunol 2002;15:174-177. 
% Jeebhay MF. Occupational allergy associated with saltwater bony fish processing in South 
Africa. PhD (Industrial Health) thesis, University of Michigan, 2003. In: Dissertation Abstracts 
International (Publication no. 3106356), Proquest Information and Learning, 2003;64:09 
(section B), 4293. 
96 Esterhuizen TM, Rees D, Kielkowski D, Lalloo UG, White N, Ehrlich R, van Schalkwyk E, 
Lalloo U. Consequences of Occupational Asthma After Diagnosis. NCOH Report 04/2001. 
Johannesburg: National Centre for Occupational Health, 2001. 
lI7 Ehrlich R, Jeebhay M. Occupational asthma in South Africa. In: Potter PC, Lee S, eds. The 
ALLSA Handbook of Practical Allergy (2nd edn.) Cape Town: Allergy SOciety of South Africa, 
2001.URL: http://www.allergysa.org. Accessed May 2006. 
(;1\ Surveillance of Occupational Diseases in South Africa (SORDSA). Alert: Diagnosis and 











for Occupational Health, 2000. 











CHAPTER 4: METHODS OF THE LUNG HEALTH SURVEY 
2002 AND THE BOLD STUDY 
4.1. Hypothesis and aim of studies 
The LHS 2002 and the BOLD studies were designed to investigate the prevalence of 
respiratory symptoms of obstructive lung disease and their associated risk factors, 
and the prevalence and risk factors for capo respectively. The hypothesis being 
examined was that the presence of chronic respiratory symptoms (other than those 
resulting from asthma) and of capo, is significantly associated with factors other 
than tobacco smoking e.g. occupational exposures, cannabis smoking, tuberculosis 
and socioeconomic status. 
4.2. Protocol overview 
The LHS 2002 was a cross-sectional study involving a 15% random sample of 
addresses recruiting persons aged ~15 years living at the sampled addresses. Study 
procedures included the administration of a respiratory questionnaire and height and 
weight measurements in the participant's homes. Tuberculin skin testing, chest 
radiography and sputum sampling were also performed for the concurrent 
tuberculosis prevalence study. 
In 2005, the BOLD study sampled the same addresses and recruited persons aged 
~40 years to participate in an international multicomponent capo study. This 
included the administration of a respiratory questionnaire and performance of pre-












4.3. Study area and study population 
Figure 5: Map of Africa and South Africa showing Cape Town1 
Cape Town is situated at the south western tip of Africa, along the Atlantic coast (see 
Figure 5). The original indigenous inhabitants of the area were the San and Khoi 
peoples, and subsequently the Xhosa-speaking Nguni people from the Eastern 
Cape. It was established by the Dutch East India Company as a halfway-house for 
sailors on the way to the East in the mid 17'h century in order to provide fresh water, 
food and shore leave. Settlers arrived in the 18th century, and were predominantly 
from England, Holland, France and Germany. People from Malaysia and 
Madagascar were also brought to the Cape in the 18th century to serve as slaves in 
the homesteads of the growing Cape colony. 
Climatic factors are thought to influence the epidemiology of respiratory disease. For 
example, the Cape Peninsula alone constitutes the smallest of the seven floral 
kingdoms of the earth, yet boasts the greatest botanical diversity. A negative aspect 
of this fact is the corresponding plethora of pollens with potential for causing allergic 
sensitisation. The Mediterranean climate is characterised by winter rainfall, which 
may impact in several ways on the frequency, severity and patterns of transmission 
of respiratory infections, particularly tuberculosis. Winter rainfall is also favourable for 
growth of moulds and fungi, both in homes and out of doors, and aspergillus-related 
sensitisation is common amongst persons presenting with asthma and other allergic 
diseases.2 
Cape Town is known for its natural beauty, making it a popular tourist destination. 
However, juxtaposed against paradise-like beaches and holiday homes for the 











significant burden of disease, notably lung disease, amongst the other problems 
associated with urban poverty, such as crime, alcoholism and gang-warfare. 
It is in one of these areas that this research was conducted - two adjacent 
predominantly low-income suburbs of Cape Town, known as Ravensmead and 
Uitsig, both located in the City of Tygerberg area. These areas are characteristic of 
other areas in the Western Cape Province. 
Figure 6: Map of Cape Metropolitan Area (CMA) showing Ravensmead and Uitsig 
Being part of an area of Cape Town known as the Cape Flats, a giant sandbar linking 
the mountain chain of the Cape peninsula to the folded mountains of the Western 
Cape, these suburbs are sandy with sparse scrub vegetation. 3 The Cape Flats was 
not populated in earlier times because of its cold and windy weather conditions and 
susceptibility to flooding during the winter. Summers are hot, dry and dusty, and the 
sandy soil is poorly suited to agriculture.4 During the early 1960's the 
apartheid/segregation policy of the Nationalist government known as the Group 
Areas Act resulted in forced relocation of persons classified as 'coloured' to newly 
established suburbs in demarcated areas of the Cape Flats. These were often at the 
outskirts of the towns that subsequently became part of the CMA. Ravensmead and 
Uitsig, which lie on the outskirts of Bellville, are two such suburbs covering 3.4 km 2 
(see Figure 6). They form part of 5 densely populated areas of 163,000 persons in 











These areas were poorly planned in terms of housing, schools, drainage, roads and 
facilities such as electricity and water. Most of the property is owned by the 
council/municipality, and rented to residents, some of whom can often ill-afford the 
cost. The pressure of poverty and housing shortages has led to significant 
overcrowding, with an average household size of 7-10 people.4 Housing ranges from 
small informal backyard shacks to modest single storey free standing homes with 
gardens, and poorer 'flats' or apartment blocks with access to facilities. Often the 
primary home owners or lessors charge rent for backyard shacks/buildings which are 
overcrowded with an average of 4.1 rooms.4 Thirty six percent of the population lives 
in these dwellings which are often not connected to water, electricity or sewage 
facilities, and therefore unsuitable for habitation.5 4 
Lower middle-income earners with better homes inhabit parts of Ravensmead. It has 
some local facilities such as a swimming pool, a community hall and a Community 
Health Centre (local state clinic). 











Figure 8: An example of housing in Uitsig 5 
Figure 9: An example of housing in Ravensmead5 
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Uitsig is a 
predominantly low 
income area with poor 
housing. 
Paradoxically, its 












Figure 10: Local Community Health Centre (State Primary Health Care Clinic) in 
Ravensmead5 
In 1996 the total population of South Africa was over forty million, of which an 
estimated four million people lived within the Western Cape Province.6 Of these, 3.5 
million lived in urban locations, making the Western Cape Province the second 
highest urbanised population (89%) in South Africa.6 At the time of the study the 
population of the CMA was 3.1 million. The population distribution in the different 
local metropolitan council areas in the CMC is shown in Table 11. Approximately 
69% of the population are in the cities of Cape Town and Tygerberg. The City of 
Tygerberg covers 423 square kilometres (19.7% of the CMA) and houses 32.3% of 
the population of the Cape Metropolitan Council (CMC).6 
Table 11: Population distribution for the CMA by municipal area 19966 
(source: Cape Metropolitan Council: 1997) 
Local Authority % Population % Total Area 
Blaauwberg Municipality 4.6% 25.6% (551 km2 ) 
City of Cape Town 36.6% 13% (280 km 2) 
City of Tygerberg 32.3% 19.7% (423 km 2) 
Helderberg Municipality 4.8% 15.2% (328 km 2) 
Oostenberg Municipality 9.3% 7.5% (162 km2) 
South Peninsula Municipality 12.3% 18.9% (407 km2 ) 











Figure 11: Population pyramid for Ravensmead and Uitsig (1996) 
(With kind permission from Professor N Beyers) 
The population of the City of Tygerberg is predominantly Afrikaans speaking. 
Ravensmead and Uitsig are considered to be relatively stable communities with low 
levels of influx and efflux. Because of the wide ethnic, cultural and geographic 
diversity in South Africa, no suburb or city in South Africa can be considered to 
represent the whole country. However, these suburbs represent a section of the 
population, at least in respect of their health needs and reliance on the state and city 
health sector for their medical needs. 
Similar to other developing countries, the population is relatively young, with forty 
percent of the residents aged twenty years or younger (see Figure 13). The shape of 
the population pyramid tapers at the higher age groups, which is typical of a 
developing country, and unlike Northern American and European countries which 











Local factors with potential effects upon respiratory health 
There are multiple local risk factors that are potentially hazardous to respiratory 
health, and could be associated with obstructive lung disease. These include air 
pollution, overcrowding, low socioeconomic status, poor nutrition and inadequate 
access to appropriate medical care. 
Ravensmead and Uitsig are situated adjacent to a small industrial area and are 
within a short distance of two larger industrial areas (see Bellville, Parow, Bellville 
South and Goodwood in Figure 6). Although two immediately adjacent areas are 
monitored for ambient air pollution, no monitoring is done in the study area. Air 
pollution data from the adjacent areas often exceed acceptable levels7 , and the study 
areas are also affected by photochemical smog knowll as the "brown haze effect" 
described in Chapter 3. A large national motorway is situaled adjacent to the suburbs 
and the Cape Town international airport is a few kilometers away, presumably a 
source of air pollution, and clearly a source of noise pollution, with ascending and 
descending airplanes frequently seen flying low over this residential area. In addition, 
smoking in the home is probably more common as opposed to out of doors. 
Environmental factors play an important role in lung health as the lungs are 
susceptible to atmospheriC pollution (both indoor and outdoor), inhaled allergens and 
microbes of which mycobacterium tuberculosis has the most lasting effect. Indoor air 
pollution is of less importance in Ravensmead and Uitsig as all homes are electrified, 
and biomass fuels are only used as a supplementary source for heating and cooking. 
However, exposures could have occurred previously or in childhood. 
Wet winters and overcrowding, caused by a housing shortage due to the Group 
Areas Act and forced removals, have resulted in the transmission and high 
prevalence of tuberculosis. Ravensmead and Uitsig are known to have one of the 
highest incidences of tuberculosis in the world, of 776/100 OOO.'i 
The HIV prevalence in the study areas was 7.9% in 2001, measured by Department 
of Health and Population Development Seventh National HIV survey of women 
attending antenatal clinics in South Africa.8 As pregnant women are considered a 
high risk group, the prevalence in the general population and particularly those over 
the age of 40 years is likely to have been much lower. Only 6% of newly diagnosed 











TB cases in the study area were HIV positive. x;; The prevalence of HIV infection in the 
Western Cape was, and remains, the lowest in the country. 
Poverty is a strong independent risk factor for COPD (see Chapter 2). The median 
household income was R2732 (US$ 546) per month in 1996 with most households 
falling in the lower end of the range. Although the average family size is five x1 , the 
number of persons living in a single dwelling is greater and sometimes people living 
in close proximity to one another are unrelated. Unemployment is high with only 36% 
of the population (~5 years of age) employed in the formal sector. Forty seven 
percent of the population have an education of less than Grade seven.xi 
Medical services are provided by two health clinics. One, in Ravensmead, is a 
Community Health Centre, which provides primary health care, emergency services 
and chronic disease services (see Figure 12). The second clinic, in Uitsig, is a small 
nurse-run clinic with limited facilities catering for TB treatment and childcare services 
such as immunisation. 
Alcohol abuse is a problem in the study areas. The density of informal taverns in the 
area is seventeen per square kilometre. 4 Although no figures are available for these 
two suburbs, the SADHS reported that 33% of men and 30% of women in the 
Western Cape Province who report current alcohol use are risky drinkers (defined as 
25 drinks per day in men and 28 drinks per day in women ).10 Additional evidence for 
alcohol abuse is the high prevalence of Foetal Alcohol Syndrome in the Western 
Cape. Similarly, a very high proportion of women continue smoking during pregnancy 
(see Chapter 3). 
4.4. The Part 1 Study: The Lung Health Survey 2002 
The Lung Health Survey was a cross sectional study of 15% of addresses in 
Ravensmead and Uitsig. It was performed from July to November 2002. The portion 
of the survey reported in this thesis involved all non-institutionalised persons aged 
?A 5 years. Only persons not residing at the address at during the study period were 
excluded. 
xii Jilhoo A, Bateman ED, van Lill S, Irusen E, Van Schalkwyk E, Beyers N. The l_ung Health Survey 2002. Prolocol 











4.4.1. Sampling frame and sample size 
In 2001, Ravensmead and Uitsig had a population of 36,334 living in 5,592 
households. The 1996 South African Population Census districts with enumerator 
sub-district (ESO) boundaries were used as a sampling frame. A geographical 
information specialist researched the study areas, and created and refined the 
sampling frame using a Geographical Information System (GIS). This is a form of 
mapping which uses aerial photography, computer graphics and databases to 
combine previously unrelated information in order to create a comprehensive map of 
the area, assigning each location a specific land-use.9 The resultant map detailed 
flats (apartments), houses and non-residential areas. The non-residential areas 
included open spaces, sports fields, churches, town halls, community centres, clinics, 
schools, shops, businesses and parking areas (see Figure 14). 
The sampling design was a cross-sectional random cluster survey. The primary 
sampling unit or cluster was an address. An address was defined as a Residential 
Geographical Location. This could be either a physical street address (name and 
number) or the name and number of a flat. The reason for choosing an address as a 
cluster was firstly, administrative ease, and secondly, to fit in with the sampling 
design required for the aims of other sub-studies in the LHS2002, and particularly the 
tuberculosis prevalence study, in which household contacts were to be studied. A list 
of addresses was obtained from the local municipality 
The average number of persons per address was calculated by dividing the number 
of people in an ESO by the number of addresses in that ESO. Of the total number of 
addresses, 656 (11.73%) were flats (apartments) and the remaining 4,936 (88.27%) 
were houses (single storey dwellings, some semi-detached). The number of persons 
per address in flats and houses were very similar, and ranged from 6.63 to 13.83 in 
flats and 5.5 - 12.9 in houses. The sample comprised 839 addresses which was a 
15% simple random sample of all addresses (see Figure 15). 
Trained community workers enumerated the occupants in each selected residential 
address, Le. a new household census was performed prior to the data collection in 
order to accurately update the 1996 census information, which had been performed 
six years prior to the study. A 'dwelling questionnaire', completed for each dwelling at 
each residential address, collected demographic details of all residents, e.g. age and 
sex. A dwelling was defined as a place that provided shelter, cooking, washing and 











dwelling or dwellings at the same address or on the same plot of land lO, i.e. all 
residents at each address. 
During the re-enumeration census, consent was sought from persons residing at 
each address. If the head of the household did not give consent for the household to 
be included, the address was replaced by a neighbouring address according to a 
fixed rule. The sampled house was replaced by a house to the right of it, and if that 
household refused, by the house to the left of the sampled household. This process 
was continued until a household willing to participate was located. Written informed 
consent was requested from all participants. The total number of potential 
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Figure 12: A map of Ravensmead and Uitsig identifying the addresses sampled 
(squares), and those selected tel replace addresses where occupants did not consent to 











5845 addresses J 
5592 residential addresses I 
~--~ 
253 addresses = other than 
residential 
~6 Flats (11.73%) 
Persons per flat: Uitsig and 
Ravensmead 
Mean number of persons of all 
ages per residential location: 10.23 
(range 6.63 - 13.83) 
[?936 Houses other than flats 
l 
Persons per house: Uitsig and 
Ravensmead 
Mean number of persons of all ages 
per residential location: 9.2 (range 5.5 
- 12.9) 
Take 15% random sample = 839 addresses (14.3% are flats) 
Figure 13: Flow diagram of steps followed to establish the population samplex1 
The sample size was based on the requirements for the concurrent tuberculosis 
prevalence survey. Owing to the relatively low prevalence of tuberculosis (in 
comparison with the expected prevalence of obstructive lung disease) a larger 
sample size was required than was necessary for studying respiratory symptoms 
such as chronic bronchitis. However, for studying the latter, it was assumed that the 
prevalence of chronic bronchitis would be 10.4% (based on the 1998 SADHS 
provincial average11 ) Therefore, a sample size of 3500 would give a 95% confidence 











4.4.2. Study procedures 
Individuals 15 years and older were assessed as follows: 
1, Informed consent 
2, Adult questionnaire 
3, Measurement of height and weight 
4, Tuberculin skin test 
5, Examination for the presence of a Bacille Calmette-Guerin (BCG) scar 
6, Chest radiograph 
7, Sputum sample for smear examination for acid-fast bacilli. All smear positive 
sputum samples were set up for culture on Lowenstein Jensen slants, 
4.4.2.1. Ethical considerations and informed consent 
Permission to conduct the study was sought and obtained from the Head of the Local 
Department of Health (Cape Metropolitan Council) and the Provincial Department of 
Health. The Study was approved by both the Research Ethics Committee of the 
Health Sciences Faculty at the University of Cape Town and the University of 
Stellenbosch, 
An information sheet accompanied the informed consent document. This described 
the study, clearly indicated that participation was voluntary and assured 
confidentiality (see Appendix 1). The interviewers explained this information to 
potential participants, who were given the opportunity to ask questions, No study 
procedures were undertaken unless the participants indicated that their questions 
had been answered to their satisfaction. Written signed informed consent was 
requested. Minors under the age of 18 years provided verbal assent and were 
required to obtai  written informed consent from a parent or legal guardian, without 
which participation was not possible. All home interviews were conducted by trained 
interviewers and height, weight and tuberculin skin testing was conducted by 
registered nursing staff. Chest radiographs and collection of sputum samples were 
performed by qualified radiographers and a physiotherapist respectively, 












4.4.2.2. Lung Health Survey Questionnaire 
Development of the questionnaire 
A respiratory questionnaire was developed by the author in conjunction with the 
project team. This was an iterative process, involving multiple revisions, and took 
approximately ten months during the planning stage of the survey. The final 
questionnaire included questions irom the European Community Respiratory Health 
Survey (ECRHS) (e.g. wheeze and phlegm questions) and other disease-specific 
international questionnaires, such as the American Thoracic Society Division of Lung 
Diseases-78 (ATS-DLD-78) (e.g. dyspnoea questions). Additional questions that had 
not been validated in other countries, for example, on exposures and symptoms of 
tuberculosis, were incorporated. Questions relating to demographic information, 
respiratory symptoms and diagnoses, potential risk factors of interest (including 
confounders) and healthcare utilisation were compiled into a single questionnaire 
(see Appendix 2). 
The vast majority of inhabitants spoke Afrikaans, a pidgin language with Dutch as its 
predominant root, with words borrowed from German, Xhosa, Malaysian, French and 
English. Most persons were bilingual, speaking English as their second language 
with variable proficiency, The local dialect of Afrikaans differs from other parts of the 
country in terms of word-use and accent. The questionnaire was thus adapted, 
piloted and translated into Afrikaans by translators familiar with the local terminology. 
Training of interviewers 
Training of the fieldworkers was carried out in a three day workshop which covered 
questionnaire administration as its main component. The study background and 
objectives were presented and the interviewers were trained in basic questionnaire 
administration technique, The training involved the discussion of each question and 
role play of the study visit. This was performed individually and in small group 
sessions. The author and other team members critically appraised the role play and 
identified and discussed areas of concern. The need for standardisation without 
individual interpretation or explanation of questions was emphasized. All interviewers 










wnFigure 14: Some 01 the interviewers at the study site 
Administration of questionnaires 
Trained interviewers administered the questionnaire in a door-to-door household 
survey, both during and after working hours, to ensure inclusion of the working 
population. Quality control involved observation of interviewers by the project 
leaders, and scrutiny of all completed questionnaires for completeness, accuracy and 
consistency. Approximately 70% of the questionnaires were completed in July and 
August 2002, which are the winter months in South Africa. 
Figure 15: The Adult Lung Health Survey 2002 Questionnaire (right) and the 












Height was measured by asking the participant to remove their shoes and stand tall 
on a level surface, with their head, shoulders, buttocks and heels (together) firmly 
against a wall. Ensuring that the head was straightened, a headboard was placed 
firmly on top of the head at right angles to the wall, and a pencil line drawn where the 
headboard met the wall. The distance from the floor to the line was measured using a 
tape measure and recorded to the nearest 0.1 cm. Nurses were trained to avoid the 
error of parallax by ensuring that they read the height measurement in the same 
horizontal plane as the pencil mark. 
4.4.2.4. Weight 
Participants were asked to remove their shoes and heavy outer clothing and stand on 
the digital scale which was placed in a firm flat surface. Weight was recorded to the 
nearest 0.1 kg. Calibration of the scales was checked against an object of known 
weight. 
4.4.2.5. Tuberculin Skin Testing and presence if BeG scar 
The WHO standard tuberculin test (Mantoux method) employed a single batch of 
PPD (purified protein derivative) RT 23 (Statens Seruminstitut, Copenhagen). Two 
TU (0.1 ml RT 23) was injected intradermally in the ventral aspect of the left forearm, 
by an experienced nurse, and read after a period of 72 hours by the same person. 
The diameter of the induration in millimetres was measured in the transverse aspect 
of the left forearm with a set of callipers calibrated to the nearest 0.5mm. The 
presence or absence of a BCG scar was recorded by an experienced nursing sister. 
4.4.2.6. Sputum collection and processing 
Adults were asked to expectorate into the sputum jar, close it tightly and place it in a 
plastic bag provided. This was performed in a room with laminar airflow and 
ultraviolet light in order to prevent potential spread of organisms. This process was 
facilitated by a physiotherapist who explained the process of expectoration. Sputum 
specimens were processed using standardised methods. The macroscopic 
appearance of the sputum was recorded and sputum smears were stained with the 
Ziehl Neelsen technique. Each slide was examined for at least 20 minutes. Smear 
results were reported as +, ++, +++. Specimens were cultured on Lowenstein Jensen 











4.4.2.7. Chest radiograph 
The participants were requested to present for a chest radiograph at a nearby clinic. 
Transport was provided. In privacy, all females were asked whether they are 
pregnant, and if so, the chest radiograph was performed with a lead abdominal 
shield. Anteroposterior chest radiographs were performed by a trained radiographer, 
using 200 MA radiograph apparatus producing 35cm by 43cm films. The author or an 
experienced pulmonologist screened the films for serious abnormalities requiring 
urgent attention and these were referred (by means of a home-delivered referral 
letter and radiograph) to the Respiratory Clinic at the Tygerberg Hospital or Groote 
Schuur Hospital (or to their private doctor if the participant wished). There were a 
total of 40 patients identified for urgent referral and they had a wide range of 
conditions such as tuberculous pleural effusions, cardiac failure and lung cancer. The 
radiographs were read by an experienced pulmonologist using a modified version of 
the International Labour Organisation (ILO) Classification Reading Form. A 
subsample was reread by another physician in order to assess agreement and 
evaluate the form as an epidemiological tool. 
Sputum sampling, Tuberculin Skin Testing and chest radiographs were performed as 
part of the component tuberculosis prevalence survey, and detailed results will not be 
reported in this thesis. 
4.4.3. Data capture and statistical analysis 
Double data-entry by a data capturer as well as a fax recognition system was used to 
capture and store the data in order to reduce the element of human error. The fax 
recognition system was an original prototype internet based-instrument called 
Prospect, developed by Dr David Carman. This was security controlled by a 
password system. Prospect involved an interface between the fax and computer, 
which allowed for the automatic 'reading' of questionnaire responses. The author 
checked the discordant data entries of the fax recognition system and the hand 
capture and corrected discrepancies against the original paper documents, which 
had been scanned into the Prospect system. A Microsoft Access database of the 
adult questionnaire responses was created. The author then extracted the data from 
the database by compiling queries in Access and importing the results of these 
queries into a STATA database. Analysis was performed using the survey estimation 
commands in the STAT A 9.1 ® statistical package, taking into account both clustering 
and weighting (see Appendix 8 for the method used for developing analysis weights). 











replacement, and different sampling weights were applied to the replaced addresses. 
More details on the statistical analyses are included in the chapters of results that 
follow. 
4.4.4. Safety and Medical Issues: Procedure for referral of subjects 
The adult questionnaire contained an "action alert" against the questions referring to 
recent haemoptysis, untreated respiratory symptoms (such as dyspnoea) and 
systemic symptoms suggestive of tuberculosis, such as fever and loss of weight. 
After completion of the questionnaire, the interviewer referred the relevant 
questionnaire to the co-ordinating doctor (the author), who decided on one of the 
following courses of action. 
Urgent referral was offered to participants who reported recent haemoptysis or who 
presented with any other obvious medical emergency. They were provided with a 
referral letter to either, the Respiratory Clinic at Tygerberg Hospital, or to the 
Respiratory Clinic at Groote Schuur Hospital for further assessment and 
management. Relevant details of the reason for referral were entered onto the 
standard referral letter and the patients were contacted and encouraged to attend the 
clinic on the same day, or within days. Participants could elect (at their own expense) 
to attend a private doctor, if they preferred. Where necessary, these participants (or 
other acute medical emergencies) were transported in the study vehicles to the 
Medical Emergency! Casualty Department of Tygerberg Hospital for urgent 
assessment and care. The author also made a few home visits when interviewers 
were concerned about the illness of a participant. There were no adverse events 
associated with the conduct of study procedures. 
Non urgent referral was offered to participants who reported untreated respiratory or 
systemic symptoms. The participants were given a referral letter, written by one of 
the coordinating doctors, usually within a week. Their radiographs were viewed by 
one of the doctors on the team. The patients were contacted and referred to the 












4.5. The Part 2 Study: The Burden of Obstructive Lung Disease Study 
(BOLD) 
4.5.1. Sampling Design 
The sampling plan was developed in collaboration with the BOLD sampling 
consultant. A population-based single-stage cluster sample was originally drawn in 
2002 for the Lung Health Survey as described above. The main differences in 
sampling procedure between the two studies was that the second study sampled 
only adults aged 40 years or older, and a replacement procedure for households 
unwilling to participate was not employed. Instead, the original simple random 
sample of 833 addresses which had been selected for the Lung Health Survey 2002 
was employed. The initial intention was to randomly select a subset of 520 of the 833 
originally selected addresses and sample all C1ge eligible individuals living at those 
addresses. However, owing to a lower than expected response rate, during the 
conduct of the study, the plan had to be adapted such that all 833 addresses were 
sampled. 
For the purposes of BOLD, the original LHS 2002 enumeration lists compiled in 2002 
were used as a guide, but these were updated to ensure that all age-eligible persons 
currently living at the selected addresses were listed and, if possible, recruited. The 
re-enumeration of the original planned 520 addresses was performed prior to 
commencing the study and the remaining addresses were enumerated during the 
study. 
The majority (approximately two thirds) of the adults aged 40 years and above, who 
resided at the sampled addresses, participated in both the LHS 2002 and the BOLD 
Study. The additional one third of participants in the BOLD study comprised either 
LHS 2002 nonresponders or new persons residing at the sampled addresses. 
The original sampling frame of 5592 addresses, assumed that none of the old 
addresses had been demolished and that no new addresses had been added in the 
intervening time between the two studies. As these had been stable residential areas 
for about 40 years, with very little undeveloped land that could be used to build more 
houses, this assumption seemed reasonable. Information from local housing services 
provided a small number of new addresses that had been added since the original 











whole population of this new stratum were sampled. These addresses yielded a total 
of four eligible individuals, as most of the new houses were inhabited by persons 
aged below 40 years of age. 
Although these new addresses effectively define a second stratum, the small size of 
this group suggested that formally accounting for them in the analysis would be 
unlikely to affect the prevalence estimates in any meaningful way. Accordingly, data 
on the four eligible individuals have been included in analyses, and the sample was 
treated as a single-stage cluster sample, with sampling weights calculated using the 
original 833 households as the sampling frame. For the LHS 2002, the addresses 
from both suburbs were pooled prior to drawing the sample. Thus, in the absence of 
the added households, this is viewed as a simple one-stage cluster sample from the 
combined sample of 5,592 addresses with no stratification by suburb (viz. 
Ravensmead versus Uitsig). See Appendix 9 for details on analysis weights. 
4.5.2. Recruitment 
Staff visited the initial sample of 520 addresses in order to invite them to participate 
and to enumerate the household in terms of the persons aged ;;:40 years. This was 
done in I\lovember 2004 and information in the form of a "study flyer", a single page 
introduction to the study, was given to the potential participants. Interviewers 
answered questions about the study. Where the participants had access to a 
telephone, their number was requested and recorded, and they were subsequently 
called in order to make an appointment for the study visit. This was the minority of 
cases, as many people did not have telephones. The remainder of persons at the 
833 addresses were approached by interviewers during the study period, and the 
same procedure was followed, with provision of information and a study flyer. In 
many cases appointments were made for the study visit. 
During the enumeration, when no-one was home, staff placed a "study flyer" in the 
post box or under the door if there was no post box. During the fieldwork period of 
January to June 2005, field staff visited the houses up to a maximum of 5 times on 
different days, and at different times (e.g. after hours, Saturdays) in order to attempt 
contact. Staff received varying responses from the potential participants. Those that 
declined outright and indicated that they would under no circumstances take part in 
the study were not approached again. Others, for whom the time or circumstances 
were not favourable at the time of the approach, were visited repeatedly until they 











For most of the study period (January to April 2005), four field teams worked in shifts. 
Towards the end of the study period two to three field teams were sufficient as 
participant numbers had reduced and recruitment became more difficult (May to June 
2005), and more evening and weekend shifts were required in order to recruit 
working participants. One field team continued into July 2005 in order to hand-
deliver copies of the spirometry results, referral letters and invitations to a study 
feedback meeting. 
4.5.3. Study procedures 
Individuals ;:::.40 years of age were assessed as follows: 
1. Informed consent 
2. Pre and postbronchodilator spirometry 
3. BOLD questionnaires 
4. Height 
5. Weight 
4.5.3.1. Ethical considerations 
Permission to conduct the BOLD study was obtained from the Provincial Department 
of Health. Ethical approval was obtained from the UCT Research Ethics Committee 
of the Faculty of Health Sciences. Pulmonary function testing was performed by 
trained registered clinical technologists under supervision of a medical practitioner. 
Written informed consent in accordance with the guidelines for Good Clinical Practice 
was taken prior to all study procedures for both studies. Participation was voluntary. 
Patient information sheets, informed consent forms and procedures as well as all 
methodologies have been reviewed and approved by the University of Cape Town 
Research Ethics Committee (see Appendix 3). In order to ensure confidentiality, no 
names or participant information was shared with anyone outside the project team. 
Participants were identified by means of a study number and there was no entry of 
names onto the web-based data transfer system for either questionnaire or 
spirometry data. Care was taken to explain study procedures during the informed 
consent process, and interviewers and technologists ensured that queries were 
answered to the participant's satisfaction. Interviewers were appropriately instructed 











All participants had their spirometry read by the author, and brief written practical 
advice regarding smoking cessation, or referral to their local health facility or private 
doctor, was provided for participants with untreated symptomatic disease. A copy of 
each participant's lung function with a referral letter, if necessary, was hand delivered 
to the participant's home (see Appendix 7) and participants were also invited to 
attend a community meeting to discuss the study results (see Appendix 6). 
4.5.3.2. Training and preparation for the field work 
Prior to undertaking the protocol, staff were trained and certified in study procedures 
at a 5-day training workshop in London, England. Two members of the research 
team, (the author and a clinical technologist) attended a central training session to be 
trained as "master trainers" and were certified to train additional staff at their sites. 
The coordinating centre monitored training and ensured that all staff who participated 
in the study were properly certified. 
Initial staff training was performed over a one week period. The author facilitated and 
performed the questionnaire training and training on all study procedures. Initial 
spirometry training was performed jointly with a clinical technologist, and continued 
thereafter by the author. Three days of intensive training were followed by spirometry 
certification. This training followed the structure of the international standardised 
training to a large extent, but site-specific details were included. A short workshop 
was held with an anthropological researcher who has had considerable previous 
experience in the study area in order to brief the team regarding the sociocultural 
details of the community. These and other logistical issues were debated and 
discussed. 
Prior to the formal training, BOLD team members were given the questionnaire and 
the detailed instructions, in order to practice administering it on colleagues and 
friends to familiarise themselves with the instrument. This allowed for raising 
awareness of difficulties and questions that would need discussion. 
Compared to the central BOLD training, local training included more detailed 
question and answer sessions. Each question was reviewed and the interviewer 
instructions were discussed in detail. A pilot study was performed at the end of the 
training week, and a feedback day including review of training was held thereafter. 
Further review and training in the form of several mock sessions of different 











continued intermittently over the next two weeks, while completing the preparations 
for the study. Team members were made aware of the standards required for 
questionnaire administration and spirometry. They were encouraged to ask 
questions/clarifications and discuss their opinions, as well as introduce any new 
issues at the end of the session. 
A strict standardised approach was adopted according to the BOLD protocol 
regarding questionnaire administration. In particular, the team members were trained 
never to try to interpret what the respondent meant by a given answer. Unless 
specific instructions were provided for interpreting responses to a given question, the 
interviewers were instructed to offer to read the question again, and if applicable, list 
the response options. Participants were encouraged to make their best guess. The 
burden of supplying a response was always placed on the participant. In the event of 
a participant not understanding the question or requesting an explanation, the 
interviewers were instructed not to try to provide their own explanation of the 
question, as this could introduce added variability, due to different interpretation of 
the questions from one interviewer to another. The BOLD central operations centre 
developed detailed instructions for administering and coding each study 
questionnaire to standardise how the questionnaire was administered and responses 
were scored. Attempts were made to conduct the questionnaire in a comfortable, 
private setting. 
4.5.3.3. BOLD Questionnaires (see Appendix 4) 
There were a total of seven sub-questionnaires, which focused on different aspects 
of the study. These were translated and incorporated into one document for ease of 
administration. 
The following questionnaires were administered: 
1. BOLD Spirometry /Safety questionnaire: This questionnaire was used to 
ascertain whether it was safe to attempt spirometry in the participant. 
2. BOLD Core Questionnaire: Data on demographics, respiratory symptoms, 
risk factors and respiratory diagnoses 
3. BOLD Occupational Questionnaire: A history of occupational exposure to 
specific agents 
4. BOLD Biomass Fuel Questionnaire: Information on exposure to biomass fuels 
used for cooking or heating 












6. BOLD minimal data questionnaire (for non responders only): basic 
demographic data and smoking status and comorbidity 
7. Participant tracking questionnaire (for all eligible persons notwithstanding 
participation): demographic data and reason for nonresponse, if 
applicable/available. 
The BOLD Core questionnaire was developed by the BOLD international team, using 
where possible, existing validated questions or parts of questionnaires that have 
been used in international studies. The scope of the BOLD questionnaires was to 
gather information about respiratory symptoms (cough, sputum, wheezing, shortness 
of breath), exposure to potential risk factors, occupation and respiratory diagnoses 
(asthma, emphysema, COPD, chronic bronchitis, etc.).12 Additionally, information on 
co-morbidities, health care utilisation, medication use, activity limitation, and health 
status was sought.12 
The questionnaires included sections taken from the 1978 ATS/DLD Respiratory 
Symptom Questionnaire and the questionnaires used in the European Community 
Respiratory Health Survey and the US Lung Health Study. It also included the Short 
Form 12 (SF-12) to assess overall health status. 12 The BOLD questionnaires were 
translated from English to colloquial Afrikaans by the Stellenbosch University 
Language Centre following the recommended progress of translation, back-
translation, review and forward translation in order to ensure high quality and 
understandability. 
All participants were required to complete the BOLD Core questionnaire, Stages of 
Change, Occupational and Biomass questionnaires. There was also a Minimal 
Data/Refusal questionnaire for participants who are not willing to participate in the full 
protocol, which collected basic demographic data and brief information on smoking 
status and comorbidities. All questionnaires were administered by trained staff. All 
eligible participants, irrespective of their participation, had a participant tracking form 











wnFigure 16: Questionnaire administration in a participant's home 
In addition to the BOLD questionnaires, respiratory questionnaire items that formed 
part of the South African Demographic and Health Survey questionnaire of 1998 
were included. These were used to assess consistency of questionnaire responses, 
and evaluate the performance of the questions in relation to the gold standard of pre-
and post-bronchodilator spirometry. This component of the study was requested by 
the South African Medical Research Council under project direction by Dr Krisela 
Steyn, the Head of the Chronic Diseases of Lifestyle Group. These additional 
questions were included in a separate short questionnaire and administered after all 
of the BOLD questionnaires, but utilised the same 10 as used on the BOLD 
questionnaires so that the data from the various questionnaires could be merged for 
analysis at a later stage. The findings of this validation study will not be reported in 
this thesis. 
4.5.3.4. Measurement of height 
The height of each participant was measured using a portable rigid extendable 
stadiometer which was placed against a wall (see Figure 17). The participant was 
asked to remove his/her shoes and hat, and height was measured with the subject 
standing on a firm level surface that was perpendicular to the stadiometer. He/she 
was instructed to stand erect with the feet flat on the floor, heels together, touching 
the base of the stadiometer. The back, shoulder blades and buttocks were to be in 
contact with the wall. The clinical technologist ensured that the participant's weight 











inward. The participant was asked to face straight ahead and the technologist 
ensured that his/her head was in the horizontal (Frankfort) plane. At the time of the 
measurement, the participant was asked to inhale deeply and maintain a fully erect 
position without altering the load on the heels. The head board was brought down 
snugly, but not tightly, on the top of the participant's head and height was recorded to 
the nearest 0.1 centimeter. Care was taken to avoid the error of parallax by ensuring 
that the eye of the technologist was at the same level of the head board. Small step 
stools were used extensively for this purpose, and great care was exercised in 
measuring height in order to achieve maximal accuracy (as height is a predictor of 
lung function). 
Figure 17: Measurement of standing height 
4.5.3.5. Measurement of Body mass 
Body mass was measured using a digital scale. The scale was placed in a firm level 
surface. The participant was asked to remove heavy outer clothing, hats, heavy items 
in the pockets (such as wallets and keys) and shoes. The technologist ensured that 
the scale read zero before the measurement. The participant was then asked to 
stand on the centre of the scale platform, with arms relaxed at the sides and head 
erect, looking straight ahead. When the digital readout stabilised, the technologist 












The methods developed for BOLD are suitable for field studies where temperature 
and humidity cannot be controlled, as it would be in ideal climate-controlled 
pulmonary function laboratories. The BOLD methodology requires the use of the ndd 
EasYOne™ spirometer. This spirometer fulfils requirements with respect to 
performance criteria relating to reliability of measurement, suitability for field use, and 
ease of access to data. This spirometer employs new ultrasound technology to 
assess flow rates and volumes and is not a closed system, which could potentially 
have created a source of cross-infection. Although the ndd Easyone® does not 
require calibration, calibration was checked and recorded on a daily basis using a 
three litre calibration syringe that had been stored next to the spirometer. 
A safety questionnaire preceded all study procedures and was administered 
immediately following the informed consent (see Appendix 4). This questionnaire 
gathered information regarding the following: 
1. Whether the manoeuvre would endanger the health of the participant 
2. Whether the administration of a bronchodilator would pose a potential health 
risk, e.g. myocardial infarction in the last three months 
3. Whether there was a temporary condition that would endanger the health of 
the participant, e.g. recent cataract surgery or major surgical procedure 
The participant's resting pulse was also recorded and if > 120 beats/min, the test was 
not performed, the field physician (author) was informed and the patient was referred 
to the nearest health facility. If there was any contraindication to spirometry, the 
participant was excluded from participating, and a minimal data and participant 
tracking form was completed. 
A new spirette and spacer was used for each participant. The spirette was discarded 
and the spacers were sterilised at the end of each day. A cleaning procedure using a 
bactericidal solution that kills Mycobacterium tuberculosis and other microbes was 
used to sterilise spacers at the end of each day. 
During the informed consent procedure, the purpose of the test was explained to the 
participant. The participant was assured that the procedure does not cause injury or 
pain. They were informed that in order to get valid results, they would have to blow 
out as hard and fast as possible, and that they would need to repeat the procedure a 
few times. The participant was asked if they wished to use the bathroom prior to the 











Technologists used a no-rinse hand sterilant to wash their hands and the 
participant's hands prior to the test. A paper towel was used to remove the 
mouthpiece (the Spirette™) from its packaging and insert it into the spirometer. The 
test was performed with the participant sitting in a chair without wheels. Dentures 
were left in place, unless they were loose, in which case the participant was asked to 
remove them. All manoeuvres were performed with a noseclip in place. The 
expiratory manoeuvre was then both explained and vigorously demonstrated to the 
participant, emphasising the amount of effort needed and correct placement of the 
mouthpiece. The participant then attempted the first manoeuvre and if this was 
satisfactory, two subsequent tests were performed. 
The ndd easyone provided a useful feedback system in order to ensure good quality 
of expiratory manoeuvre. The feedback comprised specific messages after each 
attempt and scoring the quality of the test (A to E), indicating whether the quality of 
the loop was satisfactory. Feedback messages were easy to communicate to the 
patient such as "do not hesitate", "blow harder", "attempt <6 seconds" etc. In addition, 
the technologist was able to view the manoeuvre on the spirometer screen. A 
maximum of eight tests in total were attempted, and the standards required met or 
exceeded the ATS standards for acceptable equipment technique. 











The following measures are recorded from each attempt, and the best of three were 
saved: 
1. Forced Vital Capacity (FVC) 
2. Forced Expiratory Volume in one second (FEV1) 
3. The ratio of FEV1 to FVC ( FEV1/FVC) 
4. Forced Expiratory Volume in six seconds (FEV6 ) 
5. The ratio of FEV 1 to FEV 6 ( FEV 1/FEV 6) 
Three acceptable manoeuvres were needed to determine reproducibility and a 
minimum of two reproducible manoeuvres were required. The two highest values for 
FVC and FEV1 were taken from acceptable forced expiratory manoeuvres that 
displayed minimal variability of within 200 millilitres of the second highest FVC and 
FEV1. The volume-time curves were inspected to determine if the size and shapes of 
the curves were reproducible. The ATS standards for spirometry were followed, 
which requires FEV1 and FVC to be the best acceptable and reproducible 
manoeuvres. It was not necessary that they be taken from the same manoeuvre. The 
FEV1/FVC and FEV1/FEV6 ratios were calculated as the ratio of the individual 
measurements. 
Spirometry was measured before and after the administration of an inhaled, short-
acting bronchodilator. Two puffs (200 micrograms) of Ventolin® (Salbutamol) were 
administered to participants using a spacer, and a stopwatch was used to ensure that 
a minimum of fifteen minutes had passed before the postbronchodllator 
measurements were taken. 
4.5.4. Data entry and management 
An experienced data capturer based at the South African lMedical Research Council 
entered questionnaire data into a secure web-based data entry system. On a daily 
basis, questionnaire data were transferred directly to the Operations Centre, usilng a 
web-based data entry system. They were sent to a coordinating centre in Portland, 
Oregon, USA, where the questionnaires were scrutinised for completeness and 
quality. The data entry system used real-time edit checking, along with double entry 
of selected fields, to ensure that errors in data entry were minimized. 
Spirometry data were downloaded daily and then uploaded onto a secure web-site. 
The transmission of spirometry records was done through secure, encrypted Internet 











standard format (in an Access database), initially daily and later weekly. The use of 
the same spirometers and software made this both practical and easy. Duplicate data 
was stored at the University of Cape Town Lung Institute. The centre's data 
management system generated and provided the field team with periodic reports on 
the quality and completeness of the dataset. The centre was also provided with 
aggregate demographic data on the target population such as socio-economic status 
and air quality data for the geographic area in which the target population resides. 
Once data collection was completed and queries resolved, the coordinating centre 
provided an electronic copy of the data for analyses. A copy of the data was also 
retained at the coordinating centre for pooled, international cross-site analyses. 
The spirometry measurements used for analysis include FVC, FEV1, FEV6 , peak 
flow, and total expiratory time. This allows for cornparisons of FEV1/FVC and 
FEV1/FEV6 as measures of airflow Iimitation.12 All spirometry data was sent 
electronically to the BOLD Operations Centre in Portland, Oregon and they 
forwarded the data to the Pulmonary Function Reading Centre (PFRC), where each 
manoeuvre was graded and an overall quality score assigned to each participant's 
spirometry data. The PFRC also reviewed the quality of manoeuvres from each 
pulmonary function technician in order to monitor the quality of their work, so that 
corrective action could be taken if this was less than optimal. 12 
4.5.5. Quality Control 
The BOLD project employed several measures to ensure a high level of quality 
control in all aspects of the study. Formal written procedures were available for all 
aspects of the study, from the selection of the study sample to the questionnaire, 
lung function testing, and the use of the data management system. 
During fieldwork, the author performed periodic quality control visits reviewing each 
member of the team in the field, and gave them detailed feedback after the visit. 
Comment was made on interpersonal skills, accuracy of questionnaire 
administration, spirometry, time man~gement etc. Queries and logistic or other 
problems were dealt with on an ad hoc basis. 
Weekly staff meetings were held to discuss the week's progress, problems and 
solutions, and to evolve new strategies for recruitment and improved study 











identified problem areas and selected parts of the initial training were sometimes 
repeated in conjunction with discussions. 
The ndd EasyOne™ Spirometer met high standards of quality control while still being 
affordable and suitable for field use. Staff from the PFRC directed the training of 
master trainers in lung function testing and supervised ongoing quality control 
monitoring of pulmonary function technicians. Several possible problems preventing 
acceptable manoeuvres were identified during training such as involuntary epiglottis 
closure, an early termination of the manoeuvre, variable effort, coughing, and 
leakage due to the participant's inability to keep a tight seal. More common problems 
included not taking a deep enough breath, or not exhaling as forcefully as possible at 
the start of the manoeuvre. 
The BOLD operations centre also kept a strict quality control scoring system of each 
technologist and fed back regularly in order to inform the team of their performance. 
If a technologist was performing poorly, they were required to be retrained before 
continuing any further measurements. This mechanism was not necessary during the 
study, as team members were experienced in performing good spirometry and were 
able to provide good quality spirometry in the vast majority of cases. Even though 
this was a population survey with a proportion of elderly and infirm participants, 89% 
of the spirometry performed was classified as acceptable by the BOLD PFRC. 
4.5.6. Data analysis 
Data was analysed using the STATA statistical programme, which has commands 
and analysis techniques specifically designed for survey data, in order to calculate 
estimated population prevalence from the sample data, accounting for both clustering 
and weighting (see Appendix 8 and 9). All analyses were performed by the author at 
times in consultation with a statistician. Descriptive statistics, prevalence and age 
and sex stratified data are presented with 5% significance values using the chi 
squared test. 
4.5.6.1. Quality control of spirometry 
The quality scores for the FEV1, FVC, and flow measurements were also recorded. 
According to ATS criteria, measurements that had a quality score of less than 2 (i.e., 











excluded.xiii The quality of the individual manoeuvres (e.g. effort, proper start, length 
of expiration, cough and other artefacts, etc.) and the reproducibility of the tracings 
are combined in the quality scores. 
Individual tracings were reviewed for adequacy and unacceptable efforts were 
excluded. From among the remaining acceptable manoeuvres, the quality scores 
reflect the level of agreement for FEV1 and FVC, as described in table 12. The 
quality control procedures used by the Pulmonary Function Reading Centre were 
more comprehensive than those recommended by the manufacturers of the ndd 
spirometer. In a few cases, acceptable ndd quality control scores were considered 
unacceptable by this stricter review process. 




3 acceptable tests and variability" less than 76 ml 
3 acceptable tests and variability" between 76-150 ml 
3 acceptable tests and variability" between 151-200 ml 
2 acceptable tests or variability" between 201-250 ml 
--9------ ________________________ ~ __ g __ ~~~ta b I~Jt3~t?_..2I:._\{9_~i9J2i1lti~.9~~at~!:.Jh~Q __ 2 50 m I 
Separate QC scores for FEV1 and FVC 
"Difference between two highest FEV 1 or FVC readings 
4.5.6.2. Classification of derived spirometry variables 
The ndd spirometer retained a maximum of three tests. For each of these three 
manoeuvres the FEV1 , FEV3 to FEV1, FVC, peak expiratory flow (PEF), and FEF2575 
was collected. The results from the "best" manoeuvre (i.e. the test resulting in the 
highest sum of FEV1 and FVC) were used to define COPD as a postbronchodilator 
FEV1/FVC ratio of <70%. 
Pre- and post-bronchodilator FEV1 and FVC are defined as the maximum of the 
corresponding FEV1 and FVC values from the acceptable manoeuvres. Thus the 
FEV1 and FVC do not necessarily come from the same manoeuvre. Additionally, 
there is no guarantee that either comes from the "best" manoeuvre (defined as that 
manoeuvre with the highest sum of FEV1 and FVC). This is in keeping with the 
'''' Gillespie S, Kimes T, Cheek P, Allison M, Vollmer W_ South Africa Cover Memorandum for BOLD spriometry data. 











American Thoracic Society (ATS) guidelines. The following variables were used to 
classify the population according to GOLD COPD Stages 0-4, and to calculate the 
reference equations: 
1. Pre FEV1 = Maximum pre FEV1 if quality score >1 
2. Post FEV, = Maximum post FEV1 if quality score >1 
3. Pre FVC = Maximum pre FVC if quality score >1 
4. Post FVC = Maximum post FVC if quality score >1, 
5. Pre FEV1/FVC = Maximum pre FEV1/FVC if both pre FEV1 quality score >1 
and pre FVC quality score >1 
6. Post FEV1/FVC = Maximum FEV1/FVC if both post FEV1 quality score >1 and 
post FVC quality score >1 
Any quality control score <1 was considered a missing value. 
It is important to note that the definitive COPD variable (FEV1/FVC<70%) is 
calculated as the ratio of the maximal values, rather than the maximum of the 
individual ratios. 
4.5.6.3. Risk factor analysis 
Risk factor variables were coded mainly as binary or categorical or less often, as 
continuous variables, where appropriate. Results of univariable analysis of risk 
factors are presented. Multiple logistic regression models were created for binary 
respiratory symptom outcomes providing odds ratios and 95% confidence intervals. 
Population attributable fractions are reported for each outcome. For the BOLD study, 
prevalence statistics are presented by age, sex and pack year categories. Multiple 
logistic regressions were performed with GOLD Stage I and Stage II as outcomes. 
Furthermore, a multinomial regression, with three mutually exclusive categories of 
COPD, was used to compare the risk factor profiles for moderate and severe 
disease. Further details of statistical analysis are presented in the relevant chapters. 
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CHAPTER 5: RESULTS OF THE LUNG HEALTH SURVEY 2002: 
PREVALENCE OF RESPIRATORY SYMPTOMS, DIAGNOSES, 
RISK FACTORS AND HEALTHCARE UTILISATION 
5.1 Introduction 
This chapter presents the results from the Lung Health Survey Questionnaire on 
prevalence of self-reported respiratory symptoms and symptom-complexes and self-
reported doctor diagnoses. Prevalence of risk factors and healthcare utilisation is 
also reported here. These results describe the study population in terms of symptoms 
of obstructive lung disease and potential determinants of this disease. 
5.2. Statistical methods 
Demographic details, symptom prevalence and self-reported disease prevalence of 
the interviewer administered questionnaire were analysed by age and sex. The initial 
few tables below describe the demographics of the population and represent the 
unweighted sample data. Thereafter, both clustering and weighting were taken into 
account when calculating prevalences. The estimated population prevalences are 
reported with accompanying standard errors. These were obtained from the 'Survey 
Analysis' commands in the STATA® statistical package. The primary sampling unit 
was set as the address identifier (cluster) and the population weight was set as the 
individual weights calculated by taking both replacement and the response rate into 
account. This allows for accurate estimation of population statistics (See Appendix 
8). 
Data are presented for the whole population aged ~ 5 years, and stratified by sex 
where relevant. Where tables are stratified by sex, Pearson's chi-squared test is 
reported to assess whether there is a significant difference in prevalence between 
men and women. This test is reported in a column to the right of the gender-stratified 
prevalences, and the overall p value or the p for trend is reported. Where 
appropriate, analyses in persons ~ 40 years of age have been performed e.g. 
prevalence of dyspnoea. 
Tobacco smoking is categorised into 'light to moderate' smoking of 1-14 cigarettes 
per day, and heavy smoking of >15 cigarettes per day. Current cannabis smoking 











day(heavy) based on the fact that 3-4 joints per day constitutes heavy smoking and is 
equivalent to 20 or more cigarettes per day.1 Earlier literature has considered ;::2 
joints per day as heavy use.2 
5.3. Results 
At the enumeration visit, 625 out of the 839 addresses (74%) consented to 
participation via the head of the household/s. Of the 214 non consenting addresses, 
212 were replaced and two could not be replaced (see Chapter 4).Four addresses 
were found not to exist. Demographic characteristics (age and sex) of the occupants 
of 81 of the non-participating and all the participating addresses were collected. A 
comparison of the age and sex characteristics of the replaced addresses and the 
non-consenting addresses showed no significant difference with respect to age (t test 
::: 0.33; p ::: 0.74) or sex (OR::: 1.0; CI: 0.82 - 1.23) of the occupants,xiv The final 
sample consisted of 833 addresses with 3971 eligible persons aged ~ 5 years, of 
which 3512 gave consent and participated in the questionnaire. Age and/or sex data 
was missing or incorrect for 29 individuals (therefore not analysable on this basis) 
leaving 3483 (88%) with sufficient data for analysis. Of these 75% (2608) had a chest 
radiograph and attempted to provide a sputum sample and 45% (1170) produced a 
sputum sample for the TB prevalence survey.Xiv 
5.3.1. Population demographics 
5.3.1.1. Age and sex distribution 
Table 13: Age and sex distribution of study sample ~5 years of age (n = 3483) 
_____________________________ ~IL ___ ~ _____ . __ !!~. _________ Wom~.!l ___ . ___ J).~_Cll_~~__ 
N % n % n % 












































* Pearson's chi-squared test reporting the significance of the difference between men and women. 
The age and gender distribution of the sample is shown in table 13. The sample 
proportions mirror the population proportions quite closely. There were a higher 











for the study areas (see Chapter 4, Figure 13). Approximately 70% of the sample 
was aged between 15 and 44 years, and 27.8% were teenagers and young adults 
aged 15 to 24 years. This needs to be borne in mind when interpreting population 
prevalence and symptoms of chronic bronchitis and COPD, which are primarily 
diseases of older persons. 
In addition, small numbers of men in the >65 year age group could be indicative of 
early male mortality and/or relative longevity of women. The total number of men in 
the sample was 1493 (42.9%) and of women was 1990 (57.1 %) and this distribution 
was significantly different (p = 0.002). The sample was made up almost exclusively of 
persons of mixed ethnic origins (see Chapter 4). Data on ethnicity were not collected. 
5.3.1.2. Socioeconomic factors 
Table 14: Sociodemographic characteristics of the study population (n = 3483) 
Characteristics All Men Women p* 
Income per person per month** <0.001 
>R2000/month 631 (18.4) 26.0 (1.3) 12.8 (0.9) 
R 1 000-R2000/month 623(18.2) 19.4 (1.1) 17.3 (0.9) 
<R1000/month 2168 (63.4) 54.6 (1.4) 69.9 (1.1) 
Education <0.001 
>12 years 701 (20.1) 22.8 (1.2) 18.2(1.0) 
8-12 years 1842 (52.9) 53.4 (1.4) 52.6 (1.2) 
1-7 years 832 (23.9) 21.1 (1.1) 26.0 (1.1) 
None 106 (3.0) 2.8 (0.4) 3.3 (0.4) 
Employment 
Employed 1480(42.7) 52.5(1.4) 35.4(1.1) <0.001 
~9El~rTlJ:)I_Q~~g. _____ ~ ____ ~~_______ ___ JQ§]_{ 57. 3J ___ 41·_§J_l·_11.~fiLUJ _____ ~ _____ _ 
* Pearson's chi-squared test reporting the significance of the difference between men and women. 
kkR1000month-US$ 98.77 at the time of the study 
The majority of the population had attended some level of secondary school, 
representing between 8 and 12 years of education. Many reported having had tertiary 
education, but in some cases this was curtailed prior to completing a course, diploma 
or degree. Unemployment levels were high with 57.3% of persons not earning at the 
time of the study. Of the unemployed persons, 664 were seeking work (20.1 % of men 











reasons including being homemakers, disability, etc. The majority of the community 
were longstanding residents of the areas and the median number of years resident 
was 23.7 years. 
5.3.2. Symptom prevalences 
5.3.2.1. Cough and sputum 
Table 15: Prevalence of symptoms of cough, sputum production, haemoptysis and 
related quality of life (n=3483) 
Symptom All All Men Women p* 
___ . ___ . __ ._.. __ ._~ ~ .. ~. ___ .... _ .. _~ __ ~ _______ ._. __ ~ ___ . D/~{§.l:l_~ __ ~ol~§~ ____ % (S~. _________ . __ . 
Recent cOl1gh 681 19.5 (0.8) 21.1 (1.2) 18.4 (1.0) 0.041 
Haemoptysis in last month 
Haemoptysis in last 12 months 
Usual winter morning phlegm 
Usual day/night winter phlegm 
Phlegm for at least 3 months 
each year 
Phlegm for at least 3 months a 
year for at least 2 successive 
years** 
Chest problems that affected 
daily activities in the last 12 
months 
Chest illnesses with phlegm 
production 
Number of phlegm producing 












1.1 (0.2) 1.6 (0.3) 0.7 (0.2) 0.007 
1.5 (0.2) 2.2 (0.4) 1.1 (0.2) 0.004 
25.3 (0.9) 29.2 (1.4) 22.3 (1.1) <0.001 
16.7 (0.8) 18.1 (1.1) 15.6 (0.9) 0.056 
9.6 (0.6) 11.1 (0.9) 8.4 (0.7) 0.007 
7.2 (0.5) 8.7 (0.9) 6.1 (0.6) 0.004 
6.6(0.5) 5.9(0.7) 7.1 (0.6) 0.148 








---- ~.----.--.-----.-.-- ~- -.-.-.---.-.------.--------.---~------_::____c__ 
* Pearson's chi-squared test reporting the significance of the difference between men and women. 
** British Medical Research Council definition of chronic bronchitis 
A high proportion of the study population (25.3%) complained of usual winter morning 
phlegm and recent cough (19.5%). In general, men had more phlegm-producing 
symptoms than women (all phlegm questions) and 2.2% of men reported 
haemoptysis in the last 12 months, which was also more prevalent in men than 












Percentage 16 i 























2 I: Women 
>65 
Figure 19: Prevalence of chronic bronchitis (British MRC definition) by age and sex 
(n=3483) 
The British MRC definition of chronic bronchitis was met in 7.4% (6.1 % of women 
and 8.7% of men aged 15 and over). This is defined as cough and phlegm for at least 
3 months each year for at least two successive years. The prevalence of chronic 
bronchitis in persons aged 40 years and older was 12.6% in men and 9.2% in women 
(not shown). Figure 19 depicts the age and gender related prevalence of chronic 
bronchitis, Prevalence rose sharply with age up to the age group 55-64, but was 
consistently higher in men. The subsequent decrease in prevalence in the over 65 
age group is most likely a survivor effect or a cohort effect. 
Quality of life was affected in 6.6% of the population who reported that they had 
chest illness that had affected their daily activities in the last 12 months. Phlegm-
producing chest illness lasting a week or more was reported by 5.7%, with no gender 
preponderance. Greater severity, suggested by the presence of two or more such 












5.3.2.2. Wheeze, breathlessness with wheeze, night waking 
Table 16: Prevalence of wheeze and rhinitis (n=3483) 
---.--------------------~~-------------- ------- ---------_. 
Symptom All All Men Women p* 
______________ ~ ________ lnJ ___ ~_{?_~ _____ ~J?EL _________ !o_ (S~L ___________ _ 
Wheeze in last 12 months 449 12.9 (0.7) 12.4 (1.0) 13.3 (0.8) 0.5 
Shortness of breath with wheeze 344 9.9 (0.6) 8.9 (0.8) 10.7 (0.8) 0.087 
Wheezing without a 'cold' 282 8.1 (0.5) 8.3 (0.8) 7.9 (0.7) 0.7 
Night waking from shortness of 
breath or tight chest in last 12 258 7.4 (0.5) 7.4 (0.8) 7.4 (0.6) 0.9 
months 
Ever had problems with 
sneezing, runny or blocked nose 636 18.3 (0.7) 19.5(1.1) 17.4 (0.9) 0.1 
when not having a 'cold' 
In last 12 months, ever had 
problems with sneezing, runny or 
545 15.7 (0.7) 17.1(1.1) 14.6 (0.8) 0.042 
blocked nose when not having a 
'cold' 
--~'-'.-- .. ---.---------.---~---------------~------~-.".--------~~~ -_. -~--"--~.-. -- ---- ----_._._--.----------
~ Pearson's chi-squared test reporting the significance of the difference between men and women. 
The population prevalence of wheeze in the last 12 months was 12.9%, with 9.9% 
experiencing shortness of breath with wheeze. Wheezing without a cold was noted 
by 8.1 % and night waking with shortness of breath or a tight chest in the last 12 
months reported by 7.4%. There were no significant gender differences in the 
prevalence of any questions concerning the symptom of wheeze. 
Ever having symptoms associated with allergic rhinitis were reported by 18.3% of the 
population and 15.7% had these symptoms in the last 12 months. These symptoms 












Table 17: Prevalence of symptoms of breathlessness by age (n=3483) 
n % n % _§)I!!1Jl1()rt1~ ______ ._ .. ______ ~ ___ . _______ . _______ . 
---"~-~~.~~------------~-".--------.--- ... -.~-------------
Any problem with breathing 427 12.3 224 15.9 
Breathing problems 
1. Continuously (breathing never normal) 65 1.9 40 2.8 
2. Repeatedly (but breathing returns to being 
completely normal) 
227 6.5 118 8.4 
3. Occasionally 
131 3.8 63 4.5 
Shortness of breath on walking fast on the level or 
705 20.2 425 30.2 
light incline (Grade 0) 
On the level, walks slower than peers of the same 
442 12.7 302 21.5 
age as a result of shortness of breath (Grade 1) 
Stops for breath when walking at own pace on the 
357 10.3 251 17.9 level (Grade 2) 
Stops for breath after 100m on the level (Grade 3) 338 9.7 236 16.8 
Too short of breath to leave the house, or on 
224 6.4 171 12.2 
dressing/undressing (Grade 4) 
Problem walking as a result of a condition other than 311 8.9 244 17.4 
__ ~_~9!J()'"-lt:!I1ll..Qi~~a~~_._______ _. __ ~ ___ ~ ____________ 
- ----~.-----~---.---.-.-----~-------- - -- - ~--'-'--"-"-"----'------'---------
High prevalences of dyspnoea were reported by persons aged 15 and older. Persons 
who had problems walking as a result of a condition other than heart or lung disease 
(such as joint disorders) were excluded from answering questions relating to walking. 
The prevalence of dyspnoea was higher in the persons aged 40 and older. 
Grade two and higher dyspnoea was present in 1 0.3% of the population aged 15 and 
above and in 17.9% in persons aged 40 and older. Grade 2 was defined as stopping 
for breath while walking at one's own pace on level ground. As this level of dyspnoea 
is associated with a greater likelihood of heart or lung disease, it is used as a 












Table 18: Prevalence of dyspnoea by sex in persons aged between 15 and 40 (n=2077) 
---._-----_ ... __ .. -_ ... _-". -.~---
--.-------.--.---------.-.~---.... _ .. _- ----~--.-.-,,-.----.-.. --.-.. _. -- ---
Symptom All All Men Women p* 
------_ .. ------.. -. -- -~------------.----.. ----.---.---.. ---.-- ... ~~.I1 __ ~_ %J~~~ ___ . ___ Jd~~ ___ ~._~~.L~~L_. ____ . ___ 
Any problem with breathing 203 9.8 (0.7) 10.7(1.0) 9.1 (0.9) 0.2 
Breathing problems 
1 . Continuously (breathing 25 1.2 (0.2) 1.1 (0.3) 1.3 (0.3) 
never normal) 
2. Repeatedly (but breathing 
109 5.3 (0.5) 6.1 (0.8) 4.6 (0.6) 0.4 returns to being completely 
normal) 
3. Occasionally 68 3.3 (0.4) 3.5 (0.6) 3.1 (0.5) 
Shortness of breath on walking fast 
on the level or light incline (Grade 280 13.5 (0.8) 11.2(1.1) 15.3(1.1) 0.011 
0) 
On the level, walks slower than 
peers of the same age as a result 140 6.8 (0.6) 5.9 (0.8) 7.4 (0.8) 0.181 
of shortness of breath (Grade 1) 
Stops for breath when walking at 
106 5.1 (0.6) 4.9 (0.8) 5.3 (0.7) 0.7 own pace on the level (Grade 2) 
Stops for breath after 100m on the 
102 4.9 (0.6) 4.7 (0.8) 5.1 (0.7) 0.7 
level (Grade 3) 
Too short of breath to leave the 
house, or on dressing/undressing 53 2.6 (0.4) 2.1 (0.5) 2.9 (0.5) 0.2 
(Grade 4) 
Problem walking as a result of a 
condition other than heart or lung 67 3.2(0.4) 3.6 (0.6) 2.9 (0.5) 0.4 
disease ----_ .. _-_. __ ... --------------_ .. _-_.".-_.-- ---_._----_._---"-----------_._._-_._---------".----------------------.... ------
* Pearson's chi-squared test reporting the significance of the difference between men and women. 
A relatively low prevalence of dyspnoea of any grade was noted in persons aged 
between 15 and 40 years (see Table 18.) and there appear to be no significant 
differences in prevalence between men and women. However, the women will be 












Table 19: Prevalence of dyspnoea by sex in persons aged ~40 (n=1406) 
--------~-- ----.---~-----------.------.,-------.------~--.---.-"-----_._--------_._--_._----_.- - -.--_ .. _-------
Symptom All All Men Women p* 
. __ ..... _._._.~. ____ ... __ ................ _ ... _ ...____ .. ___ rl_ ..... _._~(dSsL. _____ ~~. (S E) %(S~ ----- -_.. ---~--.-----
Any problem with breathing 224 15.9 (1.0) 15.0 (1.5) 16.5 (1.3) 0.4 
Breathing problems 
1. Continuously (breathing 40 2.8 (0.5) 3.8 (0.9) 2.2 (0.5) 
never normal) 
2. Repeatedly (but breathing 
118 8.4 (0.8) 8.2(1.1) 8.5 (1.0) 0.016 returns to being completely 
normal) 
3. Occasionally 63 4.5 (0.6) 2.8 (0.7) 5.7 (0.8) 
Shortness of breath on walking fast 
on the level or light incline (Grade 
425 30.2 (1.3) 26.2 (1.9) 33.0 (1.7) 0.006 
0) 
On the level, walks slower than 
peers of the same age as a result 302 21.5 (1.2) 19.1 (1.7) 23.2 (1.5) 0.064 
of shortness of breath (Grade 1) 
Stops for breath when walking at 
251 17.9(1.1) 17.1 (1.6) 18.4 (1.4) 0.5 
own pace on the level (Grade 2) 
Stops for breath after 100m on the 
236 16.8 (1.1) 15.9 (1.6) 17.4 (1.4) 0.5 
level (Grade 3) 
Too short of breath to leave the 
house, or on dressing/undressing 171 12.1 (0.9) 10.1 (1.3) 13.5 (1.2) 0.054 
(Grade 4) 
Problem walking as a result of a 
condition other than heart or lung 244 17.4(1.1) 17.1 (1.6) 17.6 (1.3) 0.8 
disease ---_.- ------- .-_._-"._---- -----------.-------------~~-~-""--------------.-.-----~------.-. ._---------_._-------- ----~-.---.. --
• Pearson's chi-squared test reporting the significance of the difference between men and women. 
A high prevalence of dyspno a symptoms (all grades) was noted in persons aged 
:~o years. Dyspnoea of grade two and higher occurred in 17.9% of this age group. 
Dyspnoea was more prevalent in women, but this was not statistically significant at 
the 5% level and could possibly reflect a reporting bias. Overall, 38.3% of the 
population reported the presence of at least one respiratory symptom (wheeze, 
cough/phlegm, or dyspnoea). 
5.3.2.4. Symptoms of TB or systemic disease 
Many participants reported the presence of a cough of recent onset (19.5%). 
Haemoptysis, a symptom more likely to be suggestive of tuberculosis in this context, 
was reported by 1.1 % of the community and by 1.5% in the last 12 months. Details of 
























































----:-cc---:-=------~-~----.-- .... --- -~~~--.. -~------.-.--.. -
* Pearson's chi-squared test reporting the significance of the difference between men and women. 
Other non-specific systemic symptoms such as weight loss (12.1%) and night sweats 
(9.2%) were more common. The prevalence of night sweats was 12% in men and 8% 
in women (see Table 20.). Fever (current) was less common (2.7%). All symptoms 
suggestive of tuberculosis were more prevalent in men than women (p<0.05), but the 
differences in prevalence were not significant for the non-specific symptoms of fever 
and weight loss (p=0.18 and 0.13 respectively). 
5.3.3. Self-reported doctor diagnoses 
Table 21 presents participants' responses to the question on whether a doctor or 
healthcare worker had ever told them that they had any of the following diseases -
tuberculosis, asthma, nasal symptoms, chronic bronchitis/emphysema, heart 
disease, other chest disease or pneumonia. 
Table 21: Self-reported doctor-diagnosed chest diseases (n = 3483) 
Doctor-diagnosed chest All All Men Women p** 
~dise~:~ ____ ~ ________ ~ _____ ~ __ I"l _____ ~_~% (~~L~ ____ !oJSEL ____ ~ (S~). 
"--~--.-"-~. -~ 
Tuberculosis 337 9.7 (0.6) 12.0 (0.9) 8.0 (0.7) <0.001 
Asthma 245 7.0 (0.4) 4.6 (0.5) 8.8 (0.6) <0.001 
'Hayfever' 235 6.7 (0.5) 5.5 (0.6) 7.6 (0.6) 0.011 
Chronic bronchitis/emphysema 193 5.5 (0.4) 4.8 (0.6) 6.1 (0.6) 0.1 
Heart disease 170 4.9 (0.4) 4.0 (0.5) 5.5 (0.5) 0.04 
Other chest disease*'* 29 0.8 (0.2) 0.7 (0.2) 1.0 (0.2) 0.4 
Pneumonia 9 * * * * 
* Asterisks indicate that a figure is based on fewer than 25 weighted cases and has been suppressed. 
*' Pearson's chi-squClred test reporting the significance of the difference between men and women. 
*** These participants reported a number of non specific answers like "one lung weaker" and other 











The most commonly self-reported doctor-diagnosed chest disease was tuberculosis 
(9.7%) which was more common in men than women (12.0% vs. 8.0%), followed by 
asthma (7.0%), which had a female predominance (8.8% vs. 4.6%). 'Hayfever' was 
next with a prevalence of 6.7%, women again more affected than men. Despite high 
levels of symptoms of cough and sputum production, chronic bronchitis was reported 
by 5.5%, with no gender difference in prevalence. The prevalence of heart disease 
was 4.9%, with women more likely to have reported the condition than men (4.0% vs. 
5.5%). Other chest diseases and pneumonia were uncommon reported diagnoses. 
5.3.4. Distribution of risk factors 
5.3.4.1. Tobacco smoking 
Table 22: Population estimate of tobacco exposure by sex (n=3483) 
---- ------------------- -- ----- -----
All All Men Women 
n % (SE) % (SE) % (SE) p* 
__ _________________________ j_!l~34?3) _______ 1~=~4831 ____ J'!=ji~~~.Jn=!!:J!l~L _____ _ 
Never smokers 1475 42.4 (1.0) 32.8 (1.3) 49.6% (1.3) 
Ex smokers 266 7.6 (0.5) 8.0 (0.7) 7.3% (0.6) 
Current smokers (any 
1734 49.9(1.1) 59.1 (1.4) 43.0 (1.3) 
amount) 
Current 1 - 14 
1339 38.5 (1.0) 42.9(1.4) 35.3 (1.2) 
cigarettes per day 
Current ::::1 5 
<0.001 
cigarettes per day 
354 10.2 (0.6) 14.1 (1.0) 7.3(0.7) 
__ F>ip~~rn()_k.Lng~nly ________ _=l1 ____________ J_'_~iQ~? J _______ -.? ___ ?iQ:-4L ___ QA_f QJJ__ _ ___________ _ 
* Pearson's chi-squared test reporting the significance of the difference between men and women. 
More women than men had never smoked (49.6% vs. 32.8%). Half the population 
(1734 or 49.9%) were current smokers at the time of the study, comprising 59.1 % of 
men and 43.0% of women. Two thirds of men and half of women (67.1 vs. 50.4%) 
have smoked at least one cigarette a day for at least one year, constituting for this 
community, amongst the highest recorded prevalences of smoking in the world (far 
exceeding national and even provincial averages), particularly amongst women. This 
high prevalence of ever smoking was accompanied by low rates of quitting, reflected 











The distribution of tobacco exposure in men and women was significantly different 
(p<0.001). The majority of smokers were light to moderate smokers (1 t014 cigarettes 
per day), with slightly higher proportions of women falling into this group (42.9% vs. 
35.3%). More men than women smoked more than 14 cigarettes per day (14.1% vs. 
7.3%) and men were more likely to have smoked ::::20 cigarettes per day than women 
(see Table 24). It is important to note that even though men and women smokers had 
similar absolute values as totals, the proportion of men who smoked was much 
higher as they formed 43% of the population and women 57%. Pipe smoking only 
was practiced by the minority (41 persons; 1.3%) and very few persons smoked both 
pipes and cigarettes (5 persons). Pipe smoking was practiced predominantly by men 
(1.0%) and was very uncommon amongst women in this community. 
Table 23: Prevalence of ever smoking tobacco by age and sex (n = 2000) 
All All Men Women 
n % (SE) % (SE) % (SE) p* 












47.1 (1.7) 54.5 (2.6) 41.2 (2.2) 
59.4 (20) 65.5 (2.8) 54.8 (2.5) 
66.1 (1.9) 72.9 (2.4) 60.1 (2.6) 
67.8 (2.3) 81.7 (2.8) 58.2 (3.0) <0.001 
59.3 (2.8) 76.0 (3.9) 49.2 (3.5) 
.. _. ____ I.C>.taL ___ .1Q.Qg.~ __ 5L~JLQL ___ §Lljlc1)_. __ .... ~Q..±..(tlL __ ~._ .... 
* Pearson's chi-squared test reporting the significance of the difference between men and women. 
The prevalence of ever smoking tobacco was high at all ages in both men and 
women, with the lowest prevalence found in women aged over 65. The difference in 
prevalence of ever smoking in men and women was significant (p<O.001). Table 23 
shows that 47.1 % of persons aged between 15 and 24 years had ever smoked, 
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Figure 20: Prevalence of ever smoking tobacco by age and sex (n = 3483) 
Table 24: Quantity of tobacco ever by sex (n= 1962) 
Cigarettes All All Men Women 
per day* 
n % (SE) % (SE) % (SE) 
- ---.-.~-... ----.--~--- .. ~=1~~~1 ____ ln:::_196~)._ . .... ... _ .. {':l:::_9_~§J. ____ . (n=977) 
1 to 5 794 40.5 (1.3) 33.9 (1.7) 47.1(1.7) 
6 to 10 678 34.5 (1.2) 35.6(1.6) 33.5 (1.5) 
11 to 15 153 7.8 (0.6) 9.6 (1.0) 5.9 (0.8) 
16t020 267 13.6(0.8) 16.6(1.2) 10.6(1.1) 
p* 
<0.001 
>.?_O ____ . ____________ ~Q______. __ 3 .4_i9.:?L._. __ ~: 3 (0.7) _~Ji.i.o . 51_.u __ . _________ _ 
* Pearson's chi-squared test reporting the significance of the difference between men and women. 
Although 2000 persons had ever smoked tobacco at the time of the study, only 1962 
persons gave complete data on the number of cigarettes per day. Three quarters of 
smokers (see Table 24 - 40.5% plus 34.5%) smoked between 1 and 10 cigarettes 
per day, making light to moderate usage the norm. Men were heavier users than 
women, with approximately 30% of men smoking more than 10 cigarettes per day. 
Almost half of women smokers (47.1%) smoked between 1 and 5 cigarettes per day 











Table 25: Patterns of tobacco smoking (n=2000) 
All: median Men: median Women: median 
(25th _ 75th (25th _ 75th (25th _ 75th 
________________________ ~ _________ cen1!~ _____ centil& ________ ~eJ:ltileL __ _ 
Age started smoking 16 (15 -19) 16 (15 -18) 17 (15 - 20) 
(range = 6-60 years of age) 
Age stopped smoking 
(in ex smokers*) 
Number of years 
smoked 
35 (25 - 46) 
16.3 (7.0 - 27.6) 
35 (27 - 46) 34 (25 - 46) 
16.7 (7.3 - 27.8) 15.7 (6.6 - 27.5) 
£Cl~k_le~r~ __ ~ ________________ 2l1:L~_=JJJ~L_~ __ (~_:~_=_t~:~L __4~5_(LI-=J2:~1 __ _ 
* An ex smoker is defined as a person who stopped smoking more than one month ago before the 
survey date. 
A quarter of smokers had already started smoking by age 15 and half of smokers 
were smoking by age 16, while a further quarter had started by age 19, indicating a 
young age of onset of tobacco use. The median number of pack years is low at 5.3 
and 75% of the population had a smoking history of less than 11.9 pack years. Men 
had a higher exposure than women (median 6.3 vs. 4.5 pack years). Half of those 
that did stop smoking did so by age 35. Both men and women had smoked for a 
similar number of years (median of 16.7 vs.15.7 years). In the light of the fact that 70 
percent of the population is under the age of 45 years, a median of 16.3 years of 
smoking is high. 
5.3.4.2. Cannabis smoking 
Table 26: Population estimate of cannabis exposure by sex (n=3483) 
All 
n 
Never smokers 3088 
Ex smokers 173 
Current smokers (any amount) 222 
Current 1 - 2 joints per day 89 









% (SE) % (SE) 
77.0 (1.2) 97.5 (0.4) 
9.8 (0.8) 1.4 (0.3) 
13.2 (1.0) 1.2 (0.3) 
5.2 (0.6) 0.6 (0.2) 
3.4 (0.5) 0.3(0.1) 
p* 
<0.001 
_ ''ElfJ~~~n~~lQggt'!Iy ___________ ____ ~ ______ ~:2_(9·~ __ ~4::U9~~L_~:3 __ (Q:1L ___________ 
* Pearson's chi-squared test reporting the significance of the difference between men and women. 
Regarding smoking, 411 persons (12%) admitted to smoking substances other than 











directly "Have you ever smoked cannabis" (395 participants). Twenty three percent of 
men and 2.6 percent of women admitted to ever smoking cannabis. The majority of 
cannabis smokers were male and just under half of male smokers (9.8% of the male 
population) had already quit at the time of the survey. A significant proportion of men 
were current cannabis smokers (222 participants - 13.2%). 
As very few females admitted to regularly smoking cannabis, female estimates are 
based on 51 female ever smokers and should thus be interpreted with caution. "Pipe" 
smoking (a pipe usually being a makeshift 'pipe' - see Figure 3) was practised by 
118 persons and 76 of these (2.2% of the total population or 34.2% of cannabis 
users) smoked cannabis pipes exclusively. The remainder (42 persons) smoked both 
joints and pipes. 
Of all persons who had ever smoked cannabis, 92.1 percent also smoked tobacco 
and only 7.9% had never smoked tobacco. There were thus very few exclusive 
cannabis smokers. Of all those who had ever smoked tobacco, 18.1 % had ever 
smoked cannabis. Of all current tobacco smokers, 11.5% currently use cannabis (not 
shown). 
















































... __ ~ __ .. __ __ I()!al ______ 39~ ______ ~_11·;3_i9~ ____ 23:.9 __ C1_·~_2~§J~~L________________ 
• Asterisks indicate that a figure is based on fewer than 12 weighted cases and has been suppressed . 








































15-24 25-34 35-44 45-54 55-64 >=65 
Age (years) 
Figure 21: Prevalence of ever smoking cannabis by age and sex (n=3483) 
Cannabis smoking has been practiced by a significant proportion of men in this 
population (23.0%), compared to 2.6% of women with relatively few commencing 
during each decade after the third decade (Figure 21 and Table 28). 
Table 28: Prevalence of current smoking of cannabis by age and sex (n=3483) 
... _ .. ------_._._--------_._-_._---_ ... __ . __ ... _--
All All Men 
_ ..... _______ . _________________ '! __ .. ________ ~t?_il?_~ ______ %J~~L_ 
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__________ IQt?L _____ 222 _________ §.·Ll:_(Q:?1. _____ .1~'_W..-.Qt __ .. _J.:.£.JQ·:3l __________ _ 
* Asterisks indicate that a figure is based on fewer than 12 weighted cases and has been suppressed. 
** Pearson's chi-squared test reporting the significance of the difference between men and women. 
Table 28 shows that a higher proportion of men are current cannabis smokers than 
women (13.2% vs. 2.6%; p<0.001). The highest prevalence of current cannabis 
smoking was in men aged 35 - 44 (16.7%), and amongst women it was in the 15 - 24 
age group (2.0%). This prevalence drops off by almost a half by the sixth decade and 











Table 29: Patterns of cannabis smoking (n=395) 
All: median Men: median Women: median 
(25th _ 75th centile) (25th - 75thcentile) (25th - 75th centile) 
____________ ~_~ _______________________ lr1_::~~§1 _______________ JI1~~~~ __________________ irl'::§!L~ ___ _ 
Age started smoking 18(16-20) 17 (16 - 20) 18 (16 - 23) 
(range = 6-60 years of age) 
Age stopped smoking 25 (19 - 33) 25 (19 - 35) 24 (19 - 29) 
(in ex smokers*; n=173) 
Number of years smoked 9 (3.2 - 20.9) 10 (3.8 - 21.9) 4.3 (1.8--11.1) 
____ JQiQtyeClfs** _________________ ____ 2!~~i§L= Q~~L _________ ~~?_J19--2Z=1Ql _____ ~-LL{~ _ _::_?§:~1 __ _ 
, An ex smoker is defined as a person who stopped smoking more than one month before the date of 
interview. 
*' 1 joint year = average of 1 joint per year for 1 year2 
Most cannabis smokers had started smoking cannabis in their late teens and stopped 
in their late 20's or early 30's. A quarter of smokers had already started smoking by 
age 16, half by age 18 and three quarters by age 20, indicating a young age of onset 
of cannabis use. Half of those that quit smoking cannabis did so by 25 years of age. 
Men smoked for a greater number of years than women (median of 10 vs. 4.3 years). 
In the light of the fact that 70 percent of the population is under the age of 45 years, a 
median of nine years of smoking is significant. The median number of joint years is 
high at 27.6 and 75% of the populat on had a smoking history of less than 68.4 joint 












5.3.4.3. Childhood chest illness 
Table 30: Prevalence of childhood chest illness by sex (n=3483) 
All All Men Women p** 
History of childhood chest illness 
with coUgh and shortness of breath 341 9.8 (0.5) 9.9 (0.8) 9.7 (0.7) 0.9 
«12 yrs of age) 
History of repeated/chronic 
231 6.6 (0.4) 6.4 (0.6) 6.8 (0.6) 0.6 
childhood chest illness 
Hospitalised for at least one night 114 3.3 (0.3) 3.5 (0.5) 3.1 (0.4 0.5 
Recall of diagnosis assigned to 
childhood illness'** 
Total 253 7.3 (0.5) 6.7 (0.6) 7.7 (0.6) 0.3 
• Asthma 124 3.6 See text See text 
• Bronchitis 63 1.8 See text See text 
• TB 27 0.8 * 
,. 
Pneumonia 19 0.5 * * * • 
Other 18 0.5 * * * • 
"- --.-----~-------.. ---------~--.------~ ---.-----~----------.-~~------.. --.---.----.------.---- _ ... _------- --------------- - -----------
* Asterisks indicate that a figure is based on fewer than 12 weighted cases and has been suppressed. 
** Pearson's chi-squared test reporting the significance of the difference between men and women. 
*** Not specified whether by doctor or other person (e.g. parent, friend etc.) 
A history of childhood chest illness with cough and shortness of breath «12 yrs of 
age) was recalled by 9.8% of the population. Approximately two thirds of the latter 
gave a history of repeated or chronic childhood chest illness (6.6%) and one third 
(3.3%) recalled being hospitalised for at least one night. There were no significant 
gender differences. 
Asthma was the most commonly reported childhood chest illness (3.6% of the 
population). Of these, two thirds were women (62.8%) and approximately one third 
were men (37.2%), in keeping with the known female predominance of asthma. 
Similarly, of the 1.8% of the population who reported bronchitis as a childhood 











5.3.4.4. Occupational Exposures 
Table 31: Prevalence of lifetime occupational exposure by sex (n=3483) 
Silica exposure e.g. sand blasting, 
grinding, pottery, mining, 
gravestone/stone mason (1) 
Dust, gas, strong smells, chemicals, 
damp exposure (2) 
Occupational exposure (1 and/or 2) 






All Men Women 
8.6 (0.5) 16.1 (1.0) 2.9 (0.4) 
23.6 (0.8) 32.9 (1.3) 16.7(0.9) 
26.3 (0.8) 37.1 (1.4) 18.1 (1.0) 







-~--.. ---.----~-- -- -----. "_._.N __ . __ ". __________ ~ _____ ·· _______ .. __ ._. ______ ~ ___ ._. ___ ~_ 
, Pearson's chi-squared test reporting the significance of the difference between men and women. 
Exposure to silica was more commonly reported by men than women (16.1 % vs. 
2.9%) as was general dust exposure (32.9 vs. 16.7). Occupational exposure was 
classified as a combination of silica and/or general dust exposure and has been used 
in the univariable and multivariable logistic regression in chapter six, as the variable 
for occupational exposure. Some persons (4.5%) reported having had to leave work 
because occupational dust exposure affected their breathing. 
5.3.4.5. Caged birds 
Table 32: Prevalence of exposure to caged birds (n=3483) 
All All Men Women p* 
• Pearson's chi-squared test reporting the Significance of the difference between men and women. 
Many participants (12.4%) reported keeping caged birds which is a common hobby in 
Cape Town. This exposure is a potential risk factor for lung disease through its 











5.3.4.6. Alcohol use 
Table 33: Prevalence of alcohol use in the population sample (n=3483) 
Drinks alcohol (current) 
Number of weekend days drinks alcohol (Friday to Sunday) 
2 
3 




















Table 34: Population estimate of number of days of alcohol use per week (n = 3483) 
Number of days of 









% (SE) % (SE) 
50.8% (1.4) 76.6% (1.2) 
1 - 2 762 21.9% (0.8) 29.0% (1.3) 16.6% (1.0) 
3-4 307 8.8%(0.6) 13.7%(1.0) 5.1%(0.6) 
p* 
<0.001 
~5 _____________________ J~~ ______ 3.JD~o_lO ·LU ____ ~,_4Yo (0. 7) ____ 1}~ (0.31 ________ . ___ _ 
* Pearson's chi-squared test reporting the significance of the difference between men and women. 
Alcohol use was reported by 35.1 % of persons. Of these, most used alcohol on the 
weekend, with 9.5% consuming on one weekend day, 14.4% on two weekend days 
and 10.1% on 3 weekend days. Most persons (21.9%) drank alcohol on 1-2 days per 
week. The patterns of alcohol use in men and women were significantly different with 
76.6 % of women reporting no alcohol use, compared to only 50.8% of men who 
claimed to be teetotallers (p<0.001). 
For the purposes of defining regular alcohol use as a risk factor, this was defined as 
use on 3 weekend days and ;::2 week days. 208 persons (6%) fell into this group, 
while 3275 (94%) were either non, light or moderate users. Quantification of alcohol 
use was difficult and inaccurate, owing to the fact that the most common pattern of 
use involved sharing bottles of alcohol amongst a group of persons, so these data 











5.3.4.7. Domestic fuels 
Table 35: Prevalence of domestic fuel use (n=3483) 
- -------- ---------------------------- ----------------------------- ----------------------------------
Fuel Type Cooking Cooking Heating Heating 
_____________________________________ r:! ___________ !"oJ~I::L __________ '! _____ ___ ~_L~~) _____ _ 




















__ LJ!l_knQl."Jr~_ __________________ ____ ~_~ ___________ ~]_ (Q:_~2 ______ 1§_1 3 _______ ~1~_~JYR __ _ 
Current use of fuel other than electricity for cooking or heating was minimal, with 
95.3% of persons using electricity. There are no data from the LHS on previous use 
of biomass fuels. Data on previous use have been collected in the part two study 
(BOLD) and also shows limited duration of exposure as this is an urban community. 
Data in Table 35 are not presented stratified by sex owing to the small numbers in 
groups using fuels other than electricity. 
5.3.4.8. Body Mass Index 
Table 36: Distribution of Body Mass Index categories by sex (n= 2758) 
Body mass Index All All Men Women p* 
__ ________________________________ . _________ 11______ %~~I::J_ ____ 'Y~~EJ _ ___ ~l§!=J __ ... _._----_._----
Underweight (BMI<18.5) 309 11.0 (0.7) 15.3(1.1) 8.0 (0.7) 
Normal weight (BMI 18.5 - 24.9) 1233 43.9 (1.0) 53.3 (1.6) 37.3(1.2) 
<0.001 
Overweight (BMI 25 - 30) 653 23.2 (0.8) 20.6 (1.3) 25.0(1.1) 
_Q_Q.(3se_.LBl\I!l_~~QL _________________ ~ _______ ?_2:Q_(Q..~L ___ JQJU19l ____ ?~.:LLL?) __ 
* Pearson's chi-squared test reporting the significance of the difference between men and women. 
Body Mass Index (BMI) is defined as weight in kilograms divided by the square of 
height in metres. A normal BMI was present in 53.3% of men and 37.3% of women 
aged ~ 5 years. The prevalence of overweight and obesity in women was 25.0% and 
29.7% respectively. A large gender difference is seen in the comparative figures for 
men - 20.6% and 10.8% respectively. Underweight was more prevalent in men 












The prevalence of a history of tuberculosis is presented above in Table 21. It was the 
most commonly diagnosed respiratory illness in this population (9.7% of persons had 
a history of pulmonary tuberculosis), and was more common in men (12% in men vs. 
8% in women, p<0.001). 
From the concurrent tuberculosis prevalence survey (a component study of the 
LHS2002), the prevalence of active tuberculosis was 10 per 1,000 (95% CI: 6.2 to 
13.8 per 1,000), an estimate which was based on 26 bacteriologically confirmed TB 
cases (smear or culture positive) from a total of 2608 persons who provided a 
sputum sample. xiv Ten out of the 18 smear positive cases had been previously 
treated (3.8 per 1,000; 95% CI: 1.5 to 6.2 per 1,000), and eight were new cases (3.1 
per 1,000; 95% CI: 0.9 to 5.1 per 1,000). Thus more than half of the prevalent smear 
positive cases were previously treated. xiv 
5.3.5. Healthcare utilisation 
5.3.5.1. Treatment 
Table 37: Treatment for lung disease, including nasal allergy (n=3483) 
Disease n % - --------- .----- ----- ------- --- -- ._---------- ~----- -------------~--.---------~--.--------~.-------~ ---.- - ----~--------
Takes medication for chest disease, including nasal allergy* 
Asthma 
Hay fever 






















The majority of persons who are on medication were receiving medication for asthma 
(3.6%) and allergic rhinitis (2.8%), despite the high prevalence of symptoms of lung 
disease. One percent of the population reported receiving treatment for chronic 
xiv Den Boon S, van Lill SWP, Borgdorff MW, Enarson DA, Verver S, Bateman ED, Irusen E, Lombard CJ, White NW, 












bronchitis/emphysema. Of all persons with doctor-diagnosed asthma, 48.2% were on 
current treatment for asthma at the time of the study. Of all persons with doctor-
diagnosed chronic bronchitis/emphysema, 12.1 % were on current treatment for the 
same at the time of the study. 
5.3.5.2. Use of services 
Table 38: Source of medication, medical care and emergency medical care for lung 
disease (n=3483) 
Source of Medication Healthcare provider for Healthcare provider for 
..... ____ . _____ . ______ . __ .. ___ . _. __ ... ___ .. _______ rrl~!lLca_'_c:"!':.~_. ______ . __ ~me'1l.E!.I'l(;l_I!l..fJ~Jc:~_I.E.are __ _ 
Health Care Usually Sometimes Usually Sometimes Usually Sometimes 
_EE~vj<:!e-,"- __ ._. ___ ._. __ . ____ I1J'Y~L ____ n .. CO!r>L_ ......... _ .. __ I'l.e!ol_ ______n_t!oJ. __________ I1 __ (~L. _______ I1_e~oL_ ... _ 
Clinic/day hospital 157 (4.5%) 66 (1.9%) 370 (10.6%) 210 (6.0%) 324 (9.3%) 144 (4.1%) 
Private Hospital 5 (0.1%) 7 (0.2%) 160 (4.6%) 111 (3.2%) 100 (2.9%) 82 (2.4%) 
Provincial Hospital 24 (0.7%) 14 (0.4%) 49 (1.4%) 33 (1.0%) 59 (1.7%) 46(1.3%) 
Chemist/PhClrmacy 57(1.6%) 26 (0.8%) 22 (0.6%) 19 (0.6%) 21 (0.6%) 17(0.5%) 
Private doctor 41 (1.2%) 33 (1.0%) 26 (0.8%) 34 (1.0%) 10(0.3%) 13 (0.4%) 
Traditional Healer 0(0.0%) 0(0.0%) 3 (0.1%) 4 (0.1 'Yo) 0(0.0%) 0(0.0%) 
2 (QJo(o1. ___ ilj(LQ.%) ._m. ____ 0 (0.0%.L ______ HQ-'1"/oL __ . ___ B.tQc2%) . __ 
The majority of persons (4.5%) usually received medication from the local district 
health clinic or day hospital (a state-run health service), and some visited a pharmacy 
(1.6%) or a private doctor (1.2%). 
At least 8.4 percent of the population had a chest illness severe enough to cause 
them to attend a healthcare provider within the last 12 months, and the most 
commonly attended facility was a community health clinic (day hospital), followed by 
a private doctor or provincial hospital (usually by referral only). 
The majority of individuals in Ravensmead and Uitsig attend the local district health 
clinic/day hospital for emergency care for chest illnesses (9.3%), but a minority 
always consulted a private doctor (2.9%). A small proportion used two or more 
providers interchangeably. The nearest provincial hospital (Tyberberg Hospital) is 












Table 39: Hospitalisation and quality of life limitation due to chest illness (n=3483) 
n % 
--~~-.~.- ... -- "--------~------------------.--.--.-----"---.. ----.-.--- "------- -----_ .. _-- -- - .. ----~----------.-
































Almost seven percent of the population had attended a hospital emergency 
department in the last year for chest illness, about half of whom had attended only 
once. Slightly more men than women had attended (8% of men vs. 6% of women, 
not shown). Hospital admission for at least one night (owing to chest illness) was 
reported by 2.2% of persons, indicating that there is a significant proportion of 
uncontrolled or severe chest illness in this community. Of those with any respiratory 
symptoms, 11.3% had attended an emergency department in the last year, and 4.7% 
were hospitalised in the last year. Between 2.2 and 2.7 percent of persons had 
reported loss of productivity and/or activities of daily living as a result of chest 

































" ___ "" __ "_"" ___ "" _____ "_" ____ " _____ " ______ " _____________ Jy~ ______________ " ____ "_" __ " _______ " _____ """ ___ """_" __ "_"""_" 
MRC chronic bronchitis 23" 1 3"3 29.4 159 6.0 
Wheeze in last 12 months 28.5 2.1 32.1 19.9 4.7 
Wheeze with breathlessness 33.4 2.4 37.5 23.3 6.1 
Dyspnoea grade 2+ 21.6 3.0 27.3 15.2 4.9 
Recent cough 11.3 2.4 19.1 8.1 2.9 
Usual winter mornillg cough 13.8 2.3 19.0 9.3 30 
with phlegm 
Any respiratory symptom 13.1 1.7 18.3 8.6 2.3 
_ (?rl'C~L!t~~_aJLo~J _______ " ______________ ."" __ " ___ " __ " __ " " ________ " __ " _____________ "_""" __ . _________________ ""_"" __ "_"_ 
Table 40 represents subgroup analyses for persons with respiratory symptoms. The 
minority of persons with respiratory symptoms have reported a doctor-diagnosis of 
asthma, and even fewer have reported a diagnosis of chronic bronchitis/emphysema. 
Only 18.3% of persons with any respiratory symptom are on treatment. Many are 
diagnosed and treated as asthma. 
5.3.6. Chest radiography 
A total of 2608 participants had a chest radiograph performed, which represented 
three quarters (74.9%) of those who answered questionnaires. No abnormalities 
were found in 73.1 % of radiographs (1908 films) and 26.9% had some abnormality 
reported. Parenchymal abnormalities occurred in 11.3%, pleural abnormalities in 
5.2% and central structure abnormalities in 6.4% of films. Abnormalities inconsistent 
with tuberculosis were found in 12.9% of all films (337 films). 
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CHAPTER 6: RISK FACTORS FOR SYMPTOMS OF CHRONIC 
LOWER RESPIRATORY DISEASE 
6.1. Introduction and structure of the chapter 
This chapter addresses the second question in this thesis: "What are the risk factors for 
symptoms of obstructive lung disease in this community (the determinants of 
obstructive lung disease)?" As there are several forms of obstructive lung disease and 
several symptoms and symptom complexes whereby they may present, none of which 
necessarily correlate with one another, this analysis of risk factors examines each of 
these symptoms/complexes separately. Perhaps the most distinctive is the diagnosis of 
chronic bronchitis because it is defined by symptoms, without the need for 
physiological assessment. The five symptoms/symptom complexes that will be 
analysed as clinical outcomes are: 
1. Chronic bronchitis (British MRC definition) - chronic cough and phlegm for at 
least 3 months per year for at least two successive years. 
2. Recent cough' 
3. Wheeze in the last 12 months 
4. Wheeze with breathlessness in the last 12 months 
5. Dyspnoea (Grade 2 and above) in the last 12 months 
These are the common symptoms of obstructive lung disease in adults. In the context 
of the study population, reported symptoms are likely to be a better marker of 
obstructive lung disease than doctor-diagnosed illness. Reasons for this are 
underdiagnosis due to limited access to clinical services, and misclassification due to 
absence of lung function testing in most of the clinical facilities that serve this area. As 
demonstrated in Chapter 5, prevalence of these symptoms of obstructive lung disease 
in adults is very high. 
In the assessment of association between these symptoms (as outcomes) and their 
known and suspected risk factors, the following factors were analysed: age, gender, 
i 
Recent cough was the only other question on cough without reference to phlegm in the LHS2002 questionnaire. The 
choice of this symptom as one of the outcomes could be criticised as arbitrary. It was Included in the questionnaire as a 
marker for ulltreated recent onset tuberculosis, owing to the high prevalence of TB in this community. Nonetheless, its 











income, education, tobacco smoking, cannabis smoking, occupational exposure, 
childhood chest illness, previous tuberculosis, domestic fuels, alcohol and body mass 
index. 
Among the identifiable environmental causes of obstructive lung disease in adults, 
modifiable causes are of particular importance, as targeting them in the public health 
arena would allow for a significant improvement in the burden of obstructive lung 
disease. In particular, tobacco use, cannabis use, occupational exposures, obesity and 
tuberculosis merit attention. 
6.2. Statistical Analysis 
The entire dataset from the Lung Health Survey was used for this analysis. Data were 
analysed using the survey estimation commands in the ST ATA® statistical package. 
Appropriate adjustment for clustering, replacement and response rate was made by 
setting the primary sampling unit as an address identifier, and specifying individual 
weighting based on the replacement status and response rate for the age group (see 
Appendix 8). The number and percentage of persons reporting each outcome 
according to risk factor groups are shown in the first column of each outcome table. 
Most variables have been coded as categorical variables and one of the levels of the 
variable that is considered to be "normative" was chosen as the reference group, 
allowing for comparison between this group and the other listed categories. For the few 
instances where continuous variables are used, odds ratios refer to the measure of 
effect of a one unit increment of that variable. 
Univariable logistic regression was first employed in order to assess the relationship of 
the chosen outcomes and risk factors without correcting for the effect of other known 
risk factors and confounders. Estimated unadjusted odds ratios, 95% confidence 
intervals and their corresponding p values are reported in the middle two columns of 
each outcome table. 
Multivariable analysis was the main statistical tool used to elucidate the relationships 
between the above-mentioned outcomes and various risk factors. All variables of a 
priori interest were included, and depending on whether the univariable associations 
were significant or not, risk factors were either included or excluded from the 











there was a good reason to exclude them. Confounders that have been included in the 
analyses are doctor-diagnosed asthma, doctor-diagnosed heart disease and allergic 
rhinitis. 
A priori suspected interactions between variables were tested by including interaction 
terms in the final models, and they are reported if significant. Since tobacco smoking is 
the major risk factor for obstructive lung disease in adults, but not all smokers develop 
obstructive lung disease, interactions between tobacco smoking and other risk factors 
were examined for significance. 
The last two columns of each table show the fully adjusted odds ratios, 95% confidence 
intervals and corresponding p values. The model-building process was carried out with 
an inclusive slant, and stepwise logistic regression was not employed in the final 
modelling process because the reasons for including most of the putative risk factors 
was based on strong clinical evidence from published literature, as discussed in 
Chapter 2. The results of the adjusted multivariable logistic regressions represent the 
most important part of this chapter and are discussed in detail in Chapter 8. 
For each multivariable logistic regression, a Goodness of Fit Test was applied in order 
to assess how well the chosen combination of variables in the fitted models explained 
the outcome in question. 1 2 A good fit occurs when the differences between the 
observed and expected (fitted) values are small, and there is no systematic contribution 
of the differences to the error structure of the modeL3 As it is essential to take the 
survey design into account, the Hosmer-Lemeshow Goodness-of-Fit test statistic was 
appropriately adjusted for clustering and weighting by using the STATA survey 
estimation package. A p value closer to 1 indicates a good result for this test because it 
means that the observed and fitted values are not significantly different. Models with p 
values greater than 0.05 can be considered to be satisfactory for the outcome in 
question. 
Population attributable fractions have been calculated for those risk factors that are 
significant and modifiable, and they are reported and interpreted on the assumption of 











*Population Attributable fraction = p (POR -1)/ [p (POR-1) +1] where POR = prevalence 
odds ratio as an estimate of relative risk, and p = prevalence of the risk factor in the 
population. 
6.3. Results 
6.3.1. Descriptive characteristics of the sample 
Figure 22 lists the questions that were analysed in this chapter. Table 41 summarises 
the descriptive characteristics of the population in terms of the distribution of risk 
factors in the sample. Some of this information is included in Chapter 5. It is presented 
here to describe the categories, and the distribution of the categorical variables entered 











Figure 22: Questions included in this analysis (see Appendix 2 for details) 
1) Do you cough and produce phlegm on most days, for at least 3 months per year for at least 
2 successive years? 
2) Do you have a cough that began recently? 
3) Have you had wheezing or whistling in your chest at any time in the last 12 months? 
4) Have you been at all breathless when the whistling noise was present? 
5) Do you ever have to stop for breath when walking at your own pace on the level? 
Do you ever have to stop for breath after walking about 100 yards? 
Are you too breathless to leave the house or breathless on dressing or undressing? 
6) Do you usually bring up any phlegm from your chest first thing in the morning in the winter? 
7) What is your usual monthly income (from all sources)? 
8) What level of education did you reach? 
9) Has a doctor/health worker ever told you that you have heart trouble? 
10) Has a doctor/health worker ever told you that you have asthma? 
11) Has a doctor/health worker ever told you that you have TB? 
12) a) Have you smoked cigarettes for a year or longer? 
b) How old were you when you started smoking? 
c) Do you smoke now (within the last month)? 
d) If no, how old were you when you stopped smoking? 
e) On average, how much do you smoke or did you smoke? Number of cigarettes per 
day/number of pipe bowls per day. 
13) a) Have you ever smoked cannabis? 
b) How old were you when you started smoking cannabis? 
c) Have you smoked cannabis in the last month? 
d) If 110, how old were you when you stopped smoking? 
e) On average, how much do you smoke or did you smoke? Number of cigarettes per day/ 
number of pipe bowls per day. 
14) Have you ever worked in a job that exposed you to silica dust, or involve sand blasting? 
grinding, pottery, work in a quarry/mine or grave stone manufacturing? 
15) Have you ever been exposed to other dusts, gases, strong smells, chemicals, fumes, at 
work? 
16) Do you recall having any chest illnesses with cough and shortness of breath when you 
were a child? «12 years) 
17) What fuels are mostly used in the dwelling you spend most of your evenings? 
18) Do you drink alcohol? (See Appendix for details) 
19) Have you ever had a problem with sneezing, or a runny, or blocked nose when you DID 
NOT have a cold or the flu? 











Table 41: Distribution of characteristics of the population by gender (n=3483) 
Income": >R2000/month 
R 1 000-R2000/month 
<R1000/month 












Tobacco: Never smoked 
Ex smoker 
Current 1-14 cigarettes /day 
Current >15 cigarettes/day 
Non cigarette only (pipe)*" 
8MI: normal weight 18.5-25 
Overweight BMI >25 & <30 
Obese BMI?:30 
Underweight BMI <18.5 
Cannabis: Never 
Ex Cannabis smoker 
Current 1-2 joints/day 
Current :::B joints/day 
Cannabis pipe only 
Occupational exposure: Never 
Ever 
Childhood chest illness: Never 
Ever 
Previous tuberculosis: Never 
Ever 
Domestic fuels: Non- smoky 
Smoky 



































































































































Alcohol use: Non, light, moderate 3275 (94.0) 1341 (89.8) 1934 (97.2) <0.001 
Heavy 208 (6.0) 152 (1 0.2) 5~_(~~~L~______ _ _______ _ 
-"-c-ili--sq-LJare-(j test-iorthe-difference between men and women; **R1000month-US$ 98.77; ***small 











6.3.2. Analysis of risk factors for chronic bronchitis (Table 42) 
Although present in a minority, the strongest risk factor for symptoms of chronic 
bronchitis in this population was heavy cannabis smoking of 23 joints per day (OR 5.3; 
95 % CI: 2.5 - 11.4). Smoking 1-2 joints per day and a history of cannabis smoking 
were associated with a 3.5 and a 2.5 times increased risk respectively, exceeding even 
tobacco smoking in strength of association. Exclusive cannabis pipe smoking was also 
a significant risk factor (OR 3.6; 95% CI 1.7- 7.6) 
Tobacco smoking of 1-14 cigarettes per day was associated with a 2.1 fold increase in 
risk, and >15 cigarettes per day with a 2.7 times increase in risk. Although there were 
small numbers of exclusive pipe smokers, this activity resulted in a 4.6 times increased 
risk. Being an ex tobacco smoker was not a risk factor for chronic bronchitis after 
adjusting for the other listed variables. 
Occupational exposure was significantly associated with a 2 fold increased risk and 
both heavy alcohol use and tuberculosis showed borderline associations with chronic 











Table 42: Analysis of risk factors for chronic bronchitis using survey estimation logistic 
regression (n = 3483) 
n (%) with Unadjusted * Adjusted OR * 
~ ... ~ .~ .. ~~ ....................... _~.~._~. __ ~.~~::... .. ~._.~ __ OR t~§!() .. ~~L~~.~.~_~~~J~!)o;()~ IL~~ .. _. ~_~ .... . 
IncomeH : >R2000/month 
R1000-R2000/month 
<R1000/month 












Current 1-14 cigarettes/day 
Current >15 cigarettes/day 
Non cigarette only (pipe) 
8MI: Underweight 
18-24.9 normal weight 
Overweight BMI >25 & <30 
Obese BMI.=::30 
Cannabis: Never 
Ex Cannabis smoker 
Current 1-2 joints/day 
Current ~ joints/day 















Asthma: Never diagnosed 
Ever diagnosed 
Alcohol use: Non, light, 
25 (3.9) 1.0 <0.001 1.0 0.001 
27 (4.4) 1.1 (0.6 - 1.9) 0.9 (0.5 - 1.8) 
195 (9.0) 2.4 (1.5 - 3.8) 1.9 (1.1 - 3.2) 
25 (3.6) 1.0 <0.001 1.0 0.0434 
99 (5.4) 1.6 (1.0 - 2.5) 1.3 (0.8 - 2.1) 
113(13.6) 4.3(2.7-6.7) 1.9(1.1-3.3) 

































1.0 <0.001 1.0 <0.001 
1.5 (0.9 - 2.3) 
2.4 (1.6 - 3.6) 
3.9 (2.6 - 5.9) 
4.0 (2.5 - 6.4) 
2.4 (1.3 - 4.3) 
1.2 (0.7 - 2.0) 
1 .7 (1.1 - 2.7) 
2.9 (1.8 - 4.7) 
2.9 (1.7 - 4.9) 
2.5 (1.3 - 4.9) 
1.0 <0.001 1.0 <0.001 
2.5 (1.4 -- 4.2) 
3.0 (2.1 - 4.2) 
4.8 (3.1 - 7.4) 
14 (6.6 - 29.7) 
1.8 (1.2 - 2.7) 0.488 
1.0 
0.6 (0.4 - 0.9) 
0.6 (0.4 - 0.9) 
1.0 <0.001 
3.5 (2.3 - 5.4) 
5.0 (3.0 - 8.3) 
7.4 (4.0 -13.6) 









2.7 (1.6 - 4.5) 
4.6 (1.9-10.7) 
1.0 <0.001 
2.5 (1.5 - 4.2) 
3.5 (1.8 - 6.7) 
5.3 (2.5 -·11.4) 
3.6 (1.7 - 7.6) 
1.0 <0.001 
2.0 (1.4 - 2.8) 
1.0 0.08 
1.5 (1.0 - 2.3) 
1.0 0.72 
0.9 (0.7 - 1.3) 
1.0 <0.001 1.0 0.05 
2.8 (2.0 - 3.9) 1.5 (1.0 - 2.2) 
1.0 0.55 
1.3 (0.6 - 2.8) 
1.0 <0.001 1.0 <0.001 
4.9 (3.5 - 6.9) 4.9 (3.2 - 7.6) 
moderate 213 (6.5) 1.0 <0.001 1.0 0.05 
nH.~9~Y~_.~~. __ ~ ____ uu~~.m ... _._l~{18.8) 3.3 (2.3 - ~J1 JJ?fLQ-=-?_·~L_ n.~~~~._ 
• overall p value is reported for categorical variables; "Chronic bronchitis; '*'R1 OOOmonth-US$ 98.77; 











Income and education are considered a proxy for socioeconomic status. Unlike in the 
South African national survey (SADHS)4, there was no evidence of correlation between 
these two variables (Pearson's correlation coefficient = 0.305; p<0.001) and both were 
retained in the final model. Earning less than R1000 per month was significantly 
associated with chronic bronchitis (OR 1.9; 95% CI: 1.1 - 3.2) after adjusting for all the 
other risk factors and confounders. Despite the small range in income groupings, twice 
as many persons in this group had chronic bronchitis (9.0% vs. 3.9% and 4.4% in the 
slightly higher income groups). 
Although individual categories were significant in the univariable but not in the 
multivariable model, lower levels of education were associated with an increased 
prevalence of chronic bronchitis, seen in the increasing odds ratios with decreasing 
levels of education. P for trend was 0.009 (OR 1.3; 95% CI: 1.1 - 1.7) indicating an 
upward trend (not shown). 
Increasing age was clearly associated with chronic bronchitis. It is notable that 
significantly increased risk starts from the 35 - 44 year age group which has an OR of 
1.7 (95% CI: 1.1 - 2.7). There is almost a three fold risk in the 45-64 year age group 
(OR 2.9), and the slight decrease in risk in the >65 group. Diagnosed asthma was 
included in this model as a confounder and adjusting for asthma strengthens the 
validity of the other associations. A history of childhood chest illness did not show 
significant association at the 5% level after adjustment for asthma. 
Interactions between gender and BMI (p = 0.34) and gender and occupational 
exposure (p = 0.08) were not significant, as was an interaction between smoking and 
TB (p = 0.5). 
The Hosmer-Lemeshow Goodness of Fit Test (for survey analysis) indicated that this 












Table 43: Analysis of risk factors for recent cough using survey estimation logistic 
regression (n=2758) 
-----------------~---- ---.. _ .. -
----~--~-------.-------•.. --- . ----------_."-
n with Unadjusted p* Adjusted OR p* 
recent OR (95% CI) (95%CI) 
.-.-.. --~-------
Income**: >R2000/month 81 (12,8) 1,0 <0.001 1.0 0.008 
R 1 OOO-R2000/month 90 (14.5) 1.1 (0.8 - 1,6) 0.9 (0.6 1.4) 
<R 1 OOO/month 499 (23.0) 2.0 (1,6 - 2.6) 1.4(1.0 2,0) 
Education: >12 years 87(12.4) 1.0 <0.001 1.0 <0.001 
8-12 years 308 (16.7) 1.4(1.1-1.9) 1.3 (0.9 1.8) 
1-7 years 253 (30.4) 3.1 (2.3 - 4.1) 1.8 (1.3 2,7) 
None 33 (31.1) 3.2 (2.0 - 5.1) 3.0 (1.6 5.6) 
Age (years): 15-24 150(15.5) 1.0 <0.001 1.0 0.5 
25-34 121 (16.3) 1.1 (0.8 - 1.4) 1.1 (0.8 1.6) 
35-44 165 (22.5) 1.6(1.2-2.1) 1.3 (0.9 1.9) 
45-54 108 (22.9) 1.6(1.2-2.1) 1.2 (0.8 1.7) 
55-64 86 (26.0) 1.9(1.4-2.6) 1.5 (0.96- 2.2) 
>65 50 (21.1) 1.5(1.0-2.1) 1.2 (OJ 2.0) 
Tobacco: Never 175 (11.9) 1.0 <0.001 1.0 <0.001 
Ex smoker 55(20.7) 1.9 (1.4 - 2.8) 1.2 (0.8 1.7) 
Current 1-14 cigarettes/day 298 (22.3) 2.1 (1.7 - 2.6) 1.5(1.2 1.9) 
Current >15 cigarettes/day 132 (37.3) 4.4 (3.3 - 5.9) 3.1 (2.2 4.4) 
Non cigarette only (pipe) 18(43.9) 5.8 (3.1 - 11.0) 1.4 (0.6 3.1 ) 
BMI: Underweight 94 (30.4) 1.7 (1.2 - 2.2) 0.073 1.6(1.1 2.1 } 0.052 
18-24.9 normal weight 256 (20.8) 1.0 1,0 
Overweight BMI >25 & <30 109 (16.1) 0.8 (0.6 - 1.0) 1.0(0.7 1,3} 
Obese BM.=::30 112(18.2) 0.8(0.7-1.1) 1.0 (0.8 1.4) 
Cannabis: Never 521 (16.9) 1.0 <0.001 1.0 <0.001 
Ex Cannabis smoker 55 (31.8) 2.3 (1.7 - 3.2) 1.6 (1.1 - 2.4) 
Current 1-2 joints/day 41 (46.1) 4.2 (2.7- 6.5) 2.9 (1.6 5.1 ) 
Current ~ joints/day 27 (47.4) 4.4 (2.6 - 7.6) 2.2(1.1 4.3) 
Cannabis pipe only 37 (48.7) 4.7 (2.9 - 7.6) 2.7 (1.4 5.1 ) 
Occupational exposure: 
Never 443 (17.2) 1.0 <0.001 1.0 0.010 
Ever 238 (26.0) 1.7(1.4-2.0) 1.3(1.1 1.7) 
Childhood chest illness: 
Never 583 (18.6) 1.0 <0.001 1.0 0.1 01 
Ever 98 (28.7) 1.8 (1.4 - 2,3) 1.3 (0.9 1.8) 
Gender: Female 366 (18.4) 1.0 0.041 1.0 0.074 
Male 315(211) 1.2(1.0-1.4) 0.8 (0.6 - 1.0) 
Previous tuberculosis: 
Never 551 (17.5) 1.0 <0.001 1.0 <0.001 
Ever 130 (38.6) 3.0 (2.3 - 3.8) 2.0 (1.5 2.7) 
Domestic fuels: Non-
smoky 660 (19.3) 1.0 0.039 1.0 
Smoky 21 (31.3) 1.9 (1.0 - 3.5) 
Asthma: Never diagnosed 604 (18.7) <0.001 0.043 











Table 43 continued: 
n (%) with Unadjusted P* Adjusted OR p* 
recent OR (95% CI) (95%CI) 
... _. . __ .... ____ ... .___ ... _.E~1J_9~______ .. _ .... _ .. __ ... _____ .. _ .. ___ .. ___ .... _ ............. -......... --.-.... -... -
Heart disease: Never 
diagnosed 
Ever diagnosed 
Allergic rhinitis: Never 
diagnosed 
Ever diagnosed 










2.1 (1.4 - 3.3) 
<0.001 1.0 
2.3 (1.8 - 3.0) 
<0.001 
<0.001 
moderate 596 (18.2) 1.0 <0.001 1.0 0.002 
._~e?V'j __ .... ____ ........... _._ .. _._ .. ____ 8514t2:~ __ ._~J~:~_~=-4-~). _____ .... ....?.:Q.CL }_-= __ ~:~L ...... __ ... _ ....... . 
* overall p value is reported for categorical variables; **R1 OOOmonth-US$ 98.77 
6.3.3. Analysis of risk factors for recent cough (Table 43) 
As is the case with dyspnoea, low levels of education and income were strong 
predictors of recent cough. Cigarette smoking, any level of cannabis smoking, 
occupational exposure and being underweight were significant risk factors. Persons 
with previous tuberculosis were also twice as likely to have reported recent cough. 
Hosmer and Lemeshow Goodness of fit: p = 0.951. 
6.3.4. Analysis of risk factors for wheeze (Table 44) 
Tobacco pipe smoking (OR 3.9; 95% CI: 1.5-10) and smoking ~ 5 cigarettes per day 
(OR 3.6; 95% CI: 2.3 - 5.6) were the strongest predictors for wheeze in the last 12 
months. Smoking 1-14 cigarettes per day resulted in a 2.2 times increased risk, and 
previous smoking showed borderline association after adjusting for the tabled risk 
factors. 
As was the case with chronic bronchitis, current and previous cannabis smoking and 
cannabis pipe smoking were strongly associated with wheeze in the last 12 months, 
resulting in a >2 fold increase in risk, as was past tuberculosis (OR 2.1; 95% CI. 1.5 -
2.9). Obesity (BMI>30) resulted in an almost two fold increased risk (OR 1.9; 95% CI: 
1.3 - 2.7). There was a doubling in the risk of wheeze over the age of 35 years, in 
comparison to the 15 - 25 year age group. Occupational exposure and female gender 
were positively associated with wheeze and heavy alcohol use and heart disease were 
marginally associated in the adjusted analyses. l\Jeither income nor education level 
showed association with wheeze after adjustment. The Goodness-of- fit for this model 











Table 44: Analysis of risk factors for wheeze in the last 12 months using survey estimation 
logistic regression (n=2758) 
n (%) with Unadjusted p* Adjusted OR p* 
..____ .. _ _. ____ "".~.eez~ __ . ___ .Q~J.95% .~lt __ ._ .. _ .. __ (9.5°[?.<::!>.:_._______ 
Income**: >R2000/month 62 (9.8) 1.0 <0.001 1.0 0.054 
R1000-R2000/month 56 (9.0) 0.9 (0.6 1.3) 0.7 (0.5 -1.2) 
<R1000/month 326(15.0) 1.6(1.22.2) 1.2(0.8-1.8) 














Current >15 cigarettes/day 
Non cigarette only (pipe) 
BMI: Underweight 
18-24.9 normal weight 




Ex Cannabis smoker 
Current 1-2 joints/day 
Current d3 joints/day 















Asthma: Never diagnosed 
Ever diagnosed 







































2.6 (1.9 3.6) 
2.6 (1.5 4.5) 
1.0 
1.2 (0.8 1.7) 
2.2 (1.6 3.0) 
2.9 (2.1 4.0) 
3.2 (2.2 4.5) 
2.5 (1.7 3.7) 
<0.001 1.0 0.036 
1.3 (0.9 - 1.9) 
1.5 (1.0 - 2.3) 
1.6 (0.7 - 3.9) 
<0.001 1.0 0.001 
1.0 (0.6 - 1.6) 
1.8 (1.2 2.8) 
2.1 (1.4 3.2) 
2.0 (1.2 3.3) 
2.2 (1.2 4.0) 
1.0 <0.001 1.0 <0.001 
3.3 (2.3 4.6) 
2.1(1.6 2.7) 
3.7 (2.7 5.0) 
4.7 (2.2 10.3) 
1.6 (1.0 -. 2.6) 
2.2 (1.6 - 3.1) 
3.6 (2.3 - 5.6) 
3.9 (1.5 -10.0) 
1.3 (0.9 1.9) 0.013 1.2 (0.8 - 1.9) 
1.0 1.0 
1.0 (0.7 1.3) 
1.5 (1.2 2.0) 
1.0 
2.8 (1.9 4.0) 
2.8 (1.7 4.5) 
3.4 (1.9 - 5.8) 




4.4 (3.4 5.7) 
1.2 (0.8 - 1.7) 
1.9(1.3-2.7) 
<0.001 1.0 
2.0 (1.2 - 3.3) 
2.4 (1.2 -- 4.8) 
2.7(1.3-5.7) 









1.0 0.468 1.0 0.Q18 
0.9(0.81.1) 0.7(0.5-0.9) 
1.0 <0.001 1.0 <0.001 
2.9 (2.2 3.7) 2.1 (1.5-2.9) 
1.0 0.015 1.0 
2.4(1.1 4.7) 
1.0 <0.001 1.0 <0.001 
9.9 (75 13.2) 7.2 (4.9 -10.6) 
diagnosed 408(12.3) 1.0 <0.001 1.0 0.047 











Table 44 continued: 
--------.---------------------~--------------------------------------------------
n (%) with Unadjusted p* Adjusted OR p* 
__________ _______________________ ....,~ee2!~ _____ ~~J~§Jo C I) * _____________ i~~_~<:;Jt________________ __ _ 
Allergic rhinitis: Never 
diagnosed 
Ever diagnosed 
Alcohol use: Non, light, 
272 (9.3) 
177 (32.5) 
1.0 <0.001 1.0 
4.7 (3.8 - 5.9) 3.9 (2.9 - 5.1) 
moderate 402(12.3) 1.0 <0.001 1.0 
<0.001 
0.050 
_ f::lfLay.y _____________________ i?j?L£iL ___ ~J_iL~_::::L~L ________ J~_litg_~_?_.} L ___________ _ 
*overall p value is reported for categorical variables; '*R1 OOOmonth-lJS$ 98.77 
6.3.5. Analysis of risk factors for wheeze with breathlessness (Table 45.) 
Wheeze with breathlessness showed similar associations to wheeze in the last 12 
months with the notable exceptions that cannabis smoking displayed an even more 
robust association, associated with a risk of up to 3.5 times more than those that had 
never smoked cannabis. Heavy alcohol use was also associated with a slightly higher 
risk (OR 1.7; CI: 1.1 - 2.8). 
This was a good model with the observed and expected values not differing 











Table 45: Analysis of risk factors for wheeze with breathlessness in the last 12 months 































Tobacco: Never smoked 86 (5.8) 





Non cigarette only (pipe) 
8MI: Underweight 
18-24.9 normal weight 
Overweight BMI >25 & <30 
Obese BMI.=::30 
Cannabis: Never 
Ex Cannabis smoker 
Current 1-2 joints/day 
Current ~ joints/day 

































OR (95% CI)* 
1.0 
1.1(0.7-1.8) 
2.0 (1.4 - 2.9) 
1.0 
1.3 (0.9 - 1.9) 
3.0 (2.1 - 4.3) 
2.7 (1.5 - 4.9) 
1.0 
1.7 (1.1 - 2.5) 
2.7 (1.9 - 3.9) 
3.4 (2.3 - 5.0) 
3.9 (2.6 - 5.8) 
3.0 (1.9 - 4.7) 
1.0 
3.2 (2.2 - 4.7) 
2.0 (1.5 - 2.7) 
3.0 (2.1 .- 4.3) 
2.3 (0.7 - 7.0) 





2.6 (1.7 - 3.9) 
2.7 (1.5 - 4.7) 
3.8 (2.1 - 6.7) 
1.8 (0.9 - 3.6) 
1.0 
2.0 (1.6 - 2.6) 
1.0 
4.6 (3.5 - 6.0) 
1.0 
0.8 (0.6 - 1.0) 
1.0 
3.0 (2.2 - 4.0) 
p* Adjusted OR 
(95%CI)* 
p* 
<0.001 1.0 0.034 
1.0 (0.6 - 1.7) 
1.6 (1.0 - 2.5) 
<0.001 1.0 0.5 
1.2 (0.8 - 1.8) 
1.5 (0.9 - 2.4) 
1.4 (0.5 - 3.5) 
<0.001 1.0 
1.7(1.0-2.9) 
2.7 (1.6 - 4.4) 
2.8 (1.7 -- 4.7) 
2.9 (1.6 - 5.0) 
2.8 (1.5 - 5.5) 
<0.001 
<0.001 1.0 <0.001 




2.1 (1.4 - 3.0) 
2.5 (1.5 - 4.0) 
1.5 (0.5 - 4.6) 
1.3 (0.8 -- 2.1) 
1.0 
11 (0.7-1.7) 
1.8 (1.2 - 2.7) 
1.0 
2.1 (1.2- 3.6) 
3.3 (1.5 - 7.2) 
3.5 (1.6 - 7.6) 




2.3 (1.5 - 3.4) 
0.087 1.0 










smoky 331 (9.7) 
13(19.4) 
1.0 0,046 1.0 
Smoky 2.2 (1.0 - 5.0) 
Asthma: Never diagnosed 229 (7.1) 1.0 <0,001 1.0 <0.001 
Ever diagnosed 11.6 (8.7 -











Table 45 continued: 

















OR (95% CI)* 
1.0 
2.2 (1.5 -- 3.3) 
1.0 
5.3 (42 .. - 6.7) 
p* Adjusted OR 
(95%CI)* 
<0.001 1.0 
1.5 (0.9 - 2.5) 
<0.001 10 




light, moderate 305 (9.3) 1.0 <0.001 1.0 0.025 
tl~_~~'i __ ._______ ____ . _____ 3~J!1L?1_. ____ ?~i1J)_-=_}~.?t_~ ___________ J_·LtL~_=__Z~ED ____________ _ 
*overall p value is reported for categorical variables; **R 1 OOOmonth-US$ 98.77; *** small numbers in 
these groups 
6.3.6. Analysis of risk factors for dyspnoea (Table 46) 
Low socioeconomic status was strongly associated with dyspnoea viz. earning less 
than R 1000 per month and less than a high school education. Having no education 
increased the likelihood of dyspnoea threefold, After the age of 35 risk steadily 
increased and over 65s had the highest odds of dyspnoea (OR 5.7; 95% CI: 3.1 -
10.7). 
Any level of current cigarette smoking, past cannabis smoking, and being either obese 
or underweight were all significant risk factors. Occupational exposure showed an 
association of borderline significance after adjustment. Persons with a previous history 
of tuberculosis were twice as likely to have reported dyspnoea of grade two or higher. 
Confounding by diagnosed asthma and heart disease were taken into account, both 











Table 46: Analysis of risk factors for dyspnoea (grade 2 or higher) in the last 12 months 
using survey estimation logistic regression (n=2758) 
- -- ------_.- - - - -------------_._----- ----------~----.---~ - ------ ----------------~--.-------.--------------
n (%) with Unadjusted p* Adjusted OR p* 
-------------- ___ ~y_spn0E!Cl _____ ~819~~ CIL _______ . _____ ~ ___ ~_~o;o~Jl _____ ~____ ___ __ 
Income**: >R2000/rnonth 35 (5.6) 1.0 <0.001 1.0 <0.001 
R1000-R2000/rnonth 44 (7.1) 1.3 (0.8 - 2.1) 1.1 (0.6 - 2.0) 
<R1000/rnonth 326 (15.0) 3.0 (2.1 - 4.3) 2.4 (1.5 - 3.8) 
Education: >12 years 39 (5.6) 1.0 <0.001 1.0 0.017 
8-12 years 155(8.4) 1.6(1.1-2.3) 1.4 (0.9 - 2.2) 
1-7 years 181 (21.8) 4.7 (3.3 - 6.8) 1.9 (1.2 - 3.0) 
None 32 (30.2) 7.4 (4.4-12.3) 3.1 (1.5-6.4) 
Age: 15-24 45 (4.6) 1.0 <0.001 1.0 <0.001 
25-34 46 (6.2) 1.4 (0.9 - 2.1) 1.3 (0.8 - 2.2) 
35-44 86 (11.8) 2.7 (1.9 - 4.0) 2.7 (1.7 - 4.4) 
45-54 88(18.7) 4.7 (3.2 - 6.9) 3.1 (18-5.1) 
55-64 74 (22.4) 5.9 (3.9 - 9.1) 3.7 (2.1 - 6.4) 
>65 67 (28.3) 8.1 (5.2 - 12.6) 5.7 (3.1 - 10.7) 
Tobacco: Never srnoked 113 (7.7) 1.0 <0.001 1.0 0.007 
Ex srnoker 54 (20.3) 3.1 (2.1 - 4.4) 1.4 (0.9 - 2.2) 
Current 1-14 
cigarettes /day 160 (12.0) 1.6(1.3-2.1) 1.7(1.2-2.4) 
Current >15 cigarettes/day 68 (19.2) 2.9 (2.0 - 4.1) 2.6 (1.7 - 4.2) 
Non cigarette only( pipe) 9 (22.0) 3.4 (1.6 - 7.3) 2.0 (0.7 - 5.5) 
8MI: Underweight 48 (15.5) 1.7 (1.2 - 2.5) <0.001 1.7(1.1-2.8) <0.001 
18-24.9 norrnal weight 119(9.7) 1.0 1.0 
Overweight BMI >25 and 
<30 74(11.3) 1.2 (0.9 - 1.6) 1.4 (0.9 - 2.0) 
Obese BMI?:30 103 (16.7) 1.9 (1.4 -- 2.5) 2.0 (1.4 - 2.8) 
Cannabis: Never 334 (10.8) 1.0 0.007 1.0 0.2 
Ex Cannabis srnoker 34(19.7) 2.0 (1.3 -- 3.0) 1.8 (1.0 - 3.1) 
Current 1-2 joints/day 15 (16.9) 1.7(1.0-3.0) 1.5 (0.7- 3.3) 
Current :28 joints/day 14 (24.6) 2.7 (1.5 - 4.8) 1.4 (0.6 - 3.3) 
Cannabis pipe only 10(13.2) 1.2 (0.6 - 2.6) 1.1 (0.5-2.6) 
Occupational exposure: 
Never exposed 263(10.2) 1.0 <0.001 1.0 0.041 
Ever exposed 144 (15.8) 1.6(1.3-2.1) 1.4 (1.0 - 1.9) 
Childhood chest illness: 
Never 333 (10.6) 1.0 <0.001 1.0 0.144 
Ever 74(21.7) 2.3(1.7-3.1) 1.3 (0.9 - 2.0) 
Gender: Fernale 249 (12.5) 1.0 0.092 1.0 0.314 
Male 158 (10.6) 0.8 (0.7 - 1.0) 0.8 (0.6 - 1.2) 
Previous tuberculosis: 
Never 327(10.4) 1.0 <0.001 1.0 <0.001 
Ever 80 (23.7) 2.7 (2.1 - 3.5) 2.1 (1.5 - 2.9) 
Domestic fuels: Non-srnoky 397 (11.6) 1.0 0.5 1.0 
Srnoky 10 (14.9) 1.3 (0.6 - 2.8) 
Asthma: Never diagnosed 319 (9.9) 1.0 <0.001 1.0 <0.001 











Table 46 continued: 
n (%) with Unadjusted p* Adjusted OR p* 
___ ______ dysp_noe_a __ O_RJ~~O(()_ giL __ _____ ~?O/~Cl) __ ~ _____ ~~~~ _ ~~~~~_ 











1.0 <0.001 1.0 
5.4 (3.9 - 7.4) 3.3 (2.1 - 5.2) 
1.0 <0.001 1.0 
3.1 (2.5 -. 3.9) 2.9 (2.2 - 3.9) 




Heav'1______ __________ }ll1JL~_~1 ·~J.:L~?_~_=_?Jl.L _____ . ~ _ _ ___ l:§_LLO_~]: 5) .~ ______ _ 
**R1000month-US$ 98.77; Goodness of fit: p= 0.509 
6.3.7. Population Attributable Fractions (PAF) 
In order to estimate the percentage of a given outcome in a population that can be 
attributed to or caused by a given risk factor, population attributable fractions have 
been calculated e.g. just under a third of chronic bronchitis cases in the population 
could have been avoided if no persons smoked 1-14 cigarettes per day. 
Table 47: Population attributable fractions for chronic bronchitis 
Percentage Prevalence Odds Population 
Risk Factor exposed to Ratio (multivariate Attributable 
. _________. _______________ . ______________ rls k!~~t()!_ ~__ __ moc!~L __________ J:!:'!£tionj!()L ___ ._ 
Income <R1000/month(poverty) 63.4 1.9 36.3 
Light/moderate tobacco smoking 38.5 2.1 29.8 
Heavy tobacco smoking 10.2 2.7 14.8 
Occupational exposure 26.3 2.0 20.8 
Past cannabis smoking 5.0 2.5 7.0 
Moderate cannabis smoking 2.6 3.5 6.1 
Heavy cannabis smoking 1.6 5.3 6.4 
Past TB 9.7 1.5 4.6 
Poverty (earning<R1 000 per month) was responsible for 36.3% of all chronic bronchitis 
in this population. Tobacco smoking was collectively the cause of 45.5%, cannabis 
smoking 19.5%, and occupational exposure also significantly implicated with a PAF of 
20.8%. One of the assumptions made in calculating population attributable fractions is 
that they are completely adjusted for confounders, which is often not the case, and this 
results in the total adding up to more than 100%. This inaccuracy of PAF's does not 











Table 48: Population attributable fractions for wheeze 
Percentage Prevalence Odds Population 
Risk Factor exposed to Ratio (multivariate Attributable 
__ ~i~_~f~c;!~~_____ m~~_~J)~_~_E!~E_~_~rlJ~l 
Light/moderate tobacco smoking 
Heavy tobacco smoking 
Occupational exposure 
38.5 2.2 31.6 
Past cannabis smoking 
Moderate cannabis smoking 
























Socioeconomic factors were not significantly implicated in the causation of wheeze. 
Tobacco smoking was the major risk factor (PAF = 52.5%) and cannabis smoking was 
responsible for 11 %. The PAF associated with obesity was 16.5% and that with 
tuberculosis was 9.6%. 
Table 49: Population attributable fractions for wheeze with breathlessness 
Percentage Prevalence Odds Population 
Risk Factor exposed to Ratio (multivariate Attributable 
____ ~ ___ ~~ ________________ ~ ____ '1~!f~E!~ ________ ~_!rl~eIL __________ ~ __ E .. ~~ti~l"lj'k'oL_ 
Light/moderate tobacco smoking 38.5 2.1 29.8 
Heavy tobacco smoking 10.2 2.5 13.3 
Occupational exposure 26.3 1.5 11.6 
Past cannabis smoking 5.0 2.1 5.2 
Moderate cannabis smoking 2.6 3.3 5.6 
Heavy cannabis smoking 1.6 3.5 3.8 
Past TB 9.7 1.9 8.0 
Obesity 21.9 1.8 14.9 












Table 50: Population attributable fractions for dyspnoea of grade 2 or higher 
Percentage Prevalence Odds Population 
Risk Factor exposed to Ratio (multivariate Attributable 
___ ___ ___ _____________________________ ris ~!<t.~!~.r: ____________ I1"1~c:I.~L ______________ Fra~!i~Il_('y~t __ _ 
Income <R1000/month(poverty) 63.4 2.4 47.0 
l\Jo education 
Less than high school education 
Light/moderate tobacco smoking 
Heavy tobacco smoking 
Occupational exposure 



























Socioeconomic factors feature prominently on the causation of dyspnoea. Poverty was 
a risk factor to which 47% of dyspnoea was attributable. Low levels of education/no 
education were responsible for 23.8%, tobacco for 35.2% and obesity for 18%. 
Table 51: Population attributable fractions for recent cough 
Percentage Prevalence Odds Population 
exposed to Ratio (multivariate Attributable 
______ . _________ . ___________ . ___ .. _ ..__________ . _____ ~ ____ !j!;;~.!<l£.t<:>.I". ______ f!1..<:>.c:t~JL_~ _____ f!actj.9_n_l~L __ _ 
Light/moderate tobacco smoking 38.5 1.5 16.1 
Heavy tobacco smoking 10.2 3.1 17.6 
No education 3.1 3.0 5.8 
Less than high school education 23.9 1.8 16.1 
Occupational exposure 26.3 1.3 7.3 
Past cannabis smoking 5.0 1.6 2.9 
Moderate cannabis smoking 2.6 2.9 4.7 
Heavy cannabis smoking 1.6 2.2 1.9 
Past TB 9.7 2.0 8.8 
Tobacco and cannabis smoking, socioeconomic factors and past T8 featured in the 
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CHAPTER 7: RESLIL TS OF THE BURDEN OF OBSTRUCTIVE 
LUNG DISEASE STUDY (BOLD): SPIROMETRY 
7.1. Aims of this chapter 
This chapter addresses two questions posed in this thesis: "What is the prevalence of 
CO PO as defined by the Global Obstructive Lung Disease (GOLD) Initiative?", and 
"What are the associated risk factors for CO PO?" The definition and severity 
classification of CO PO used in the BOLD methodology is that of the GOLD guidelines. 
This, in contrast to the questionnaire-based approach described in the chapters above, 
is based predominantly on the results of spirometry performed before and after use of a 
bronchodilator. 
7.2. Statistical analysis 
The data reported were analysed using the survey estimation commands in the 
STATA® statistical package. Weighting and clustering were appropriately adjusted for 
by means of setting the primary sampling unit as an address identifier, and the 
individual weights according to the number of responders as a fraction of the total 
number of eligible participants at each address (see Appendix 9 for details on 
weighting). The first few tables describe the study population and tables thereafter 
report population estimates, corrected for both clustering and weighting. 
7.2.1. BOLD Prediction Equations 
Local prediction equations wer  derived from the study data on healthy never smokers, 
who had not reported asthma, emphysema, chronic bronchitis, COPD or TB. 
Regression models for each of prebronchodilator FEV1, FVC, and FEV1/FVC were 
fitted separately for men and women, using age and height as predictors (Table 52.). 
Age-squared and age-height interaction terms were also initially included in the model, 
but were removed due to non-significance. The height term for the FEV1/FVC model 
was also not significant, so these models included only age. It must be noted that the 
local equations are not reliable owing to the very small number of healthy never 
smokers in this population, particularly in men. 
The second set of equations used were the NHANES III equations for Caucasian 
subjects. I A summary of the best fitting f\IHANES regression equations are presented 











explained by the model, suggesting that the equations based on this model are very 
accurate predictions for the population on which it is based (white Caucasians). These 
equations were considered suitable for use in the BOLD study for the following 
reasons: 
1. During clinical evaluation of patients in Cape Town, reference equations for 
Caucasians are used for the study population. However there is no evidence for 
the accuracy of this practice. 
2. Using local equations could mask the effect of other site-specific exposures 
(anything from the intrauterine environment to air pollution etc.), and there is 
one viewpoint that suggests that there is little evidence to suggest that ethnicity 
is a significant factor causing differences in lung function. Ethnicity may, and 
often does, act as a proxy for socioeconomic status, particularly in low-income 
local areas in South Africa. An alternative viewpoint is that there may be ethnic 
differences in lung function. For example, differences in height measurements 
based on the longer legs of African Americans due to a smaller trunk-leg ratio 
than their Caucasian counterparts may be important. This results in 
comparatively lower FEV1 and FVC and higher FEV1/FVC ratios in African-
Americans in the NHANES III study.1 
3. Using standardised equations permits direct comparison with other sites. 
Table 52: Summary of best-fitting regression models for healthy never-smoking men and 








-0.01970 0.02614 0.47491 0.3166 
-.02276 0.03487 0.57160 0.3400 
-.08279 4.92228 0.0348 
Women FEV1 195 -0.D1088 -0.02421 0.02181 0.35198 0.5492 
FVC 182 -1.24134 -0.02460 0.03330 0.40957 0.5260 
FEV1/FVC .180 89.62623. -0.19073 6.11079 0.1201 
-lrn-umt)er-oisubjects-use-dto fit the modEll. Dataexclu-ded-from analYSis if q-ual;tyscore-;Oor1~------











Table 53: Summary of best fitting regression models for healthy never-smoking white men 
1 and women from the US NHANES III survey 
_ ._§E!llc!E!t_. ____ Qlltco 1llE!__._(;.~"s!.~,,! _____ ~gE!_. ________ t!eig h~ .. _____ M E!~ ____ . R2 ._-------_ .. _--_. 
Men FEV , 0.5536 -0.01303 0.00014098 -0.000172 0.8510 
FVC -0.1933 0.00064 0.00018642 -0.000269 0.8668 
FEV1/FVC 88.066 -0.207 0.3448 
Women FEV1 0.4333 0.00361 0.00011496 -0.000194 0.7494 
FVC -0.3560 0.01870 0.00014815 -0.000382 0.7344 
Two sets of predicted values were calculated for FEV1, FVC and FEV1/FVC for each 
participant and thereafter % predicted values for each measure were calculated. For 
the purposes of risk factor analyses, predicted and %predicted values for 
postbronchodilator tests using the NHA~IES equations are used to classify COPD. 
7.2.2. Risk Factor Analysis 
Univariate analysis of each potential risk factor is presented, first for GOLD Stage I and 
higher, and second, for GOLD stage" and higher. Multivariable logistic regression for 
these two binary outcomes is also presented. Current literature suggests that stage II 
and higher COPD is the most conservative threshold to define persons with 
symptomatic disease. 2 Moderate or severe disease is of public health significance and 
may require treatment, affect quality of life and productivity. 
In addition, another adjusted risk factor analysis of COPD using multinomial logistic 
regression is presented, classifying the outcome into a reference category of 
normal/GOLD stage 0; and two reported categories - GOLD Stage 1111 (mild/moderate 
disease) and GOLD stage III/IV (severe disease). 
This categorisation was chosen for two reasons. Firstly, the numbers in this sample are 
too small to classify COPD into 4 mutually exclusive categories for the purpose of 
logistic regression, because there are only 34 persons with GOLD Stage I disease. 
Secondly, the risk factors for mild/moderate disease might be different to those for 
severe disease. These results are presented in Table 79, and add an important 











The following equation was used to calculate pack years: 
Number of cigarettes per day/20 X total number of years smoked 
i.e. twenty cigarettes a day for one year or one cigarette a day for 20 years equals one 
pack year. 
7.3. Results 
Ten of the 833 eligible addresses proved to not exist and non-residential land uses 
such as a dam and a parking lot were found at the sites. This was thought to have 
occurred owing to severe flooding in the area many years ago. Of the remaining 823 
addresses, 800 were fully enumerated and tracking forms were completed for all age-
eligible people living in these 800 households, irrespective of participation. 
1377 eligible persons from 833 addresses 
jJ ~ 
Responders Nonresponders 
958 consented and a) 121 provided minimal data} 
provided full questionnaire data questionnaire 
(70% response rate) b) 298 had a tracking form 
D ~
896 attempted spirometry 64 excluded from performing 




49 excluded (poor quality spirometry) 
("nonresponders") 
847 with good quality spirometry 
(62% response rate) 
4 79 nonresponders 
Figure 23: Response rates and disposition of participants in the BOLD study 
Of 1377 potential participants, 115 answered the minimal data questionnaire (5 
questions on smoking, age etc.) but did not consent to further participation. The core 
questionnaire was completed by 958 consenting individuals, 64 of whom were 
excluded from performing spirometry for medical reasons, e.g. severe illness. Of the 
896 that attempted spirometry, 49 were excluded for not meeting quality control 











7.3.1. Sample statistics 
Table 54: Comparison of responders and nonresponders for the BOLD study 
Age (n = 896) (n = 479) 
40 - 49 356 (40%) 196 (41 %) 0.006 
50 - 59 276 (31 %) 139 (29%) 
60 -69 178 (20%) 72(15%) 
70 + 86 (10(Yo) 72(15%) 
Gender (n = 896) (n = 479) 0.003 
Male 335 (37%) 218(46%) 
Female 561 (63%) 261 (54%) 
Smoking status (n = 895) (n = 180)# 0.03 
Current 411 (46%) 66 (37%) 
Ex 193(22%) 38 (21 %) 
Never 291 (33%) 76 (42%) 
Doctor-diagnosed asthma, 
emphysema, CB or capo t 
(n = 896) (n = 180) 0.02 
Yes 170 (19%) 21 (12%) 
No 726 (81 %) 159 (88%) 
Other co-morbid conditions:!: (n = 896) (n = 180) 0.94 
'(e~ ____ ~ ___ .. _._.______ 49§{~~~().L_____ 1 00 (56%) ____ . ______ _ 
l'lo_. __ ____ . ___ ... ___ _ ._ .. 40 1. (~~~o) _~. __ . ______ ~9 ii.4!oL __________ _ 
*Responders are those who have core questionnaire data and any post BD Spirometry; 
** Nonresponders are eligible individuals at contacted households for whom at least one of these data 
elements is not available (including those with only pre BD spirometry). 
***Two-sided p-value based on Pearson chi-square test. 
r Per Question 3 on minimal data questionnaire for non responders, Question 12,13,14,15 on GOre 
questionnaire for responders 
t Per Question 4 on minimal data questionnaire for non responders, Question 16 on core questionnaire for 
responders 
Ii Data on age and gender was available for more individuals than the other measures. 
Table 55: Age and sex distribution of all persons who attempted spirometry* and those 
with good quality spirometry** 
--- --.-----.----- ----.-.---. --_.-._.-
.. _ ____ .. __ ____ . __ ~~!~!!1pted~pi ro me_t~.Y.* ___ . ____ . __ .~ ___ Q.Q9d .q ua I ity_§pJ~~!!1.~!~y~: ________ . 
_A.9~ _______ ... t\!!!'. ___ ~_~n_!!J!'~L ___ "'!0!!1~I1_I1J~) __ ~JL!!_. _ _.JYI~n _ll_eM_YJ..om~n_'l~L 
40-49 356 139(41.0%) 217(39.0%) 335 132(42.0%) 203(38.0%) 
50 - 59 276 101 (30.0%) 175 (31.0%) 263 92 (29.0%) 171 (32.0%) 
60--69 178 67(20.0%) 111(20.0%) 167 63(20.0%) 104(20.0%) 
70:r___. ___ 1l_fi ___ ~( 8.0 %) 58 nC2:9_o01~. ______ ?'? __ . ___ ~EJjQ· 0 ~ __ . __ ~(lQ-,-Q~0 __ . 
All _ .. __ J~9~. . )}~1:rrc1.~<1 __ ~£?.1(6~:{)(Y?)__ EJ41 ... __ ill_D7.2~L __ .?_3~i§.2 .. _~o0L __ 
* Any persons who have core questionnaire data and any postbronchodilator spirometry. 











Table 55 shows that men and women constituted 37% and 63% of the sample 
respectively, both before and after the participants with poor spirometry were excluded. 
These proportions are similar to the population estimates for Ravensmead and Uitsig 
(43.8% and 56.2% for men and women respectively) in Table 56. 
7.3.2. Population estimates of COPO 
Table 56: Population age and sex distribution based on sample* and from the national 
census data (weighted) ** 
. __ ._ ..... - .. - .. --_._._. __ .. _ .... _._._ .. __ .... _-_._----_ .. _--
Estimated Census data 
--.. ----.. ---... -.---.--.. -.--... --.-.. - .. ---:-c-
Age Men % Women % All % Men% Women % All % 
----_. -.----.---.-----.. ~- --_. --------- ---_._._--_ ... -.-." ---~----------~-~--------.-.-~.----~------ ---------------_ .... _--- .. _-----"-------------------
40 -49 20.2% 23.5% 
50 - 59 12.9% 16.5% 
60- 69 7,3% 10,6% 
70+ 3.4% 5,6% 
All 43.8% 56.2% 
'Weighted estimate based on responders, 






Table 57: Prevalence* of current smoking by age and sex 
Age All % (SE) Men % (SE) Women % (SE) 
------------~--.---.. -~---.-----.----.--------------------------------
40 -49 55.8% (2.9) 63.3% (4.3) 49.3% (3.7) 
50-·59 49.1% (3.4) 54.6% (5.3) 44.8% (4.1) 
60 - 69 38.5% (4.0) 50.8% (6.6) 30.1 % (4.6) 
70+ 23.2% (5.3) 41.1 % (9.9) 12.1%(4.2) 
-------------------- -----_.-._-------------- --
Ail 47.8% (1.9) 56.9% (2.9) 40.6% (2.3) 






The current smoking rates in the population (Table 57) are 56.9% and 40.6% among 
men and women respectively, indicating that there has been no reduction in smoking 











Table 58: Prevalence* of ever smoking by age and sex 
Age All % (SE) Men % (SE) Women % (SE) 
40- 49 71.0% (2.7) 80.7% (3.5) 62.6% (3.5) 
50 - 59 73.1 % (2.9) 84.7% (4.0) 63.9% (3.9) 
60 -. 69 68.2% (4.0) 83.7% (5.2) 57.6% (4.9) 
70+ 53.1% (6.1) 88.1 % (5.1) 31.5% (6.4) 
---.- --~-,-.. -.------,--------.~-- .. -,---,--.-.----------.,-----------_. -----------,-,--------- _.- ---
Ali 69.5% (1.8) 83.0% (2.2) 59.0% (2.3) 
'Weighted population (~stimate, with SE shown in parenth(~sis. 
The prevalence of ever smoking in Table 58 shows a consistently high prevalence in 
men (between 81% and 88%). Women aged more than 70 years have the lowest 
exposure of 31.5%, considerably different from their younger counterparts. 
Table 59: Distribution* of pack years of smoking 
Pack years All % 
Never smoker 30.5% 
0-10 29.7% 














'population estimates: weighted frequencies based on responders. 
Men have had a considerably higher cumulative exposure to tobacco smoking than 
women as shown in Table 59. The majority of women smokers have a 0 - 10 pack year 
history, and 41 % of women have never smoked cigarettes. Over 50% of the men in this 
population have a pack year history of >10 pack years and a quarter have a pack year 











Table 60: Mean (SO) of Post BO Spirometry by sex and smoking status* 
Men Women 
Current Ex Never Current Ex Never 
I\J 181 85 49 211 96 224 
FEV1 (I) 
~£'II'gjIL~~_~ 
2.55 (0.77) 2.60 (0.72) 3.06 (0.60) 1.94 (0.54) 1.85 (0.56) 2.09 (0.57) 
)~~~jQJ§L__~2~i 9:7 5L __ ~_J-,80 (0. ~~L_~:~§l~9-'.?]J~_?·42 (0:5_~Lm_~?' 60~(9&~). 
FEV1/FVC 71.2 (12.8) 73.0 (12.3) 80.6 (5.5) 74.3 (11.2) 76.0 (10.1) 80.3 (7.8) 
~IToL_~_~__m_~_~_ ~_ "'~_~_m __ ~~'~m ___ ""_"_~~_m~mm~_' ______ "'~m~"~'"_'. ___ . ___ ~ __ ._~~.~ ___ ~_~,_" ~ _~~~_~_'_~_~_mm~ ____ ~' _ 
'Core questionnaire and postbronchodilator spirometry with quality scores>1 for FEV1 and FVC. Results 
are for observed sample only and are not population estimates. 
Mean FEV1, FVC and FEV1/FVC values are consistently lower for current and ex 
smokers than never smokers in both men and women. 
There was a significant difference in mean FEV1 for current vs. never smoking women 
and men (p = 0.003 and p<O.001 respectively). Mean FVC was significantly different in 
current vs. never smokers for men only. Mean FEV1/FVC for current vs. never smokers 
is also significantly different in both men and women (p<0.001 for men and women) 
The differences between mean FEV1 , FVC and FEV1/FVC in ex- vs. never smokers 
were not significant in men and women. 
Table 61: Estimated population prevalence (SE) of GOLD Stage I or higher COPD* by age 
and sex 
Age All % (SE) Men % (SE) Women % (SE) 
40 ~ 49 15.0 (2.2) 
50 ~ 59 24.7 (3.1) 
60 ~ 69 33.5 (4.0) 
70+ 44.8 (6.0) 
All 23.8 (1.6) 











The prevalence of GOLD Stage I or higher COPD was 23.8% overall, 28.7% in men 
and 20.0% in women. Prevalence in the over 60 age group for men and the over 70 
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Figure 24: Estimated Population Prevalence of GOLD Stage I or higher COPO by age and 
sex 
Table 62 Estimated population prevalence (SE) of GOLD Stage I or higher COPO' by pack 
years and sex 
Men % (SE) Women %(SE) All % (SE) 
Pack years Never smoker 4.6 (3.4) 12.6 (2.7) 10.7 (2.2) 
0-10 23.4 (4.8) 24.1 (3.7) 23.8 (3.0) 
10 - 20 38.4 (5.7) 25.1 (5.2) 32.3 (4.0) 
20+ 41.9 (5.3) 27.2 (5.2) 35.8 (3.8) 
'Post BD FEV,/FVC<70% 
A dose-response relationship is suggested by the increasing prevalence of COPD with 
increasing cumulative pack year exposure in men (range: 23.4% to 41.9%). This trend 
is not clear in women (24.1 % to 27.2%). Additionally, never smoking women have a 
higher prevalence of GOLD Stage I or higher COPD than their male counterparts (12.6 
vS.4.6%). 
The prevalence of GOLD Stage I and higher COPD was 10.7% in never smokers, 
24.9% in former smokers and 31.4% in current smokers. The corresponding 












Table 63: Estimated population prevalence (SE) of GOLD Stage II or higher COPD' by age 
and sex (Local equations) 
Age All % (SE) Men % (SE) Women % (SE) 
40-49 9.1(1.9) 13.5 (3.3) 6.4 (1.9) 
50-59 17.3 (2.6) 18.8(4.1) 16.2 (3.2) 
60-69 19.8 (3.3) 22.8 (5.6) 17.8 (3.7) 
70+ 21.3 (4.6) 28.2 (8.6) 16.5 (5.0) 
All 14.8 (1.3) 17.8 (2.3) 12.4(1.5) 
'Post BO FEV1/FVC<70% and post BO FEV1<80% expected 
The prevalence of GOLD Stage II and higher COPD using local equations confirms a 
prevalence of 17.8% in men and 12.4% in women, with men having a consistently 
higher prevalence than women in all age categories. 
Table 64: Estimated population prevalence (SE) of GOLD Stage II or higher COPO' by age 
and sex (NHANES equations) 
Age All % (SE) Men % (SE) Women %(SE) 
40 - 49 12.3 (2.0) 17.5 (3.6) 7.8 (2.1) 
50 - 59 20.2 (2.7) 20.8 (4.3) 19.8 (3.4) 
60-69 28.1 (3.7) 34.8 (6.6) 23.4 (4.3) 
70+ 30.8 (5.2) 28.2 (8.6) 32.7 (6.9) 
All 19.1 (1.5) 22.2 (2.4) 16.7 (1.7) 
'Posl BO FEV1/FVC<70% and posl BO FEV1<80% expected 
Using the I'JHANES III equations resulted in a higher prevalence of GOLD Stage II and 
higher COPD (22.2% in men and 16.7% in women) than local equations (see Table 63 
and 64). The age distribution of Stage II and higher is graphically represented in Figure 
25 below, notably showing high prevalence of moderate to severe disease in the 
youngest age group (40 - 49 years). indicating that lung function impairment starts at a 











Figure 25: Estimated population prevalence of GOLD Stage II or higher COPD* by age and 
sex (using NHANESIII Equations) 
• Post BO FEV1/FVC <70% and post BO FEV1 <80% 
Table 65: Estimated population prevalence (SE) of GOLD Stage II or higher COPD* by pack 
years and sex (Local equations) 
Pack years All % (SE) Men % (SE) Women % (SE) 
Never smoker 4.4 (1.3) 3.1 (3.0) 4.9(1.4) 
0-10 16.0 (2.5) 14.3 (3.8) 17.5 (3.4) 
10 - 20 20.7 (3.5) 25.3 (5.1) 15.3 (4.2) 
20+ 23.1 (3.3) 24.7 (4.5) 20.7 (4.8) 
'Post BO FEV1/FVC<70% and post BO FEV1<80% expected 
Table 66: Estimated population prevalence (SE) of GOLD Stage II or higher COPD* by pack 
years and sex (NHANES equations) 
Pack years All % (SE) Men % (SE) Women % (SE) 
Never smoker 7.0 (1.5) 3.1 (3.0) 8.2 (1.8) 
0-10 19.6 (2.7) 16.2 (3.9) 22.5 (3.6) 
10 - 20 25.6 (3.6) 30.8 (5.3) 19.4(4.6) 
20+ 30.7 (3.7) 33.9(5.1) 26.1 (5.1) 











There is a higher prevalence of GOLD Stage II or higher CO PO in women never 
smokers than their male counterparts (8.2% vs. 3.1 %). Again, the dose-response effect 
in women is less steep (Figure 26). The reason could be the categorisation of pack 
years - most women have a cumulative exposure that is nearer the lower end of the 
category, e.g. 11 pack years, whereas more men are at the higher end of the category, 











Men Women All 
• Never Smokers 
0-10 pack years 
EI 10-20 pack years 
~ 20+ pack years 
o Total 
Figure 26: Estimated prevalence of GOLD Stage II or higher COPD" by pack years and sex 
(using NHANES III equations) 
* Post BD FEV1JFVC <70% and post BD FEV1 <80% 
Table 67: Sample statistics and population prevalence of GOLD COPD in mutually 
exclusive stages by sex 
GOLD Stage All n (%) for sample All % (SE) Men % (SE) Women % (SE) 
0 651 (76.9) 76.2 (1.6) 71.3 (2.7) 80.0 (1.9) 
34 (4.0) 4.7 (0.9) 6.5 (1.6) 3.3 (1.0) 
2 109 (12.9) 12.4 (1.2) 14.2(2.1) 11.0 (1.4) 
3 48 (5.7) 6.2 (0.9) 7.3(1.6) 5.4 (1.1) 
4 5 (0.6) 0.5 (0.2) 0.7(0.4) 0.3 (0.2) 
The prevalence of GOLD Stage II COPD was higher than other GOLD stages (12.9%) 
and most persons with COPD were in GOLD stages II and III. Overall, 19% of the 
population, and the majority of persons with COPD had moderate to severe disease 
(Table 64). The difference in prevalence of COPD between men and women was not 











7.3.3. Symptoms in the BOLD sample 
Table 68: Estimated population prevalence (SE) of Chronic Cough* by age and sex 
Age All % (SE) Men % (SE) Women % (SE) 









70+ 6.3 (2.6) 8.9 (5.0) 4.7 (2.7) 
.. -.-~----.---.---.--------~.- .. -------~-------------.--------"---------------- ------_.-------
All 11.9 (1.2) 13.2 (2.1) 11.0 (1.4) 
'Reported cough for three months or more per year. 
Chronic cough was more commonly reported by younger women than older women, 
potentially indicative of an overlap with asthma in 40 - 50 year old women (bimodal 
distribution). There was a high prevalence of chronic cough in men in all the age 
categories (13.2% overall). 
Table 69: Estimated population prevalence (SE) of Chronic Cough* by pack years and sex 
Pack years All % (SE) Men % (SE) Women % (SE) 
Never smoker 3.9 (13) 5.1 (3.5) 3.5 (1.2) 
0-10 14.3 (2.3) 12.7 (3.5) 15.8 (3.1) 
10- 20 15.4 (2.9) 14.4(4.1) 16.5(4.1) 
20+ 17.8(3.1) 18.3 (4.3) 17.0 (4.5) 
*Reported cough for three months or more per year. 
The prevalence of chronic cough increases in both men and women as packyears 
increase, with similar prevalence in both sexes. 
Table 70: Estimated population prevalence (SE) of Chronic Phlegm* by age and sex 
Age All % (SE) Men % (SE) Women % (SE) 
40-49 17.1 (2.3) 17.9 (3.8) 16.4 (2.8) 
50 - 59 13.3 (2.3) 14.6 (3.8) 12.3 (2.6) 
60 - 69 12.1 (2.4) 15.7(4.4) 9.7 (2.7) 
70+ 8.4 (3.0) 8.9 (5.0) 8.1 (3.7) 
----"._---------- -_ ... _. . -----------------~--~.-------------.,--------.-.----- --_ .. _----_.-.-
All 14.3 (1.3) 15.9 (2.2) 13.1 (1.6) 











Chronic phlegm production was reported by 15.9% of men and 13.1 % of women. Again 
similar prevalence in both sexes was noted. 
Table 71: Estimated population prevalence (SE) of Chronic Phlegm* by pack years and sex 
Pack years All % (SE) Men % (SE) Women % (SE) 
5.8 (1.5) 8.3 (4.6) 
15.0 (2.5) 12.6 (3.6) 
18.2 (3.2) 16.9 (4.3) 
21.9 (3.4) 22.1 (4.6) 
'Reported Phlegm for three months or more per year. 
A dose-response relationship with increasing pack years is evident. 
Table 72: Estimated population prevalence (SE) of Self-reported Chronic Bronchitis* by 
age and sex 
Age All % (SE) Men % (SE) Women % (SE) 
40-49 6.1 (1.4) 5.2 (2.3) 6.8 (1.8) 
50- 59 5.1 (1.4) 5.5 (2.5) 4.8 (1.6) 
60-69 4.0 (1.5) 6.5 (3.2) 2.4 (1.4) 
70+ 1.1 (1.1) 3.0 (2.9) 0.0 (0.0) 
~---~--. -- ----~-- --._---. ----~-----... ,-~-----~--------~.-.. ---------------------,._-
All 5.0 (0.8) 5.3(1.4) 4.7 (1.0) 
'Chronic bronchitis is defined as both chronic cough and chronic phlegm for two or more years. 
The prevalence of self-reported chronic bronchitis of 5.0% is lower than expected 
considering the 7.2% reported in the Lung Health Survey 2002 in participants aged 15 
years and older. This will be discussed in Chapter 8. 
Table 73: Estimated population prevalence (SE) of Self-reported Chronic Bronchitis* by 
pack years and sex 
Pack years All % (SE) Men % (SE) Women % (SE) 
--------.------------_. -------... -.---.-----.----.---.--.----.---------.-~---------
Never smoker 1.0 (0.6) 0.0 (0.0) 1.4 (0.8) 
0-10 






















The low prevalence of self-reported chronic bronchitis in women with a >20 pack year 
history is curious (5.1 % vs. 11.8% in men) and is discussed in chapter 8. 
Table 74: Estimated population prevalence (SE) of Doctor-Diagnosed COPD*by age and 
sex 
Age Men % (SE) Women % (SE) All % (SE) 
40 - 49 5.9 (2.1) 9.0(2.1) 7.5 (1.5) 
50 - 59 8.2 (2.9) 5.9 (1.8) 6.9 (1.6) 
60 - 69 2.5 (1.8) 11.7(3.1) 8.0 (2.0) 
70+ 5.9(4.1) 8.1 (3.7) 7.3 (2.7) 
All 6.0 (1.4) 8.5 (1.2) 7.4 (0.9) 
'Includes chronic bronchitis, emphysema or COPO. 
Doctor-diagnosed capo is considered to be a less reliable indicator of obstructive lung 
disease in the survey area. The prevalence in women is higher than that in men (8.5% 
vs. 6.0%). Figure 27 summarises the prevalence of GOLD Stage I and higher, Stage II 
and higher and doctor-diagnosed capo, highlighting the difference in prevalence 










'Post so FEV,/FVC<70% 
** Post so FEV,/FVC <70% and post SO FEV, <80% 
"'Includes chronic bronchitis, emphysema or COPO 
All 
• *GOLD 1+ 
**GOLD 2+ 
~ ***Doctor Dia nosed 
Figure 27: Population prevalence of GOLD Stage I or higher, Stage II or higher (NHANES III 











Table 75: Estimated population prevalence (SE) of Doctor-Diagnosed COPD"' by pack years 
and sex 
Pack years All % (SE) Men % (SE) Women % (SE) 
Never smoker 6.0 (1.6) 7.5 (4.3) 5.5 (1.6) 
0-10 7.3(1.6) 5.5 (2.3) 8.8 (2.2) 
10 - 20 8.1 (2.1) 4.7 (2.4) 12.2 (3.7) 
20+ 9.3 (2.4) 6.9 (2.9) 12.6(4.1) 
*Includes chronic bronchitis, emphysema or COPD. 
Women have approximately twice the prevalence of doctor-diagnosed capo in 
comparison to men in all three pack year groupings. This could be due to 
comparatively higher health service utilisation in women, or more symptomatic disease. 
7.3.3. Analysis of risk factors for COPO 
Table 76 describes the population aged 40 and over in terms of the distribution of risk 
factors for capo. The variables analysed from the BOLD dataset were age, sex, 
tobacco (including passive smoking), past TB, education level, occupational exposures, 
smoky domestic fuels, BM!, childhood hospitalisation for chest illness and family history 
of CaPO/emphysema/chronic bronchitis. Confounders included in the analyses were 
doctor-diagnosed asthma and heart disease. 
Information on cannabis smoking, income and alcohol use were collected in the Lung 
Health Survey and the effective sample size for these variables was smaller than all the 
other variables (approximately two-thirds of participants had this data - 580 of 847), 
and thus only univariate analysis is presented in the tables as they were not included in 
the final multivariate model. Logistic regression adjusting for these risk factors was 
performed in a separate model and results are presented in the text. Because of the 
interval between the surveys, this data might not represent the variable status at the 
time of the BOLD survey. 











Table 76: Distribution of characteristics of the BOLD sample by sex* (n = 847) 
Characteristics 
Men (n ::: 315) Women (n::: 532) 
p* n n 
-----.~------.~~ .. -- .--
Income t (n ::: 574): 
104 (181) 61 (29.5) 43(11.7) >R2000/rnonth <0.001 
R 1 000-R2000/month 89 (15.5) 35 (16.9) 54(14.7) 
<R1000/month 381 (66.4) 111 (53.6) 270 (73.6) 
Education (n ::: 847): >12 
years 43(5.1) 20(6.4) 23 (4.3) 0.137 
8-12 years 420 (49.6) 166 (52.7) 254 (27.7) 
1 ~7 years 344 (40.6) 116(36.8) 228 (42.9) 
None 40 (4.7) 13 (4.1) 27(5.1) 
Age (n::: 847): 40-49 335 (39.6) 132(41.9) 203 (38.2) 0.5 
50 -- 59 263(31.1) 92 (29.2) 171 (32.1) 
60·- 69 167(19.7) 63 (20.0) 104 (19.6) 
30 82 (9.7) 28 (8.9) 54 (10.2) 
Any specific occupational 
exposures (n = 847): 
Unexposed 547 (64.6) 162 (51.4) 385 (72.4) <0.001 
Exposed 300 (35.4) 153 (48.6) 147 (27.6) 
Tobacco (n ::: 846): Never 
smoked 195 (23.0) 42(13.3) 153(27.8) <0.001 
Passive smoker 75 (9.3) 7 (2.2) 72 (13.5) 
Ex smoker 181 (21.4) 85 (27.0) 96(18.1 ) 
Current smoker 392 (46.3) 181 (57.5) 211 (39.7) 
Tobacco pack year 
categories (n = 845): 0 276 (32.7) 51 (16.3) 225 (42.3) <0.001 
0-10 242 (28.6) 94 (30.0) 148 (27.8) 
10 - 20 161 (19.1) 77 (24.6) 84 (15.8) 
~O 166(19.6) 91 (29.1) 75(14.1) 
BMI (n ::: 847): <18.5 
(underweight) 65 (7.7) 36( 11.4) 29 (5.5) <0.001 
18.5-25 (normal weight) 250(29.5) 134 (42.5) 116 (21.8) 
>25 and <30 (overweight) 228(26.9) 90(28.6) 138 (25.9) 
2:30 (obese) 304 (35.9) 55(17.5) 249 (46.8) 
Cannabis t (n ::: 580): 
Never 516 (89.0) 148 (71.2) 368 (98.9) <0.001 
Ex-smoker 31 (5.3) 30 (14.4) 1 (0.3) 
Current smoker 33 (5.7) 30 (14.4) 3 (0.8) 
Cannabis t (n ::: 580): 
Never 516 (89.0) 148 (71.2) 368 (98.9) <0.001 
Ex-smoker 31 (5.3) 30 (14.4) 1 (0.3) 
Current 1-2 joints/day 13 (2.2) 11 (5.3) 2 (0.6) 
Current ;:B joints/day 8(1.4) 7 (3.4) 1 (0.3) 
Cannabis pipe only 12 {2.D 
-------------- _. -.---~--.- ... ------- --------~-----.~--~---- ---~ -- .. -----.----~----
'Persons with acceptable quality spirometry results; test for difference between men and women 











Table 76 continued: 
Occupational exposure 
(dusty job) (n = 847): Never 452 (53.4) 124(39.4) 328 (61.6) <0.001 
Ever 395 (46.6) 191 (60.6) 204 (38.4) 
Childhood hospitalisation 
(n = 847): Never 815 (96.2) 302 (95.9) 513 (96.4) 0.731 
Ever 32 (3.8) 13(4.1) 19 (3.6) 
Previous tuberculosis 
(n = 847): Never 719 (84.9) 253 (80.3) 466 (87.6) 0.006 
Ever 128 (15.1) 62(19.7) 66 (12.4) 
Domestic fuels (n = 847): 
I\lon- smoky 457 (53.4) 160 (50.8) 297 (55.8) 0.042 
Smoky 390 (46.0) 155(49.2) 235 (44.2) 
Asthma (n = 847): 
Never diagnosed 724 (85.5) 279 (88.6) 445 (83.6) 0.192 
Ever diagnosed 123 (14.5) 36(11.4) 87 (16.4) 
Alcohol uset (n = 580): 
Non, light, moderate 548 (94.5) 183 (88.0) 365 (98.1) <0.001 
Heavy 32 (5.5) 25 (12.0) 7 (1.9) 
Heart disease (n = 847): 
Never diagnosed 769 (90.8) 297 (94.3) 472 (88.7) <0.001 
Ever diagnosed 78 (9.2) 18(5.7) 60 (11.3) 
Family history of COPD (n 
= 847): No 715 (84.3) 277 (87.9) 438 (82.3) 0.122 
_ y~_ .. _. __ . ___ ... _~ .. _._ ... __ ~. ____ ._. __ ~_1l.~Jl~·Zl. ___ 38_~------Q~J'!LZL---.-----~-
*Persons with acceptable quality spirometry results;'* Chi test for difference between men and women 
***small numbers in this group; **R1 OOOmonth-US$ 98.77; tFrom LHS2002 questionnaire responses. 
Two thirds of the population earned less than R1000 per month, 15% R1000 - R2000 
per month and 18.1 % >R2000 per month. More than half the population had >8 years 
of education, but 5.1 % of women and 4.1 % overall reported no education at all. There 
were no significant differences between men and women regarding age (p = 0.5) and 
>70% of this sample was aged <60 years. 
More men had a history of specified occupational exposures than women (48.6 vs. 
27.6) and 35.4% overall. These occupations included any of the following: hard-rock 
mining, coal mining, sandblasting, working with asbestos, chemical or plastics 
manufacturing, flour, feed or grain milling, cotton or jute processing, foundry or steel 
milling, welding, fire fighting, or farming. Additionally, to the question "Have you ever 












Table 76 shows the distribution of tobacco exposure. A total of 9.3% were passive 
smokers. Active smokers who had additional passive smoke exposure were excluded 
from this category and included in current or ex-smoking categories. Division of 
cumulative tobacco exposure into pack year categories showed that just under a third 
of this population had a 0 - 10 pack year history, but 19.1 % and 19.6% respectively had 
a 10 - 20 pack year history and a >20 pack year history respectively. 
A large proportion of women - 25.9% and 46.8% - were overweight and obese 
respectively. 
There were small numbers in the cannabis exposure categories, both when cannabis 
was coded quantitatively and categorically, as never, ex and current* (see Table 76). A 
history of tuberculosis was reported by 15.1 % of the sample. Domestic fuel exposure 
for more than 6 months was reported in 46% - most of this was past/childhood 
exposure as electrification had been introduced in the area many years before the 
study. Diagnosed asthma was an important confounder to consider and was reported 
in 14.5% of the sample. A family history of chronic bronchitis, COPD or emphysema 











Table 77: Analysis of risk factors for GOLD Stage I or higher COPD using survey 
estimation logistic regression (n = 847) 
•• _ ••••••• ~ __ ~_.~ ___ ~~ __ " " _____ ~~ _ __ .u ~ _~.~._~__ _~ __ ~ _~~ _____ ._~_~~ •• ~_. ___ •• __ • __ _ 
n (%) with Unadjusted OR p Adjusted OR 
Stage I (95% CI) (95%CI) 
COPD 
.-'-~'-".- -~---~~.~-~ ------~---.~-.---~~~-~~-------~------- .. -"'~-""'" 
Income*: >R2000/month 16* (15.4) 1.0 0.03 
R1000-R2000/month 22* (24.7) 2.2 (1.0 - 4.7) 
<R1000/month 97(25.5) 2.1 (1.1-3.8) 
Education: >12 years 5 *(11.6) 1.0 
8-12 years 79 (18.8) 2.0 (0.7 - 5.4) 
1-7 years 98(28.5) 3.4(1.3-9.1) 
None 14*(35.0) 6.1(1.8-20.1) 
Age: 40 49 46 (13.7) 1.0 
50 59 60 (22.8) 1.9 (1.2 - 3.0) 
60 69 56 (33.5) 2.9 (1.8·- 4.2) 
:::::70 34(41.5) 4.6(2.6--8.4) 
Any specific 
occupational exposures 
n = 847: Unexposed 
Exposed 









18-24.9 normal weight 




Ex Cannabis smoker 
Current 1-2 joints/day 
Current 28 joints/day 
Cannabis pipe only 
Cannabis 2**: Never 
Ex Cannabis smoker 































0.9 (0.7 - 1.3) 
1.0 
1.0 (0.4 -- 2.5) 
2.7 (1.4 - 5.4) 
3.8 (2.1 - 7.0) 
1.0 
2.6 (1.5 - 4.6) 
4.0 (2.2 - 7.2) 
4.7 (2.7 - 8.1) 
6.3 (3.3 - 12.0) 
1.0 
0.5 (0.3 0.8) 
0.4 (0.3 - 0.6) 
1.0 
2.1(1.0 4.7) 
1.2 (0.3 4.5) 
10.3 (1.9 56.9) 
1.4 (0.4 5.6) 
1.0 
2.1 (1.0 4.7) 





















2.4 (1.4 - 4.3) 
4.5 (2.5 8.3) 




1.6 (0.9 3.0) 
3.1 (1.6 6.0) 
2.5 (1.4 - 4.5) 
7.2 (3.4 - 15.1) 
1.0 
0.6(0.4 1.1) 




1.3 (0.9 - 2.0) 
hospitalisation: Never 188 (23.1) 1.0 0.867 1.0 



















Table 77 continued: 
- -------'----------.---.----- .. ----.~-------~-,--.-.--.. - -~-------- ------------ ----- ----- ------- - -- - ---------------




OR (95% CI) 
p Adjusted OR 
(95%CI) 
P 
-----_._------_._--_ .. _------------ ----- - -~ - -~----- ----- - ----------------------- --- ------ _.---"---------
Gender: Female 101 (19.0) 1.0 0.006 1.0 
Male 95 (30.2) 1.6 (1.1- 2.3) 
Previous TB: Never 133 (18.5) 1.0 







Heart disease: l'Jever 
diagnosed 
Ever diagnosed 
Family history: No 
Yes 
Alcohol use: Non, light, 
moderate 
Heavy 














2.5 (1.7 - 3.9) 
1.0 
0.8 (0.4 -- 1.6) 
1.0 
1.3 (0.8 - 2.1) 
1.0 
1.8 (0.8 - 3.9) 
<0.001 
0.039 
1.0 (0.7- 1.6) 
1.0 
3.4 (2.1 - 5.6) 
1.0 











_f::;.E:lr_<:lia.flIl_~~~~L _______ . __ ._?L(~~~?J ______ L~j9·~.:=_.?:~L _____________________ . ___ . ___ . _________ _ 
A history of 10 - 20 pack years resulted in a three fold increased risk and >20 pack 
years in a 2.5 fold increase for GOLD Stage I and higher COPD. Analysis of age 
revealed a linear association with a sharp gradient. Persons over the age of 70 had 8_7 
times the risk of the 40 - 50 year age group. Previous TB was significantly associated 
with COPD (see later). 
There was a strong association with being underweight, but the direction of effect 
cannot be established here, as many persons with COPD have muscle wasting and 
weight loss in the later stages of disease, and loss of weight is also associated with 
current (and perhaps past) tuberculosis infection, itself a risk factor. Only 7.7% of the 
population was underweight but 72.3% of this underweight group had COPD (Table 
77). Overall, 24.0% of all persons with GOLD Stage I and higher CO PO were 
underweight. Obesity seemed to be associated with a small protective effect (p = 
0.022). Approximately 41 % of persons defined as GOLD Stage I COPD by spirometry 
had a history of self-reported asthma. Misclassification could be a significant concern 
here as COPD/emphysema is commonly referred to as "asthma". There was no 











Table 78: Analysis of risk factors for GOLD Stage II or higher COPO (NHANES equations) 
using survey estimation logistic regression (n=847) 
n with Unadjusted OR P Adjusted OR 
(95%CI) Stage II 
COPO .. _ ...... __ .. _ ...•.... __ .. --.----~. 
Income*: >R2000/month 10 (9.6) 
R1000-R2000/month 16 (18.0) 
<R1000/month 84 (22.1 ) 
Education: >12 years 2 (4.7) 
8-12 years 69 (16.4) 
1-7 years 79 (23.0) 
None 12 (30.0) 
Age: 40 - 49 37 (11.0) 
50 59 51 (19.4) 
60 69 48 (28,7) 
:::::70 26(31.7) 
Any specific occupational 
exposures n = 847: 
Unexposed 
Exposed 








8MI: <18 (underweight) 
18-24.9 (normal weight) 
>25 and <30 (overweight) 
=:::30 (obese) 
a) Cannabist: Never 
Ex-smoker 
Current 1-2 joints/day 
Current ;S joints/day 
Cannabis pipe only 









































2.8 (1,7 4.7) 
3.2 (1.7 - 5.8) 
1.0 
0.7 (0.5 1.0) 
1.0 
1.5 (0.6 3.9) 
3.7 (2,0 - 6.7) 
4.8 (2.8 8,0) 
1.0 
3.2 (1.8 - 5.8) 
4.6 (2.5 - 8.3) 
5.9 (3.4 - 10.3) 
7,1 (3.7 13.7) 
1.0 
0.5 (0.3 - 0.8) 
0.4 (0.3 0.7) 
1.0 
1.8 (0.8 4.3) 
0.4 (0.1 - 3.1) 
6.7 (1.5 - 30.2) 
1.8 (0.5 - 7.2) 
1.0 
1.8 (0.8 - 4.3) 





3.0 (0.4- 22.0) 
2.5 (0.3 _. 18.0) 









2.3 (1.3 - 4.3) 
4.2 (2.3 - 7.9) 




2.0 (1.0 3.9) 
3.6(1.8 7.1) 
3.3 (1.7 6.4) 
8.5 (40 -17.8) 
1.0 
0.6 (0.3 1.0) 




1.0 (06 - 1.5) 
hospitalisation: Never 156(19.1) 1.0 0.98 1.0 
Ever 6(19.4) 1.0(0.4-2.6) 

















Table 78 continued: 
- .--~--.-,~---- .. -,--.--------.,~"- --_ .. _--,. __ .,---,.------" ----------.---------------------~.-"~------.--,-.---... -----_._-- "-"'--------.----~-----
n (%) with Unadjusted p Adjusted OR p 
Gender: Female 
Male 








Heart disease: Never 
diagnosed 
Ever diagnosed 
Family history of COPD: 
No 
Yes 




Stage II OR (95% CI) (95%CI) 
COPD 
--_._._._._"._---_._, ... ,-- .. _ .. _---",-- -----'~------------------~.--.---
87(16.4) 1.0 
75 (23.8) 1.4 (1.0 - 2.0) 
109 (15.2) 1.0 












1.3 (0.9 - 1.8) 
1.0 
3.0 (1.9 -- 4.6) 
1.0 
0.6 (0.3 -- 1.2) 
1.0 
1.3 (0.8 - 2.2) 
1.0 
1.6 (0.7- 3.7) 
0.054 1.0 
0.9 (0.5 - 1.4) 
<0.001 1.0 
3.2 (1.9 - 5.4) 
0.151 1.0 
1.4 (0.9 - 2.1) 
<0.001 1.0 









_ J~ye~ __ qiCl.9Q.2~~.Q___________~C2Q~L~L ____ .1:!_{ O. 9 -::._~~1L ___________ . ___ ... ____________ ________________ _ 
**R1000month-US$ 98.7 t Data obtained from LHS2002. 
Table 78 shows the analysis of GOLD Stage II and higher COPD to be similar to that of 
GOLD stage I and higher COPD, with significant associations with tuberculosis (OR 
3.2; 95% C/: 1.9 - 5.4), underweight (OR = 8.5; 95% C/: 4.0 -17.8) and tobacco 
packyears. 
A multivariate model (n= 571) including cannabis (ever vs. never) and income failed to 












Table 79: Analysis of risk factors for COPD by GOLD staging using survey estimation multinomial logistic regression (n = 847) 











































§tage I and II 
Adjusted OR (95% CI) 
1.0 




2.7 (1.3 - 5.6) 
2.3 (1.2 - 4.2) 
5.7 (2.6 - 12.3) 
1.0 
0.7 (0.4 - 1.2) 
0.5 (0.3 - 0.9) 
1.0 
1.4 (0.9 - 2.1 ) 
1.0 
1.2 (OJ - 1.9) 
1.0 































28 (52.8 ) 
24(45.3) 
29 (54J) 
§tiige III and IV COPD 
Adjusted OR (95%CI) 
1.0 
1.5 <0.7 - 3.3) 
1.07(1.036-1.1 
1.0 
2.4 (0.6 - 9.2) 
13.8 (3.8 -50.3) 
7.7 (2.2 - 27.0) 
16.1 (5.8 -44.8) 
1.0 
0.4 (0.1 -1.4) 
0.6 (0.2 - 1.6) 
1.0 
1.2 (0.6 - 2.4) 
1.0 
0.7 (0.3 - 1.5) 
1.0 
8.9 (4.2 - 18.9) 
1.0 
1.8 (0.8 - 3.7) 
1.0 31 (58.5) 1.0 
1.3 
























The multinomial model (Table 79) showed a significant association of previous TB as a 
risk factor for COPD. The risk increased from 2.6 times increased risk for 
mild/moderate COPD (Stage 1/11) to 8.9 in severe CO PO (Stage III/IV). 
Asthma was associated with a 2.3 times increased risk for mild/moderate COPD and 
this risk almost quadrupled to 8.6 for severe disease. 
Cumulative smoking exposure of 0 - 10 pack years was not associated with a 
significantly increased odds of mild/moderate CO PO (p= 0.07) or severe COPD 
(p=0.2). A smoking history of 10 - 20 pack years carried a risk of 2.7 for mild/moderate 
disease and a risk of 13.8 for severe disease, (19.1 % of the population smoked 10 - 20 
pack years). A history of >20 pack years (19.6% of the population) was associated with 
a 2.3 times increased risk of mild/moderate disease and a 7.7 times increase for 
severe disease. The size and plausibility of effect is considered below by means of 
calculated population attributable fractions. 
Being underweight was associated with a 5.7 fold and 16 fold increased odds of 
mild/moderate and severe disease respectively. There appeared to be some small 
protective effect for mild/moderate disease associated with obesity (OR 0.5; 95% CI: 
0.3 - 0.9, p= 0.03). 
Interactions between BMI and gender, BMI and asthma, and TB and smoking were 
tested in the final model and none of them were found to be significant (p =0.6; P = 0.8 
and p =0.8 respectively). 
Summary of association with tuberculosis 
The prevalence of GOLD Stage I and higher COPD in those with and without a history 
of TB was 49.7% vs. 19.1% respectively (p<0.001). One third (32.1%) of persons with 
GOLD Stage I and higher COPD had a past history of TB. 
The prevalence of GOLD Stage II and higher COPD in those with and without a history 
of TB was 42.2% vs. 14.9% respectively (p<0.001). One third (34.1%) of persons with 
GOLD Stage II and higher COPD had a past history of TB. 
Table 77 shows that a strong association of GOLD Stage I and higher CO PO with a 











maintained with GOLD Stage II and higher COPD (OR 3.2; 95%CI 1.9 - 5.4) (Table 
77). Multinomial modelling has shown that the risk associated with past tuberculosis is 
highest in those with severe COPD (OR 8.9; 95%CI 4.2 - 18.9). 
Of all persons with COPD, 13.3% were never smokers. In never smokers with past 
tuberculosis, 18.3% had GOLD Stage I or higher COPD, but this estimate was based 
on small numbers (4/20 persons - estimate corrected for weighting and clustering). 
In never smokers with no past tuberculosis, 9.7% had GOLD Stage I or higher COPD 
(23/226 persons). The difference between the above two groups was not statistically 
significant (p=0.2), but no inferences can be made from estimates with such small 
numbers. Consequently the relationship of TB as a risk factor for COPD in never 
smoking men and women could not be examined separately to see if past tuberculosis 
was associated with COPD in never smokers. 
Radiology to detect current and previous tuberculosis was performed in 75% of 
persons in the LHS2002, but not on those in the BOLD cohort. However, in the latter, 
two thirds had taken part in the LHS2002, and 58% (493/846) of the BOLD sample had 
a chest radiograph from the LHS2002. Radiographic evidence of tuberculosis was 
present in 17.4% of the BOLD sample. 
The prevalence of GOLD Stage I and higher COPD in those with and without evidence 
of TB on chest radiograph was 60.3% vs. 16.2% respectively (p<0.001). In those with 
GOLD Stage I and higher COPD, 44% had evidence of tuberculosis on chest 
radiograph. 
Overall 10.1 % of the population (aged ~O years) had evidence of bronchodilator 
reversibility, defined as a ::dOOml and ;:;::J 2% change in FEV1. Reversibility was present 
in 19.4% of participants with GOLD Stage I or higher COPD and 7.3% of those with no 
CO PO (p<0.001). Reversibility was present in 13.9% of those persons with a past 











Table 80: Population attributable fractions for GOLD stage II (NHANES) or higher COPD 
Percentage Prevalence Odds Ratio Population 
Risk Factor exposed to (Stage II or higher Attributable 
_~~ ___ ~ _____ ~ ~ .. _~~_~~~_~I"i~~~!~to r ___ -.!"~g!_~~.~~~!l~'!Ii><:l~.IL_~ _£r~ction (%) ~ __ _ 
0-10 pack years 28.6 2.0 22.2 
10- 20 pack years 19.1 3.6 33.2 












GOLD Stage II or higher was chosen as the outcome with which population attributable 
fractions were calculated as this is a threshold of practical and public health 
importance. 2 , i.e. the prevalence odds ratios are from this model. Collectively, 86.5% of 
GOLD Stage II and higher CO PO was attributable to cigarette smoking. Tuberculosis 
was responsible for 25%, and 36.6% was attributable to being underweight. Again, one 
of the assumptions made in calculating population attributable fractions is that they are 
completely adjusted for confounders, which is often not the case, and this results in the 
total adding up to more than 100% 
No calculation was made of a PAF for cannabis and income (socioeconomic status) as 
they had been excluded from the final model (see above). 
7.4. References 
,-Hankinson et al. Spirometric reference values from a sample of the general U.S. population. 
Amer J Respir Crit Care Med, 1999;159:179-187. 
2 Celli BR, Halbert RJ, Isonaka S, Schau B. Population impact of different definitions of airway 





















CHAPTER 8: DISCUSSION 
8.1. SUMMARY OF THE MAIN STUDY FINDINGS 
1. The prevalence of respiratory symptoms in this community is high at 38.3%, 
reflecting the high rates of smoking and exposure to other harmful exposures in adults. 
2. Other significant modifiable factors found to be associated with respiratory 
symptoms were cannabis smoking, pulmonary tuberculosis, occupational exposures, 
childhood chest illness and low socioeconomic status. 
3. This is the first African study to examine the effects of cannabis smoking on 
respiratory health at a population level. A strongly positive association between 
cannabis smoking and respiratory symptoms was observed, but the small numbers and 
the resulting difficulty of quantitation of cannabis exposure prevented an assessment of 
a relationship with capo and dose-dependency. 
4. The prevalence of capo in persons aged ~o years from Ravensmead and Uitsig in 
Cape Town (GOLD Stage I or higher of 24%) is amongst the highest yet reported from 
any part of the world. 
5. The prevalence of capo is high in both men and women reflecting the high 
prevalence of smoking among women in this community. 
6. The majority of capo is classified as GOLD Stage II and higher (19.1 % of the 
population :::!l.0 years), confirming that the capo is established and clinically significant 
and likely to be associated with significant morbidity, mortality and use of health 
resources. 
7. The prevalence of capo in never-smoking women is high, reflecting the aetiological 
role of risk factors such as tuberculosis, and/or early life lung insults. This raises the 
question of whether all those with symptoms and airflow limitation have capo or other 
forms of lung disease associated with these features - for example, post-tuberculous 
lung disease and bronchiectasis. 
8. The demonstration that a history of previous pulmonary tuberculosis is the strongest 
predictor of capo (in terms of odds ratio, rather than the proportion affected) raises 
several questions: the first of which is whether capo associated with previous 
tuberculosis should be considered as capo or as a special sub-group of capo that 
requires further study. This would be to characterise the pathophysiology (e.g. 
prevalence of AHR in this group), elucidate the mechanisms causing airflow 
obstruction, and examine its responsiveness to treatments developed for smoking-
related COPD. 
9. These studies confirm that obstructive lung disease (asthma and CaPO) is 
underrecognised and undertreated, and that greater provision needs to be made for the 











8.2. DISCUSSION OF METHODOLOGY: 
The Lung Health Survey 2002 and The BOLD study 
8.2.1. Study area and sample 
Details of the study population and reasons for their selection for these studies have 
been provided in Chapters 3 and 4. The results of the study vindicate this choice, in 
that there was a sufficiently high response rate, mix of respiratory symptoms and 
COPD, and other respiratory diseases, and of risk factors to permit analysis of 
associations and interactions. The next relevant question is the generalisability of the 
prevalence findings to other parts of South Africa. This is difficult to estimate but is 
likely to be limited, owing to the heterogeneity of the South African population with 
respect to income, socio-economic status, occupational exposures, background 
prevalence of infections, and infectious diseases like tuberculosis, smoking and 
environmental atmospheric pollution. In recent years, the prevalence of HIV infection, 
with its attendant effects on the prevalence of lung disease and on survival, has added 
to the complexity of exposure to risk factors. 
However, the prevalence results give an indication of the likely considerable burden of 
COPD in low-to-middle income urban South Africans, which represents a large 
proportion of the population. In fact, the growing number of persons living in urban 
poverty worldwide is likely to share many exposures with this group, making the 
evaluation of associations relevant to these contexts. From the SA Census figures of 
2001, 56% of the population live in urban areas 1, and 38.6% of the population fall 
below the poverty line of R3000 per capita per annum.2 In addition, in terms of 
smoking, although smoking rates in adults are high in this province, it is similar in 
others, particularly amongst males. However, amongst females the Western and 
Northern Cape are highest. Thus, to varying and proportionate extents, similar findings 
are likely in other regions and communities with similar risk exposure. The analysis of 
risk factors provides a means of profiling different areas and communities in South 
Africa for the likelihood of a high burden of COPD and symptoms of lung disease. 
8.2.2. Survey design 
A limitation of cross-sectional studies, like those reported here, are that, while they 
permit assessment of associations between risk factors and disease, they cannot 
confirm causality. Exposures and disease are assessed at the same time. 











be assessed, unless the exposure remains constant over time e.g. sex, gene 
sequences. The associations may be chance phenomena (possible with small sample 
sizes), consequential or causal. 3 
8.2.3. Bias 
Selection bias 
As in most population-based studies, sampling was limited to the non-institutionalised 
population indicating that those from the area who were in prison or hospitalised were 
underrepresented, making selection not truly random. However, it is known that the 
characteristics of institutionalised persons are different to the rest of the population. 
Secondly, only persons who were relatively "well" participated in the studies, and in the 
case of the BOLD study, only those who were able to perform satisfactory lung function 
tests were included in the study. Both of these represented further sources of selection 
bias. Reasons for not performing lung function testing included Illness such as recent 
surgery, being bedridden, or inability to comply with the requirements of the test. 
Causes of the former and latter are many, and result in exclusion of a significant 
proportion of potential participants. In this study the total number excluded was 111 
amounting to 11.6% of the random sample. Causes include inability to tolerate or 
adequately seal the lips around the mouthpiece or inability to perform reproducible 
forced expiratory manoeuvres. These reasons for excluding participants are more 
common in community studies where participants are untrained and unaccustomed to 
lung function testing, in the elderly, the frail, and patients with severe airflow 
obstruction. This presents a special challenge in COPO studies like the BOLD study, 
since these are performed in persons 40 years and older, many of them in older 
decades and with high prevalence of COPO and co-morbid diseases, particularly in this 
population. A selection bias thus operates against the disease in question, and the 
results are likely to under- rather than over-estimate the true prevalence. 
Non-response bias is a form of non-systematic bias that is unavoidable because of the 
ethical need to ensure voluntary participation. In the LHS2002, replacement of non-
responding households was undertaken, attempting to retain the geographic location of 
the original address, and in the hope of retaining characteristics such as 
socioeconomic status. However, some degree of bias would still have been introduced 











want to participate because of concerns about stigmatisation - perception that their 
household might be regarding as unhealthy, harbouring tuberculosis and other lung 
disease - or simply that they were not interested or did not want to divulge medical 
histories and other personal details of their household. Analysis of the responding vs. 
non-responding addresses confirmed that the age and sex of occupants of these 
categories were not significantly different. In addition, appropriate adjustment for 
replacements was made in the analyses. Since crude (unadjusted) prevalence 
estimates were very similar to prevalence estimates adjusted for clustering and non-
response in both studies, it can be concluded that the effect of non-response is likely to 
have been minimal. 
In the BOLD study, replacement procedures were not employed, resulting in a lower 
response rate. However, this response rate was still more than adequate for a 
population-based survey. In addition, demographic data were collected on the non-
responders and this was compared to that of responders. Responders were found to 
be significantly different from non-responders with respect to age, sex, smoking status 
and whether or not they had doctor-diagnosed asthma, COPD, chronic bronchitis or 
emphysema, but were similar regarding the presence of comorbidity. Comparisons 
were also made of responders with and without quality spirometry and no significant 
differences were found for all the parameters mentioned above (results not presented). 
An unusual additional form of "non-response" bias may have operated in the studies. 
Owing to funding and logistical difficulties the two studies could not be performed 
contemporaneously, but were performed two years apart. The delay in performing the 
BOLD study had several consequences. Firstly, a proportion of potential participants 
were lost to 'follow up' owing to death and relocation. This resulted in the BOLD study 
having to recruit additional participants. Secondly, it prevented direct comparison of 
results of the LHS2002 with the results of BOLD in all patients. Finally, the validity of 
responses to the LHS2002 questionnaire to health (and lung disease) status measured 
two years later has to be questioned. However, the latter provided the opportunity for 
comparing the reproducibility and consistency of responses over time - an analysis 
that has not been presented in this report. It should be noted that the BOLD study was 
designed to be an independent cross-sectional study, and sampled all individuals aged 
~O years residing at the sampled addresses at the time of the study, and 
consequently does not coincide entirely on the LHS2002 sample. Approximately two 











In both studies, considerable effort was made to avoid the "sick population effect", 
which is the converse of a healthy worker bias, where old and sick persons who are at 
home during the day, are overrepresented. To avoid this effect, participants were 
recruited at various times of the day, especially in the evenings and at weekends, in 
order to ensure that working persons were adequately represented. This strategy also 
resulted in higher response rates. 
A final limitation which might have influenced the results of the studies is that the 
standardised BOLD questionnaire did not include questions on cannabis use and 
income. Consequently, we were unable to include one third of the BOLD sample in the 
analysis of the effects of cannabis on the prevalence of COPD (information was 
available from LHS2002 on only 580 of the 847 persons in the BOLD cohort). Since 
both cannabis and income were strongly associated with symptoms of obstructive lung 
disease in the LHS2002 analysis, their association with COPD was of particular 
interest. In the final multivariable analysis a separate model was run with the sample 
size of 580 persons, but this limited the power of the study and only limited conclusions 
could be drawn (as a consequence of the numbers with categorised cannabis exposure 
being low). 
Information bias 
On order to minimise interviewer bias, interviewers were trained appropriately using 
standard training (detailed in the manual of procedures of both studies), so that there 
was no interpretation of responses, or differences in effort to elicit responses. This 
point was stressed throughout the studies and quality control involved observation of 
interviewing, feedback and retraining (if necessary). Quality control in the BOLD study 
was more stringent than that employed in the Lung Health Survey, particularly with 
regard to interviewer technique and coaching to avoid pitfalls. In addition, the use of 
spirometry, an objective test for the presence of the target disease added more 
certainty than is possible with self-reported symptoms or self-reported doctor-
diagnoses. 
Some level of recall bias is inevitable in any questionnaire-based study. Participants 
may either exaggerate exposures such as to occupational agents (overreporting), or 
minimise exposures such as cannabis or cigarette smoking (underreporting). The 











usually toward underreporting. For cannabis smoking, the magnitude of the bias is 
suspected to be higher in women, in whom it is less socially acceptable in this 
community. Women may be more embarrassed to declare use. However, since 
cannabis smoking is illegal, a disclosure bias is likely to operate in both sexes, but 
despite this, the prevalence of cannabis smoking in men is high. The difficulties in 
estimating this bias in population based-studies is acknowledged and it renders 
calculation of cumulative exposure of cannabis (joint-years) and even tobacco smoking 
(pack-years) somewhat inaccurate. This may account for the reported lack of evidence 
of a dose-related effect of cannabis smoking on COPD. 
8.2.4. Misclassification 
Asthma vs. COPO 
Diagnosing asthma and CO PO in adults in epidemiological studies can be difficult 
without the clinical perspective of a physician, especially in smokers and older persons. 
Respiratory questionnaires are good screening tools for identifying symptoms of 
obstructive lung disease, but most guidelines agree that spirometry should be the basis 
for diagnostic confirmation of COPD4 and an important tool for asthma diagnosis. 5 
However, as discussed below, even spirometry has limitations, and cannot on its own 
distinguish asthma and COPD. Instead, the most reliable diagnosis of both conditions 
requires both history and spirometry. Physical examination plays only a small part in 
this assessment, making it possible to perform population-based studies with symptom 
questionnaires, for the purpose of estimating prevalence. Other methods employed in 
surveys are questions on 'doctor-diagnosed' disease (asthma or COPD). However, this 
is an imprecise method and is highly dependent on health resources and access to 
physicians (and specialists) and confirmatory investigations like spirometry. For 
example, in a setting like Ravensmead/Uitsig, where most care is received in public 
primary care facilities that do not have spirometry, and where access to specialist 
clinics is limited, only the most severe cases of COPD and possibly even of asthma are 
likely to be diagnosed, and many of the diagnoses might be wrong. Thus, 
underdetection and underestimation of prevalence and severity are to be expected. 
The condition most reliably reported in surveys is chronic bronchitis, since this relies 
entirely upon symptoms that can be elicited in a questionnaire. In the current studies, 
the diagnostic imprecision of distinguishing asthma from COPD was acknowledged. 











instances it would not be possible to exclude some contamination from asthma, either 
as pure cases, or in the form of patients with mixed disease (both asthma and CaPO). 
In epidemiological terms, a method of reducing misclassification is to focus on the older 
age-groups, where capo is more common than asthma (the reverse being true for 
those under 40 or 45 years). This was the only filter that was applied in the BOLD 
study. 
In other settings, questionnaire responses perform well in differentiating persons with 
COPO from those with asthma. Besides age, increasing pack years, slow progressive 
worsening of cough or dyspnoea, breathing-related disability or hospitalisation, sputum 
quantity >15ml per day, "cold going to the chest", and receipt of treatment for COPO 
have all been helpful in identifying subjects with COPD.5 
Tile use and interpretation of spirometry in diagnosing capo also requires some 
discussion. According to the GINA guidelines, asthma is defined as "a chronic 
inflammatory disorder of the airways in which many cells and cellular elements playa 
role. 6 The chronic inflammation causes an associated increase in airway 
hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, 
chest tightness and coughing, particularly at night or in the early morning. These 
episodes are usually associated with widespread but variable airflow obstruction that is 
often reversible, either spontaneously or with treatment".6 By contrast, COPD is defined 
as "a disease state characterised by airflow limitation that is not fully reversible. The 
airflow limitation is usually both progressive and associated with an abnormal 
inflammatory response of the lungs to noxious particles or gases".4 Thus, the nature of 
airflow limitation differs in these conditions, but some important spirometric differences 
cannot be assessed in a cross-sectional survey - namely, its episodic nature, diurnal 
variation, variability over short periods of time, tendency to return to normal in asthma, 
and partial or total irreversibility, and progressive nature for capo. 
What can be assessed is reversibility following use of a bronchodilator, and whether 
the latter results in values that can be viewed to exclude persistent airflow obstruction 
(and FEV1/FVC ratio of >70%). In COPD, the airflow limitation is only partially 
reversible (or poorly reversible). Thus, when testing for the presence of COPD, a post-
bronchodilator test is recommended and most informative, whereas for asthma, FEV1 
measured before and after bronchodilator and/or tests of AHR are the standard 











Another feature that is of some value is the mC1gnitude of response to a bronchodilator. 
Although improvement of greater than 200ml (and .:::12% of prebronchodilator value) is 
considered in guidelines to represent a significant improvement suggesting the 
presence of asthma, it has a poor discriminant value between these two conditions, but 
improvement of 400ml is recommended as a more robust indicator of asthma.7 Thus, 
for the purpose of surveys like the BOLD study that involve spirometry, certain rules 
apply. The presence of a FEV1/FVC ;::1'0% and reversibility :::200ml and ~ 2% of 
baseline FEV1 suggests asthma or is compatible with COPD with a reversible 
component. In addition, in asthma, the FEV1 between attacks can be normal or near 
normal. In COPD, in all but Stage I, a reduced FEV1 is required. A value of .:::70% is 
specified in the GOLD definition, but as discussed later, it can be argued that other 
figures, or even a figure that diminishes with increasing age, might be more reliable in 
confirming airflow obstruction. To ensure that it is 'fixed' rather than temporary 
bronchospasm, in COPD it is specified that the FEV1 (and FEV1/FVC) should be 
postbronchodilator. By contrast, a pre-bronchodilator value is more useful in asthma, 
since diagnostic evidence of obstruction may disappear following bronchodilator use. 
In surveys, only a single spirometric measure is possible, or at most, as in the BOLD 
methodology, a pre- and post-bronchodilator value. Clinical studies have demonstrated 
that such single assessments are likely to underestimate asthma, since only a little 
over half of asthmatic patients demonstrate reversible airflow obstruction at any single 
assessment.s This may be because their airflow limitation is mild and intermittent, or 
because they are receiving effective controller therapy (like inhaled corticosteroids), or 
because they have recently taken a bronchodilator. 
Respiratory symptoms caused by non obstructive lung disease and other organ 
systems 
Although in epidemiological studies, all chronic cough, sputum, wheeze and dyspnoea 
is assumed to be caused by obstructive lung disease, there are many other causes that 
need to be considered, particularly in communities with high levels of pulmonary co-
morbidity like tuberculosis and pneumonia. For example, although bronchiectasis is a 
rare cause of cough in developed countries, it is a common consequence of pulmonary 
tuberculosis, measles and other forms of viral and post-viral infections in poor 
communities, and bears a strong relationship with socio-economic status. Furthermore, 











turn reflects access to care, more likely to be deficient in poor communities. Thus, while 
this cause of cough can be largely disregarded in developed countries, it should at 
least be considered in low-income communities. 
Other pulmonary causes of respiratory symptoms include rare diseases like sarcoidosis 
and other interstitial lung diseases, bronchiolitis obliterans, allergic bronchopulmonary 
aspergillosis, endobronchial tumours or cysts, Churg-Strauss syndrome and chronic 
eosinophilic pneumonia among many others.9 The prevalence of these disease entities 
is very low in comparison to that of obstructive lung disease, and likely to be constant 
across survey areas (when comparing one community with another). Misclassification 
of these diseases, which is almost inevitable with the limited screening involved in 
prevalence surveys, has little practical significance, and a trivial effect on the 
assessment of risk factors for pulmonary disease. 
Upper airway causes of respiratory symptoms include post nasal drip, congenital 
anomalies, infections, post traumatic injury, foreign bodies, vocal cord paralysis and 
extrinsic compression by tumours or inflammatory masses.9 Furthermore, left 
ventricular failure caused by valvular heart disease, cardiomyopathy, congenital heart 
disease and other cardiac disease may result in intermittent or persistent cough and 
even wheeze. Because Ravensmead and Uitsig appear to have a high prevalence of 
ischaemic heart disease, this cause may be significant in the over 40 year age group. 
For this reason, adjustment for diagnosed heart disease was made in multivariate 
analysis of risk factors for all associated symptom outcomes, i.e. cough, wheeze and 
dyspnoea. Known common gastrointestinal causes of respiratory symptoms include 
gastro-oesophageal reflux, oesophageal spasm and chronic gastric aspiration. These 
were not considered in the current surveys. 
8.2.5. Questionnaires 
The LHS2002 and the BOLD study questionnaires included questions that have been 
validated in other studies elsewhere in the world. The translation into Afrikaans, the 
language of the community studied, might have introduced a bias resulting from 
differences in language usage or interpretation. The BOLD study questionnaire went 
through a stringent forward and back translation process by language specialists in 
order to minimise this bias. During analysis, differences were noted in the reporting of 
"cough" and "phlegm", in keeping with prior knowledge of language usage by 











phrasing or local word use in a questionnaire can have a significant effect on 
prevalence estimates. 1o Many persons who denied cough reported phlegm production, 
not necessarily linking the two processes to each other. The original MRC questions 
using the term "bring up phlegm" was used instead of "cough up phlegm", which was 
appropriate in this setting because of local Afrikaans word usage. Importantly, the term 
used in Afrikaans is different to that used for vomiting because "bring up" in South 
African English usage can be used to describe vomiting in certain local contexts. 
Ethnic differences in word descriptors used during bronchoconstriction have been 
described elsewhere 11, and similarly, differences in terminology for respiratory 
symptoms exist within different South African ethnic groups. Several other questions in 
the LHS2002 questionnaire were new, and developed for the study. These included 
questions relating to cannabis smoking and tuberculosis risk factors. The validity of 
some of the questions will be considered with the results of spirometry in a separate 
study, and are not presented here. Both the LHS2002 questionnaire and the BOLD 
questionnaire have the potential to be translated into the other national languages and 
be used in other parts of South Africa to assess lung health. 
8.2.6. Spirometry as an outcome measure 
Using measurements such as FEV1 and FVC as a surrogate marker for severity of 
parenchymal damage and lung function, has been criticised owing to the fact that they 
are difficult manoeuvres that are highly effort dependent. 12 In addition they require very 
well trained technologists/healthcare workers for performance and quality control in 
order to be valid (of which there are very few in South Africa). The BOLD study 
employed a limited number of well-trained technologists and nurses in order to 
minimise inter-observer bias, and followed ATS recommendations for the performance 
of tests. The ndd Easyone® spirometer was well suited for a field study owing to its 
light robust design, accurate measurements and ability to be used in non- temperature 
and pressure controlled circumstances. In addition, its feedback system allowed for 
immediate identification of performance errors, accompanied by simple advice to 
correct the manoeuvre e.g. "don't hesitate", "blow <six seconds" etc. 
It has been suggested that a more moderated manoeuvre such as the slow vital 
capacity may be a better indicator than a maximal effort manoeuvre. 12 However, even 
though the reproducibility of a slow vital capacity manoeuvre is better than that of the 











(2003) described FEV1 as problematic because the standard deviation of repeated 
measurements of FEV1 is larger than the annual decline in FEV1, even in heavy 
smokers. 13 However, Enright et al (2004) emphasize that in large-scale studies, 90% of 
persons perform FEV1 with a limit of variation of 120ml.
14 
Other tests can be used to improve the precision of the diagnosis of COPD. These 
include more challenging lung function tests like the single breath CO diffusion capacity 
test, studies of lung compliance, and high resolution CT scans. 12 However, such 
methods are expensive, and not practical for community surveys, presenting problems 
in that they cannot be performed in the field. In addition, some procedures, like CT 
scanning, involve exposures that may not be acceptable for community-wide 
screening. Response rates for off-site tests in surveys are also significantly lower. For 
example, in the LHS2002, all participants were invited to present for a chest 
radiograph. In spite of provision of transport and the favourable location of the 
Radiograph site less than 1-2km from their homes, the response rate was only 75%. 
The GOLD staging of severity of COPD using FEV1 has been criticised as empiric and 
non-informative. However, it has recently been shown to perform well in a large study 
performed in the USA, the Atherosclerosis Risk in Communities (ARIC) study.15 In this 
eleven year cohort of persons aged 43- 66 at baseline, there was a clear increase in 
risk of increasing mortality from GOLD stages 0 to 4 (Hazard ratio 1.4 to 5.7). The 
presence and severity of respiratory symptoms were shown to also predict mortality. 
The GOLD classification uses postbronchodilator FEV" raising concerns that the use 
of prebronchodilator measurements by some studies could lead to over estimation of 
the prevalence and severity of disease. 16 Postbronchodilator measurements reduce 
(but do not eliminate) misclassification of asthma and there is some evidence to 
suggest that postbronchodilator FEV1/FVC ratio is a better indicator of COPD than 
other measurements. Currently, reference values for prebronchodilator measurements 
are used for postbronchodilator results, a practice that may result in underestimation of 
disease severity. A first attempt at deriving postbronchodilator reference values has 
recently been published by Johannessen et al. 17 There has also been recent interest in 
FEV6 and FEV1/ FEV(3 as a surrogate for FVC and FEV1/FVC respectively, in order to 











8.3. DISCUSSION OF MAIN RESULTS 
8.3.1. The Lung Health Survey 2002: Prevalence of Respiratory Symptoms 
( ~5years) 
Overall, 38.3% of the population reported the presence of at least one respiratory 
symptom, which is in keeping with high symptom prevalences found in other parts of 
the world such as Italy, Estonia, Sweden and Finland.2o 21 Usual winter morning 
phlegm was the most commonly reported symptom (25.3%), followed by recent cough 
(19.5%), wheeze (12.9%) and dyspnoea grade 1 or higher (12.7%). Over seven 
percent of the population experienced night waking from dyspnoea or a tight chest in 
the last year, which suggested moderate to severe disease. 
A significant proportion (18.2%) of persons aged ~ 40 had grade 2 (or higher) 
dyspnoea. For the whole adult population :2':15 years or above this figure was 10.3%. 
This is a very high prevalence of breathlessness for the whole population, and, if 
correct, is likely to impact significantly upon productivity and activities of daily living. Its 
correlation with other symptoms and with spirometry in the BOLD study suggests that 
this is a valid observation. 
A high prevalence (18.3%) of rhinitis symptoms was recorded, with men reporting 
significantly higher symptom prevalence in the last 12 months than women, possibly 
pointing to high levels of atopy in this community and/or greater exposure to 
occupational irritants (general dusts) or non-specific causes of rhinitis. Wheeze, chronic 
bronchitis and general dusts were significantly associated in the adjusted analysis of 
rhinitis (not presented). 
Of the doctor-diagnosed respiratory conditions, asthma was the most commonly 
diagnosed obstructive lung disease (7%) followed by chronic bronchitis/ernphysema 
(5.5%). However the problems associated with these diagnoses have been noted 
above. 
8.3.2. Chronic bronchitis vs. COPO 
The prevalence of chronic bronchitis in this population was higher than the national 
average prevalence and increased with age. Prevalence was higher in men than in 











reported rates of smoking in these groups. However, a surprise finding was that, 
despite a higher prevalence of smoking in men, the prevalence of physician-diagnosed 
chronic bronchitis in women was higher. This requires further consideration. Gender 
differences in prevalence of chronic bronchitis and emphysema have been reported 
previously.22 Firstly, both chronic bronchitis and COPD are caused by cigarette smoke, 
and they may occur together or one without the other. Alternatively, cough and phlegm 
may, and often does, precede the development of airflow obstruction. Secondly, 
symptoms of chronic bronchitis, although well defined, are not specific, and similar 
symptoms may result from asthma (which is more common in adult women than men), 
heart failure, or simply reflect the greater tendency of women to report symptoms. 
This variable association between chronic bronchitis and COPD is evident in the results 
of the BOLD study. In persons with chronic bronchitis aged ~O years (British IVIRC 
question from BOLD study), half (49.8%) had COPD. Conversely, just under a quarter 
(22.1 %) with CO PO reported symptoms of chronic bronchitis. Although this figure 
appears low, as reflected in Table 81, almost 60% of patients had chronic sputum 
production ('usual phlegm') 
Usual phlegm was a more common symptom in those with COPD than the MRC 
definition of chronic bronchitis, which could signify less symptomatic disease or 
underestimation of symptoms. Of all persons with COPD ~O years, half reported usual 
phlegm in the absence of a cold (51.9%) and this prevalence was even higher for those 
with Stage II and higher disease (58.2%). Both these figures are similar to that 
recorded from other countries. For example results from Brazil show that 7.8% of 
2'3 persons reported chronic bronchitis and 15.2% had COPD .. 
A subgroup analysis of the prevalence of symptoms in persons with no COPD, GOLD 
Stage I and Stage II COPD is presented in Table 81 suggesting the unreliability of 
symptoms in indicating the presence of clinically significant COPD (Stage II). 
Table 82 indicates the frequency of COPD in subgroups of symptomatic individuals, 












Table 81 The frequency of respiratory symptoms, doctor-diagnosed disease and treatment 
in participants with COPD vs. those with no COPD * 
% with usual phlegm 
% with chronic cough** 
% with chronic phlegm 
% with chronic bronchitis*** 
% with wheeze 
% with wheeze +dyspnoea 
% with dyspnoea grade 2+ 
% with diagnosed CB 
lem physema/COPD 
% with diagnosed asthma 
% on any treatment in last 12 
months 
---.--~~~--.. ---".- -----"""-- _ ... _----. 
Subgroup Subgroup with GOLD Subgroup with 
with no Stage I or higher GOLD Stage II or 


































* questionnaire responses from the BOLD study; ** most days, 3 months per year***British MRC definition 
of chronic bronchitis 
Table 82: The frequency of CO PO in persons with respiratory symptoms, doctor-
diagnosed disease and those on treatment in persons aged ;,40 years * 
::-:--:=--=-- - ---------------------~----------
% with no % with GOLD Stage I % with GOLD Stage 
COPD or higher COPD II or higher COPD 
-c-------:c----,----------------- ----------------------------------------~--------------- ---------------- ------
Usual phlegm n=261 61.6 38.4 34.5 
Chronic cough n= 98 51.9 48.1 46.6 
Chronic phlegm **n=117 56.3 43.7 40.7 
Chronic bronchitis*** n=100 50.3 49.8 48.0 
Wheeze n=235 62.8 37.2 32.9 
Wheeze +dyspnoea n=145 53.0 47.0 44.2 
Dyspnoea grade 2+ n=138 62.4 37.6 33.2 
Diagnosed CB 49 51.0 44.7 
lemphysema/COPD n=63 
Diagnosed asthma n=123 59.7 40.3 36.4 
Any treatment in last 12 47.7 52.3 46.3 
months n=82 
-----.---~-- .----~---~.------ ------._- ~----- -------------_._------ ------------------------- ... -0_----- _~ ___ 
* questionnaire responses from the BOLD study; ** most days, 3 months per year***British MRC definition 











8.3.3. Healthcare utilisation 
Under recognition 
The results of the LHS2002 confirm the suspicion that symptomatic obstructive lung 
disease is underrecognised in the community. Of all persons reporting one or more 
current respiratory symptoms, only 13.1 % had ever been diagnosed by a healthcare 
practitioner to have asthma, and 1.7% chronic bronchitis/emphysema. The remainder 
had either not presented for diagnosis or had not been offered a diagnosis. This result 
is consistent with that of Bheekie et al (1998) in a study of asthma in a low-to middle 
income area of Cape Town.24 
Failure to present for care is a significant reason for undiagnosed respiratory disease, 
as, particularly for chronic symptoms, patients accept the presence of respiratory 
symptoms, particularly if they are smokers, and view a smoker's cough as normal.25 In 
clinical practice, patients often deny respiratory symptoms and upon further probing 
refer to a "normal cough", some feeling that their symptoms warrant neither reporting 
nor treatment. 
Not surprisingly, many persons (57%) with documented airflow limitation (GOLD Stage 
I and higher) had no reported diagnosis of any obstructive lung disease, similar to 
findings from the NHANES III study.26 
This pattern of underdiagnosis of respiratory disease is documented in a study of 
children in Cape Town which showed that the parents of 53% of children with current 
asthma symptoms acknowledged that their children had ever had asthma and 37% 
acknowledged that they had current asthma.27 Only 23% of the recognised group were 
on daily treatment compared with 3% in the unrecognised group. Current treatment 
was associated with having private medical insurance and higher socioeconomic 
status. Although current guidelines suggest inhaled long acting beta agonists in certain 
cases, they are of little practical use to the public sector where these drugs are not 
available28 , and even in the private sector where middle income earners would not be 
able to afford them easily.33 
Van Schalkwyk et al studied asthma in the LHS2002 sample of 2422 people, aged 20-
44 years. 79 Twelve percent of those persons with doctor-diagnosed asthma displayed 
non-reversible obstruction, as did 13% of those with asthma-like symptoms, compared 











due to airway remodelling, or probable COPO, which was suspected to manifest at an 
earlier age in this population, owing to high cumulative exposures, particularly smoking. 
There was also a high prevalence of AHR, with 23% of asymptomatic persons with no 
previous diagnoses testing positive to a methacholine challenge test. The reasons for 
this could be related to the high prevalence of smoking and tuberculosis, the former 
being known to be associated with AHR. 
Undertreatment 
Of all persons with doctor-diagnosed asthma, less than a half (48.2%) reported having 
received current treatment for asthma, suggesting undertreatment in many. However, 
since the indication for treatment is different for asthma and COPO, this must be 
considered according to diagnosis. In persons who reported doctor-diagnosed chronic 
bronchitis/emphysema, only 12.1% were on current treatment at the time of the study. 
Curiously, only 33% of persons who were on current treatment for chronic 
bronchitis/emphysema reported a doctor diagnosis. It is not possible to determine 
whether in the 67%, the patients were thought to have this diagnosis and simply not 
informed of this fact. Alternatively, since the treatment of asthma is similar to that for 
COPO, some of these might have been misdiagnosed or undiagnosed asthmatics. In 
either event, it points to the apparently imprecise diagnosis of respiratory symptoms in 
the health facilities and/or by private practitioners who serve these study areas, and/or 
unreliability of these questions in this setting. 
This difference in treated proportions of asthma and COPO probably reflects not only 
the diagnostic difficulties of diagnosing the latter in primary care and without 
spirometry, but also uncertainty about appropriate treatment for this condition and 
when to commence it. However, a proportion of those not treated, would have had 
chronic bronchitis for wrlich no specific therapy is indicated, and where the emphasis in 
primary care is simply to stop smoking. Not surprisingly, only 22.5% of those 
participants with GOLO Stage II or higher COPO were receiving any form of treatment. 
Seven percent of the population reported requiring emergency care in a hospital 
emergency department in the last 12 months due to lung disease. This is a significant 
proportion of the general population, indicating uncontrolled and or severe lung disease 
in this community, and may indicate problems of access to care, misdiagnosis, 
unavailability of medication and poor adherence to therapy or comorbidity. Studies of 











diseases, including problems relating to health services and others that are associated 
with poverty. Health services-related problems include poor access (e.g. lack of 
transport especially in older adults), a preference for oral treatment,3D unwillingness of 
the doctor and patient to label disease and inadequate follow-up.33 Even in low income 
areas a combination of private practitioners and the teaching hospital (tertiary referral 
centre) was chosen in preference to local day hospitals.31 Ehrlich et al (1998) found 
that only 23% of the recognised asthmatic children were on daily treatment compared 
with 3% of their unrecognised counterparts. 27 Current treatment was associated with 
having private medical insurance and higher socioeconomic status. These 
observations are probably relevant to COPD as well. 
Moosa et al (1996) have documented a local perception that inhalers are "addictive or 
weaken the heart',3o 33, which could account for decreased compliance which was 
reported in another local study by Jones et al. 32 The latter study also documented that 
parents reported poor levels of service by doctors and public sector clinics, concluding 
that there was an urgent need to improve public sector asthma care and patient 
education, a sentiment that can be echoed for adult COPD. In addition, prescribers 
may have a preference for "broad spectrum" symptomatic treatment in addition to 
syrups being cheaper per unit purchase.33 Evidence for this practice was also found in 
the SADHS where only 15% of patients used inhaled corticosteroids and 15% used 
inhaled beta agonists, with larger proportions using oral xanthines and adrenergics (39 
and 28% respectively), while the rest did not report any regular treatment. This group 
included patients with "asthma and chronic bronchitis".39 
8.3.4. The BOLD study (~40years): Prevalence of capo 
The prevalence of COPD (GOLD Stage I or greater of 24% overall, 29% in men and 
20% in women) in persons aged ~40 years in Ravensmead and Uitsig is amongst the 
highest reported in a community study to date (see Chapter 2, Table 3). Amongst men, 
the next highest figures from surveys employing the similar methods are from Finland 
(22%) and Japan (16.4%)? 35 Even more striking was the very high prevalence in 
women (20%) for which there were no comparable estimates in the published literature. 












The prevalence of GOLD Stage II or higher COPD is also very high - 19% overall 
using the NHANES III equations and 15% using locally derived prediction equations, 
indicating that most affected participants have moderate to severe disease. These high 
rates may reflect the high prevalence of smoking in the study population; current 
smoking, 56.9% in men and 40.6% in women, and ever smoking, 83% in men and 59% 
in women. 
Prevalence of COPD in women over 70 appears to be relatively higher than in men 
using the NHANES equations. Prediction equations do not perform well in persons over 
the age of 70 years because using a fixed ratio (FEV,/FVC) to define airway 
obstruction overestimates COPD in this age-group. I' It might also be a healthy survivor 
effect as fewer males were represented in this age group, which may mean that males 
with COPD and other health effects of their smoking had resulted in their premature 
death, whereas in women, less and lighter smoking had allowed better survival with the 
burden of COPD occurring in a later decade of life. In addition these local equations 
are unreliable due to a number of factors. 
8.3.4.1. Local equations vs. NHANES equations 
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Figure 28: Estimated Population Prevalence of GOLD Stage II or higher COPD by age -











Estimates of the prevalence of COPD are influenced by the prediction equations that 
are applied to the results. As can be seen from Figure 8.1, the prevalence is higher 
when the NHANES prediction equations are used. Although it can be argued that local 
prediction equations, that is, equations derived from the study sample and then applied 
to the whole population to detect those with disease, might appear more appropriate, 
there are problems with this approach. 36 Firstly, since the majority of both men and 
women have smoked, and have a high prevalence of respiratory symptoms and co-
morbid respiratory disease, equations are based on small numbers of non smokers 
with no history of respiratory disease. 
An alternative approach is to use predicted equations from 'healthier' or less affected 
communities in South Africa of the same ethnic group. However, ethnically-determined 
predicted values for lung function are thought to be flawed by the close association of 
ethnicity with socioeconomic status. Studies by Goldin et al have considered ethnicity 
in South Africa to be a surrogate for socio-economic status, and suggest that the same 
prediction equations should be applied to all South Africans; supporting the hypothesis 
that "race" is not a direct genetic predictor of lung size. 37 This is the approach used in 
the SADHS survey.39 Differences in poor communities related to influences dating back 
to intrauterine conditions (e.g. poor nutrition, and maternal smoking affecting lung 
growth and development) and those associated with poverty that extend into old age 
(e.g. continuing smoking, repeated respiratory infections, air pollution) need to be 
considered. An additional consideration is that residents of the study area are almost 
entirely of mixed ethnicity, and Caucasian predicted values are applied in clinical 
practice, presumably because other South African local equations are based on groups 
with Nguni or Sotho lineage, (but there is no evidence for this assumption). In a study 
of this nature, where the interest is in studying risk factors, it is more appropriate that 
equations be used that correctly identify the affected individuals, so that the effect of 
exposures can be quantified. In this circumstance, it can be argued that the NHANES 
III equations, even though they were derived from a white U.S. population, are 











8.4. Evaluation of Risk factors in the LHS2002 and BOLD studies 
8.4.1. Tobacco Smoking 
Prevalence and pattern of exposure 
Prevalence of current smoking was very high among both men and women (59.1 vs. 
43%) with the majority smoking between 1-14 cigarettes per day (light to moderate). 
Lifetime prevalence of ever smoking in both sexes is extremely high, compared with 
other countries, particularly amongst women (67.1 vs. 50.4%) and even higher in the ~ 
40 year age group (83 vs. 59%). Most women smokers smoked between 1-10 
cigarettes per day, the largest number fewer than 5 per day. 
These results contrast with the smoking patterns in most developing countries, where 
women generally smoke less than men. However smoking in urban areas is fast 
growing worldwide, for example in China (78 in men vs. 35% in women).3B Data from 
South Africa also shows that this difference usually less pronounced in urban than in 
rural areas. 39 However, the causes of the pattern of smoking amongst women in this 
study can be interpreted to some extent by the nature and history of the community. 
Firstly, it is a population in economic transition which, although poor, has some 
disposable income. Secondly, it has adopted urban habits, with restricted options for 
recreation. Thirdly, alcohol abuse is prevalent, dating back to the 'dop' system amongst 
farm workers, who received a daily ration of cheap wine, and often also cigarettes, as 
part payment for their labour. Smoking thus became entrenched as a social norm in 
both men and women. Finally, amongst women the pattern of smoking is light, 
suggesting that smoking is a social release. Most employed women work in factories 
where smoking is the norm during tea and lunch breaks. They may smoke to relieve 
the boredom, or because all their peers and friends do, and they smoke less in their 
homes. The majority of participants continue to smoke, as evidenced by the relatively 
small number of ex-smokers (7.6%), confirming both the addictive qualities of nicotine 
and the entrenched social acceptability of smoking. Smoking is still widely considered 
to be a socially acceptable practice, especially in the Western and l\Jorthern Cape 
Provinces, and equally amongst men and women. 
The ratio of current to never smokers was lowest in the>65 age group. The lower 
prevalence of smoking in the older age groups could signify a healthy non-smoker 
survivor effect (most likely). Alternatively, higher quit rates with increasing age, or 











have started smoking (the 1940's) did not encourage smoking. However, the latter is 
not likely (at least not for men) when one considers the prevalence of ever smoking. 
The trend for the proportion of smokers to decrease after the age of 40 is present in the 
study sample, but is not as marked as in other developed countries like Sweden.·10 Men 
tended to be heavier smokers than women, with more men reporting a history of more 
than 20 pack years, similar to other countries such as Estonia. 41 Also contributing to 
cumulative exposure is an early median age of onset of smoking of 16 years of age 
which is concerning considering that lung growth is still in progress at this age. 
Although tobacco usage has decreased overall in South Africa, it is clear that in the two 
years between the two studies, current smoking prevalence did not change in this 
population. 
Relationship between tobacco smoking and respiratory symptoms 
As expected, cigarette smoking is strongly associated with all measured respiratory 
symptoms (chronic bronchitis, cough, wheeze and dyspnoea) in a dose-dependent 
manner with odds ratios between two and three Of concern is the high prevalence of 
smoking in the young with early onset, especially in women. It is acknowledged that 
some of these symptoms may be due to a diagnosis of asthma which is adjusted for in 
the multiple logistic regression analysis. 
Cigarette smoking resulted in a two to three fold increased risk for chronic bronchitis 
after adjustment for other factors. Former smoking was not associated with the 
presence of chronic bronchitis, in keeping with a median quit age of 35 years, 
suggesting lower cumulative exposure in ex-smokers as a result of fewer years of 
smoking and perhaps also fewer cigarettes per day in this group, or a reversible effect. 
Although exclusive use of a pipe rather than cigarettes was relatively rare, it was 
associated with the greatest risk of chronic bronchitis (OR 4.6, 95% CI: 1.9 - 10.7). 
This could possibly be the result of an absence of filtration, greater puff volume, 
different retention times, particle size or tar yield, but these have not been quantified or 
studied before, in relation to risk for chronic bronchitis or COPD. However, such factors 
have been postulated to be of relevance in cannabis smoking.42 
In keeping with other studies43 44, the analysis of smoking as a potential confounder of 
other associations, particularly that of cannabis use, odds ratios from 5 different 











commencement of smoking, current quantity and time since cessation in order to 
correct for 'residual confounding'. The odds ratios for all other risk factors did not vary 
significantly from the final model, confirming that the effect of smoking as a confounder 
was not significant, and that the associations of chronic bronchitis with other risk 
factors are robust. 
Pipe smoking was only significantly associated with wheeze in the last 12 months. Past 
smoking was not significantly associated with any respiratory symptoms, which is in 
keeping with a median quit age of 35 years, indicating that stopping smoking 
decreases risk to close to that of never smokers. 
Relationship between tobacco smoking and COPD in the ~O age group (as defined by 
GOLD) 
In contrast to estimates suggesting that 15% of smokers develop COPD4,,, 31 % of 
current smokers, and 29.3% of ever smokers in this population aged ~O years have 
developed GOLD Stage I or higher COPD - twice the prevalence suggested by Barnes 
et al (2000). The BOLD study showed a COPD prevalence of 51.6% in ever smokers 
aged ?l0 years, which compares favourably with the results of the study reported by 
Lundback et al in which COPD was found in 50% of 76 - 77 year old ever smokers. 46 
This finding suggests that, either half of ever smokers will develop COPD by age 70, or 
that the prediction equations for FEV1/FVC ratio and FEV1 for persons ?l0 years are 
not appropriate, as suggested b  Hardie et al. 11 As pack years increased, COPD 
prevalence increased to 41.9% in men smoking >20 pack years. A high prevalence of 
COPD was also noted in persons aged 40 - 49 years, suggesting that COPD may 
begin at an earlier age in this population. In addition, not all individuals with COPD 
follow the classic linear course suggested by Fletcher and Peto (1977). The high 
prevalence of COPD in this community suggests that a higher proportion of individuals 
may follow the course that describes a faster decline in lung function, or that they 
started off with a lower baseline lung function that could be related to socioeconomic 
deprivation. 
Environmental Tobacco Smoke (ETS) 
In Ravensmead and Uitsig, the exposure to environmental tobacco smoke in the home 
is high. Although only 9.3% of persons aged ~O years reported ETS exposure, the 
prevalence and pattern of exposure needs to be interpreted in the context of high rates 











mutually exclusive categories of smoke exposure had to be created, and thus former 
and current smokers were not included in the ETS group, even though they may have 
been exposed to ETS in addition to their current or past active exposure. In addition, 
there was no information available on those who were exposed in the workplace, which 
is a significant area of exposure shown to be associated with an increased risk of 
COPD,41 48 49 nor was an assessment made of environmental tobacco smoke exposure 
in places of recreation. The results of a study performed in Germany suggest that the 
risk of chronic bronchitis is increased three times by a daily exposure of more than 
eight hours.50 
Amongst men, a common past-time is alcohol (beer/low-quality wine) consumption in 
informal taverns (shebeens), which are often shacks/houses with little or no ventilation, 
and where smoke exposure is intense. In separate studies performed in the 
Ravensmead/Uitsig area, these social exposures in this setting have been associated 
with increased transmission of tuberculosis, presumably due to tuberculosis contacts in 
this setting.51 The effect on the development of respiratory symptoms and disease from 
tobacco and cannabis exposure may be an additional factor and requires further study. 
In the LHS2002, more non-smoking women than men reported passive exposure to 
cigarette smoke (13.5 vs. 2.2%), but these figures need to be viewed against the higher 
smoking prevalence in men. Becklake and Kauffmann (1994) have suggested that 
women may be more susceptible to the effects of tobacco smoke.52 Exposure to ETS 
contributes to the greater prevalence of respiratory symptoms in non-smokers, 
especially amongst non-smoking women. 53 In Ravensmead and Uitsig, overcrowding in 
small volume houses or flats is common, suggesting that if even one of the family 
members smoked, the rest of the inhabitants are exposed to a considerable amount of 
ETS. 1\10 conclusions can be drawn from the BOLD data on ETS exposure in persons 
~O years as there were only 9 persons with Stage I or higher COPD who had 
exclusive ETS exposure (owing to the high prevalence of current and ex smokers, 
which have been considered to be mutually exclusive from passive smokers). 
8.4.2. Smoking of cannabis 
Prevalence and pattern of exposure 
Twenty three percent of men in the LHS2002 reported ever smoking cannabis and 











percent) reported current use, confirming the status of regular cannabis use in this 
community, as an acceptable lifelong habit rather than an experimental phenomenon 
amongst adolescents and young adults. This pattern indicates that cannabis smoking 
in this community is not the domain of younger adults, as it is in many first world 
countries. Secondly, a link between tobacco and cannabis use is evident. The median 
age of onset of cannabis smoking is only one year later than that of cigarette smoking. 
This has implications for public health interventions - both need to be addressed 
simultaneously in the young. Thirdly, unlike tobacco smoking, it is uncommon amongst 
women. However, the illegal status of the drug poses a problem for the collection of 
accurate data, and can give rise to distorted prevalence figures (see Information Bias). 
Relationship between cannabis smoking and respiratory symptoms 
Cannabis emerged as one of the strongest predictors for chronic bronchitis, surpassing 
even tobacco smoking in strength of association with odds ratios ranging from 3.5 
(95% CI 2.3 - 5.4) for ex smokers to 7.4 (95% CI 4.0 - 13.6) for heavy smokers. To our 
knowledge, this is the first study in Africa to evaluate cannabis use at a population level 
in the context of respiratory disease. A study from Tucson, Arizona reported more 
coughing, phlegm production and wheeze in cannabis smokers aged less than 40 
years, irrespective of whether they also smoked tobacco. 54 Non- tobacco smoking had 
a larger effect on respiratory function than tobacco smoking alone, and the effect of 
both types of smoking was additive. Sherrill (1991) and Tashkin (1997) both showed 
that long-term cannabis smoking increased bronchitic symptoms. 55 42 54 
Even in young adults, it has been shown that cannabis use is associated in a dose 
dependent manner with decline in FEV,/FVC ratio, and that it is additive with tobacco in 
its effect on lung function.56 Our findings suggest that the respiratory risks of long term 
cannabis smoking are independent of tobacco smoking. This has important public 
health implications as there currently appears to be little awareness of the prevalence 
of use and respiratory effects of cannabis. In fact, a common perception of users and 
the lay public is that it is safe, and instead, its marginal bronchodilator effects in asthma 
are cited as evidence that it is "good for the lungs".51 This view has been promoted in 
lay publications. 58 Clearly this situation requires the attention of those involved in 
smoking cessation initiatives. 
Cannabis smoking was also significantly associated with an increased risk for wheeze 











recent cough, in a dose dependent manner. However, cannabis pipe smoking was only 
significantly associated with recent cough. Unlike cigarette smoking, past cannabis 
smoking was significantly associated with all of the above symptoms, suggesting that 
stopping smoking does not decrease risk, despite the median age of quitting being only 
25 years (compared to 35 years for tobacco smokers). The strength of these 
relationships with respiratory symptoms may be influenced by underreporting of 
cannabis use due to its illegal status. In spite of this, almost 20% (PAF) of chronic 
bronchitis in this community is attributable to cannabis smoking. 
Relationship between cannabis smoking and COPD (as defined by GOLD) 
More than one third (39.1 %) of all ever cannabis smokers were shown to have Stage I 
COPD. However, like Tashkin et al (1997)42, owing to the small sample size of 
cannabis smokers and possible confounding with tobacco smoke, an association 
between cannabis smoking with COPD could not be confirmed. However, univariable 
analysis showed a positive association with ever smoking cannabis and GOLD Stage I 
and higher COPD (OR 2.1; 95% CI: 1.2 - 3.7), for which there were significant sample 
numbers (64 persons with the exposure and 25 of these with the outcome of COPD). 
Multivariable analysis showed no association of ever smoking cannabis and either 
GOLD Stage I and higher or GOLD Stage II and higher (NHANES). This does not 
exclude the possibility of a positive relationship, as there was a trend toward heavier 
cannabis smokers being at a significantly higher risk than former or current "light" 
smokers, but the numbers in these categories were too small to confirm these 
associations. Studies that include sufficient numbers of heavy cannabis smokers are 
needed to examine this relationship appropriately, as these findings could have public 
health significance in terms of smoking cessation. However, the current evidence is 
sufficient to consider cannabis as a likely contributory, if not sufficient cause, both of 
chronic respiratory symptoms and COPD. In view of its common use in South Africa, 
this should be the topic of further focussed research. 
8.4.3. Previous TB 
Prevalence and pattern of exposure 
South Africa was ranked 8th in the world for the total number of TB cases per country 
and tenth in the world for incidence rates per population in 2003. 59 xiv The incidence of 
T8 in the Western Cape Province is the highest in the countrlO and in Cape Town in 
2002, the notification rate was 266 per 100,000.61 In Ravensmead and Uitsig, the 











100,000 in 1994 to 299 per 100,000 in 1998 and 341 per 100,000 in 2002.62 63 xvi The 
LHS2002 reported the prevalence of tuberculosis in the study area to be very high at 
10 per 1,000 (95% CI: 6.2 - 13.8 per 1000).Xiv A history of previous doctor-diagnosed 
TB was reported by 9.7% of adults aged ~ 5 years and with significantly more men 
reporting past TB than women (12 vs. 8%; p<0.001). Persons aged ~O years had a 
higher prevalence of past TB of 15.1% (19.7 in men vs. 12.4% in women; p=0.006). 
Moreover, 12.9% of the population had chest radiograph evidence that was consistent 
with tuberculosis, possibly suggesting some proportion of undiagnosed disease. 
The most concerning issue in Ravensmead and Uitsig is that previously treated smear-
positive TB cases form more than half of the prevalent smear-positive cases, which is 
considered to be reinfection rather than reactivation.64 65 A discussion of this work and 
the reasons for high rates of transmission in the community are beyond the scope of 
this report. However, the impact of TB upon lung health and its association with 
obstructive/other forms of respiratory disease in adults is a particular focus of interest. 
Relationship between previous pulmonary tuberculosis and respiratory symptoms 
A history of tuberculosis was shown in the LHS2002 to be associated with twice the 
adjusted risk of wheeze, breathlessness with wheeze, dyspnoea of grade two or 
greater and recent COUgh. This strong and consistent adjusted association indicates 
that tuberculosis is an important cause of symptoms of airflow limitation. In the adjusted 
model for chronic bronchitis using the British MRC definition, the relationship was less 
strong (OR 1.5; 95% CI: 1.0 - 2.2). However, past TB was strongly associated with 
usual winter morning cough with phlegm. It is also possible that some individuals with 
airflow limitation have bronchiectasis related to childhood tuberculosis, but fulfil the 
definition for chronic bronchitis. Between 9 - 10 percent of current respiratory 
symptoms in this population can be attributed to past tuberculosis. 
Relationship between previous pulmonary tuberculosis and capo in the ?:lIO age 
group (as defined by GOLD) 
The major findings of the analysis were that almost half (49.2%) of all persons with past 
tuberculosis had GOLD Stage I and higher COPD, i.e. one in two past TB sufferers 
ends up with airflow limitation, and the vast majority of them have Stage II and higher 
xvi Den Bool1 S, van Lill SWP, Borgdorff MW, Enarson DA, Verver S, Bateman ED, Irusen E, Lombard CJ, White NW, 












COPD (42% of all past TB patients). One third (32.1 %) of all the persons with GOLD 
Stage I and higher COPD had a history of past TB. 
The association of GOLD Stage I and higher COPD and previous pulmonary TB was 
strong (OR 3.4; 95% CI: 2.1 - 5.6) and the association with GOLD Stage II and higher 
COPD much the same. Multinomial modelling showed that the combination of GOLD 
Stage I and II COPD (exclusively) resulted in an OR of 2.6 (95% CI: 1.5 - 4.6), 
confirming the significant risk of mild to moderate COPD. However, a nine fold increase 
in association of past TB was apparent with GOLD Stage III and IV exclusively (OR 
8.9; 95% CI: 4.2 - 18.9). These estimates, though based on relatively small numbers, 
are considered to be robust, owing to the large number of persons with the exposure 
within this group. Twenty eight out of the 53 persons (53%) with GOLD Stage III or IV 
COPD had a history of past TB, i.e. over half of the group. This can be compared to a 
parallel estimate for GOLD Stage I or II CO PO of one quarter of the group (25%) 
having a history of TB. After heavy smoking, past TB was found to have the strongest 
association with COPD. There was no significant interaction between TB and smoking 
but the effect of TB and smoking is additive in the "causation" of COPD. 
A quarter of all moderate to severe COPD in this population is attributable to past 
tuberculosis (PAF = 24.9%). This is possibly the first time that a population-based 
estimate of TB-attributable CO PO has been calculated. This finding raises the question 
as to whether CO PO associated with TB should be considered to be COPD or requires 
separate consideration as a special sub-group included in COPD classification 
systems. 
Firstly, the association of tuberculosis with COPD is not new, but has been studied by 
others who have described both obstructive and restrictive lung disease in hospital-
based and occupational cohorts. If this should not be called COPD, but post-
tuberculous obstructive lung disease, should all persons with a history of TB, even 
distant (such as in childhood) and uncomplicated, be ineligible for a diagnosis of 
COPD? While this would be reasonable as a means of excluding patients with obvious 
radiologically evident fibrosis and bronchiectasis, it would have two negative 
consequences: to exclude the many patients with trivial evidence of structural lung 
damage following tuberculosis, which is a majority of such patients; and to 
underestimate the effects of their concurrent smoking. In view of the high prevalence of 











developing TB, and/or of having more severe disease with worse outcomes, excluding 
TB as a co-morbidity of COPD (and vice versa), will diminish the impact and relevance 
of this association. In addition, the importance of smoking cessation for both the 
prevalence of COPD and tuberculosis could be inappropriately minimised. 
However, it might be argued that it is important to exclude patients with known TB, as 
the mechanism of airflow limitation is different in such patients and not likely to respond 
to the treatments available for smoking-related COPD. This pronouncement is 
premature since; firstly, the mechanisms of airflow limitation in tuberculosis are not 
known and have not been fully studied. Furthermore, they are likely to vary in different 
forms of pulmonary disease, and at different times in the course of disease. Thus 
during the active phase of bronchogenic spread, prebronchial and peribronchiolar 
inflammation and lymphoid tissue enlargement with various degrees of bronchial wall 
necrosis and ulceration are the likely causes. 
During healing, endobronchial and peribronchial fibrosis become likely mechanisms. In 
those in which there is extensive lobar destruction, cavitation and post-tuberculous 
bronchiectasis, airflow in affected areas is likely to be affected in an unpredictable 
manner, with obstruction, or even restriction being the consequences. However, when 
confined to one lobe or limited parts of upper lobes, damage to some bronchi or one or 
two segments is likely to have a limited effect on overall spirometric values, and the 
weight of evidence points to a more generalized distribution of pathology accounting for 
the airflow limitation. Such abnormality can best be localised on a high resolution CT 
scan where the relationship between airway damage and areas of emphysema and 
gas trapping can be examined. At least anecdotal evidence in South African clinical 
practice suggests that the majority of patients with significant airflow limitation have 
evidence of emphysema in areas not affected by tuberculosis, and secondly, it is 
thought that airflow obstruction is rare in patients with tuberculosis who have never 
smoked. No conclusions regarding this could be made from the BOLD study owing to 
small numbers of non smokers with past TB. There was, however, no significant 
interaction between past tuberculosis and smoking. 
Instead, the hypothesis to examine is whether the combined effects of smoking and 
tuberculosis promote more rapid progression of COPD in all regions of the lung 
including those not affected by TB. Regarding responsiveness to treatment of CO PO 











of 'pure' smoking-related disease. This needs to be carried out in prospective trials. 
However, again, anecdotal experience of clinicians practicing in this region, is that 
these patients while not demonstrating reversibility on spirometry, benefit from 
conventional guideline-based management of their airflow limitation, comprising 
sustained use of bronchodilators (especially long-acting bronchodilators), and in some, 
inhaled and even oral glucocorticosteroids. This requires further study. 
A high proportion of persons with GOLO Stage I or higher COPO (44%) had evidence 
of tuberculosis on chest radiograph supporting the aetiological role of tuberculosis by 
means other than self-reporting of disease. Sixty percent of persons with evidence of 
TB on the radiograph had GOLO Stage I or higher COPO, pointing to the high 
prevalence of COPO/airflow obstruction in those with previous TB. 
Even if participants with TB are excluded from the analysis, the proportion with COPO 
remains high (19.1 %). However, it is clear that past tuberculosis plays a significant role 
in the aetiology of COPO in the study population. 
Another possible confounder in this study is the possibility of HIV infection. HIV 
infection status was not tested in this study, but its influence is likely to have been small 
for several reasons. Firstly, HIV infection per se is not known to be associated with 
CO PO, and secondly the HIV infection rates in the study area are assumed to be lower 
than the overall suburb rate of 7.9% the year before the study (2001 ).56 Prevalence 
estimates for Cape Town cover a wide range with very high prevalence in some areas 
and much lower rates in others. Statistics are obtained from antenatal sampling and the 
rates are highest in this young sexually active group, rather than the ~O year age 
group surveyed here.57 
B.4.4. Occupational exposures 
Relationship between occupational exposures and respiratory symptoms 
General occupational exposure to dust gases, chemicals or fumes and or silica dust 
was common with 26% of the LHS2002 population reporting exposure. Men had a 
significantly greater prevalence of exposure (37 vs.18%; p<O.001). Independent of 
cigarette smoking, occupational exposures were associated with a two fold increased 
risk of chronic bronchitis. Weaker, but significant associations with wheeze and cough 
were observed. This could be due to the crude nature of the question, which can have 











information on length of exposure indicating that some persons with limited or 
questionable exposures were included in the exposed group. Other studies have 
shown the effects of occupational exposure and cigarette smoking to be additive.58 
Relationship between occupational exposures and COPD in the ?40 age group (as 
defined by GOLD) 
The BOLD study collected data on specific occupational exposures (35.4%) as well as 
general exposures (46.6%). Although general exposures were associated in a 
univariable analysis of GOLD Stage I and higher COPD, this association was not 
present after adjusting for other risk factors. Specific occupational exposures were 
grouped together such that a variable named "any specific occupational exposure" was 
created in order to have sufficient number of exposed persons with COPD, which 
probably diluted the effects. This limitation could mean that it is possible that one or 
more specific occupational exposures had a relationship with COPD, but there were 
not enough persons with the exposure with quality spirometry, or with COPD, in order 
to analyse further. No significant association could be detected between specific and 
general occupational exposures and COPD. However, apart from the small numbers in 
both studies, the questions on occupations and exposures were limited and so were 
prone to subjective assessments of an unpleasant or potentially harmful work 
exposure. Although such questions have been shown to be useful in large studies, 
especially within relatively homogeneous exposure environments (that is, when they 
are used to quantify exposure) rather than in mixed exposure environments where the 
relative hazard of different exposures is difficult to differentiate.69 
8.4.5. Air Pollution 
Indoor air pollution 
Relationship between air pollution and respiratory symptoms 
In the SADHS, indoor cooking in poorly ventilated homes was found to be associated 
with an increased prevalence of chronic bronchitis. This is attributable to the 
combustion products from biomass fuels used for cooking and heating. 70 African 
women in rural areas have been shown to have a higher prevalence of symptoms of 
airflow limitation than their urban counterparts, despite having lower rates of all forms 
of smoking. However, fewer than 2% of the LHS2002 population reported use of 
biomass fuels and over 95% of the homes have electricity. A limitation of the study was 











this exposure to analyse. In univariate analysis of the LHS2002 data, an association 











Relationship between indoor air pollution and COPD in the ~O age group (as defined 
by GOLD) 
In the BOLD study, domestic fuel exposure was not shown to be associated with 
COPD. However, bias owing to misclassification was likely. Fuel exposure in the 
"exposed" group was unlikely to have been of both significant duration and intensity, 
again diluting a possible effect. The definition of fuel exposure was insufficiently 
specific and therefore, as with questions on occupational dust exposure, results were 
likely to be biased towards the null. When a stricter definition was applied, there was 
insufficient power owing to small numbers. Most exposures were likely to have 
occurred in childhood in the older age groups. Thus, no conclusions regarding biomass 
fuel exposure are possible from this study. 
Outdoor Air pollution 
The questionnaire did not include a question on air pollution, as other standardised 
questions have demonstrated poor validity in population studies owing to their 
subjective nature. Air pollution levels for two neighbourhoods bordering the study have 
confirmed low to moderate median levels of PM 10 particles and other pollutants, but 
experience a pattern of frequent peaks of pollution exceeding the recommended 
levels. 71 Cape Town is known to be susceptible to "brown haze", a form of 
photochemical smog when conditions are still (see Chapter 3). This is generated from a 
number of sources including large busy motorways and the international airport nearby, 
and is dissipated at times by the strong winds that blowout to sea in either a south-
easterly or north-westerly direction. 
Although no comment can be made about the health effects of urban air pollution in the 
study site, chronic bronchitis and symptoms of emphysema have been associated in 
studies performed in other countries (NHANES, SAPALDIA etc).72 73 Lower lung 
function and a more rapid decline in lung function suggest that air pollution may be 
involved in the pathogenesis of COPD74, but evidence is less good for chronic effects 
than for acute. In addition, air pollution has also been suggested to be associated with 
increased morbidity and mortality from respiratory conditions and higher rates of 
hospitalisation or admission to emergency departments due to COPD on days with 
elevated pollution. 74 However, most recommendations are based on the incidence of 
cardiac death, as mortality from COPD has not been shown to be higher in polluted 
areas in the American Cancer Society study.75 There is little information from other 











8.4.6. Childhood chest illness 
Ten percent of the population (>15 years) reported a history of childhood chest illness 
with cough and breathlessness. Wheeze and wheeze with breathlessness were 
strongly associated with a history of childhood chest illness suggesting that symptoms 
begin in childhood, suggesting both asthma and in keeping with the hypothesis that 
childhood chest illness is associated with symptoms of airflow limitation in later life. A 
history of childhood chest disease was weakly associated with chronic bronchitis. The 
analysis was adjusted for doctor-diagnosed asthma. 
There were too few persons with a history of childhood chest illness in the BOLD 
sample to examine this relationship, the only question being on hospitalisation during 
cbildhood for respiratory disease. 
8.4.7. Socioeconomic status 
Income 
Eighty two percent of the population, more of them resident in Uitsig, were below the 
poverty line, earning less than R2000 per month. The unemployment rate was very 
high (57%) and only 19% of the total population reported that they were actively 
seeking work. The rest were not seeking work for a variety of reasons such as being 
homemakers, retired or disabled. Income is considered a proxy for socioeconomic 
status and despite problems with accuracy of reporting owing to the sensitive nature of 
the question, it is nonetheless a good indicator of socioeconomic status that has been 
used in other studies worldwide. However, the lack of variability in this predominantly 
low income area reduces the possibility of analysing the effects of income upon lung 
symptoms and disease. 
Despite the small range in income groups, the lowest income group of <R1000/month 
was strongly positively associated with the presence of chronic bronchitis and 
dyspnoea, but only marginally with wheeze. Independent of smoking, over one third of 
chronic broncrlitis (36%) and just under half of dyspnoea (47%) in this population were 
attributable to low income. Income was associated with CO PO in univariable analysis 
only. However, because of the time interval between the two studies, the data on 
income, which was obtained during the first study, may not represent household 












In keeping with findings from a national surve/o, there was a trend to increasing 
prevalence of respiratory symptoms with decreasing education levels. Lower levels of 
education were associated with dyspnoea and recent cough, but not with wheeze of 
chronic bronchitis. There was no association of low education levels with COPD in the 
BOLD study. Unlike other studies, there was also no statistical correlation between 
income and education in this population. Previous studies have shown that the 
incidences for all respiratory symptoms (including cough and phlegm) decreased with 
increasing educational level after adjusting for all other known exposures,76 and other 
studies have shown that higher educational levels are also associated with a 
decreased prevalence of smoking. 77 However, this is not true for the study population, 
where a high prevalence of smoking occurs among persons of all educational levels. 
8.4.8. Age 
Effects of age on prevalence and pattern of respiratory symptoms 
The prevalence of COPD was clearly age dependent, both the result of cumulative 
exposures (particularly cigarette smoking), and related to the use of a fixed ratio in the 
GOLD definition. In this population, the prevalence of Stage I and higher COPD ranged 
from 15% in the 40 - 49 year age group to 44.8% in the over 70 year age group. This 
contrasts with the nationwide NHANES III study from the United States that reported 
prevalences ranging from 7.3% in the 45 - 54 year age group to 22.9% in the 75 year 
age group.78 
In both the LHS2002 and BOLD studies, after the age of 35, increasing age was 
consistently associated with increasing prevalence of chronic bronchitis, wheeze in the 
last 12 months, wheeze with breathlessness, dyspnoea of grade 2 and higher. This 
increase represents a transition from symptoms attributable mainly to asthma in the 
earlier age groups to an increasing proportion of symptoms attributable to chronic 
bronchitis and COPD. 
In the LHS2002, women over 25 and men over 35 began to demonstrate an increased 
risk of symptoms of chronic bronchitis. This was followed by a steady increase in 
subsequent decades, suggesting that chronic bronchitis in these communities is 
developing at a younger age as reported in other studies79 39, and that women may be 
at greater risk at an earlier age. flO Apart from tobacco smoking, this could also be due 












Prevalence and pattern of exposure 
The study sample included many more women than men (a ratio of 5:3), and men were 
particularly under-represented in the older decades. This might represent the relative 
longevity of women and a survivor effect, in that there was a tailing off of subjects 
exposed to the most noxious influences in the highest age group, suggesting 
premature death of persons with these exposures. 
Relationship with respiratory symptoms 
The separate analysis of men and women was not pursued for two reasons. Firstly, it 
would have resulted in halving of the sample size, and secondly, it could not be clearly 
justified on the basis of non-significance of gender in the presented models. Views 
differ on this question. On the one hand performing gender specific analyses, may 
ascribe false associations by separating the sexes. On the other hand, a case can be 
made for presenting separate analyses for men and women based on the inherent 
physiological differences82 between the two sexes (host factor), which may affect the 
way in which environmental influences express their effects. Such differences in 
expression are thought to be obscured in analyses of the whole population. 
In these studies, no association of sex with chronic bronchitis was found. This is not 
surprising considering the high levels of exposure to tobacco smoking in both men and 
women. Wheeze in the last 12 months and wheeze with breathlessness were 
significantly associated with female sex and could be accounted for by the 
predominance of asthma in this group, particularly in younger women. Dyspnoea and 
recent cough were not significantly associated with sex. 
Relationship with COPD in the ?!10 age group (as defined by GOLD) 
Susceptibility of women to tobacco smoke resulting in a decreased FEV1 has been 
shown to be higher in other studies. 81 82 No association was observed between sex and 
the presence of COPD in either the univariable or multivariable analyses. The study 
does therefore not provide support for the hypothesis that women are more susceptible 
to the effects of tobacco smoke than men83 fl4, or that they are inclined to develop more 











On the contrary, the dose-response gradient of pack-years of cigarette smoking with 
COPD was less steep in women than in men, which, if anything suggests less 
susceptibility to the effects of cigarette smoke. However, this result should be 
interpreted with caution, as the patterns of exposure were very different between men 
and women. In women the majority were in the 0-10 pack year group and fell nearer 
the lower end of this category whereas the median in men tended towards the higher 
end of the category. Moreover, the distribution of smokers with COPD into the other 
pack-year categories was also different for men and women. Whereas approximately a 
quarter of women with COPD fell into each of the four pack year categories, just under 
one quarter of men had a 0 - 10 pack year history and approximately 40% had a 10 -
20 pack year history and 40% had a >20 pack year history (see Table 59). 
In South Africa, a respiratory survey of a black Johannesburg workforce showed 
bronchitic symptoms in men to be related to smoking and previous occupational 
exposure and in women to relate to smoking, even of low intensity.86 Occupational 
exposure appears to be more significant in women suggesting that women may be 
more susceptible to developing chronic bronchitis than men, or that their exposures are 
of a different type and/or intensity. Chen et al (2000) have indicated that an increased 
biological susceptibility to tobacco smoke among women could be an explanation for 
the significantly higher hospitalisation rate and the increasing COPD mortality rate for 
women. 87 The same could be true for occupational exposures, but this hypothesis is 
not supported by the LHS2002 or BOLD study. 
COPO in never smoking men and women 
A significant proportion of both men and women with COPD gave no history of 
smoking. For Stage I or higher COPD, these proportions of never smokers were 12.6 
vs. 4.6% for Stage I or higher and 8.2 vs. 3.1 % for Stage II or higher respectively. 
These differences between the prevalence in non-smoking women and men were only 
present when the NHANES prediction equations were used, but not with the local 
equations, indicating a potential masking of disease when local prediction equations 
from groups with high prevalence of exposures is used. The figure of 12.6% non-
smoking women having Stage I or higher COPD is slightly higher than the range 
reported from other series (5 -12 %)88. 
It is worth noting that women are more prone to other diseases that can affect 











respiratory symptoms. These included lung disease associated with autoimmune 
diseases like rheumatoid arthritis, systemic lupus erythematosis, and bronchiolitis 
obliterans. In other settings, but not in this study, biomass fuel exposure is a 
consideration. On the other hand, the low proportion of never smoking men with CO PO 
(4.6%) confirms that tobacco smoking remains the main risk factor for the development 
of COPO in men in this community. TB in non-smokers has been discussed earlier. 
8.4.10. BMI 
Prevalence and pattern of exposure 
Seventy one percent of women aged ~O years were either obese (45%) or overweight 
(26.1 %), which is a particularly high prevalence. This can be postulated to be partially 
due to ingestion of poor quality food (associated with poverty) and a sedentary lifestyle. 
The factors influencing body weight in women, many of whom are predominantly 
housebound and multiparous, are beyond the scope of this discussion but could have 
an impact on respiratory health in so far as the association of obesity with 
breathlessness and a restrictive abnormality in pulmonary function. The corresponding 
figures for men were 27.7% overweight, 17.4% obese and 10.6% of men underweight. 
Relationship with respiratory symptoms 
Underweight men had twice the risk of chronic bronchitis compared to those with 
normal weight, indicating that these persons may have concurrent COPO with systemic 
effects. A U-shaped distribution of BMI was noted in relation to wheeze, wheeze with 
breathlessness and dyspnoea but significant associations were seen only with obesity. 
This U-shaped distribution has been noted by others in relation to chronic respiratory 
disorders.B9 Being underweight was associated with cough and chronic bronchitis. 
Weight loss is a recognised complication of advanced CO PO and is attributed to the 
non-pulmonary effects of this disease. gO Weight loss is a feature of active tuberculosis 
and is usually temporary. However, in those that develop severe complications like 
bronchiectasis with chronic lung sepsis, this may be associated with persistent weight 
loss. 
Relationship with COPD in the ~O age group (as defined by GOLD) 
A strong association was observed between being underweight and COPO. It is 
assumed that the direction of effect is that COPO has caused weight loss. However, 
owing to the cross sectional nature of the study design, confirmation of the direction of 











past TB (19.4%), and a fifth of all those with a history of TB were underweight (21.4%) 
but there was no evidence of an interaction between BMI and past TB, confirming their 
independent associations with COPD. 
8.4.11. Other risk factors 
The high degree of variation in susceptibility to developing chronic bronchitis and 
COPD is not fully understood. Apart from alpha1- antitrypsin deficiency, other gene 
polymorphisms have shown associations, but results have been inconsistent in 
different populations.
g
! Such predilections have not been examined in the studies 
reported here. 
8.5. Implications for health in South Africa and future research 
Advocacy for COPO 
Adult obstructive lung disease, in particular COPD is a disease that deserves greater 
emphasis amongst health care providers and, in particular, from primary healthcare 
practitioners, and from those responsible for health promotion. The high prevalence 
and severity of disease demonstrated in the LHS2002 and BOLD study predict a heavy 
burden of morbidity and mortality in this community. Since the Ravensmead/Uitsig 
suburbs are probably representative of a large proportion of the South African 
population in terms of socioeconomic status, these findings have significant, if not 
alarming implications, which require further discussion and planning. 
Firstly, in the public health arena, COPD deserves a higher priority status than it 
currently enjoys.92 Although never prominent, it has lost ground in public and health 
planners' consciousness to the much more pressing problems of HIV/AIDS and 
tuberculosis. This may be attributed to several factors. Firstly, it is perceived as a 
condition affecting only older people, many of whom are not economically active. 
However, this deserves closer scrutiny in South Africa. The current studies confirm, not 
only a high prevalence, but evidence that the disease affects a significant proportion of 
people in their 40s and 50s, and even in their 30s when they are at the height of their 
working careers. Moreover, particularly in working class communities, older persons 
are the carers for small children of those that are fortunate enough to find work. Failure 
to make provision for the care of these patients with CO PO may result in their being 
unable to manage such responsibilities. With modern treatments, activities, freedom 
from exacerbations and quality of life is considerably improved. With good care which 











through a variety of measures and rehabilitation based on sound advice and a modest 
prescription of activities, patients have long survival and good functionality. This care is 
not currently available nor viewed as possible in community health facilities in South 
Africa. Instead, outdated attitudes persist, such as considering COPO as a self-inflicted 
disease that deserves less attention than other health needs.93 Under-recognition and 
undertreatment, as confirmed in this study is common. A mechanism for advocacy for 
patients with COPO is required in South Africa. 
Fortunately, at a global level there is an increasing interest and emphasis on improving 
the recognition of and quality of care offered to patients with COPO. Global initiatives, 
as described above include GOLD, the development of the BOLD methodology, and 
several other international initiatives. In l\IIarch 2006 the WHO launched the Global 
Alliance Against Chronic Respiratory Diseases (GARO) which has as its goals 
"increasing awareness of the importance of the burden of chronic respiratory disease 
(CRO)", which should be regarded as significant diseases and a serious global health 
problem by all. Included in the aims of this alliance are the fostering of country-focused 
initiatives for surveillance, prevention and control of chronic respiratory diseases; 
improving the quality and the affordability of care to patients with CRO in developing 
countries; improving the education and training of health care workers and personnel 
dealing with CRO; and integrating or coordinating initiatives that governmental and 
international nongovernmental organizations are currently undertaking in developing 
countries, thus avoiding duplication of efforts and wasting of resources." 
A particular concern is the global shift of these diseases to developing countries and in 
particular to those with an improving Gross National Product, and potential purchasing 
power for cigarettes. For COPO, the largest burden is now in low to middle income 
countries, like South East Asia and China.94 In South Africa, the government has made 
laudable strides in improving tobacco control by banning tobacco advertising and 
restricting smoking in public places, but it is clear that more action is required. 
Addressing smoking 
An encouraging feature of COPO is that it is a disease that is almost entirely 
preventable, and even achieving smoking cessation in patients with established 
disease improves health status and slows or arrests the rate of deterioration of COPO. 
The current research has contributed to this approach in several ways. It has confirmed 











for a majority of women with COPD. Smoking cessation is essential in those currently 
affected. Secondly there is a need for intensified effective and aggressive anti-
smoking-initiation interventions directed at primary, high schools and even tertiary 
institutions, as few people start smoking after age 19.95 Reviews of the effectiveness of 
such interventions have shown a reduction in smoking prevalence of between 5 and 
30%, and identify the social influence resistance model as the most effective. 96 
However there are concerns about the long-term effect of these interventions are that 
they have a limited period of effect96 , so they need to be part of a comprehensive 
approach to tobacco control which includes increased taxation, media campaigns, 
advertising restrictions and legislation. This could be the first step to empowering South 
Africans to make informed choices regarding smoking. It is a well known fact that 
changing established health-related behaviour in adulthood is a difficult task. 97 
Further research can contribute to this initiative. For example, by examining and 
addressing factors that perpetuate and entrench smoking behaviour in South Africa, 
particularly in the Western Cape. Current interventional research in low-income 
pregnant women at state antenatal facilities in the Western Cape has attempted to 
address this question, but results are not available yet. 98 99 In the BOLD study 
information on the "Stages of Change" of smoking behaviour was collected with the 
intention that analysis of this will shed some light on the psychosocial aspects of 
smoking behaviour in Ravensmead/Uitsig that will prove useful in designing smoking 
cessation and other community programmes. 
Monitoring of tobacco usage is a research focus of the national Demographic and 
Health Surveys. Concomitant monitoring of policy and control efforts and evaluation of 
their effectiveness is necessary in order to track health consequences of health and 
control policies. Tobacco control research deserves greater support as a national 
resea rch priority. 
At the provincial level, where the responsibility for the primary and secondary health 
service lies, motivations need to be made for the provision of nicotine replacement 
therapy and pharmacological therapy such as bupropion, although other health 
priorities are currently likely to take precedence. This can be done by presenting health 
budget planners and resource allocators with an economic analysis of the projected 












Nurses at the primary care level can be trained to provide brief counselling 
interventions in addition to physician advice. Moreover, the first target group of such 
interventions should be healthcare workers themselves in order to strengthen the 
credibility of the interventions. Smoking prevalences as high as 61 % have been 
reported in Chinese hospital physicians. lOO Similarly, in 2003, 50% of nurses ~O years 
working at Tygerberg Hospital (the local tertiary hospital situated at the periphery of the 
study area), were current smokers, and 48% of smokers started smoking during or 
after their training. 101 
At the local authority level, the second important step in prevention is the development 
of smoking cessation programmes that are widely available and accessible to 
communities that depend on public primary health care facilities for health advice and 
care. Several simple tools have been developed to assist carers in their approach to 
this need. One such method, developed by the U.S. Public Health Service is the five 
A's (Ask, Advise, Assess, Assist and Arrange ).102 Even if the documented 16% of 
persons 103 respond to this intervention, cost saving in terms of productivity, quality of 
life, mortality and health service costs could be significant. Additional counselling by 
nurses has been shown to almost double the quit rate. 104 
Findings from the LHS2002 have suggested that smoking increases the risk of 
M.tuberculosis infection.105 The BOLD study has found that the converse is also true -
the lung damage from TB is an aetiological agent for COPD. Including smoking 
cessation as part of the TB control programme would be a useful intervention, as South 
Africa faces considerable financial difficulty in merely maintaining their existing 
healthcare services. Inclusion of smoking cessation into other programmes would 
prove to be more feasible and cost effective. Programmes for HIV/AIDS, cancer 
control, cardiovascular disease, family planning and maternal health should be 
considered because smoking is an independent risk factor for many diseases other 
than COPD. 106 Brief counselling interventions by pharmacists could be another 
strategy, as many rely on pharmacists for health information. 
A starting point for promoting smoking cessation is at community level in the study 
area. This has and will be approached in several ways, firstly, through community 
report-back meetings. The author and colleagues formally communicated the main 
results of both the studies to the members of the Ravensmead and Uitsig communities 











of the LHS2002 were presented to the communities and the second was held in 2005, 
informing the community of the results of the BOLD study. These events were intended 
to be not only an expression of appreciation for the community's involvement in the 
project, but an opportunity for promoting smoking cessation and lung health. Further 
local follow-up is planned (see Appendix 6). 
An organised national response to COPD is needed. An organisation exists for the 
prevention and control of asthma (National Asthma Education Programme), which has 
brought asthma into the public domain. A similar initiative needs to be created for 
COPD or the National Asthma Education Programme could be expanded to include 
COPD and links with the existing National Council Against Smoking can be created. 
Public knowledge on CO PO seems to be extremely limited. COPD and smoking need 
to be put into perspective considering that COPD accounts for much higher morbidity 
and mortality than lung cancer, which is a better known association. 
Addressing tuberculosis and poverty 
Both the SADHS and this study have confirmed the role of tuberculosis in contributing 
to the burden of obstructive lung disease in South Africa.107 108 The TB-attributable 
COPD subgroup requires further investigation in terms of pathophysiological 
mechanisms associated with airflow Iimitation.93 Research into the specific 
characteristics of this subgroup is necessary to characterise the entity in terms of 
features such as AHR, severity and response to bronchodilators and corticosteroids, 
which will assist in defining optimal treatment for this group. 
The overwhelming issue of poverty and its effects upon lung health also needs to be 
addressed if the burden of respiratory disease is to be reduced. Low socioeconomic 
status is itself an independent risk factor for respiratory symptoms. In addition, poverty-
associated factors such as overcrowding, smoking, poor nutrition and alcohol abuse 
create an immune deficient state that predispose individuals to TB and a proportion of 
these will develop significant airflow limitation that limits quality of life and productivity 
and increases morbidity, mortality and health system costs. TB control is already a 
national priority but the management strategies for TB require review in the light of the 
run-away increase in the incidence of this disease in the face of the HIV/ AIDS 
epidemic, and the fact that recurrences are being shown to represent transmission 
rather than reactivation. Prevention of overcrowding, and focused efforts to eradicate 











Town do not earn enough to push their household above the poverty line, making them 
the "chronic working poor".109 
Addressing cannabis smoking 
This study has shown that the population prevalence of cannabis smoking is high in the 
study area, and that a significant proportion of respiratory symptoms can be attributed 
to this habit. The results also suggest, but do not confirm that heavy cannabis smoking 
is associated with the development of COPD. The negative respiratory health effects of 
cannabis need to be highlighted and publicised by health promotive activities in the 
health service and the media in order to increase public awareness in South Africa, 
which is currently virtually non-existent. The incorporation of an anti-cannabis smoking 
message into tobacco smoking cessation programrnes is imperative in areas where 
cannabis smoking is highly prevalent. Indeed, we have no knowledge of where these 
are, as there is little information on the pattern and prevalence of usage in South Africa. 
Despite problems of underreporting, the inclusion of questions on cannabis use in the 
next national Demographic and Health Survey would be helpful to give some idea of 
the magnitude and distribution countrywide, which would in turn assist in focusing 
further research and anti- smoking interventions in the a propriate groups. In addition, 
further research should be directed towards confirming or clarifying the link between 
cannabis use and COPD, including considering the effects of dose. A further aspect is 
to clarify the additive roles of tobacco smoking and also methaqualone (Mandrax®) use 
as part of the cannabis smoking routine, and whether the 'white pipe' method of 
smoking is more harmful to health. 
Another important research question is a possible relationship between cannabis 
srnoking and tuberculosis. Recent studies have shown that cannabis reduces immune 
function by impairing host defences against respiratory pathogens 110, and it can be 
hypothesised that cannabis is a risk factor for both M.tuberculosis infection and 
disease. Further population studies and enquiry into the mechanisms of this 
association are encouraged to assess this relationship. Data from the LHS2002 will be 
interrogated to investigate this question in a separate body of work. 
Addressing air pollution 
This study shows that electrification has been successful in reducing exposures to 
biomass fuels, as very few participants reported current exposure. Indoor air pollution 











bronchitis.39 Certain areas of South Africa such as the Northern Province have a large 
rural population of approximately 88.1 %, many of whom are dependent on biomass 
sources for cooking and heating. 111 As biomass fuel use is directly related to poverty, 
suggested interventions include financial support measures through income generation 
and micro-credit and increasing accessibility of cleaner fuels to the poor. 112 However, 
interventions need to be locally appropriate and participatory in nature if they are to be 
sustainable and successful, especially if the alternative (biomass) is free. 
The goal of country-wide electrification needs to be a continued focus. Short and 
intermediate term solutions include better indoor ventilation by means of innovative 
stove and chimney designs such as the ceramic chimney-less stoves 112 that have been 
piloted in other African countries 113, and could be promoted in some parts of South 
Africa. Substitution of biomass fuels for less polluting agents such as kerosene or liquid 
petroleum gas is another alternative, but they require funding and are associated with 
other risks such as accidental poisoning of children. g3 Potential solutions need to be 
novel and cost effective e.g. solar water heating.g3 114 
It is paradoxical that creation of much South African electricity is via the burning of coal, 
which itself results in significant outdoor pollution. g3 115 There is hardly any data on 
outdoor air pollution in South Africa, apart from the Vaal Triangle study.116 This area of 
research needs to be extended with the emphasis of monitoring and evaluating the 
respiratory effects of industrial and urban pollution in the large cities where, like Cape 
Town, photochemical smog is a visible problem. 117 Along with research, awareness of 
the effects of indoor air pollution needs to be increased at a national governmental 
level and increased intersectoral112 collaboration with NGOs and health agencies 
should be promoted so that efforts can be strengthened and supported by unified 
efforts. 
Addressing occupational exposures 
The prevention of occupational exposures can be achieved by substitution of 
hazardous materials, containment of exposures such as dust fumes and gases by 
engineering processes and by local exhausts or general exhausts or the use of 
respiratory masks (which are less effective). Key to this process of preventing and 
reducing exposures is worker education. Statutory occupational dust exposure limits 
are geared at reducing respiratory hazards, but recent evidence suggests that some 











needed to examine the exposure - response relationship between occupational dusts 
and COPD, including the effect of tuberculosis in the occupational setting, particularly 
amongst miners.93 
The Occupational Health and Safety Act (No. 85 of 1996) and the Mine Health and 
Safety Act (No. 29 of 1996) stipulate controls for the reduction of workplace exposures. 
However, enforcement of these measures is not effectively practiced. Reluctance of 
employers to put the measures into place, owing to cost implications, absent or 
ineffective risk assessment and monitoring of airborne hazards, occur even in 
industries with known respiratory risk (e.g. metal and coal mining).93 This lack of ability 
to control exposures by enforcing existing legislation hampers the process of reducing 
and eliminating respiratory hazards in the South African occupational context and is 
due to factors such as skills shortages, fragmentation of enforcement efforts and 
attenuated trade union power. 119 
Diagnosis and treatment 
Early diagnosis and appropriate treatment of persons with COPD is the aim of 
published guidelines, but their translation into practice is a challenging process. Local 
and international guidelines emphasise control of risk factors (especially smoking 
cessation and known aetiological factors such as occupational exposures), early 
diagnosis, optimal drug therapy and patient education.93 120 121. This study has shown 
significant underdiagnosis and undertreatment of symptomatic lung disease. 
However, there are multiple barriers to the practice of guidelines in the public sector 
primary care. A barrier to the recognition of obstructive lung disease and guideline 
practicability is the level of service obtained in state primary health clinics which are 
overburdened, under serviced, and sometimes lack availability of medication and time. 
In addition, the underuse of spirometry as a diagnostic tool and management aid is 
associated with lack of equipment, skills, practitioner knowledge, in addition to 
insufficient time. Failure to use even a peak flow meter in the primary care setting is 
concerning. 27 The creation and distribution of appropriate skills is a challenge that is 
being addressed by the provision of pulmonology skills (particularly clinical 
technologists) at tertiary and secondary hospitals. 122 The Practical Approach to Lung 
Health in South Africa Study (PALSA) is a novel approach that operates in primary care 
clinics and assists nurse practitioners identify COPD and other priority lung diseases 











evidence-based, and is provided in an attractive well-illustrated form that is easy to use 
and even demonstrate to patients. 123 PALSA, which is being rolled out in both the 
Western Cape and Free State provinces, incorporates in its integrated guideline a 
module on asking about smoking and a simple guide to counselling patients on 
smoking cessation. This is a unique package that has been developed for use by 
health professionals in that it includes the promotion of smoking cessation at the 
primary care level. 123 These and similar initiatives need to be promoted and introduced 
into other provincial health services. 
The contribution of the pharmaceutical industry is important in increasing awareness of 
COPD. Research into the pathophysiological aspects of obstructive lung disease and 
optimal drug therapy assist in improving treatment, quality of life and provide hope for 
COPD patients. However, these improvements reach only the 17% of South Africans in 
the private health sector, and those that attend private practitioners and receive 
prescriptions. 
Another barrier to improving management of COPD is the high cost of medication, 
which is particularly important in the resource limited public sector. 93 There are many 
other pressing health issues that compete for funding at the primary health care level, 
notably HIV-related disease and infections. Health managers need to be made aware 
of the exact cost comparisons of providing appropriate medical management and the 
treatment of uncontrolled disease.9:J Economic analyses of the projected costs for 
COPD in South Africa, based on statistical models are essential to motivate for 
appropriate resource allocation. This is one of the aspects of the BOLD study that will 
assist in creating a perspective on CO PO in South Africa. 
8.6. Concluding remarks 
The prevalence of respiratory symptoms and COPD in this predominantly low-income 
urban area of South Africa is high in both men and women reflecting high levels of 
smoking and past TB in the community. These results highlight the need for 
prioritisation of COPD as a health problem requiring targeted strategies for prevention, 
diagnosis and treatment. As smoking confers the highest attributable risk for CO PO in 
most settings, the one practical and achievable goal for the reduction of the burden of 
obstructive lung disease is to develop a strong initiative to address tobacco control and 











the state health service and other health organisations if the predicted damage is to be 
reduced. 
The BOLD study is the first in Africa to use internationally standardised methodology 
and provides a basis for comparisons of the prevalence of COPD with other parts of 
South Africa, other countries on the African continent and further afield. In settings 
where spirometry is not practical, the questionnaire and approach used in the LHS2002 
study provides a standardised tool for monitoring of prevalence of symptoms of 
respiratory diseases, and prevalence of risk factors. This information can be used to 
develop or strengthen strategies to stem and reverse the tide of obstructive lung 
disease. 
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INFORMATION SHEET FOR LUNG HEALTH SURVEY 2002 RAVENSMEAD AND UITSIG IN 
PERSONS 15 YEARS AND OLDER IN RAVENSMEAD AND UITSIG. 
You are invited to take part in a study to determine the prevalence of TB and chest diseases in people 
living in Ravensmead and Uitsig. About 5000 people will take part. Information on the study is supplied 
in this document. A trained fieldworker will be on hand to explain the contents and answer all your 
questions. Please ensure that you understand everything contained in this document. If you decide to 
participate, you will be required to give written consent before you take palt 
Who is doing the study? 
This study is being performed by health workers of the TB Research Centre of the University of 
Siellenbosch (Tygerberg Hospital) led by Professor Nulda Beyers, and the Lung Institute of the 
University of Cape Town, led by Prof. Eric Bateman. 
Drs Du T oit Loots (tel. 021-9389177), Anamika Jithoo (021-4066877), Emma van Schalkwyk (021-
9389594) are responsible for the day- to --day running of the study. 
What is the purpose of the study? 
In spite of a good TB tracing and treatment programme in the areas of Ravensmead and Uitsig, the 
number of TB cases remains high. The purpose of this study is to determine the number of people who 
are currently or have been infected with TB, or have other forms of lung disease like asthma and 
emphysema. We will look for factors that increase the risk of developing these diseases and the effect 
of these diseases upon the community. When trlis survey has been completed, it is our intention to 
conduct two further studies involving smaller nurnbers of residents of Uitsig and Ravensmead, who are 
identified in the first study. We will invite both people without lung disease, and some with chest 
complaints, to take part in the later studies. Separate information pamphlets and consent forms will be 
provided for these studies. 
What is T8? 
Tuberculosis (TB) is an infectious disease caused by bacteria (germs) which are spread through 
coughing. TB infection affects mainly the lungs, but can also affect other parts of the body, such as the 
lining of the brain (meningitis), and glands. The areas of Uitsig and Ravensmead, like other parts of the 
Western Cape has a higher number of TB cases than most other parts of South Africa. In spite of a 
good programme for tracing and treating persons with active TB infection, many persons with TB are not 
diagnosed quickly, and go on infecting other people, including friends and family without knowing it. 
Early infection with the organism can be detected with a skin test, sputum (phlegm) examination, and 
chest X-Ray. These will be performed on all that enter the study. 
Other Lung Diseases that will be studied? 
We will be asking questions and looking at X-Rays for signs of other lung diseases like asthrna, chronic 
bronchitis and emphysema. We will also ask questions about your home, habits and work that might 
have an effect on your lungs. We will also look for evidence of lung damage caused by TB. In this way 
we will be able to assess how much of a problem lung diseases are in your cornmunity. 
This research proposal has been approved by the Medical Ethics Committee (Research Ethics) 
of the Universities of Stellenbosch and Cape Town and is being performed with the permission 










Participation in this study is strictly on a voluntary basis. You are free to withdraw from this study at any 
stE1ge, without any consequences for you. No financial reward will be given to any persons taking part in 
this study. 
Are there any risks for people who take part in this survey? 
Taking part in this study does not pose any severe risks to you or your family. However, the following 
will be required of those taking part: 
1) You will be asked to sign a consent form after you have read and understood tbis information 
leaflet. You will be given an original copy of this leaflet and the consent form to keep. 
2) You will be asked to complete (with the help of a trained interviewer) a detailed questionnaire 
about your health 
3) A TB skin test, called the Tuberculin test will be performed on all that take part. In about 70% 
of persons it may form a red, slightly tender lump on the upper arm, at the injection site, within a 
day, which could last for several days, up to two weeks. Occasionally, it may blister, or form a 
shallow sore (ulcerL or cause tender glands under the arm. A health worker will record the 
result of the test after 3 days, when the reaction is strongest. If necessary, shall be will provided 
some cortisone cream to rub on the area to reduce the pain and swelling. 
4) You will be given an appointment and transport to attend the Tygerberg Hospital X-Ray 
Department for a chest X-Ray within a few days or weeks of completing the questionnaire. At 
this visit your arm will be examined for a scar from previous TB vaccination. Your height and 
weight will also be recorded. You will then have a chest X-Ray. If you are female, in privacy, 
you will be asked if you are pregnant and if so, your abdomen will be covered by a lead shield, 
to prevent your baby from being exposed to the X-Ray. The chest X-Ray will be reported on by 
experienced specialists. The radiation risk of a standard chest X-Ray is very small. 
5) You will be asked to try and cough up some phlegm for examination for T8 organisms. 
What is the benefit for you, of taking part in this study? 
The information gained from this study will be used to provide suggestions for improving health services. 
(Community Health Centres, hospitals, medications etc.) 
This study may benefit you if you have a lung problem of which you are not aware. 
What will happen if these tests show that you have a lung problem? 
After you have completed the questionnaire, the answers will be screened within days for symptoms 
that suggest lung disease that needs immediate attention. Such persons will be contacted within days, 
to have a chest X-Ray and be referred to a doctor at either the local Community Health Centre, or if 
they prefer, to their private doctor. If considered necessary, they might be referred to the Lung Clinics at 
either Tygerberg or Groote Schuur Hospitals. If the X-Ray or phlegm examination shows TB, you will be 
referred to the local TB Clinic for treatment. 
Confidentiality of information and privacy of the participant 
All personal information obtained during this study will remain strictly confidential. 
The answers will be transferred to a computer, but your name Will not be included, and you will be 
identified by a coded number. No information about individuals will be released to any other parties but 
the research team, without your further consent. When the results of research are published( for 
example, in medical joumals), no personal details that might identify individuals, or individual 










Thank you for reading this information sheet. If you have any questions, please ask them now. 
The interviewer will be pleased to answer them. If you wish to take part, please read and sign the 
2 consent forms. 
Please keep this information sheet and a copy of the consent form in a safe place, for your 
records. 










INFORMED CC~NSENT FCm.M FOR TIl E LUNG HEALTH SlJRVEY 
(FOR PERSONS AGE 15 YEARS AN» OLDER) 
• I cOllfirm lhat [ have read the inronn~ltinn slJeet, and tilat the inforlllatiull and 
procedurcs involved in my taking parI ill the survey have heen explained to me. 
• I confirlll that I have had the opportunity to ask ljLlestiotls about the smvey and 
that 1 alll satisfied with the answers ,md explanatiol1s that have hcen provided. 
• I have been given lime and opportunity 10 read thl' inforlllation carefully, to 
discllss it with olhers and (0 decide whether or not to take part in this survey. 
• I agree to Lake part in the sllrvey. 
SUbjl'ct's signatul'C: ~ _____ ... _ .. ~ .. 
S 1I bjec I ' s na me :_. _______ ... ~ __ .. ~_ .. __ ._~_. ___ . __ . __ .. __ ... _~ ____ .~.(p Ie (1St' pri n t) 
Thl' pcrs!)n who conducts the infonncd ('onscnt disclIssion must also sign and date 
this form. 
Signa t LIfe: "_~ __ "'_'.' __ .". __ ~' ... __ '_ .. "_"_' __ ._. _____ ._ .. _~ d ate .~ __ . __ _ 
N ,lmc: ~_' __ " _____ ' __ ~_~" ___ ' ___ "' __ ' __ ~' ____ "~"_' __ '_'_ ( please p ri n t ) 
Signature of witness, if applicable. 
Wit n essed h y: (p ri n t n a III e): __ .. _~~__ _._ ... ___ ... __ . __ ~ .. _._. __ .... _. __ .. _. __ . ___ .. __ ... 




















I C8J~O' •••••••••••••••••••••••••••••••• 
Please read these 3 instructions carefully before completing the questionnaire: 
1 Do not write anywhere outside the spaces provided. 
2 Indicate correct answers in check boxes with an X, i.e. IZl 




4 Interviewer number 
5 T oday's date 
6 Sex U Male [] Female 
7 Date of birth 
8 If you do not know your date of birth, what was your age on your last birthday? 
9 How many years have you lived in the present home? 
10 How many years have you lived in Ravensmead/Uitsig? 
11 Where did you live before this? 
12 What is your employment status (check all that apply)? 
Employed 
[] Self-employed 
U Employed by government 
[] Employed in private sector 










Disability grant for chest disease 
Disability grant for other disease 
Child support grant 
If unemployed go to Question 14. 
13 If you are employed, please state the nature of your job. 
[] Street vendor U Taxi driver Factory worker 
[] Hair dresser U Child minder [] Office worker 
n Shop owner [] Health care worker Other (Please specify): 
14 What is your usual monthly income( from all sources)? 
U Less than R 500 [] R 3 OOO-R 4 000 R 8 OOO-R 10000 
[] R 500-R 1000 lJ R 4 OOO-R 5 000 R 10 OOO-R 13 000 
[] R 1 OOO-R 2 000 [] R 5 OOO-R 6 500 Greater than 13 000 
n R 2 OOO-R 3 000 U R 6 500-R 8 000 
15 What level of education did you reach? 
Highest grade completed: Initiated tertiary education 
16 What is your marital status? 
[] Single (never been married) 
[] Married 
[] Widowed 

















We are now going to ask you some questions about chest problems ...• 
17 Has a doctor/health worker ever told you that you have (check all that apply): 
18 
Ii Heart trouble? 




U Hay fever? 
U TB? 
'--I Other chest trouble? Specify: 
If you have had TB, when and where was it treated? 
Start of treatment End of treatment 
1 I m ,j y y yJ 
2 
3 
I", ,y,/ , y { "I 
I In rr./ Y y y,l 
Clinic/Hospital Name I----l 
19 Do you have a cough that began recently? UY Ot~ 
If 'yes', when did it start? I / .............. / I 
del ",oro yyyy 
20 Are you coughing up blood now or in the last month? 
21 Have you coughed up blood in the last 12 months? 
If 'yes', when did it start? 
22 Do you usually bring up any phlegm from your chest first thing in the morning in the winter? 
23 Do you usually bring up any phlegm from your chest during the day, or at night. in the winter? 
If 'no', go to question 24. 
23.1 Do you bring up phlegm like this on most days for as much as 3 months each year? 
23,2 Have you had coughing and phlegm on most days for a minimum of 3 months a year 
and for at least 2 successive years? 
24 In the last 12 months, have you had any chest illnesses that have kept you off work, 
indoors at home, or in bed? [Jy Oti 
If 'no' go to question 25. 
24,1 Did you produce phlegm with any of these chest illnesses? 
24,2 In the last 12 months, how many such illnesses, with (increased phlegm), did you have 
which lasted a week or more? 
25 Do you ever have trouble with your breathing? 
If 'no' go to question 26. 
25,1 Do you have this trouble LJ Continuously, so that your breathing is never quite right? 
U Repeatedly, but it always gets completely better? 
U Only rarely? 
26 Are you disabled from walking by any condition other than heart or disease? 
[]'r [Jtj 













• 3093 ~~ID' •••••••••••••••••••••••••••••••• • 
27 Are you troubled by shortness of breath when hurrying on the level or walking up a slight hill? 0'" Ut~ 
28 
If 'no', go to Question 28. 
27.1 Do you have to walk slower than people of your own age on the level 
because of breathlessness? Oi' UN 
27.2 Do you ever have to stop for breath when walking at your own pace on the level? [],.. Ot~ 
27.3 Do you ever have to stop for breath after walking about 100 yards 
(or after a few minutes) on the level? Oy ON 
274 Are you too breathless to leave the house or breathless on dressing or undressing? 
Have you had wheezing or whistling in your chest at any time in the last 12 months? 
If 'no', go to question 29. 
28.1 Have you been at all breathless when the whistling noise was present? []y Ot~ 
28.2 Have you had this wheezing or whistling when you did not have a cold? 
28.3 Have you been woken by an attack of shortness of breath or tightness in your chest 
at any time in the last 12 months? 0'1' Utj 




when you DID NOT have a cold or the flu? Ch' ON 
If 'no', go to question 30. 
29.1 In the last 12 months, have you_had a problem with sneezing, or a runny, or blocked nose 
when you DID NOT have a cold or the flu? 0'''' I-Itj 
Do you have to change your clothes or bedding because of night sweats? 01' ON 
If 'yes', when did it start? d dl ro ,j y y y(1 
Y "I d dim ",1 ( y 
Are you troubled by fever? oi' otj If yes: when did it start? 
d d/o, ,j .( y Are you losing weight? 0'1 nt~ If yes', when did it start? 
33 Do you recall having any chest illnesses with cough and shortness of breath 
when you were a child «12 years)? Uy Otj 
If 'no " go to Question 34. 
33.1 Did you have such an illness repeatedly? 0'" liN 
33.2 Did you ever sleep in a hospital for such an illness? 
33.3 Do you recall the name of the illness? 0'0' ON If yes', specify: 
34 Have you smoked cigarettes for a year or longer? ,-1'( ot~ 
If 'no', go to Question 35. 
34.1 How old were you when you started smoking? 1 J 
34.2 Do you smoke now (within the last month)? 0 ... · Utj 
If 'no', how old were you when you stopped smoking? 
34.3 On average, how much do you smoke or did you smoke? 












I 3~4 •••••••••••••••••••••••••••••••• 
~l§JD' 
Have you ever smoked anything other than tobacco? Lb' D~l If 'no', go to Question 36. 
35.1 Have you ever smoked cannabis? ny D~~ If 'no', go to Question 36. 
35.2 How old were you when you started smoking cannabis? 
35.3 Do you smoke now (within the last month)? Dy II~~ 
D 
D If 'no', how old were you when you stopped smoking? 
35.4 On average, how much do you smoke or did you smoke per day? 
Number of joints per day: II Number of pipes per day: 1_ I 




pottery, work in a quarry/mine or grave stone manufacturing? ny CI~~ 
Have you ever been exposed to other dusts, gases, strong smells, chemicals, fumes, at work? 
If 'no', go to Question 38. 
37.1 Have you ever had to leave your job because it affected your breathing? Dy CI~l 
Do you or your immediate neighbours keep pigeons/birds in a cage (not chickens)? 
Have you ever been told that you snore? If 'no', go to Question 40. 
39.1 According to what others have told you, please estimate how often you snore. 
[] Rarely 
[] Sometimes 
[] Once a week 
CI 3 to 5 times a week 
D Every night or almost every night 
Ii Do not know 
39.2 How loud have others said your snoring is? 
CI only slightly louder than heavy breathing 
[] about as loud as mumbling or talking 
LI louder than talking 
[] extremely loud (can be heard through a closed door) 
LI do not know 
40 According to what others have told you, how often, if ever, do you gasp, choke, 
or make snorting sounds during sleep? 
[] never LI often (at least once a week) 
LI rarely [] very often(every nighUalmost every night) 
[] sometimes [] Do not know 
41 According to what others have told you, how often, if ever, do you seem to have momentary periods? 
during sleep, when you stop breathing, or you breathe abnormally? 
[] never n often(at least once a week) 
LI rarely [] very often(every nighUalmost every night) 
LI sometimes LI Do not know 
42 Are you currently taking any medicines(including inhalers, aerosols, or tablets) 
for any chest diseases, including nasal allergies? LI\' []N If 'no', go to Question 43. 
42.1 For what conditions are you taking these medicines (check all that apply)? 




Ii Hay fever? 
I I TB? 














I ~95 •••••••••••••••••••••••••••••••• 
~~ID· 
I 
42.2 Where do you receive your chest medicines? 
usually occasionally 
(check one only) (check all that apply) 
[] Community clinic U 
[] Private hospital U 
[] Provincial hospital U 
CI Pharmacy 1--1 
[] Private practitioner [] 
U Traditional healer I-l 
n A friend [] 
43 Where do you usually go for medical care for chest problems? 
usually occasionally 
(check one only) (check all that apply) 
r--I Community clinic II 
[] Private hospital [] 
[] Provincial hospital n 
II Pharmacy [] 
U Private practitioner [] 
L.J Traditional healer U 
[] A friend U 
43.1 In the last 12 months, have you visited the above for your chesUlung disease? Uy I-lt~ 
If yes', how many times? II 
44 Where do you usually go for emergency treatment for your chest problems? 
usually occasionally 
(check one only) (check all that apply) 
CI Community clinic II 
CI Private hospital [] 
Ii Provincial hospital n 
CI Pharmacy [] 
CI Private practitioner [] 
[] Traditional healer U 
U A friend U 
45 Have you visited a hospital casualty department or emergency room 
because of your chesUlung disease in the last 12 months? II"" []tl 
If yes', how may times? 1 1 
46 Have you spent at least one night in hospital because of your chesUlung disease 
in the last 12 months? []y Dt-l If yes', how many days? D 
47 If you are currently employed, have you lost any days of work because of your chesUlung disease 
in the last 12 months? U'i [Jt-l If yes: how many days? ,--I 
48 Whatever your working situation, have there been any days when you have had to give up other activities 
(e.g. looking after the children, the housework, studying) because of your chesUlung disease, 
in the last 12 months? Dy DN 













•••••••••••••••••••• ••••• • •• •• •• 
49 Do you drink alcohol? 11'1 []N If 'no', go to Question 50. 
50 
51 
49.1 How many days do you drink during the week (Monday to Thursday)? I~ days 
49.2 How many days do you drink over weekends (Friday to Sunday)? 
I I 
days 
49.3 How much would you drink on a typical drinking day? 
Wine [ Jml shared by D persons 
Brandy / whisky I~ ml shared by n persons 
Beer I-Iml shared by I~J persons 
Other alcoholic drinks I Iml shared by Cl persons 
On average, how much time do you spend in the following modes of transport? 
days/week hours/day 
Taxi LI LJ 
Train D I I 
Bus 
II I I 
Private car 1-----' I I 
Other specify: I '1 
------------------------------------~ 
What amount of time do you spend on average in the following places (other than home)? 










specify: I ---I 
L-__________________________________ ~ 
52 What fuels are mostly used in the dwelling you spend most of your evenings? 
53 
For Cooking For Heating 
(check one only) (check one only) 
[] Wood or coke [] 
II Gas LJ 
[] Electricity LJ 
[] Paraffin n 
Ii Spirits 1-1 
Have you ever spent time in a prison? []r' 11~1 If yes, please specify dates and place: 
I 1Ill,):=J I fI' rrr/ Y y ( (I 
Prison 






















INFORMATION SHEET FOR THE BOLD STUDY (LUNG HEALTH SURVEY PART 2): PERSONS 40 YEARS 
AND OLDER IN RAVENSMEAD AND UITSIG. 
You are invited to take part in a study examining how common smoking-related lung disease is.(emphysema and 
chronic bronchitis) This is a follow up study of the Lung Health Survey 2002, for which you have already 
answered a questionnaire, in 2002. Information on this further study is supplied here. A trained fieldworker will be 
on hand to explain the contents and answer any questions. Please be satisfied that you understand everything 
contained in this document. If you decide to participate, you will be asked to give written consent before you take 
part. Participation is entirely voluntary. 
Who is doing the study? 
This study is being performed by the University of Cape Town Lung Institute, led by Professor Eric Bateman and 
Dr Anamika Jithoo, in conjunction with by health workers of the TB Research Centre of the University of 
Stellenbosch (Tygerberg Hospital) led by Professor Nulda Beyers. 
Dr. Anamika ,Iithoo (021-4066850)and Sister Christine Johannisen (tel. 021 4066850) and are responsible for the 
day-to-day running of the study. 
What is the purpose of the study? 
In our first study last year, you participated in a questionnaire, had a chest X-Ray, a sputum sample for TB, and 
measurement of your height and weight. 
The aim of this study is to measure the breat~ling capacity of a randomly selected group of participants. This will 
assess the breathing capacity of the population, which will yield information about smoking related lung disease 
(emphysema), asthma, occupational lung disease, TB, and the validity of the first questionnaire. Some persons 
with symptoms of lung disease are also included in this study. 
You have been randomly (like the flip of a coin) chosen to perform simple breathing tests that will take up about 
30 minutes of your time. Your selection does not mean that YOIJ have a lung disease. 
What do we mean by smoking-related lung disease? 
Smoking related lung disease is most commonly called emphysema and/or chronic bronchitis. People in the 
medical field refer to these two diseases as Chronic Obstructive Pulmonary Disease. 
This disease of the lungs is much more common than many people suspect, and you may not even know that you 
have it, because the symptoms only occur later in the course of the disease. The symptoms are cough, phlegm 
production, shortness of breath and wheeze. The same symptoms also occur in persons with asthma and other 
lung diseases. 
Cigarette smoking is the main cause of emphysema. The ingredients of cigarettes, when smoked over a long 
period of time, cause damage to the lungs, and decrease their function. If one continues to smoke, the damage 
becomes greater, as time passes. This ongoing damage to the lungs can be stopped by stopping smoking. 
What is asthma? 
Asthma is a disease of the lungs that causes symptoms of cough, phlegm production, shortness of breath and 
wheeze or tight chest. It is one of the most common respiratory complaints in the world, and affects many people 
. Asthma attacks are most commonly triggered by allergies to airborne particles of house-dust mites, grass or tree 
pollens, fungal spores and skin flakes from furry animals such as cats and dogs. Certain foods and additives can 
also trigger off asthma, when eaten. 
Asthma cannot be cured, but it can be treated and well controlled with inhaled and oral medications, allowing 
most sufferers to lead a normal life. 
What is TB? 
Tuberculosis (TB) is an infectious disease caused by bacteria (germs), which are spread through coughing. TB 
infection affects mainly the lungs, but can also affect other parts of the body, such as the lining of the brain 
(meningitis), and glands. The areas of Uitsig and Ravensmead, like other parts of the Western Cape has a higher 
number of TB cases than most other parts of South Africa. In spite of a good programme for tracing and treating 
persons with active TB infection, many persons with TB are not diagnosed quickly, and go on infecting other 
people, including friends and family without knowing it. Early infection with the organism can be detected with a 










the study. If you suspect that you may have T8, and are not part of the study, you are advised to attend your 
local clinic for a sputum(phlegm) test. 
This research proposal has been approved by the Medical Ethics Committee (Research Ethics) of the 
University of Cape Town and is being performed with the permission of the Health Department of the City 
of Cape Town 
Participation in this study is voluntary. You are free to withdraw from this study at any stage, without any 
consequences for you. No financial reward will be given to any persons taking part in this study. 
Are there any risks for people who take part in this survey? 
Taking part in this study does not pose any significant risks to you or your family. However, the following will be 
required of those taking part: 
1) You will be asked to sign a consent form after you have read and understood this information leanet. 
You will be given a copy of this leaflet and the consent form to keep. 
2) You and a trained interviewer will complete a questionnaire about your health. Part of this is to assess 
if it is safe for you to perform lung function tests on the day of your appointment. If not, another 
appointment may be scheduled. The rest of the questions are on respiratory health. 
3) You will be asked to perform lung function tests with an experienced trained clinical technologist. 
She/he will explain the technique to you. This will involve you blowing into a breathing apparatus 
(spirometer), up to six times on two occasions, 15 minutes apart. You will be given a noseclip to wear. 
After the first set of blows, you will be given 2 puffs of Salbutamol, an inhaled medication that assists in 
opening airways that may be obstructed. You will then blow into the spirometer again. Salbutamol is a 
safe, well-tested medication. You may briefly experience a rapid heartbeat, and some tremor. 
These tests are performed in exactly the same manner at any hospital/lung clinic, according to existing 
guidelines and rules. 
A small number of persons may become a dizzy or feel faint after exerting themselves for the test. This 
us usually temporary, lasts a few seconds only, and passes away with resting. Clinic staff Will be able to 
assist you if there are any complications. 
What is the benefit for you, of taking part in this study? 
The information gained from tllis study will be used to provide suggestions for improving health services. 
(Community Health Centres, hospitals, medications etc.) 
This study may benefit you if you have a lung problem of which you are not aware. 
What will happen if these tests show that you have a lung problem? 
After you have completed the breathing tests, the results will be screened within days by one of the doctors 
participating in the study for abnormalities that suggest lung disease that needs attention. A copy of the results 
will be given to each participant, which may be reviewed by his/her own healthcare practitioner. If the results are 
sufficiently abnormal, you will be contacted within days, and given a letter referring you to a doctor at either the 
local Community Health Centre, or if you prefer, to your private doctor. If considered necessary, you might be 
offered an appointment at the Lung Clinics at either Tygerberg or Groote Schuur Hospitals, or the UCT Lung 
Institute. 
If you are not contacted or visited, you may assume that your lung function is normal, and you do not need 
referral or treatment. 
Confidentiality of information and privacy of the participant 
All personal information obtained during this study will remain strictly confidential. 
The results will be transferred to a computer, but your name will not be included, and a coded number will identify 
you. No information about individuals will be released to any other parties but the research team, unless in a 
referral letter. When the results of research are published (for example, in medical journals), no personal details 
that might identify individuals, or individual households will be included. Completed results of the lung functions 










Thank you for reading this information sheet. If you have any questions, please ask them now. The 
interviewer will be pleased to answer them. If you wish to take part, please read and sign the 2 consent 
forms. 











INFORME[) CONSENT FORM FOl{ THE nOLD STUDY (LUNG IIEALTH 
SLJI~VEY: Part 2) 
FOR PERSONS AGED 40 YEARS AND OLDEI~ 
• Il'onfirtll that I have read the information shed, and that the information and 
procedures involved in my taking pari in tile study have been explained 10 11Il'. 
• I confirm tllat I have had the oppllrtunity to ask (jutslions about the survey ~1I1d 
tilal I am satisfied with the answers and explanations that have been provided. 
• I have be('n given time ami opportunity to read the information carefully, to 
(Ji...,cus,> it with others alld to decide wheLhl'r or nnt to take part in I hi'> ,>urvcy, 
• I agree tll take part in the survey. 
Sul,j eel's s i g nat U I-e: ___ ._ .. _ .. ______ . __________________________________ clat c _. _____ ... 
Su bjeet' '> nallle: ... _ ...... _ ...... _._. ___ ._ ... _ .._____ .. ___ ...... _ .... _ ..__ ._. __ ..... __ ._ .. __ .. _ .. _._ .... _ ... _____ .\ pIca'>L' print) 
The person who l'onduds the infornll'd l'onSl~nt discllssinn must alsu sign and date 
this I·mlll. 
Signature: dale 




















Country Code _____ _ 
City Code __ __ 2 
ID 1 
Date: ____ 1 ____ 1__ __ __ __ 4-6 
d d III my y y y 
BOLD SPIROMETRY QUESTIONNAIRE 
Safety Questions 
1. In the past three months have you had any surgery on your chest or Yes 01 7 
abdomen? No 02 
2. Have you had a heart attack within the past three months? Yes 01 8 
No 02 
3. Do you have a detached retina or have you had eye surgery within Yes 01 9 
the past three months? No 02 
4_ Have you been hospitalized for any other heart problem within the Yes 01 10 
past month? No 02 
5. Are you in the last trimester of pregnancy? Yes 01 II 
No 02 
6. Does the participant have a resting pulse of greater than 120 beats Yes 01 12 
per minute? No 02 
7. Is the participant currently taking medication for tuberculosis? Yes 01 13 
No 02 
If the participant answers "Yes" to any of Questions 1 through 7, do NOT proceed with the test. 
8. Have you had a respiratory infection (cold) in the last three weeks? Yes 0 1 
No 02 
9. Have you used any medication for breathing in the last three hours? Yes 0 I 
No 02 
10. Spiromelry Outcome Pre-bronchodilator test completed Yes 01 
No 02 
Post-bronchodilator test completed Yes 01 
No 02 
Unable to obtain satisfactory spirometry (check one) 
The participant did not understand instructions 02 
The participant was medically excluded 03 
The participant was unable to physically cooperate 04 
The participant refused Os 















11. Did the participant experience any adverse events as a result of performing Yes 0 1 19 
the spirometry test? No D 2 
If yes, please briefly describe event: 
12. Please note any items about the spirometry test concerning the ability of the 
pal1icipant to adequately perform the maneuver (e.g. kyphosis, dentures, missing 
limbs, etc.). 
13. Fieldworker Number 











Country Code _________ _ 
City Code __ __ 2 
ID ___________ _ 3 
Date: ____ / ____ / _______ _ 46 
d d In III Y y y 
BOLD CORE QUESTIONNAIRE 
Demographics 
1. What is the participant's sex? Male 0 I 7 
Female 0 2 
2. What is your race? 8 
3. What is your date of birth? ____ / ____ /__ __ __ __ 9-11 
d d m my y y y 
4. How many years of schooling have you completed? 
5. What is the highest level of schooling you have 
completed? 
Pri mary Schoo I 
Middle School 
High School 
Some College (Trade/Professional/Community) 
Four-Year Co liege/Un i versity 
None 






Some College (TradelProfessionallCommunity) 
Four Year CollegefUniversity 
None 
Unknown 
Respiratory Symptoms and Disorders 
12 














These questions pertain mainly to your chest. Please answer yes or no if possible. If you are in 
doubt about whether your answer is yes or no, please answer no. 
Cough 
7. Do you usually cough when you don't have a cold? Yes 0 I 15 
No 0 2 
[lfyes, rontinue with Question 7A; lfno, skip to Question 8J 
7 A.Are there months in which you cough on most days? Yes 0 I 16 
No 0 2 
[lfyes, ask both Questions 78 & 7C; lfno, skip to Question8J 










7B. Do you cough on most days for as much as three 
months each y~ar? 
Yes 0 I 17 
No 0 2 
7C.Por how many years have you had this cough? Less than 2 years 0 I 18 
2-5 years 0 2 
More than 5 years 0 
8. Do you usually bring up phlegm from your chest, or do you usually 
have phlegm in your chest that is difficult to bring up when you 
don't have a cold? 
Yes 0 I 19 
No 0 2 
[If yes, continue with Question 8A; Ifno, skip to Question 9} 
8A.Are there months in which you have this phlegm on most 
days? 
Yes 0 I 20 
No 0 2 
[If yes, ask both Questions 8B & 8C; If no, skip to Question 9} 
8B. Do you bring up this phlegm on most days for as much 
as three months each year? 
Yes 0 I 21 
No 0 2 
8C.Por how many years have you had this phlegm? Less than 2 years 0 I 22 
2-5 years 0 2 
More than 5 years 0 3 
Wheezing/whistling 
9. Have you had wheezing or whistling in your chest at any Yes 0 I 
time in the last 12 months? No 0 2 
[llyes, ask both Questions 9A & 9B; Ifno, skip to Question 10} 
9A.In the last 12 months, have you had this wheezing Yes 0 I 
or whistling only when you have a cold? No 0 2 
9B.ln the last 12 months, have you ever had an attack of wheezing Yes 0 I 
or whistling that has made you feel short of breath? No 0 2 
Breathlessness 
10. Are you unable to walk due to a condition other than shortness Yes 0 L 
of breath? No 0 2 
[If yes to Questivn 10, please describe this condition on the line below and then skip to 





Nature of condition(s): _________________________ _ 










II. Are you troubled by shortness of breath when hurrying on the Yes 0 1 27 
level or walking up a slight hill? No 0 2 
[ljyes, ask Question llA through I1D; Ifno, skip to Question 12J 
11 A. Do you have to walk slower than people of your age on Yes 0 J 28 
level ground because of shortness of breath? No 0 2 
Does not apply 0 3 
lIB. Do you ever have to stop for breath when walking at Yes 0 1 29 
your own pace on level ground? No 0 2 
Does not apply 0 3 
11 C. Do you ever have to stop for breath after walkiog Yes 0 1 30 
about 100 yards (or after a few minutes) on level No 0 2 
ground? Does not apply 0 3 
110. Are you too short of breath to leave the house or Yes 0 I 31 
short of breath on dressing or undressing? No 0 2 
Does not apply 0 1 
12. Has a doctor or other health care provider ever told Yes 0 I 32 
you that you have emphysema? No 0 2 
13. Has a doctor or other health care provider ever told you that Yes 0 I 33 
you have asthma, asthmatic bronchitis or allergic bronchitis? No 0 2 
[If yes, ask Question 13A. IjIlO, skip to Question 14J 
13A. Do you still have asthma, asthmatic bronchitis or Yes 0 1 34 
allergic bronchitis? No 0 2 
14. Has a doctor or other health care provider ever told you that Yes 0 I 35 
you have chronic bronchitis? No 0 2 
[ljyes, ask Question 14A. 1fno, skip to Question 15J 
14A. Do you still have chronic bronchitis? Yes 0 1 36 
No 0 2 
15. Has a doctor or other health care provider ever told you that Yes 0 1 37 
you have chronic obstructive pulmonary disease (COPD)? No 0 2 











Now I am going to ask you about medicines that you may be taking to help with your breathing. I want to know about medicines that you take on a 
regular basis and medicines that you may take only for the relief of symptoms. I would like you to tell me each medicine that you take, what form 
do you take it in, and how often you take it each month. 
16. In the past 12 months, have you taken any medications for your breathing (incluulI1g medications for n<lsul congestion)? 
If participant does not take any medications to help their breathing, skip to Question 17. 
16A.Medication 
Name (not entered) 
16B.Medication 
Code --- 39 --- 44 --- 49 --- 54 --- 59 --- 64 
16C.Formulation Pills 01 Pills 01 Pills 01 Pills 01 Pills 01 Pills 01 
Inh~.de r O~ Inhaler r:l2 lnkder D~ Inhakr O~ Inl1;J lcr :J2 lnhak! 0 2 
Nebulizer 03 Nebulizer 03 Nebulizer 03 Nebulizer 03 Nebulizer 03 NebuliLer 03 
Liquid 04 Liquid 04 Liquid 04 Liquid 04 Liquid 04 Liquid 04 
Suppository 05 Suppository 05 Suppository 05 Suppository 05 Suppository 05 Suppository 05 
Injection 06 Injection 06 Injection 06 Injection 06 Injection 06 Injection 06 
Other 07 Other 07 Other 07 Other 07 Other 07 Other 07 
16D.ls the Medicine taken Most Days 01 Most Days 01 Most Days 01 Most Days 01 Most Days 01 Most Days 01 
on most days, or just when Symptoms 02 Symptoms 02 Symptoms 02 Symptoms 02 Symptoms 02 Symptoms 02 
you have symptoms, or Both 03 Both 03 Both 03 Both 03 Both 03 Both 03 
both? (If 'most days' 
ask Q / 6£, If 'symptoms '. 
ask Q /6F, if 'both', ask both 
Q/6E w1d Q/6FJ 
16K When you are taking 
the medication, how days 42 days 47 days 52 days 57 days 62 days 67 
many days a week do you 
take it? 
16F. When you are taking 0-3 01 43 0-3 01 48 0-3 01 53 0-3 01 58 0-3 01 63 0-3 01 68 
the medication, how 4-6 02 4-6 02 4-6 02 4-6 02 4-6 02 4-6 02 
man~' months in the past 7-9 03 7-9 03 7-9 03 7-9 03 7-9 03 7-9 03 
12 months have you taken 10-12 04 10-12 04 10-12 04 10-12 04 ! 0-12 04 10-12 04 
it? 




























17. Please tell me about any other products that you take or things you do to help your breathing 
that you have not already told me about. 





18. Has a doctor or other health care provider ever had you blow 78 
into a machine m dL' \ ' Il'l': in order to measure your lungs (i.e., a spirometer 
or peaktlow meter)? 
Yes 0 1 
No 0 2 
[If yes, ask Question 18A.lfno, skip tv Question 1<J} 
18A. Have you used such a machine in the past 12 months? 
19. Have you ever had a period when you had breathing problems 
that got so bad that they interfered with your usual daijy 
activities or caused you to miss work? 
[Jfyes, ask Question 19A. Ifno, skip to Questiun 2()} 
Yes 0 1 79 
No 0 2 
Yes 0 I 80 
No 0 2 
19A. How many such episodes have you had in the past 
12 months? 
_ _____ . episodes 81 
[If 19A >0, ask Questions 19B and 19C, else skip to Question 20} 
19B. For how many of these episodes did you need to 
see a doctor or n(l11:1 i1ea ll i l Cd re PUl \ ilk r in the 
past 12 months? 
19C. For how many of these episodes \\crc Y( 1U il llSp il <tii lCJ 
ll\cm i:;hl in the past 12 months? 
episodes 82 
episodes 83 
[Jf 19C >0, ask Question 19C1, else skip to Question 20} 
19C 1. All together, for how many total days were you 
hospitaUzed uvcm ight for breathing problems in 
the past 12 months? 
__ _ _ __ _ days 84 











Now I am going to ask you about smoking. First I will ask about cigarettes. 
20. Have you ever smoked cigarettes? Yes 0 1 85 
No 0 2 
(" Yes," means more thun 20 packs of cigarettes in a lifetime or more than I cip-arelle each day for a year) 
[iJyes, usk questions 20A through 20D; otherwise, skip to Question 22) 
20A. How old were you when you first started regular 
cigarette smoking? 
20B. If YOll have stopped smoking, how old were you 
when you last stopped? (If lh~ parl icipan l ha" 
not slopped "moking, r~cOlu <1-; code (1)9' ) 
____ years old 
____ years old 
86 
87 
20C. On average over the entire time that you 
smoke(d), about how many cigarettes per 
day do (did) you smoke? 
______ cigarettes/day 88 
20D. On average over the entire time that you 
smoke( d), do (did) you primarily smoke 
manufactured or hand-rolled cigarettes? 
Manufactured 
Hand-rolled 
o 1 89 
o 2 
[If the participant currently smokes cigarettes (Question 20B is '9Y' ), then ask Questions 21 A 
and 21 B. Otherwise, skip to Question 22J 
21A. In the last year, how many times have you quit smoking 
for at least 24 hours? 
______ . times 
21B. Are you seriously thinking of quitting smoking? Yes, within the next 30 days 
Yes, within the next 6 months 






22. Have you ever smoked a pipe or cigar? Yes 0 1 92 
No 0-" 
[lfyes, ask question 22A. Ifllo, proceed to question 23J 
22A. Do you now smoke a pipe or cigar? Yes 0 1 93 
No 0 2 
[If the participant has never smoked (answered "no" to both Questions 20 and 22), then skip to Questic 
25. Otherwise, "roreed to Question 23 J 
23. Has a doctor or other health care provider ever advised 
you to quit smoking? 
[If yes , ask Questions 23A and 23B. lIno, skip directly to Question 24] 
Yes 0 1 94 
No 0 2 










23A. Have you received fl h:Li lca l advice to stop smoking within 
the past 12 months? 
Yes 0 I 95 
No 0 2 
23B. Have you used any medication (prescription or non-
prescription), incl ud ing d Ili c tl l inc pdlc l1 . to help you 
stop smoking? 
Yes 0 I 96 
No 0 2 
[ljyes, ask Question 23B1, then ask Question 24. ljno, skip directly to Question 24J 
23B I.What kind of medication did you take 
to help you stop smoking? 
Nicotine Replacement 0 I 97 
24. Have you used or done anything else to help you stop smoking? 
[ljyes, ask Question 24A, otherwise skip to Question 25J 
24A. What did you do? 
Occupational Exposure 
25. Have you ever worked for a year or more in a dusty job? 
[ljyes, ask Question 25A, otherwise skip to Question 26J 
25A. For how many years have you worked in dusty jobs? 
Additional Co-morbidities 
Buproprion 0 2 
Tofranil 0 3 
Other 0 4 
Yes 0 I 98 
No 0 2 
Hypnosis 0 I 99 
Acupuncture 0 2 
Biofeedback 0 l 
Other o 4 
Yes 0 I 100 
No 0 2 
____ years 101 
26. Has a doctor or other health care provider ever told you that you had: 
26A. Heart disease Yes 0 I 102 
No 0 2 
26B. Hypertension Yes 0 I 103 
No o 2 
26C. Diabetes Yes 0 I 104 
No 0 2 
26D. Lung cancer Yes 0 I 105 
No o 2 










26E. Stroke Yes 0 I 106 
No 0 2 
26F. Tuberculosis Yes 0 I 107 
No 0 2 
[if yes to 26F, then ask 26Fl; otherwise, skip to Question27J 
26Ft. Are you currently taking medicine for tuberculosis? Yes 0 I 108 
No 0 2 
[lfno to 26Fl, then ask 26F2; otherwise, skip to Question 27J 
26F2. Have you ever taken medicine for tuberculosis? Yes 0 I 109 
No 0 2 
27. Have you ever had an operation on your chest in which a part of Yes 0 I 110 
your lung was removed? No 0 2 
28. Were you hospitalized as a child for breathing problems prior to Yes 0 I III 
the age of 10? No 0 2 
29. In the past 12 months did you get a flu shot? Yes 0 I 112 
No 0 2 
30. Has a doctor or other health care professional told your Yes 0 I III 
father, mother, sister or brother that they had a diagnosis No 0 2 
of emphysema, chronic bronchitis r COPD? 
31. Has anyone living in your home (besides yourself) smoked a cigarette, 
pipe or cigar in your home during the past two weeks? 
Yes 0 I 114 
No 0 2 
SF-12 
Interviewer: Read the following set of instructions to the participant. 
INSTRUCTIONS: This survey asks for your views about your health. This information 
will help keep track of how you feel and how well you are able to do your usual activities. 
Answer every question by marking the answer as indicated. If you are unsure about how tu 
answer a question, please give the best answer you can. 
32. In general, would you say your health is: (Check one.) Excellent 0 I 
Very good o 2 
Good 0 1 
Fair o 4 
Poor 0 5 
33. The following items are about activities you might do during a typicaJ day. 
Does your health now limit you in these activities? If so, how much? 
115 
33A. Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or 
playing golf 
Yes, limited a lot 0 I 116 
Yes, limited a little 0 2 
No, not limited at all 0 3 










33B. Climbing several flights of stairs Yes, limited a Jot 0 I 117 
Yes, limited a little 0 2 
No, not limited at all 0 1 
34. During the past 4 weeks, have you had any of the following problems with your work 
or other regular daily activities as a result of your physical health? 
34A. Accomplished less than you would like Yes 0 I 118 
No 0 2 
34B. Were limited in the kind of work or other activities Yes 0 I 119 
No 0 2 
35. During the past 4 weeks, have you had any of the following problems with your work 
or other daily activities as a result of any emotional problems (such as feeling 
depressed or anxious)? 
35A. Accomplished less than you would like 
35B. Didn't do work or other activities as carefully as usual 
36. During the past 4 weeks, how much did rajn inteIfere wjth 






Not at all 
A little bit 
Moderately 











37. These questions are about how you feel and how things have been with you during the 
past 4 weeks. For each question, please give the one answer that comes closest to the 
way you have been feeling. 
How much of the time during the past 4 weeks ... 
37A. Have you felt calm and peaceful? All of the time 0 I 
Most of the time 0 2 
A good bH of the time 0 3 
Some of the time o 4 
A little of the time 0 5 
None of the time 0 6 
37B. Did you have a lot of energy? All of the time 0 I 
Most of the time 0 2 
A good bit of the time o 3 
Some of the time o 4 
A little of the time 0 5 
None of the time 0 6 















37C. Have you felt downhearted and blue? 
38. During the past 4 weeks, how much of the time has your 
physical health or emotional problems interfered with 
your social activities (like visiting friends, relatives, 
etc.)? 
All of the time 
Most of the time 
A good bit of the time 
Some of the time 
A little of the time 
None of the time 
All of the time 
Most of the time 
A good bit of the time 
Some of the time 
A little of the time 
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Economic Impact 
Work Days Lost 
The next questions ask about work and ah l1u t times when you may have missed work due Lo 
heal th problems. 
39. At any time in the past 12 months, did you work for income? 
[ljno, continue with Questivn 39A; if yes. skip to Question 40J 
39A. During the past 12 months, did you not work for income 
mainly due to breathing problems? 
39B. During the past 12 months, did you not work for income because 
you were a full-time homemaker or caregiver? 
[ljyes, continue with Question 39C, ifno. skip to Question 44J 
39C. During the past 12 months, did health problems stop you from 
performing your usual homemaking/caregiving tasks? 
[Ijyes, cuntinue with Questiuns 39D & 39£. ifno. skip tv Question 44J 
39D. During the past 12 months, how many total days were 
you unable to perform your homemaking/caregiving 
tasks due to your health problems? 
Yes 0 1 127 
No 0 2 
Yes 0 1 128 
No 0 ? 
Yes 0 1 129 
No 0 2 
Yes 0 I 130 
No 0 ? 
days III 
39E. During the past 12 months, how many total days were __ . __ .. _ _ days 132 
you unable to perform your homemaking/caregiving 
tasks specifically due to breathing problems? 
[Please skip to question 44J 










40. Dun ng how many of the past 12 months did you work for income? 
41. During the months that you worked. how many days per week 
did you work for income? 
(when you're working) 
42. What is the usual number of hours per day you work for income? 
43. During the past 12 months, did health problems stop you from 
working for income? 
[If yes, continue with Questions 43A & 43B, if no, skip to Question 44] 
43A. Duri ng the past 12 months, how many total days were 
you unable to work for income due to your health 
problems? 
_ ____ months 133 
__ days 
__ _ _ hours 
Yes 0 1 




____ days 137 
43B. During the past 12 months, how many total days were 
you unable to work for income specifically due to 
breathing problems? 
______ days 138 
Non- Work Activities Missed 
The next questions ask about time when you may have missed your normal activities (~u l'h d ~ 
going shopping, visiting friends/relatives, going to church, or other activities) because of h l' ~ tl t h 
problems. 
44. During the past 12 months, did l led lli l pl llh lL' m ,> p l'I.'vl' lll ) ULI 1'1l) 111 
particl pat il1g ill one or ll10re t1011- \vorl lL' ldll'U Jcll\i tic .... ) 
Yes 0 I I:l9 
No 0 2 
[If yes. Wl\ l le ,- Questions 44A & 44B, ifno, ski!, I n CO!vIl'/.{·,-, U) In (/1 {he end uft/ lc 
(j// c \ l iulIl!u i rc' ,j 
44A. During the past 12 months, how many total days did 
you not participate in non-work related activities due 
to your health problems? 
44B. During the past 12 months, how many total days did 
you not participate in non-work related activities 
specifically due to breathing problems? 
days 140 
days 141 
Completed By: __ __ __ __ ! I ! 




















City Code 2 
IV 3 
Date: 4-6 
d d m m y y y y 
BOLD OCCUPATIONAL QUESTIONNAIRE 
1. Have you ever worked at any of the following? 
Number of 
Check Yes or No (If than 
for each OL 
a. Ii> 7·8 
2 
b. Coal mining DYes 1 II> 9-10 
DNo 2 
c. Sandblasting DYes I II> 11-12 
DNo 2 
d. Working with DYes 1 II> 1)·14 
DNo 2 
e. Chemical or manufacturing DYes 1 II> 15-16 
DNo 2 
f. Flour, or Yes 1 II> years 17-18 
DNo 2 
g- or DYes I II> J920 
DNo 2 
h. Foundry or Yes I Ii> 1-22 
No 2 
1- Welding DYes I II> 23-24 
DNo 2 
J. fighting DYes 1 IJJ> 25·26 
DNo 2 
k. Farming DYes 1 II> years 27-28 
DNo 2 














Check Yes or No 
for each 
DYes 1---------.. 
o No 2 
DYes 1---------.. 
o No 2 
DYes ]---------.. 
o No 2 
DYes ]---------. • 
o No 2 
2. In your present job, are you regularly exposed to dust? 
3. In your present job, are you regularly exposed to fumes? 
4. Do you usually wear a mask or respirator at your present work? 
5. What has been your usual occupation or job, the one you have 
worked at the longest? 
SA. For how many years have you worked at this job? 
6. Have you ever had to leave a job because it caused you breathing 
problems? 
Number of years 
worked (If less than 
01, enter 00) 
____ years 29-:10 
____ years 1J-32 
_____ years JJ-J4 
____ years :15-36 
Yes OJ 37 
No 02 
Yes 01 3H 
No 02 
Yes OJ :19 
No 02 
40 ---
____ years 41 
Yes 0 1 42 
No 02 
Completed By: ___ ___ ___ ___ 43 










Country Code _____ _ 
City Code __ __ 2 
ID 3 
Date: ____ 1 ____ 1__ __ __ __ 4-6 
d d rn III y ) y y 
BOLD BIOMASS QUESTIONNAIRE 
1. Has an indoor open fire with coal or coke been used in your home 
as a primary means of cooking for more than 6 months in your life? 
Yes 0 I 7 
No 02 
2. 
I 'yes to Question J, ask questions JA to J D, else skip to question 2 
lAo For how many years has coal or coke been used for cooking 
in your home? 
I B. On average, for how many hours a day have you personally 
spent cooking using coal or coke? 
Ie. Is coke or coal still used for cooking in your home? 
10. Did (does) your stove or fire have a chimney or was (is) the smoke 
vented to the outside? 
Has an indoor open fire with wood, crop residues or dung been used 
as a primary means of cooking in your home for more than 6 months 
in your life? 
If yes to Question 2, ask questions 2A to 2D, else skip to question 3 
2A. For how many years have wood, crop residues or dung been 
used for cooking in your home? 
2B. On average, for how many hours a day have you personally 
spent cooking using wood, crop residues or dung? 
2e. Are wood, crop residues or dung still used for cooking in your 
home? 
20. Did (does) the stove or fire have a chimney or was (is) the smoke 
vented to the outside? 
Form 101 Version 3.00 
___ years 8 
___ hours 9 
Yes 0 I 10 
No 02 
Yes 0 I II 
No 02 




Yes 01 15 
No 02 
Yes 01 16 
No 02 










BOLD Biomass Questionnaire 
3. Have you used an open fire with coal or coke as a primary means 
of heating your home for more than 6 months in your life? 
/fyes tv uestion 3, ask uestions 3A and 3B, else skip to question 4 
3A. For how many years have you used an open fire with coal or 
coke as a primary means of heating your home? 
3B. Do you still use an open fire with coal or coke as a 
primary means of heating your home? 
4. Have you used an open fire with wood, crop residues or dung as a 
primary means of heating your home for more than 6 months in your life? 
Yes 0 I 17 
No 02 
years 18 
Yes Ol 19 
No 02 
Yes 01 20 
No 02 
If yes to uestion 4, ask questions 4A and 4B, else skip to end of uestionnaire 
4A. For how many years have you used an open fire with wood, crop years :.> I 
residues or dung as a primary means of heating your home? 
4B. Do you still use an open fire with wood, crop residues or dung as a 
primary means of heating your home? 
Yes 0 I 22 
No 02 
Completed By: __ __ __ __ 2] 










Country Code _____ _ 
City Code __ __ 2 
ID ) 
Date: --'-----'------------
d d m III y y y y 
BOLD STAGES OF CHANGE QUESTIONNAIRE 
Please ask these questions of all participants who are current smokers. 
The following statements represent different opinions about smoking. Please rate HOW 
IMPORT ANT each statement is to your decision to smoke according to the following five 
point scale (Hand participant a card with thej'ollowing choices): I = Not important, 
2 = Slightly important, 3 = Moderately important, 4 = Very important, and 5 = Extremely 
important. 
I, Smoking cigarettes relieves tension. Not important 01 
Slightly important 02 
Moderately important 03 
Very important 04 
Extremely important 05 
2, I'm embarrassed to have to smoke, Not important 01 
Slightly impo11ant 02 
Moderately important 0) 
Very important 04 
Extremely important 05 
3. Smoking helps me concentrate and do better work. Not important Ol 
Slightly important 02 
Moderately important 03 
Very important 04 
Extremely important Os 
4. My cigarette smoking bothers other people. Not important 01 
Slightly important 02 
Moderately important 03 
Very important 04 
Extremely important Os 
5. 1 am reJaxed and therefore more pleasant when smoking. Not important 01 
Slightly important 02 
Moderately important 03 
Very important 04 
Extremely important 05 

















6. People think I'm foolish for ignoring the warnings 
about cigarette smoking. 
Not important 0 I 12 
Slightly important 02 
Moderately important 0:1 
Very important 0 4 
Extremely important 0 5 
Completed By: __ __ __ __ 13 










Country Code _____ _ 
City Code __ __ 2 
ID 1 
Date: 4-6 
d d m m y y y y 
BOLD MINIMAL DA T AlREFUSAL QUESTIONNAIRE 
Demogra p h ics 
1. What is the participant's sex? 
2. What is your date of birth? 
d d m m 
Respiratory Symptoms and Disorders 
3. Has a doctor ever told you that you have emphysema, asthma, 
asthmatic bronchitis, chronic bronchitis or chronic obstructive 
pulmonary disease (COPD)? 
Additional Co-morbidities 
y 
4. Has a doctor or other health care provider ever told you that you 
have heart disease, hypertension, diabetes, lung cancer, stroke or 
tuberculosis? 
Tobacco Smoking 
Now I am going to ask you about smoking. 
5. Have you ever smoked cigarettes? 
Male 0 1 7 
Female 0 2 
8-10 
y )' y 
Yes 0 I II 
No 0 2 
Yes 0 I 12 
No 0 2 
Yes 0 1 13 
No 0 2 
{" Yes, " means more than 20 packs vf cigarettes in a lifetime or more than I cigarette each day for a year} 
[If yes, ask Questions 5A and 5B.] 
5A.Do you now smoke manufactured or hand-rolled cigarettes? Yes 0 1 14 
No 0 2 
5B. How many cigarettes do (did) you smoke per day? _____ cigarettes/day 15 
Completed By: __ __ __ __ 16 










Country Code _____ _ 
City Code __ __ 2 
ID 3 
Date: __ 1 ____ ._------- 4-6 
d d m III y y y y 




__ years 7 
Male 0 I ~ 
Female 0 2 
Full data coiJected 0 I 9 
Partial data collected (please complete Question 4)# 0 2 
RefusedlMinimal data collectedl/ 0 .1 
RefusedfNo data collected 0 4 
Known to have permanently left area 0 5 
Temporarily out of area 0 6 
Dead 0 7 
Age ineligible 0 8 
.\ge-sex guota already filled 0 9 
Untraceable (e.g., bad address and phone) 0 10 
llnreachable (e.g., never returns mail or answers phooe) 0 II 
For those aged 18-39 years, this is just the minimal questionnaire 
/I Only applicable for those ages ~40 years 
4. For those participants where only partial data were collected, please indicate whether 
the following data were completed. 
Yes No 
Core Questionnaire 01 02 
Stages of Change Questionnaire 01 02 
Biomass Questionnaire 01 02 
Spirometry (including Questionnaire) 01 02 
Minimal DatalRefusal Questionnaire 01 02 
Person-Specific Sampling Questionnaire 01 02 








Completed By: __ __ __ __ 17 






















Quest ioMaire Administration 
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The use of a questionnaire to collect information makes it possible to obtain answers to a 
standard list of questions in a standardized way. The reliability of the questionnaire depends on 
the behavior ofthe interviewer, and therefore it is important that the questions are read exactly as 
they are printed and that no non-verbal clues are given. 
Helpful Hints for Administering the Questionnaire 
In order to minimize the amount oftime needed to administer the questionnaire, it is important to 
keep the participant focused and not to let the administration of the questionnaire (which is 
essentially an interview) evolve into a conversation. The following are some general guidelines 
that may be used to help control the direction and pace ofthe interview: 
1. Before starting the main questionnaire, explain to the participant that the questionnaire is 
very long, and unless the response categories are specified, the majority of questions require a 
simple "Yes" or "No" answer. Tell participants that, if they are unsure of an answer, to take 
their best guess. 
2. Explain that you are going to mOve through the questionnaire quickJy so as to take up as little 
of the participant's time as possible. Move quickJy from question to question, since this will 
allow very little chance for the participant to interject personal comments into the interview. 
While periodic eye contact with the participant is important, the interviewer may fmd that the 
questiolUJaire takes less time to complete if helshe keeps their eyes focused primarily on the 
questionnaire. 
Basic Rules for Administering the Questionnaire 
In addition to the preceding suggestions for completing the interview in a timely manner, the 
following rules should be followed during the interview. 
I. Verbal and nonverbal cues from the interviewer can influence participant responses. Be 
carefuJ not to give any positive or negative reinforcement by responding to a participant's 
answer with a nod, gesture, or any verbal cue. 
2. In particular, do not express surprise at a given answer, or point out what seems to be an 
inconsistency in the participant's response to two similar questions. 
3. MaintaiJl the participant's right to confidentiality during the interview by conducting it in a 
comfortable, private setting, away from other staff or family members. 
4. Never try to interpret what the respondent means by a given answer. Unless specific 
instructions are provided for interpreting responses to a given question, the interviewer 
should offer to read the question again, and if applicable, list the response options. 













Encourage the participant to make their best guess. The burden of supplying a response 
should always be placed on the participant; staff shouJd never try to interpret what the 
participant meant by a vague response. 
5. When the participant does not understand a question, or asks for clarification of what is 
meant by the question, follow the detailed instructions provided for that question. If no 
instructions are given, or if the participant is still confused after being given the appropriate 
clarification, tell the participant to use their own interpretation of the question and to provide 
the best answer they can. DO NOT try to provide your own explanation of the question, as 
this can introduce added variabi Iity due to different interpretation of the questions from one 
interviewer to another. 
6. If a subject requests further information or clarification of a question that is not possible 
according to the questionnaire rules, explain that you are required to ask the questions in a 
standardized manner and that you are not permitted to give further clarification. 
7. Words in the question that should be stressed are underlined. 
8. Text that is italicized should not be read to the participant. Such text is generally used to 
provide guidance to the interviewer for how to ask or respond to a specific question or series 
of questions. 
9. Carefully follow all the instructions printed on the questionnaire regarding sldp patterns. 
This will assure that all necessary questions are asked and that no unnecessary questions need 
to be asked. 
Interviewer Training 
Interviewers should be articulate, able to accurately and easily read the questions out loud, and 
should be able to follow the instructions. Formal medical training is not necessary, and in fact, it 
can result in less accurate responses to the questionnaire. Participants often tend to give the 
answer they think the interviewer wants to hear. Tllis phenomenon, which is known as positive 
response bias, is more likely to occur when the interviewer is perceived as an authority figure. 
Second, more educated persons can tend to interpret the participant's responses. If clinicians are 
to act as interviewers, it is important that they be conscious of this potential problem. 
Training of the interviewers requires that they be given the questionnaire and instructions to 
study for several days so they become familiar with the flow of questions. They also should 
observe trained interviewers in the process of interviewing both nonna! and symptomatic 
SUbjects. They must practice the interviewing among themselves, and then observe or participate 
in interviews in which several observers code the responses. Discrepancies in coding must be 
reviewed and discussed. Recordings of interviews can let trainees review the same interview 
several times. The process of practicing and becoming accustomed to the questionnaire can take 













from several days to several weeks. Individual sites should establish a formal process for 
training and certifying interviewers. Centralized training is provided by the coordinating center 
at the outset of the study, although not all staff may be able to attend this training. 
Prior to training, staff should have read both the questionnaire and the instructions, and should 
have practiced administering the questionnaire to co-workers and/or friends. This makes the 
formalized training session more efficient, since the interviewers are already familiar with the 
instnunent and have some idea of the questions and any difficulties they might have in 
administering the questionnaire. During the formal training session, the person conducting the 
training should review each question's purpose and discuss how to ask it; review the interviewer 
instructions for the questions; and answer any queries staff may have. Staff should then practice 
admi.nistering the questionnaire, both to gain familiarity with its administration and to identifY 
additional queries for the instructor. As part of this process, other staff should role-play different 
scenarios. Jdeally, a pool of healthy and non-healthy volunteers, covering a variety of ages, will 
also be available for the training. 
Following the formal training session, staff should continue to practice the questionnaire, and the 
"master trainer" should listen t%bserve several of these (a minimum of three is suggested). 
Only staff who are deemed competent in the administration of the questionnaire should be 
allowed to conduct interviews with study participants. 
If multi pie interviewers are used in any study, subjects should be assigned randomly to each 
interviewer, and the interviewer identification should be recorded on the questionnaire along with 
the time required to conduct the interview. 
Specific training and certification requirements are covered in Chapter 11, "Quality Control." 
Recording the Replies to the Questions 
The majority of questions have simple "Yes" or "No" responses. If there is no provision for a 
"Don't know" reply and the respondent is uncertain of the answer, first repeat the question and 
ask the participant to make their best guess. If the respondent remains unsure, record the answer 
as ''No.'' 
If the answer to the question is a number, this should be recorded directly on the lines provided. 
For continuous valued responses (such as number of cigarettes smoked or age started smoking), 
the respondent may give a range. If this happens, ask the participant to give a single value, if 
possible. Let them know it does not have to be exact, just their best guess. Ifparticipant still 
replies with a range, record the midpoint of the range. 
Where the answer is a date, the date should be written on the lines provided, one number per line. 
When the answer is a word, it should be legibly written out in full. 











version J .04 
Questionnaire Administration 
In all other cases where the interviewer is unsure how to code a response, he/she should be 
instructed to write a note in the margin of the questionnaire describing the participant's response. 
The marginal notation should then be reviewed at the clinical center to determine the proper 
code. If it cannot be coded at the clinical center, the site should contact the coordinating center 
for coding instructions. 
Some attention should also be given to the legibility of responses. Interviewers should be trained 
to write numerals (such as one" I" and seven "7") in a standardized way and to check response 
boxes in a consistent and legible manner in order avoid confusion at the time of data entry. 
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Spirometry is a medical test that measures various aspects of breathing and lung function. It is one of the 
simplest, most effective tests available for the assessment of lung function. The spirometer registers the 
amount of air a subject inhales or exhales and the rate at which the air is exhaled. The most common 
spirometric tests require that the subject exhale as forcefully as possible after taking a full, deep breath. 
The subject's effort is called thefOlwd expiratory maneuver. 
BOLD uses a spirometer (the NDD EasyOne™ Spirometer) that measures flow and volume by ultra-
sound transjt time. This spirometer is compliant with the American Thoracic Society spirometry 
standards. 
Because the results of the spirometry testing are used to determine capo status (the primary outcome for 
BOLD), the measurement must be performed according to strict standards by technicians who have been 
properly trained and certified in how to conduct the maneuver. In addition, the equipment must be 
regularly cleaned and the calibration checked. All spirometric maneuvers will be reviewed by a central 
reading laboratory to assure maximum quality of the data and to provide ongoing feedback to the 
pulmonary function technkians regarding the adequacy of the maneuvers. 
Summary of Measures 
The following measurements will be obtained through spirometry testing during the BOLD climc visits: 
A. Forced Vital Capacity (FVC) is the total volume of air exhaled in a forced expiratory maneuver (the 
act of exhaJing as hard and fast as possible after maximal inspiration). The FVC is useful for 
detecting restrictive diseases, since lower than expected results may be a sign that the lungs cannot 
inilate normally. The FVC is reduced in people with obstructive and restrictive disorders. 
B. Forced Expiratory Volume at One Second (FEVI) is the amount of air that a person breathes out 
during the first second of a forced expiratory maneuver. This is reduced in people with airflow 
obstruction. 
C. The ratio of FE VI to the }<'VC (FEVlFVC) is the most sensitive and specific index of airways 
obstruction measured by a spirometer. It is obtained by dividing the FEV I by the FVC, and is usually 
expressed as a percent (i .e., 100 x FEV /FVC ). 
D. Forced Expiratory Volume at Six Seconds (FE V 6) is the amount of air that a person breathes out 
during the first six seconds of a forced expiratory maneuver. Increasing interest is being shown in the 
FEV6, and more particularly in the FEV/FEV6 ratio, as an alternative to the FEV/FVC ratio. 
E. The ratio of FE VI to the FEV6 (FEV j IFEV6) is an alternative to the FEV,IFVC ratio. A secondary 
objective of BOLD is to evaluate the utility of the FEV,IFEV6 ratio, partiCUlarly with respect to the 
assessment of COPD. 














Spirometry testing ideally should be performed in a private, temperature-controlled room at a central 
location (such as a local health clinic). AJI of the instruments necessary for the test should be in the room. 
The room should be well lit, preferably with a window, and located in a quiet area of the clinic. These 
conditions will improve the quality and reproducibility of the results. For safety, the participant should be 
seated in a chair with no wheels. 
For many sites, it may be that testing will be done in mobile settings or in participants' households. The 
NDD EasyOne™ Spirometer is portable and has been shown to perform well in the field. Nonetheless, 
this document assumes that testing will be done in a centralized clinic facility. Sites planning to do 
otherwise should develop corresponding local procedures and document them in their local Manual of 
Procedures] 
Containers with clean mouthpieces (Spirettes TM), nose-clips, and spacers should be available in the room, 
as should be a container to collect used Spirettes TM and another to collect used spacers. A box of facial 
tissue paper, paper plate or some type of container to place dentures on or in (if needed), and a trash can 
should be placed close to the participant. 
The EasyOne™ Spirometer has been designed to need no calibration. However, a calibration check 
should be carried out daily to ensure that the spirometer is reading accurately. Instructions for performing 
the calibration check are in the NDD EasyGuide™ technical manual. The calibration syringe and adapter 
should always be stored next to the spirometer so that the temperature between the syringe and the 
spirometer are the same. This will avoid having large differences between room temperature and the 
spirometer temperature that could affect the results of the calibration tests. Ifthere is the potential for a 
large temperature difference between the calibration syringe and the spirometer, the technician should 
pull and push the piston on the syringe several times to correct the problem. If spirometry is done in the 
field (outside ofa clinical center), it is preferable to keep the spirometer and calibration syringe together 
overnight to avoid temperature differences at the time of calibration. 
Medication use prior to testing 
In order to provide a valid assessment of bronchial hyper-responsiveness, participants should be asked to 
refrain from taking their bronchodilator medications during the 6 to 12 hours prior to testing. The exact 
waiting time depends on the type of medication, as noted below. 
Type of medication period of no use 
short-acting beta-2 agonist 6 hours prior to the clinic visit 
anticholinergic inhaler 6 hours prior to the clinic visit 
oral beta-2 agonist 12 hours prior to the clinic visit 
oral theophylline 12 hours prior to the clinic visit 
oral antimuscarinic 12 hours prior to the clinic visit 
Ion g-acti ng beta -2 t'.l""g"",on",i""s,,--t (.."S""e'-'.-'re"-,v,-"e""n""t),----,-,12"-'.!h,,,-0 u""r,-"s-,\p,,-,-r-,-,i o,-,-r-,t",-o --"2thC-'-'e"-,c",,l....,i ru""'",,c-,-v-,-,is,-,-i t"--__ _ 
10 the event that the participant has not complied with these waiting periods, the spirometry should be 
done anyway, including both the pre- and post-bronchodilator maneuvers. While the assessment of 
bronchial hyper-responsiveness may be biased, the post-bronchodilator measurements should be 
unaffected, and it is these measurements that are used to define COPD 










Contraindications for post-bronchodilator testing 
Check the participant's pulse and ask certain safety questions to assure that 
bronchodilator does not pose a potentia] health risk. Specifically. 
be done if the subject has or reports any of the following: 
fi a heart attack in the last three months 
fi a resting pulse rate more than 120 beats/minute (participant should be sitting at 5 
prior to pulse rate determination) 
fi cataract surgery or a major surgical procedure in the past one month 
fi any other co-morbidity (such as unstable angina or pneumonia) that, in the 
may affect the performance of the test or jeopardize 
BOLD MOP 
Version 1.05 
If a participant has or reports any of the conditions do the measurement 
may be brought back for retesting at a later date (see below). 
Reasons to reschedule any spirometry testing 
some any spirometry testing is contraindicated due to a 
the val idity of the maneuver or endanger the health of the participant. situations include: 
fi or abdominal surgery in the 3 months 
fi of pregnancy 
fi tract infection with unresolved symptoms in the three weeks prior to the visit 
testing these individuals until the situation is resolved and should re-
for a more suitable time. If participants are brought back later for spirometry 
contact the coordinating center for instructions on processing the data. 
Conducting the Visit 
A detailed description ofthe use and operation of the NDD EasyOne TM spirometer, together with 
checks 
participant, are included in the NDD EasyGuideTh1 users' manual. All 
are expected to have read this document and to be familiar with its 
this document should be kept with each spirometer in case questions about use 
during testing. 
each participant's pulse rate prior to spirometry testing. 
rate on the spirometry form. Resting pulse rate is determined by having the participant 
5 to the measurement. Post-bronchodilator testing should not be done on 
is more than 120 beats/minute. 
also questions that are included on the Spirometry form. 
post-bronchodilator spirometry may be skipped, any spirometry may be 
document all potential safety issues in the 














In order to minimize the risk of cross-contamination, technicians should wash their hands before the start 
of the test and should use a tissue to remove a mouthpiece (the Spirette™) from its storage container for 
the participant to use. Allow the participant to insert the clean Spirette™ into the spirometer. Be careful 
to ensure that the arrow on the Spirette™ is lined up with the arrow on the spirometer. 
Testing should be conducted with the participant in the sitting position. A chair without wheels should be 
used for the testing, and the participant should sit erect with chin slightly elevated. The purpose of the 
chair is to support the participant in case slhe faints during the maneuver. 
Instruct participant to loosen any tight clothing that might restrict maximal inspiration. Some individuals 
may have difficulty doing the spirometry maneuver due to urinary incontinence. Offer the participant a 
chance to use the bathroom prior to testing. 
Dentures should be left in place if they are not loose to help keep a tight seal around the mouthpiece. If 
they are loose, have participant remove them and provide a paper plate or clean container to place them 
on or in. 
All maneuvers should be performed with the participant wearing a nose clip. This clip prevents air from 
moving through the nose during the test. 
Explain the purpose of the spirometry test 
Explain that the purpose of the test is to take some measurements to check on the health of the 
participant's lungs. Emphasize that, although the procedure does not hurt, in order to get useful and valid 
results he/she must breathe as hard and as fast as possible when told to do so and will need to repeat the 
procedure a few times. Depending on the cultural setting in which the testing is done, subjects may need 
repeated assurances that spirometry does not hurt them or damage anything. 
Demonstrate the maneuver 
Explain that the participant should take in as deep a breath as possible, and when hislher lungs are totally 
full, quickly position the mouthpiece and BLAST out the air as hard and as fast as possible. A vigorous 
demonstration of the maneuver will prevent wasted time and effort caused by the participant's lack of 
understanding. Demonstrate the correct placement of the mouthpiece. Take a deep breath and emphasize 
the maximal depth of inhalation. Then demonstrate the proper positioning ofa demonstration Spirette™ 
mouthpiece and dramatically blast the air out as fast as possible. 
Pre-bronchodilator test 
After instructing the participant about the procedure for pulmonary function testing and asking all the 
safety questions, proceed with the actual testing, following the procedures outlined in sections 5.2 to 5.4 
of the NDD EasyGuide™ users' manual. This initial series of maneuvers is performed BEFORE 
administering the bronchodilator. Follow the computer prompts until a successful test session has been 
obtained. A successful test session is defined as at least three acceptable maneuvers, with the two best 
FEV IS and the two best FVCs from these maneuvers both within 200 ml of each other. 














After at least 3 acceptable and 2 reproducible maneuvers are obta.ined, administer two puffs of 
bronchodilator to using a spacer; a set up to 15 
the last puff. During the waiting time, begin to administer the study questiormaires. 
These can be completed after the maneuver if necessary. 
Post-bronchodilator maneuver 
The (BD) maneuver can start anytime after the IS-minute wait. The same of 
at least 3 acceptable and 2 reproducible maneuvers should be followed. It is not critical that the post-BD 
maneuver done at 15 but rather that it be done at least IS minutes after the last 
administered puff of bronchodilator. The effect ofllie bronchodilator will persist, and actually slightly 
at least the next 30-40 may to fully ,",\.I A " 1-/'''''''''' 
questionnaires between the pre- and post-BD maneuvers. 
Clinical centers wishing to 
instructions on page 5.5 of 
printouts to their 
a hardcopy printout their the 
EasyGuide™ users' manual. Clinical centers to give such 
to provide guidelines for interpreting the results. 
troubleshooti problems 
Because maneuvers is on must 
guide the participant through the breathing maneuvers. It is extremely important to jnhale maximally and 
to exhale maximally. Tell the to start in a breath and to 
the mouthpiece in hislher mouth. Then tell the participant to blast out the air and to continue exhaling for 
at least 6 Observe as to follow the 
instructions, and encourage the participant to continue blowing out without re-breathing. 
Instruct the participant to remain erect not to bend over during the maneuver, and to keep their feet 
flat on the 
For the purpose of spirometry testing, "acceptable" is defined as a maneuver that is free from error. 
between maneuvers. 
The following are some errors that can be seen or calculated a maneuver that 
can or variable effort\ glottis closure, early termination, 
and leaks. 
Three maneuvers are needed to The two values for FVC and 
FEV l taken from acceptable forced expiratory maneuvers must show minimal variabil ity (within 200 
milliliters of the FVC and FEV d. It is also to the volume-time curves to 
detennine if the size and shapes of the curves are reproducible. 
The American Thoracic Society defines FEV I> and FVC as the best measurements from and 
reproducible maneuvers. It is Dot necessary that all come from 













FEV1IFVC and FEV j IFEV6 ratios are computed as the ratio of the individual measurements. In order to 
obtain these results, select the "best value" setting from the system configuration menu (see section 8 of 
the EasyGuide™ users' manual). 
When errors occur, review common errors with the participant before proceeding with additional 
maneuvers. 
Ask the participant to watch the technician perform the FVC maneuver again. The technician should 
demonstrate the correct placement of the mouthpiece, emphasize the maximum depth of inhalation, and 
then blast out the air. If the participant tries again and the reproducibility criteria are not met, the 
technician should continue administering the test as needed (up to a total of five maneuvers), assuming 
that the subject is able to continue. 
Some participants will never be able to provide three acceptable and having two reproducible maneuvers 
is OK. The goal is to meet the acceptability and reproducibility criteria, but these are not absolute 
requirements for data to be used. Previous studies have shown that inability to perform reproducible 
spirometry, even with good coaching, is an important risk factor in predicting future health. 
"REFERENCE VALUES" 
To interpret spirometric results, they must be compared either to a subject's previous results or to a 
published set of "predicted reference values." Such predicted reference values typically describe the 
average lung function for an individual of a given age, height, and sex, and such equations have been 
published for a variety of racial groups. 
Typically, lung function measurements are expressed as a percent of predicted. One hundred percent of 
predicted represents the average value for the p pUlation, but normal, healthy individuals will exhibit a 
wide range of values about this level. In general, values of80% or greater for FEV 1 and FVC are 
considered to be in the normal range. Individuals whose test results are below this level may have an 
abnormality. 
The NDD EasyOne™ spirometer offers a number of published predicted values, most of which were 
derived from studies of largely Caucasian participants. In this latter case, four ethnic correction settings 
are available that allow you to customize the amount of adjustment that is made for selected racial 
groupings. Consult the EasyGuide™ users' manual, sections 8 and 12, for more information regarding 
the use of prediction equations. 
If there are no acceptable reference values for a country, we recommend the use of the NHANES nr 
reference values, which were derived from the 3rd National Health And Nutrition Examination Survey in 
the United States. This study used a large, randomly selected subset of the entire U.S. population, which 
included a variety of ethnic groups and strict attention to quality control according to current American 
Thoracic Society guidelines. 












The the Society spirometry standards, and 
recent evaluations of commercially available spirometers emphasize the importance of spirometry 
control CQC) procedures. 
a. Participant: A may not as a breath as or as as at 
the start of the maneuver. Several possibilities will prevent a maneuver from being acceptable: an 
involuntary epiglottis closure, temporarily cutting off the flow air; an 
maneuver, the of a or a variable effort. Coughing during the 
maneuver or a leakage due to the participant's inability to keep a tight seal also will prevent from 
a maneuver. 
b. the 
c. Leaks in In and poor are 
affect the quality of the test results. 
d. A combination factors may affect the quality of the results. 
res 
a. source error, it is very to to watch 
the participant the performance and accurately review the displayed flow-volume 
curves on the computer monitor. The technician thus can guide and explain the source of error to the 
b. The instruct the on how to nPrTArTYl 
demonstrate the maneuver, and watch the participant closely during the perfonnance to avoid 
errors obtain best effort the participants. He/she must be trained to 
patterns of unacceptable maneuvers and checks. BOLD will 
feedback on each technician'S performance. 
c. Equipment: Daily spirometer calibration checks should be perfonned using a 3.00 Liter syringe as the 
"gold standard". to section 14 EasyGuide™ users' manual for instructions. 
d. of test session quality, and the 
.nt".,....,..<:J.t""rt to obtain the final FEY I 
E 
The EasyOne ™ spirometer is designed to minimize the need and maintenance 













13 and 14 in the EasyGuide™ users' manual). The surface of the spirometer and cradle may be cleaned 
by wiping with a damp cloth. If a more thorough cleaning is desired, the spirometer and its spirette cavity 
may be cleaned with an alcohol wipe or a soft cloth that has been lightly moistened with isopropyl 
alcohol. Do not let liquids flow into the Spirette™ cavity of the spirometer while cleaning. The 
disposable Spirette™ eliminates the need for cleaning the spirometer between patients. The Spirettes™ 
are designed for single patient use only, and must be removed and disposed of after each patient. 
Additional guidelines for hygiene and infection control are provided by the American Thoracic Society 
and include the recommendation that the technician and patient wash their hands after testing and that 
proper attention be given to environmental controls in settings where tuberculosis or other diseases spread 
by droplet nuclei are likely to be encountered. Participants with evidence of obvious upper respiratory 
infections should not be tested, but rather rescheduled for testing at a later date. 
Beyond battery replacement and the calibration check described below, no periodic maintenance is 
required or recommended on the spirometer or cradle. No service should be performed on the spirometer 
except by manufacturer-authorized personnel. 
On each day it will be used, and prior to the first participant tested, the spirometer should be calibrated 
with a 3.00-Liter syringe that has been stored next to the spirometer. The calibration procedure requires 
the NDD calibration adapter to connect the syringe with the spirometer. 
TROUBLE SHOOTING 
Refer to the section 15 of the EasyGuide™ users' manual for troubleshooting tips. 












Height and Weight 
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Height is used to predict lung function, so it as as V~o..J"'LU' 
ft-:lt''I"'i'lln.-:t.lnT should be standing on a finn, level surface that is perpendicular (at 
a 90° angle) to the vertical board of the height measurement 
If a is not a height 
n-o'lrLr",.rt or a non-flexible measuring device placed against the wall (or attached to the wall) 
should be used. Check to sure that, to extent 
is at a to 
is straight. 
should be instructed to remove shoes and hat, to stand erect with feet flat on the 
floor, heels together, both The 
erect with back, "''''-'-J ...... u'-', OJ, ....... """". 
device. If the participant cannot be positioned so that all 
position so that is in contact with the 
The participant's weight should be evenJy distributed on both feet, arms 
shouJd remain relaxed at the sides with palms inward. The participant shouJd facing 
of 
should be at the same level as the height indicator bar to obtain the most accurate measurement 
1). This having ona If this is 
case, a stepstool should be available in the examining room (or taken along when home 
visits). 
Ask the subject to inhale deeply and maintain a fully erect position without altering the load on 
not on 
participant's head. Record the height to the nearest 0.1 centimeter. should contact the 
if they do not have the ability to measure height to trus of precision. 
prediction of lung function, so accuracy is not as critical as it is for 
.... n'u ... """.- as all measurements is the to 
should be trained accordingJy. A balance beam or digital scale is preferred, 
a use is as as its is checked against 
standard weights. If a site needs to use a home (bathroom) scale, contact the 
The should placed on a ftrm, level surface, and iftrus 
if domg home visits. Before tak.ing the 
measurement, the to remove 
I-IU .. d .... ...,hl (such as keys or wallet) in order to be weighed in light indoor clothing. 












Height and Weight 
Ask the participant to stand in the center of the scale platform, since standing off-center may 
affect the weight measurement. Marks should be made on the platform to ensure the proper 
position of the participant's feet. The participant should stand with arms relaxed at the sides, 
head erect, and eyes looking straight ahead. 
For a balance beam scale 
Before each weight is measured, the sliding scale weights must be moved to zero and the scale 
checked to make sure that the indicator bar is at zero. If it is not, adjust the scale accordingly. 
Once the participant is on the scale, adjust the sliding scale weights until the indicator is again 
balanced (reads zero), and record the resuJts to the nearest 0.1 kg. (Sites should contact the 
Operations Center if they do not have the ability to measure weight to this level of precision.) 
Use extreme care in adding the lower beam weight to the upper beam weight, as they use 
different increments. As a further quality assurance measure, staff should \Wite down each 
number separately before adding them together. Advise the subject to remain standing in 
positjon on the scale until the weight has been recorded. This eliminates the possibility of the 
weight measure being accidentally altered by the balance beam moving as the subject dismounts. 
For a digital read-out scale 
Make sure the scale reads "0" before the subject stands on the measurement platform. When the 
digital readout stabilizes, record the observed weight to the nearest 0.1 kg. (Sites should contact 
the Operations Center if they do not have the ability to measure height to this level of precision.) 
In order to minimize the possibility of having transposed numbers, or in the case of the balance 
beam scale, having incorrectly added the two weights, before the participant dismounts the scale 
inform the participant of the weight reading and recheck it if participant indicates this is 
markedly different from what they believe their weight to be. If the repeat readings are within 
0.2 cm (for height) or 0.2 kg (for weight), simply record the initial reading. 
Equipment Maintenance 
BOLD does not have required maintenance procedures for height and weight measurement 
devices. However, the following guidelines are suggested for optimal quality control. 
Ideally, all scales used should be certified on an annual basis by a competent authority. In 
addition, we recommend bi-monthly in-house checks to ensure accuracy in the range of weights 
to be measured during the trial. The lower range is checked using 20-30 kg weights and the 
upper range using 40-50 kg weights. The technician is weighed on the scale first and this weight 
recorded. The lower weight is then placed on the scale and this weight recorded. The technician 
then gets on the scale with the weight, and this new weight is recorded. Then the higher weight 
is placed on the scale by itself and this weight recorded. Then the technician gets on the scale 
with the higher weight, and weight is again recorded. Scales that fail to meet standards within 
0.5 kg at any weight level should not be used for collection of study data and should be 
immediately reconditioned and recertified by a competent authority. 












Height and Weight 
As noted previously, we recommend a wall-mounted stadiometer for measurement of height. 
The height-measuring devices attached to many balance beam scales can give very unreliable 
readings. 
Staff Training 
All staff who will be taking height and weight measurements should be trained to do so 
according to the above procedures. Training consists of reviewing the above procedures and then 
performing duplicate measurements on each of two individuals. The trainee should do the first 
measurement of both the height and weight on the individual and then repeat the process for the 
second measurement of height and weight on the same individual. The average of the duplicate 
measurements on a given individual must be within 0.2 kg weight and 0.1 cm height of the 
trainer's measurement. In addition, both measurements on a given individual must be within 
0.2 kglO.l em of each other. 













Height and Weight 
Frankfort Plane for measuring body height 
ORBITALE: Lower margin of eye socket. 
TRAGION: Notch above tragus of ear or at upper 
margin of zygomatic bone at that point. 
FRANKFORT 
PLANE: Orbitale tragion line horizontal. 
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A goal of the BOLD study is to determine COPD prevalence in many countries and many 
different settings throughout the world. The many and varied settings and potentially large 
number of technicians and participants involved make quality control (QC) imperative. QC 
includes policies and procedures to help assure that study data may be collected, analyzed, 
compared, and combined as needed. Inadequate QC measures will severely restrict the ability of 
the BOLD project to achieve its high aims. 
QC in the BOLD project falls into three main topic areas: 1) questionnaire administration, 2) 
spirometry administration and data transfer, and 3) data entry. In order to participate in the 
BOLD study, sites must have all of the following QC measures documented, in place, and 
approved by the Operations Center. In addition, sites must have their sampling plans reviewed 
and approved by the Operations Center. 
Initial Training 
AJI BOLD sites are required to complete a training program taught by the Operations Center 
prior to beginning the study. These trainings are usually held twice yearly, once in the u.s. 
(usually either just before or after the meeting of the American Thoracic Society) and once 
outside the U.S. (usually held in the fall). These training sessions cover all three parts of BOLD 
QC as described above. The review of sampling designs will typically occur independent of the 
training sessions. 
The BOLD study recognizes that sites will not be able to send all staff to the initial training 
sessions. Therefore, the study is using the "train-the-trainer" model, where one or several people 
are trained by the Operations Center staff at one of the meetings noted above, and are then 
authorized by the Operations Center to return to their site and train all site staff on study 
procedures. The certified trainer will be the primary liaison between the study site and the 
Operations Center for QC issues. 
Questionnaire Administration 
At the initial training meeting, general principles of questionnaire administration are discussed, 
and each questionnaire is reviewed in detail. This review includes an explanation of the intent of 
each question (which may not always be clear, especially in a cross-cultural context) and specific 
instructions for asking and responding to queries regarding certain questions. To facilitate the 
training, site staff are expected to have reviewed the questionnaires and their instructions prior to 
the training. Site staff should also have translated the questionnaires (where appropriate) and 
attempted to administer the questionnaire prior to the training. This "pretraining" activity helps 
identifY problem areas that can then be addressed as part of the fonnal training. 
Upon successful completion of this training, site staff receive written certification from the 
Operations Center certifying them as master trainers for questionnaire administration. 
Spirometry Administration and Data Transfer 













Prospective master trainers receive specific training and certification regarding use of the NDD 
EasyOne™ spirometer, proper coaching technique, and spirometry data transfer methods. Upon 
successful completion of the spirometry training, staff receive written certification from the 
Operations Center certifying them as master trainers for spirometry administration and data 
transfer. 
Data Entry 
All BOLD data (with the exception of the spirometry data) are entered at the site into an Internet-
based data entry system, which performs a number of online edit checks that are designed to 
maximize the completeness and integrity of the study data. During the initial training, staff 
receive instruction in how to use the system and respond to edit queries. After the initial training 
is completed, staff are given a set of test data to enter once they return home. This assures not 
only that staff can use the data entry application, but also that the Internet connections between 
the Operations Center and the individual site are in place and working correctly. After these test 
data are entered, the Operations Center reviews them to see that they were entered correctly. If 
problems exist, the Operations Center contacts the site to resolve them. If the data are correct, 
then the Operations Center certifies the site staffperson(s) as a master trainer in data entry. 
Site Training 
Certified master trainees from the initial training are authorized by the BOLD study to conduct 
training at their own sites in questionnaire administration, spirometry administration and data 
transfer, and data entry. Selected training materials are provided as part of the BOLD MOP. 
The criteria for certification of site staff are generally the same as for the trainee at the initial 
meeting. For questionnaire administration, site staff must in addition successfully administer 
each of the BOLD study questionnaires three times to a non-study participant while being 
observed by the site's master trainer, who then informs the Operations Center that the training 
has taken place and the individual is certified. For spirometry, each staffPerson must have a 
minimum offive sets of tracings deemed acceptable after review by the pulmonary function 
reading center (PFRC), which then informs the Operations Center that the individual is certified. 
All properly certified site personnel receive a formal certification notice from the Operations 
Center once their training is complete. 
Follow-up Training 
Ongoing quality control procedures are necessary in order to maintain high standards of data 
quality throughout the BOLD study. The following procedures/requirements help to assure this 
goal is met. 
Questionnaire Administration 
Although direct observation of interviewers on a periodic basis is a desirable method of quality 
control, this may not be practical. Instead, the local master trainer is expected to review a sample 
of completed questionnaires from each interviewer for accuracy and completeness, and to 













regularly meet with field staff throughout the study in order to review problems that may arise. 
This review is especiaJly critical in the early stages of the study, so that problems can be 
identified and addressed early on. The standardization of questionnaire administration should 
constantly be stressed, and if questions arise that are not explicitly addressed in the instructions 
that accompany each questionnaire, sites are expected to contact the Operations Center for 
advice. 'rhe Operations Center in turn will post a question and answer (Q&A) document on the 
Web site so that all BOLD sites receive the same clarifications and instructions. 
Spirometry 
Data are transferred routinely to the Operations Center in the United States, where they are 
reviewed for acceptability by the PFRC. The PFRC generates regular QC reports summarizing 
the quality of each technician's data and transmits these reports to the sites through the 
Operations Center. If necessary, the PFRC may suggest additional training tl)f some site staff. 
Data Elltry 
The data entry system runs a series of data quality checks both during and after data entry. Sites 
will be notitied of potential data quality issues as they are identified by the Operations Center. 




















Information sharing and dissemination 
Meetings with the National Department of Health 
In June 2005, a presentation was made to the National Department of Health Chronic 
Diseases Directorate in Pretoria, represented by Mr Maluta Tshivase (Head of the 
Chronic Diseases Directorate) and Mrs Anne Croasdale. Results from the Lung 
Health Survey were outlined. Preliminary results of the prevalence and risk factors for 
chronic bronchitis were presented along with the details of methodology and 
fieldwork for the BOLD study. The problems of under-recognition and under-
treatment of obstructive lung disease and very high smoking rates were highlighted. 
The need for a suitable smoking cessation programmes as part of prevention efforts 
at primary care level was suggested. The project generated interest and the parties 
expressed keen interest in obtaining the full results of the study, and the 
accompanying recommendations. 
The Director of the National Council Against Smoking, Dr Yusuf Saloojee, was also 
present at this meeting in order to create links and involve his organisation as a 
stakeholder in the process. The organisation currently offers a national telephone quit 
line in order to assist people in the process of smoking cessation. This service is 
currently the only formal service for smoking cessation in the country, apart from 
privately run initiatives, for which individuals have to pay. 
Meetings with the Provincial Department of Health. 
In August 2005, preliminary results were presented to the Provincial Department of 
Health (Provincial Administration of the Western Cape) and at a meeting of Provincial 
Health Promotion section, liaising with Ms Esme Kennel, Patrician De Villiers and 
Marius Van Wyk. This presentation covered similar content to that of the National 
Department meeting. However, the preliminary COPD prevalence results for men 
and women in the study area were included. It was proposed that smoking cessation 
be included in the provincial programme for management of chronic diseases and 
offered to assist in developing an appropriate programme. It has already been 
included in the integrated programme of care for respiratory diseases called PALSA 
Plus (Practical Approach to Lung Diseases in South Africa) developed by a team at 
the UCT Lung Institute which has been adopted for implementation in primary care 
clinics in the Western Cape and Free State provinces. We will continue 
communication with the provincial and national authorities to provide whatever 










These plans for disseminating results and planning interventions are due to take 
place in the latter half of 2006 and early 2007, as the final results of the study are 
available. Other key components of this process are the production of a report, a 
series of meetings with key stakeholders, and possibly a workshop on tobacco and 
its impact upon health in South Africa. Partners will be sought to assist in this latter 
venture. The focus will be to draw attention to the problem in South Africa, share data 
on the magnitude of the problem and to harness and co-ordinate efforts from a 
variety of agencies. 
Community feedback meeting in Ravensmeadl Uitsig 
A community feedback was held in Ravensmead on August 4th 2005. The objectives 
of the meeting were to provide preliminary results of the survey to those that had 
taken part, and to any others from the community who wished to attend, to use it as 
an opportunity to highlight the need to reduce smoking in the area, and to spread the 
message of smoking cessation amongst those at risk, particularly women and 
teenagers. It was held on a weekday afternoon, with the intention of targeting women 
in the home, especially those with responsibility for looking after children. The Lung 
Health Study has confirmed very high smoking rates amongst both men and women 
in the community, who in turn expose their growing children to the hazard, and 
through their example increase the likelihood of children commencing the habit at an 
early age. The programme was intended to be entertaining, informative, challenging 
and included a light lunch as a means of thanking the community for their co-
operation and assistance with the study. The meeting, attended by more than 300 
people, was held in the Ravensmead Civic Centre. Information on lung diseases was 
presented by Prof Eric Bateman, study details and feedback by the author and a talk 
on smoking cessation by pulmonologist Dr Rod Dawson, interspersed with songs and 
jokes by a local entertainer, Mr Alvon Collison who communicated very effectively 
with the audience, and used humour and challenge, audience participation and a 
time of questions and answers on health and smoking-related issues. The event 
attracted considerable media attention (see below). 
Publicity 
The author and the research team have engaged with a variety of media to inform 
the public of the project, and raise awareness of the serious health issues 
surrounding smoking in the region. Firstly the assistance of the staff of the university 
Media Relations office were employed, who assisted in several ways. They prepared 










leader and reporters. This resulted in articles in three city newspapers and one local 
community newspaper, two radio talk shows with Prof Bateman answering questions 
from the public, and several radio news clips. Effort was made to ensure that a 
greater audience benefited from the anti - tobacco message. 
The highlight of public dissemination activities was a four-minute segment on national 
television Prime Time News on August yth 2005, which focussed specifically on the 
anti-smoking message and COPD with reference to the study and community 
meeting. 
Conferences and planned publications 
Results from the Lung Health Survey were presented at the International Union 
Against Lung Diseases in Preliminary results of the study were presented at the 
global BOLD sponsors meeting held in Copenhagen on September 18th at the Annual 
Congress of the European Respiratory Society meeting. Data on CO PO prevalence 
have been presented at the Annual Meeting of the American Thoracic Society in May 
2006 (in San Diego) and results of gender differences in COPD in smokers will be 
presented at the Annual Congress of the European Respiratory Society in Munich, 
Germany in September 2006. More work will also be presented at the Annual 
Congress of the South African Thoracic Society in March 2007. Publications on the 
prevalence of COPD, its associated risk factors and economic impact are planned for 
2006/7. 
Stakeholders 
The academic Departments of Medicine and Public Health in South Africa, the 
Government Department of Health, the South African Medical Research Council, 
public sector health facilities, clinical professionals, national and international 
researchers, community groups, the residents of Ravensmead and Uitsig, and the 
National Council Against Smoking were identified as having potential interest on the 




















Referral Letter for selected BOLD (Burden of Obstructive Lung Disease) 
Study participants to Community Health Centre: 
Dear Doctor, 
The bearer of this letter ............................................................ . 
participated in a community study of lung function and symptoms of 
respiratory disease. 
The following findings are abnormal and require further assessment: 
[J Lung Function tests 
o Chronic cough 
o Dyspnoea 
[J wheeze 
[J other .................... , ............................ ,. 
A copy of the reported pre and post bronchodilator spirometry is attached. 
Further assessment and possible treatment may be indicated. 
If you require assistance with this assessment please refer the patient to 
Tygerberg Hospital Respiratory Unit or Groote Schuur Hospital E16 
Respiratory Clinic, if necessary. 
Thank you for your assistance. 
Yours sincerely 
Prof E D Bateman and Dr A Jithoo 
UCT Lung Institute 




















Chapter 4: Method used for developin2 weight factors for the Lung Health Survcv: by 
Carl Lorn bard 
A random sample of 15% of the valid addresses (Primary Sample Units PSU) of 
Ravensmead and Uitsig was included in the Lung Health Survey. A census (number of 
people, their age and gender) was done of the PSU's. The following results were obtained 
A. 615 addresses gave full infonnation and consent 
B. 218 addresses did not give consent and only 67 of these gave full census information 
The number of addresses in B was replaced by addresses linked to the original PSU by a fixed 
procedure. Hence 
C. 21 8 replacement addresses which gave census infonnation and consent. 
The census and sample realization of the three address groups (A,B and C) is given in Tables 
1 .(Drafts given to Saskia and Schalk to type). The census and sample (realization or 
response rate) are broken down by gender and age (0-5,6-14,] 5-44,45+ years) and the 
realization proportion (sample/census) is calculated for each o[these groups. 
The response rate in the A addresses was .898 (3824/4248). 
The response rate in the C addresses was .859 (127211 481). 
From tables 1 and 3 it is evident that the response rate of older men (45+) was the lowest of 
all the subgroups, .836 and .767 in A and C respectively. Although the response rates in A and 
C subgroups are not that different, separate weights were calculated for them. 
The sampling weight (WI) for tins study will consist of the following components. 
i) The inverse of the first stage sampling probability of a PS U 
ii) The realization weight of a specific gender and age subgroup within the sample 
groups A and C. This weight is the inverse of the realization proportion or 
response rate. 
The final weight is the product of the two weights. 
Statistical issues: 
The PStTs was a single stage random cluster sample of 839 addresses drawn without 
replacement from a population of 5592 addresses. (Ask Schalk why 615+218=633 not equal 
to (39). All residents at a selected address were included in the study. The selection 
probability for a random address is therefore 839/5592 =.15. This gives a weight of 6.67. No 
adjustment is made to this weight for the replacement addresses since they are linked to the 
original selected address. Using the address weight we assume that the proportion of the 
population living in the sample address is 15% and that each individual from a complete 
sample on average represents 6.67 people in the study community. 
The realization weight projects the sample results to the corresponding census results of the 
sample. For the individuals from the A addresses this weight is on average 1/.898= 1.1 J 4 and 
11.859:=1.164 for individuals from the B addresses. The product of the address weight and 
realization weight gives the adjusted mnnber of people represented by the individuaL For 










only 90% the individuals in the sample have to represent more people from the study 
community. This is even more so for the elder mcn in the sample. 
Using the sampling weight in statistical analysis will give unbiased estimates of the 
population totals, means and prevalences. The (WI) sampling weight can be used for all 
analyses. This weight will be added to the database of the study together with specific 
subgroup indicators to facilitate domain analysis. (Required by Statu) 
The census profile of the 67 addresses which did not participate in the study is similar to the 
census profile of the 218 replacement addresses. (See table ... , drafts given to Schalk). 
Selecting neighbouring addresses for replacement limited the bias effect of this step. 
To accommodate simpler analyses (not having to use svyset in Stata) where estimating 
popUlation totals are not needed three other sampling weights were calculated that only 
adjusts for differential response rates. These weights only ensure that each address, gender 
and age subgroup has the same response rate relative to an arbitrary selected reference 
subgroup. 
The three weights are 
I. The total sample (W2) 
2. The age group 6-14 years (W3) 
3. The age group 15-44 years. (W4) 
The details of the calculations of the weights are given in ... (handwritten dral1s) 
To calculate if the sample has the smne age and gender distribution as the whole population, 
the response (realisation) was calculated for ditTerent categories dependent on age, gender and 
whether the address was in the initial sample or whether the address was re-sampled. This 
response was calculated per category by dividing the number of people in the sample trough 
the number of peoplc that should have been in there theoretically. The latter numbers were 
obtained from the Census data. Because the response was different in the various groups 
weight factors should be used to calculate prevalence numbers and associations. 
Because the sample consists of 15% of all the households in the population, outcomes should 
be multiplied by 6,67 to get true numbers in the whole population of Ravensmead and LJitsig. 
However, because of a ditferent response in the various groups, this multiply factor diflers 
slightly among the various groups. The correction made on this multiply factor for the 
different groups is weight factor 1 (WI). To calculate true numbers for the popUlation WI 
should be used. 
For the calculation of prevalence'S and associations it is enough to calculate these for the 
sample. It is not necessary to translate into the whole population first. However, it is 
important that the numbers of people in the various groups have the same distribution as in 
the whole popUlation. Therefore different weight factors were calculated. The group(s) that 
had highest response was used as reference group and got value 1. In comparison with this 
group(s) the other groups got a weight factor. This is W2. 
For children 6 - 14 years there was no big difference in response. Therefore, when only 
children are used in the analysis, the same weight factor 1 can be used (W3). When only the 




















Chapter 4: Analysis Wei1;!hts for the BOLD study: excerpt of a document by W Vollmer 
and A Jithoo 
Sampling Weight 
Since we are treating this is a one-stage cluster sample with clusters selected via simple random 
sampling, the household sampling weight isjust the reciprocal of the probability selection for 
any given address. The addresses define the primary sampling units (PSUs). 
Nh # addresses (households) in population =~ 5592 
nh = # addresses in sample (regardless of participation) = 833 
PI = p(jth PSU is selected) = (nhll'lh) 
= (# sampled addresses )/(total # of addresses) 
Since these probabilities are constant across households, we write the household sampling 
weight as 
(I) 
Thus each household in the sample represents 6.71 households in the target population. This is a 
pure sampling weight and does not retlect any adjustment for nonresponse nor any post-
stratification aqjustmentto ret1ect potential imbalance bdween the observed age-sex distribution 
of the sample and the true age-sex distribution of the population. 
Weighting Class A {{justment 
Since we know nothing about 33 ofthe original 833 households, we cannot perform a household-
based weighting class adjustment. However we can perform a person-based weighting class 
adjustment to account for participant nonresponse within each household. This adjustment 
factor, when multiplied by Wh, gives an adjusted person-based sampling weight, Wah, for each 
individual in any given household. For the residents of any given household, Wah is defined as 
Wah = Wh * (# eligible people in the household) 1 (# participants from the household). (2) 
Thus if there are two age-eligible participants in a household and only one of them participates, 
then that person's adjusted weight is 2*Wh. 
Post ~\'trat !iication Adjustment 
We stil1 would like to further adjust for the observed differential nonresponse by age and gender. 
If we had complete enumeration of all of the age-eligible participants fi'om all 833 households, 
wc could have computed a weighting class adjustment by multiplying Wh by the ratio of all 
eligible people to all actual participants within each age-sex category. That is, we would replace 
the within household adjustment factor in (2) with a class-specific adjustment factor that is 
calculated across households. 
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Since we do not have complete enumeration of the individuals in all 833 households, an 
alternative adjustment procedure is to compute a post-stratification adjustment that effectively 
weights the observed age-sex distribution among participants to match the known age-sex 
distribution in the population. 
So we assume that we wish to adjust for the 8 strata defined by gender and age (40-49,50-59, 
60-69,70+). Let k=l, ... ,8 refer to these strata and Nk and nk be the number of individuals in 
the kth strata for the total population of the two townships and for the sample of respondents, 








Nk =1 Wahi (3) 
i=l 
and the summation is over the nk individuals in the kth strata. We use the notation Wahi in (3), 
rather than simply Wah, to reflect the fact that Wah varies across these nk individuals to the extent 
that there is nonresponse within households, although realistically it will take on only a limited 
number of values. 
The final weight to be used in the analysis lor the ith individual in stratum k is then given by 
Wfin{ll =PS * W . 
kr k ahl 
where again Wahl is the weighting class adjusted weight, per fonnula (2), for this individual. If 
the response rates do not diner by age and gender and the age-sex distribution of the sample 
corresponds to that of the population as a who Ie, then PSk ;:::; 1 for all k and the post-strati lied 
weights will resemble the weighting class adjusted weights from formula (2). Otherwise the post 
stratification adjustment has the effect of forcing the estimated population age-sex distribution to 
mirror the true popUlation age-sex distribution. For instance if the response rate in stratum k is 
higher than average, then Nk will tend to overestimate Nk, and the post-stratification adjustment 
will downweight the original sampling weights slightly to compensate for this. Similarly if the 
response rate in stratum k is lower than average, then Nk will underestimate Nk, and the post-
stratification adjustment will upweight the original sampling weights slightly. The resulting 
weights assure that the population prevalence estimates of COPD wi II be appropriately weighted 
averages of the prevalences in the eight age-sex strata. 
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BURDEN OF OBSTRUCTIVE LUNG DISEASE STUDY 
SOUTH AFRICA 
BOLD SPIROMETRY 



















Test Results Your FEV1 is 35% Predicted 
Baseline 
Parameter am Illi1J.1 Irii.I.a 
FVC(L) 2.0S" 2.08" 1.91" 
FEV1(L) 1.01' 1.01' 0.89' 
FEV1/FVC 0.48' 0.48' 0.47-
PEF(Us) 3.26' 3.26' 2.93' 
MEF25-75(Us) 0.33* 0.33' 0.32' 
MEF75(Us) 1.02 1.02 0.93 
MEF50(Us) 0.39 0.39 0.39 
MEF25(Us) 0.12 0.12 0.12 
FET(s) 9.78 9.78 9.22 
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0 
FEV1 Var-0.11L 11 .1%; 
FEV1 Var-0.03L 3.6%; 
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~ ~ ~ am 
6 
1.B4- 3.48 60 
0.85' 2.85 35 
0.46' 0.82 59 
2.51' 6.70 49 





FVC Var-O.17L 8.2%; 
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Your FEV1 is 74% Predicted 
Baseline 
m.t ~ Iri.aM 
3.78 3.75 3.76 
2.66* 2.66* 2.64* 
0.70 0.71 0.70 
PEF(Us) 7.95 7.95 8.63 
MEF25-75(Us) 1.66* 1.66* 1.57-
MEF75(Us) 6.60 6.60 5.86 
MEF50(Us) 2.43 2.43 2.38 
MEF25(Us) 0.54 0.54 0.48 
FET(s) 10.48 10.48 10.79 
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FEV1 Var=0.02L 0.8%; 


























FVC Var=0.02L 0.5%; 
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